<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006109.pub3" GROUP_ID="MENSTR" ID="409205042123015913" MERGED_FROM="" MODIFIED="2017-08-09 02:34:44 +0100" MODIFIED_BY="Jane Marjoribanks" REVIEW_NO="DHH752" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2017-08-09 02:34:41 +0100" MODIFIED_BY="Jane Marjoribanks">
<TITLE MODIFIED="2017-05-10 18:37:08 +1200" MODIFIED_BY="Anne Lawson">Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</TITLE>
<CONTACT MODIFIED="2017-08-09 02:34:41 +0100" MODIFIED_BY="Jane Marjoribanks"><PERSON ID="4773" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Lethaby</LAST_NAME><POSITION>Systematic reviewer</POSITION><EMAIL_1>a.lethaby@auckland.ac.nz</EMAIL_1><MOBILE_PHONE>0274871101</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 373 7599</PHONE_1><PHONE_2>+64274871101</PHONE_2><FAX_1>+64 9 373 7503</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-08-09 02:34:41 +0100" MODIFIED_BY="Jane Marjoribanks"><PERSON ID="9CE26E7F82E26AA200CD32E53036321F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cindy</FIRST_NAME><LAST_NAME>Farquhar</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>c.farquhar@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>FMHS Park Road</ADDRESS_1><ADDRESS_2>Grafton</ADDRESS_2><CITY>Auckland</CITY><ZIP>1003</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 6309943</PHONE_1><FAX_1>+64 9 6309858</FAX_1></ADDRESS></PERSON><PERSON ID="5F70812282E26AA20077BCD52F72ABB1" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Luk</FIRST_NAME><LAST_NAME>Rombauts</LAST_NAME><EMAIL_1>luk.rombauts@bigpond.com</EMAIL_1><ADDRESS><DEPARTMENT>Monash IVF and Department of O&amp;G</DEPARTMENT><ORGANISATION>Monash University</ORGANISATION><ADDRESS_1>246 Clayton Rd</ADDRESS_1><CITY>Melbourne</CITY><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="06257B4E82E26AA2005DA364C6A83956" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jan</FIRST_NAME><MIDDLE_INITIALS>AM</MIDDLE_INITIALS><LAST_NAME>Kremer</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>jan.kremer@radboudumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Radboud University Nijmegen Medical Center</ORGANISATION><ADDRESS_1>PO Box 9101</ADDRESS_1><CITY>Nijmegen</CITY><ZIP>6500 HB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 24 361 4748</PHONE_1><FAX_1>+31 24 366 8597</FAX_1></ADDRESS></PERSON><PERSON ID="4773" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Lethaby</LAST_NAME><POSITION>Systematic reviewer</POSITION><EMAIL_1>a.lethaby@auckland.ac.nz</EMAIL_1><MOBILE_PHONE>0274871101</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 373 7599</PHONE_1><PHONE_2>+64274871101</PHONE_2><FAX_1>+64 9 373 7503</FAX_1></ADDRESS></PERSON><PERSON ID="z1212031254034465557031134336717" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Reuben Olugbenga</FIRST_NAME><LAST_NAME>Ayeleke</LAST_NAME><POSITION>Updating Officer</POSITION><EMAIL_1>r.ayeleke@auckland.ac.nz</EMAIL_1><EMAIL_2>r.o.ayeleke.12@aberdeen.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-01-31 10:50:02 +1300" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="16" MONTH="1" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="1" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="1" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-08-09 08:36:04 +1200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-09 08:36:04 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="8" YEAR="2017"/>
<DESCRIPTION>
<P>Data corrected in response to feedback. No change to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-07-25 17:01:41 +1200" MODIFIED_BY="Helen E Nagels">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-07-25 17:01:38 +1200" MODIFIED_BY="Helen E Nagels">
<DATE DAY="22" MONTH="5" YEAR="2017"/>
<DESCRIPTION>
<P>The addition of nine new studies has led to a change in our conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-07-25 17:01:41 +1200" MODIFIED_BY="Helen E Nagels">
<DATE DAY="22" MONTH="5" YEAR="2017"/>
<DESCRIPTION>
<P>This review has been updated and nine new studies have been included: <LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 11:29:46 +1200" MODIFIED_BY="Jane Clarke">
<DATE DAY="16" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Minor edits made no change to conclusion</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-16 14:39:28 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>Title changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-16 14:39:26 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>New authors added</P>
<P>All aspects of original protocol revised</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-16 14:39:23 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR">
<DATE DAY="19" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-12-23 09:59:45 +1300" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2008-12-23 09:59:45 +1300" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-11-26 13:51:31 +1300" MODIFIED_BY="[Empty name]">
<NAME>Stichting Nijmeegs Universiteitsfonds (SNUF)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION>
<P>Scholarship to support students of the University of Nijmegen to do a study, internship or research outside The Netherlands.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2008-12-23 09:59:45 +1300" MODIFIED_BY="[Empty name]">
<NAME>CVSB (Commissie Voorzieningen Studenten Budget)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION>
<P>Compensation for studying outside The Netherlands.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-08-09 08:45:00 +1200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2017-05-10 19:15:09 +1200" MODIFIED_BY="Anne Lawson">Pretreatments in in vitro fertilisation/intra-cytoplasmic sperm injection cycles</TITLE>
<SUMMARY_BODY MODIFIED="2017-08-09 08:45:00 +1200" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>The aim of this review was to assess whether pretreatment with a combined oral contraceptive pill (COCP) or with progestogen or oestrogen alone influences pregnancy outcomes in couples with low fertility undergoing assisted reproductive technology (ART)</P>
<P>
<B>Background</B>
</P>
<P>In vitro fertilisation (IVF; where an egg is mixed with sperm outside the body) and intra-cytoplasmic sperm injection (ICSI; where one sperm is injected directly into the egg) are important techniques for women who have trouble getting pregnant. IVF and ICSI cycles consist of a few steps. First the woman receives hormone therapy to stimulate her ovaries in producing egg cells (called ovarian stimulation). When a few egg cells are mature enough to be fertilised, the woman receives a single hormone injection. This triggers the ovaries to release the egg cells, so they can be gathered by the clinician. The eggs are then fertilised outside the woman's body and become embryos. One or two embryos are then transferred into the womb.</P>
<P>Before the first step in IVF or ICSI cycles (hormone therapy), a pretreatment with a COCP can be given. A COCP contains both progestogen and oestrogen. Pretreatment with a progestogen or oestrogen alone could also be used before the hormone therapy. These pretreatments suppress the woman's own hormone production. This might improve the woman's response to the hormone therapy in IVF/ICSI cycles. In this way, side events such as cyst formation (fluid-filled sac that develops on a woman's ovary) and the number of pregnancy losses might be reduced and pregnancy outcomes might be improved.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This Cochrane Review included 30 randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) assessing pretreatment with COCP, progestogen or oestrogen in 5096 women undergoing ART. The evidence is current to January 2017.</P>
<P>
<B>Key results</B>
</P>
<P>Among women undergoing ovarian stimulation in antagonist protocols, COCP pretreatment was associated with a lower rate of live birth or ongoing pregnancy than no pretreatment. There was insufficient evidence to determine whether rates of live birth or ongoing pregnancy were influenced by pretreatment with progestogens or oestrogens, or by COCP pretreatment using other stimulation protocols. Findings on adverse events were inconclusive, except that progesterone pretreatment may reduce the risk of ovarian cysts in agonist cycles, and COCP in antagonist cycles may reduce the risk of pregnancy loss compared with no pretreatment in agonist cycles.</P>
<P>
<B>Quality of the evidence</B>.</P>
<P>Overall evidence quality ranged from very low to moderate. The main problems were risk of bias and imprecision. Most studies did not describe their methods in adequate detail.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-05-25 13:35:11 +1200" MODIFIED_BY="Helen E Nagels">
<ABS_BACKGROUND MODIFIED="2017-04-07 16:57:24 +1200" MODIFIED_BY="[Empty name]">
<P>Among subfertile women undergoing assisted reproductive technology (ART), hormone pills given before ovarian stimulation may improve outcomes.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-05-24 10:58:27 +1200" MODIFIED_BY="[Empty name]">
<P>To determine whether pretreatment with the combined oral contraceptive pill (COCP) or with a progestogen or oestrogen alone in ovarian stimulation protocols affects outcomes in subfertile couples undergoing ART.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-05-10 19:16:37 +1200" MODIFIED_BY="Anne Lawson">
<P>We searched the following databases from inception to January 2017: Cochrane Gynaecology and Fertility Group Specialised Register, The Cochrane Central Register Studies Online, MEDLINE, Embase, CINAHL and PsycINFO. We also searched the reference lists of relevant articles and registers of ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-05-24 11:40:11 +1200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) of hormonal pretreatment in women undergoing ART.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-05-24 11:40:16 +1200" MODIFIED_BY="[Empty name]">
<P>We used standard methodological procedures recommended by Cochrane. The primary review outcomes were live birth or ongoing pregnancy and pregnancy loss. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-05-24 11:40:32 +1200" MODIFIED_BY="[Empty name]">
<P>We included 29 RCTs (4701 women) of pretreatment with COCPs, progestogens or oestrogens versus no pretreatment or alternative pretreatments, in gonadotrophin-releasing hormone (GnRH) agonist or antagonist cycles. Overall, evidence quality ranged from very low to moderate. The main limitations were risk of bias and imprecision. Most studies did not describe their methods in adequate detail.</P>
<P>
<B>Combined oral contraceptive pill versus no pretreatment</B>
</P>
<P>With antagonist cycles in both groups the rate of live birth or ongoing pregnancy was lower in the pretreatment group (OR 0.74, 95% CI 0.58 to 0.95; 6 RCTs; 1335 women; I<SUP>2</SUP> = 0%; moderate quality evidence). There was insufficient evidence to determine whether the groups differed in rates of pregnancy loss (OR 1.36, 95% CI 0.82 to 2.26; 5 RCTs; 868 women; I<SUP>2</SUP> = 0%; moderate quality evidence), multiple pregnancy (OR 2.21, 95% CI 0.53 to 9.26; 2 RCTs; 125 women; I<SUP>2</SUP> = 0%; low quality evidence), ovarian hyperstimulation syndrome (OHSS; OR 0.98, 95% CI 0.28 to 3.40; 2 RCTs; 642 women; I<SUP>2</SUP> = 0%, low quality evidence), or ovarian cyst formation (OR 0.47, 95% CI 0.08 to 2.75; 1 RCT; 64 women; very low quality evidence).</P>
<P>In COCP plus antagonist cycles versus no pretreatment in agonist cycles, there was insufficient evidence to determine whether the groups differed in rates of live birth or ongoing pregnancy (OR 0.89, 95% CI 0.64 to 1.25; 4 RCTs; 724 women; I<SUP>2</SUP> = 0%; moderate quality evidence), multiple pregnancy (OR 1.36, 95% CI 0.85 to 2.19; 4 RCTs; 546 women; I<SUP>2</SUP> = 0%; moderate quality evidence), or OHSS (OR 0.63, 95% CI 0.20 to 1.96; 2 RCTs; 290 women, I<SUP>2 </SUP>= 0%), but there were fewer pregnancy losses in the pretreatment group (OR 0.40, 95% CI 0.22 to 0.72; 5 RCTs; 780 women; I<SUP>2</SUP> = 0%; moderate quality evidence). There were no data suitable for analysis on ovarian cyst formation.</P>
<P>One small study comparing COCP versus no pretreatment in agonist cycles showed no clear difference between the groups for any of the reported outcomes.</P>
<P>
<B>Progestogen versus no pretreatment</B>
</P>
<P>All studies used the same protocol (antagonist, agonist or gonadotrophins) in both groups. There was insufficient evidence to determine any differences in rates of live birth or ongoing pregnancy (agonist: OR 1.35, 95% CI 0.69 to 2.65; 2 RCTs; 222 women; I<SUP>2</SUP> = 24%; low quality evidence; antagonist: OR 0.67, 95% CI 0.18 to 2.54; 1 RCT; 47 women; low quality evidence; gonadotrophins: OR 0.63, 95% CI 0.09 to 4.23; 1 RCT; 42 women; very low quality evidence), pregnancy loss (agonist: OR 2.26, 95% CI 0.67 to 7.55; 2 RCTs; 222 women; I<SUP>2</SUP> = 0%; low quality evidence; antagonist: OR 0.36, 95% CI 0.06 to 2.09; 1 RCT; 47 women; low quality evidence; gonadotrophins: OR 1.00, 95% CI 0.06 to 17.12; 1 RCT; 42 women; very low quality evidence) or multiple pregnancy (agonist: no data available; antagonist: OR 1.05, 95% CI 0.06 to 17.76; 1 RCT; 47 women; low quality evidence; gonadotrophins: no data available). Three studies, all using agonist cycles, reported ovarian cyst formation: rates were lower in the pretreatment group (OR 0.16, 95% CI 0.08 to 0.32; 374 women; I<SUP>2</SUP> = 1%; moderate quality evidence). There were no data on OHSS.</P>
<P>
<B>Oestrogen versus no pretreatment</B>
</P>
<P>In antagonist or agonist cycles, there was insufficient evidence to determine whether the groups differed in rates of live birth or ongoing pregnancy (antagonist versus antagonist: OR 0.79, 95% CI 0.53 to 1.17; 2 RCTs; 502 women; I<SUP>2</SUP> = 0%; low quality evidence; antagonist versus agonist: OR 0.88, 95% CI 0.51 to 1.50; 2 RCTs; 242 women; I<SUP>2</SUP> = 0%; very low quality evidence), pregnancy loss (antagonist versus antagonist: OR 0.16, 95% CI 0.02 to 1.47; 1 RCT; 49 women; very low quality evidence; antagonist versus agonist: OR 1.59, 95% CI 0.62 to 4.06; 1 RCT; 220 women; very low quality evidence), multiple pregnancy (antagonist versus antagonist: no data available; antagonist versus agonist: OR 2.24, 95% CI 0.09 to 53.59; 1 RCT; 22 women; very low quality evidence) or OHSS (antagonist versus antagonist: no data available; antagonist versus agonist: OR 1.54, 95% CI 0.25 to 9.42; 1 RCT; 220 women). Ovarian cyst formation was not reported.</P>
<P>
<B>Head-to-head comparisons</B>
</P>
<P>COCP was compared with progestogen (1 RCT, 44 women), and with oestrogen (2 RCTs, 146 women), and progestogen was compared with oestrogen (1 RCT, 48 women), with an antagonist cycle in both groups. COCP in an agonist cycle was compared with oestrogen in an antagonist cycle (1 RCT, 25 women). Data were scant but there was no clear evidence that any of the groups differed in rates of live birth or ongoing pregnancy, pregnancy loss or other adverse events.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-05-25 13:35:11 +1200" MODIFIED_BY="Helen E Nagels">
<P>Among women undergoing ovarian stimulation in antagonist protocols, COCP pretreatment was associated with a lower rate of live birth or ongoing pregnancy than no pretreatment. There was insufficient evidence to determine whether rates of live birth or ongoing pregnancy were influenced by pretreatment with progestogens or oestrogens, or by COCP pretreatment using other stimulation protocols. Findings on adverse events were inconclusive, except that progesterone pretreatment may reduce the risk of ovarian cysts in agonist cycles, and COCP in antagonist cycles may reduce the risk of pregnancy loss compared with no pretreatment in agonist cycles.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-05-22 16:22:43 +1200" MODIFIED_BY="Helen E Nagels">
<P>For definitions of terminology see our Glossary (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<CONDITION MODIFIED="2017-05-11 23:15:11 +1200" MODIFIED_BY="Anne Lawson">
<P>For subfertile women, assisted reproductive techniques (ART) such as in vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI) can be a way to achieve pregnancy. Pregnancy and live birth rates are higher with IVF than with expectant management (<LINK REF="REF-Pandian-2005" TYPE="REFERENCE">Pandian 2005</LINK>).</P>
<P>An IVF cycle has the following stages: ovarian stimulation, oocyte retrieval, fertilisation of the egg and transfer of the embryo. Ovarian stimulation involves the administration of gonadotrophins. These hormones stimulate growth and maturation of the follicle. Gonadotrophins include follicle-stimulating hormone (FSH) and luteinising hormone (LH). There are two different gonadotrophin preparations; human menopausal gonadotrophin (hMG) which consists of both FSH and LH, and a more recent therapy, recombinant follicle-stimulating hormone (rFSH). There is insufficient evidence of a difference between these treatments in ongoing pregnancy or live birth rate and other aspects with relation to IVF (<LINK REF="REF-Van-Wely-2003" TYPE="REFERENCE">Van Wely 2003</LINK>).<BR/>
</P>
<P>There are a number of undesirable events associated with gonadotrophin therapy that can complicate treatment and outcomes: ovarian hyperstimulation syndrome (OHSS), premature LH-surge and multiple pregnancy (<LINK REF="REF-Dodson-1989" TYPE="REFERENCE">Dodson 1989</LINK>). In some women undergoing IVF therapy, these problems occur because the endogenous FSH and LH production is too dominant (<LINK REF="REF-Awadalla-1987" TYPE="REFERENCE">Awadalla 1987</LINK>). Gonadotrophin-releasing hormone analogues (GnRHa) are administered to inhibit the production of endogenous FSH and LH (<LINK REF="REF-Awadalla-1987" TYPE="REFERENCE">Awadalla 1987</LINK>; <LINK REF="REF-Dodson-1989" TYPE="REFERENCE">Dodson 1989</LINK>). Gonadotrophin-releasing hormone (GnRH) is a hormone that occurs naturally in the woman's body and that regulates the production of gonadotrophins. There are two different types of GnRHa: agonists or antagonists. The difference lies in their mechanism of action. GnRH agonists bind to the GnRH receptors in the pituitary gland and initially stimulate the release of gonadotrophins ('flare-up'). Negative feedback causes a decrease in the number of GnRH receptors, which results in the release of fewer gonadotrophins. In a traditional treatment protocol, GnRH agonists are administered prior to commencing gonadotrophins, ensuring that the flare-up will be over by the time gonadotrophins are injected. Conversely, GnRH antagonists can be started after gonadotrophin therapy has been administered because they bind competitively to the receptor, causing immediate suppression of the endogenous production of FSH and LH (<LINK REF="REF-Tarlatzis-2006" TYPE="REFERENCE">Tarlatzis 2006</LINK>). Therefore, GnRHa can prevent a premature LH-surge and synchronise the follicle cohort.<BR/>
</P>
<P>The authors of one Cochrane Review comparing GnRH agonist cycles with GnRH antagonist cycles concluded that GnRH antagonists are associated with a substantial reduction in OHSS without reducing the likelihood of achieving live birth (<LINK REF="REF-Al_x002d_Inany-2016" TYPE="REFERENCE">Al-Inany 2016</LINK>).</P>
<P>When a few follicles reach maturity after gonadotrophin stimulation and GnRHa treatment, human chorionic gonadotrophin (hCG) is administered to trigger ovulation and 34 to 36 hours later, oocyte retrieval is undertaken and the egg is fertilised outside the body. Following fertilisation, the embryos are either transferred on day two or three (cleavage stage) or on day five or six (blastocyst stage). Luteal phase support is typically provided as a progestogen or a hCG treatment, or as a combination.</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-05-11 22:11:38 +1200" MODIFIED_BY="Anne Lawson">
<P>Oral contraceptive pills (OCP) are widely used by women of different ages to prevent pregnancy. They are also indicated for a range of menstrual and gynaecological conditions, such as acne vulgaris, polycystic ovary syndrome (PCOS) and menorrhagia (<LINK REF="REF-Arowojolu-2007" TYPE="REFERENCE">Arowojolu 2007</LINK>; <LINK REF="REF-Harwood-2007" TYPE="REFERENCE">Harwood 2007</LINK>; <LINK REF="REF-Irvine-1999" TYPE="REFERENCE">Irvine 1999</LINK>). Combined oral contraceptive pills (COCP) consisting of oestrogen and progestogen reduce the women's own production of FSH and LH by way of a negative feedback (<LINK REF="REF-Cohen-1979" TYPE="REFERENCE">Cohen 1979</LINK>; <LINK REF="REF-Gaspard-1984" TYPE="REFERENCE">Gaspard 1984</LINK>). The COCP suppresses gonadal function and, in the absence of an LH-surge, no flare-up or premature ovulation will occur. Only progestogen has a contraceptive effect (<LINK REF="REF-Erkkola-2007" TYPE="REFERENCE">Erkkola 2007</LINK>). Progestogen has the ability to slow GnRH pulsatility of the pituitary gland, thereby reducing gonadotrophin surges and, according to dose, inhibiting ovulation (<LINK REF="STD-Anderson-1990" TYPE="STUDY">Anderson 1990</LINK>; <LINK REF="REF-Erkkola-2007" TYPE="REFERENCE">Erkkola 2007</LINK>; <LINK REF="REF-Le-Nestour-1993" TYPE="REFERENCE">Le Nestour 1993</LINK>; <LINK REF="REF-Moudgal-1985" TYPE="REFERENCE">Moudgal 1985</LINK>). Oestrogen is added to the COCP to regulate the bleeding patterns, though it is also capable of reducing FSH levels (<LINK REF="REF-De-Ziegler-1998" TYPE="REFERENCE">De Ziegler 1998</LINK>; <LINK REF="REF-Le-Nestour-1993" TYPE="REFERENCE">Le Nestour 1993</LINK>).</P>
<P>Most of progestogen-only pills do not inhibit ovulation although higher doses of progestogen may do so (<LINK REF="REF-Erkkola-2007" TYPE="REFERENCE">Erkkola 2007</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-05-22 16:22:43 +1200" MODIFIED_BY="Helen E Nagels">
<P>The COCP given prior to gonadotrophin in an IVF cycle assists synchronisation of follicular development and prevents occurrence of spontaneous LH-surges (<LINK REF="STD-Gonen-1990" TYPE="STUDY">Gonen 1990</LINK>). Huirne reported similar data as well as a reduction of the occurrence of large follicles prior to day eight (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>). In another study, both the COCP and progestogen had a suppressive effect on LH and FSH secretion. However, oestrogen administration (at 4 mg/day) did not suppress serum LH and FSH concentrations (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>).</P>
<P>The resulting pituitary suppression of COCPs in GnRH antagonist cycles is associated with slower follicular growth and lower serum oestradiol levels than in antagonist cycles with no pretreatment in the early part of the cycle. This results in a longer duration of rFSH stimulation and a higher total rFSH consumption than in antagonist cycles without pretreatment (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>).</P>
<P>COCP pretreatment in an ovarian stimulation protocol before IVF can reduce cyst formation, shorten the length of GnRHa treatment and reduce the amount of gonadotrophin needed, without negatively affecting the pregnancy rate (<LINK REF="REF-Biljan-1998a" TYPE="REFERENCE">Biljan 1998a</LINK>). Pituitary suppression seems to occur earlier with progestogen pretreatment and fewer ovarian cysts are formed, when compared with no pretreatment (<LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>). COCP pretreatment can be used for scheduling oocyte retrieval on days of the working week, which is important with antagonist cycles (<LINK REF="REF-Barmat-2005" TYPE="REFERENCE">Barmat 2005</LINK>; <LINK REF="STD-Gonen-1990" TYPE="STUDY">Gonen 1990</LINK>; <LINK REF="REF-Huirne-2006b" TYPE="REFERENCE">Huirne 2006b</LINK>). Scheduling is of benefit for the clinicians and people in the laboratory, since these people usually do not work on weekends.</P>
</THEORY>
<IMPORTANCE MODIFIED="2017-05-11 23:15:33 +1200" MODIFIED_BY="Anne Lawson">
<P>There is some debate regarding the effects of the COCP upon pregnancy rate. Higher rates of clinical pregnancy and live birth have been reported when dual suppression protocols and GnRHa were compared to a GnRHa protocol without the use of oral contraceptives in non-randomised studies (<LINK REF="STD-Damario-1997" TYPE="STUDY">Damario 1997</LINK>; <LINK REF="STD-Keltz-2007" TYPE="STUDY">Keltz 2007</LINK>). However, other non-randomised studies have found no evidence of effect with regard to pregnancy rate (<LINK REF="STD-Bellver-2007" TYPE="STUDY">Bellver 2007</LINK>; <LINK REF="STD-Galera-2004" TYPE="STUDY">Galera 2004</LINK>).</P>
<P>There is a lack of consensus regarding whether pretreatment with COCP in ovarian stimulation protocols improves rates of pregnancy and live birth. Furthermore, the effects of pretreatment with progestogen or oestrogen alone on IVF outcomes is unclear. The results of many small RCTs can be pooled in a systematic review and may provide a more definitive answer regarding the role of the COCP, progestogens or oestrogens in ART.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-05-22 16:23:33 +1200" MODIFIED_BY="Helen E Nagels">
<P>To determine whether pretreatment with the combined oral contraceptive pill or with a progestogen or oestrogen alone in ovarian stimulation protocols affects outcomes in subfertile couples undergoing ART.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-08-09 08:45:08 +1200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-08-09 08:45:04 +1200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-08-09 08:45:04 +1200" MODIFIED_BY="[Empty name]">
<P>We included only randomized controlled trials (RCTs) in this review. We included both published and unpublished studies and we excluded trials with quasi-randomisation.</P>
<P>We excluded cross-over trials unless pre-crossover data were available; this type of design is inappropriate in this context.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-05-10 20:13:18 +1200" MODIFIED_BY="Anne Lawson">
<P>Women of any age with subfertility, regardless of any cause, undergoing ART.</P>
<P>We only excluded two types of participants from this review. The first was women with premature ovarian failure, because these women require a different ovarian stimulation protocol. The second was women who participated in ovarian stimulation protocols as oocyte donors.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-05-10 20:13:34 +1200" MODIFIED_BY="Anne Lawson">
<P>Pretreatment with COCPs, progestogens or oestrogens versus no pretreatment or alternative pretreatments, in GnRH agonist or antagonist cycles. We excluded studies that compared different doses of the same pretreatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-08-09 08:45:04 +1200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-08-09 08:45:04 +1200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Live birth or ongoing pregnancy (in studies not reporting live birth) per woman randomized.</LI>
<UL>
<LI>Live birth defined as the delivery of a foetus with signs of life after 20 completed weeks of gestational age, counted as live birth event. When there were multiple live births (e.g. twins or triplets), we counted these as one live birth event (<LINK REF="REF-Griffin-2002" TYPE="REFERENCE">Griffin 2002</LINK>).</LI>
<LI>Ongoing pregnancy defined as evidence of a gestational sac with foetal heart motion at 12 weeks or later, confirmed with ultrasound. When there were multiple gestational sacs in one woman, we counted these as one ongoing pregnancy (<LINK REF="REF-Griffin-2002" TYPE="REFERENCE">Griffin 2002</LINK>).</LI>
</UL>
<LI>Pregnancy loss (miscarriage) per woman randomized - defined as the sum of the number of spontaneous abortions (pregnancy loss before 20 completed weeks of gestation) and the number of stillbirths (pregnancy loss after 20 completed weeks of gestation) (<LINK REF="REF-Griffin-2002" TYPE="REFERENCE">Griffin 2002</LINK>).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-08-09 08:45:04 +1200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical pregnancy rate per woman randomized - defined as evidence of a gestational sac with foetal heart motion at six weeks or later, confirmed with ultrasound. When there were multiple gestational sacs in one woman, we counted these as one clinical pregnancy (<LINK REF="REF-Griffin-2002" TYPE="REFERENCE">Griffin 2002</LINK>).</LI>
<LI>Multiple pregnancy rate per woman randomized.</LI>
<LI>OHSS rate per woman randomized, as defined in the included studies.</LI>
<LI>Number of oocytes retrieved per woman randomized.</LI>
<LI>Days of gonadotrophin treatment per woman randomized.</LI>
<LI>Amount of gonadotrophins administered per woman randomized.</LI>
<LI>Ovarian cyst formation rate per woman randomized - defined as any intraovarian sonolucent structure with a mean diameter of 15 mm or more confirmed with ultrasound at least one week after start pituitary suppression (<LINK REF="REF-Biljan-1998a" TYPE="REFERENCE">Biljan 1998a</LINK>).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-08-09 08:45:04 +1200" MODIFIED_BY="[Empty name]">
<P>We obtained all studies that described (or might have described) RCTs of pretreatment with COCP, progestogen or oestrogen therapy prior to GnRHa (agonists or antagonists) and gonadotrophins or gonadotrophins alone in women undergoing IVF, using the following search strategies.</P>
<ELECTRONIC_SEARCHES MODIFIED="2017-08-09 08:45:04 +1200" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases:</P>
<UL>
<LI>the Cochrane Gynaecology and Fertility Group (CGF) Specialised Register, searched on Procite platform from inception to 16 January 2017 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>Cochrane Central Register of Studies Online (CENTRAL CRSO) searched 16 January 2017 on web platform (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>);</LI>
<LI>MEDLINE; searched on Ovid platform 1946 to 16 January 2017 (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). We combined this search with the Cochrane highly sensitive search strategy for identifying randomized trials (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>);</LI>
<LI>Embase; searched on Ovid platform 1980 to 16 January 2017 (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). We combined this search with trial filters developed by the Scottish Intercollegiate Guidelines Network (<LINK REF="REF-SIGN" TYPE="REFERENCE">SIGN</LINK>);</LI>
<LI>PsycINFO; searched on the Ovid platform from 1806 to 16 January 2017 (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>);</LI>
<LI>Cumulative Index to Nursing and Allied Health Literature (CINAHL Plus); searched on the Ebsco platform from 1982 to 16 January 2017 (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>). We combined this search with trial filters developed by the Scottish Intercollegiate Guidelines Network (<LINK REF="REF-SIGN" TYPE="REFERENCE">SIGN</LINK>).</LI>
</UL>
<P>We place no restrictions by language. We managed output of these searches with the reference manager, Endnote (<LINK REF="REF-EndNote" TYPE="REFERENCE">EndNote</LINK>). Through this program, duplicates can be found and removed.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-05-22 15:25:58 +1200" MODIFIED_BY="Helen E Nagels">
<P>In addition, we searched some other resources than the electronic databases mentioned above to obtain more relevant trials. We accessed all the websites on 13 January 2017, except for OpenSIGLE.</P>
<UL>
<LI>Trial registers for ongoing and registered trials: Current Controlled Trials (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A>), and the World Health Organization (WHO) International Trials Registry Platform Search Portal (<A HREF="http://www.who.int/trialsearch">www.who.int/trialsearch</A>) (<LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>).</LI>
<LI>The Virtual Health Library.</LI>
<LI>Citation indexes (<A HREF="http://scientific.thomson.com/products/sci">scientific.thomson.com/products/sci</A>).</LI>
<LI>PubMed (<A HREF="http://www.ncbi.nlm.nih.gov/pubmed">www.ncbi.nlm.nih.gov/pubmed</A>); we combined this search with random control filters for PubMed (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</LI>
<LI>Conference abstracts on the ISI Web of Knowledge (<A HREF="http://isiwebofknowledge.com">isiwebofknowledge.com</A>).</LI>
<LI>Open System for Information on Grey Literature (<A HREF="http://opensigle.inist.fr">opensigle.inist.fr</A>, accessed on 16 January 2017).</LI>
<LI>Reference lists of appropriate studies.</LI>
<LI>Handsearching of the abstracts of the 32nd annual meeting of the European Society of Human Reproduction and Embryology in Helsinki (Finland), 3 to 6 July 2016 (<LINK REF="REF-ESHRE-2016" TYPE="REFERENCE">ESHRE 2016</LINK>).</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-08-09 08:45:08 +1200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2017-05-10 20:30:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Two review authors (ROA, AL) independently scanned the titles and abstracts of all the studies found with the search to exclude those that did not meet the inclusion criteria. We discussed any disagreement or doubt, whether a study was eligible for inclusion or not, with a third review author (CF) to achieve consensus. We obtained the full text of those RCTs deemed eligible for inclusion where possible, and subjected them to critical appraisal of their risk of bias. Where appropriate, we included them in this systematic review.</P>
<P>Subsequently, we constructed a <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for those trials considered suitable for inclusion. We produced a <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table for those that did not satisfy the inclusion criteria. In this table, we listed the reasons for exclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-05-10 20:31:30 +1200" MODIFIED_BY="Anne Lawson">
<P>Two review authors (ROA, AL) independently extracted the data using data extraction forms, which we designed for this particular review (<LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>; <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>). We resolved any discrepancies by discussion and the help of a third review author (CF).</P>
<P>The data extraction forms included risk of bias criteria and methodological details. The information about the studies is included in the review and presented in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. We managed the data using Review Manager 5 software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-05-10 20:36:33 +1200" MODIFIED_BY="Anne Lawson">
<P>We assessed and reported on the risk of bias of included studies in accordance with the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), which recommends the explicit reporting of the following domains.</P>
<UL>
<LI>Sequence generation</LI>
</UL>
<P>Was sequence generation adequate (e.g. use of a random number table, a computer random number generator or coin tossing) or unclear (insufficient information about the process of sequence generation)?</P>
<UL>
<LI>Allocation concealment</LI>
</UL>
<P>Was allocation concealment adequate (e.g. use of central allocation or opaque sealed envelopes), inadequate (e.g. use of an open random allocation schedule, date of birth or case record number) or unclear (insufficient information about the process of allocation concealment)?</P>
<UL>
<LI>Blinding of participants, providers and outcome assessors</LI>
</UL>
<P>Was blinding adequate (e.g. participants and researchers were all blinded and it was unlikely that blinding could have been broken, either participants or some researchers were not blinded but outcome assessment was blinded or no blinding was used but this was not likely to influence outcomes), inadequate (e.g. no blinding or incomplete blinding and outcomes were likely to be influenced by this) or unclear (insufficient information about the process of blinding)?</P>
<UL>
<LI>Incomplete outcome data</LI>
</UL>
<P>Were outcome data addressed adequately (e.g. there were no missing outcome data, reasons for missing outcome data were unlikely to be related to true outcome or missing outcome data were balanced in numbers across intervention groups), inadequate (e.g. reasons for missing outcome data were likely to be related to true outcome) or unclear (insufficient information about the process of addressing outcome data)?</P>
<UL>
<LI>Selective outcome reporting</LI>
</UL>
<P>Was the study free of selective reporting? Adequate (e.g. the study protocol was available and all prespecified outcomes were reported or the study protocol was not available but it was clear that all prespecified outcomes were reported), inadequate (e.g. not all prespecified primary outcomes were reported) or unclear (insufficient information about the process of outcome reporting).</P>
<UL>
<LI>Other sources of bias for RCTs</LI>
</UL>
<P>Was the study free of other bias? Adequate (the study seemed to be free of other bias, e.g. comparable demographic characteristics between treatment groups), inadequate (e.g. extreme baseline imbalance, a potential source of bias related to the specific study design used or early stopping) or unclear (insufficient information about other sources of bias).</P>
<P>By using a simple form (<LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>; <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>), two review authors separately assessed these domains as 'low' (indicating a low risk of bias), 'unclear' (indicating an uncertain risk of bias) or 'high' (indicating a high risk of bias).</P>
<P>The assessments of the two review authors (ROA, AL) were compared and we resolved any discrepancies in the interpretation of the risk of bias of a study by discussion with a third review author (CF). We did not exclude any study as a result of a rating of 'Unclear' or 'High'. Where it was unclear, we contacted authors of studies about the methods used and also sought any missing data.</P>
<P>We presented the results of the risk of bias assessment in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table, including commentary about each of the domains. This led to a methodological quality summary (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-05-11 22:09:34 +1200" MODIFIED_BY="Anne Lawson">
<P>For dichotomous data, we expressed results for each study as odds ratios (OR) with 95% confidence intervals (CI). For continuous variables, we reported the data as mean differences (MD) with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-08-09 08:45:08 +1200" MODIFIED_BY="[Empty name]">
<P>To avoid analysis errors, we only pooled data that reported outcomes per woman randomized. Studies that reported 'per cycle' data were eligible for inclusion but were not included in the analyses; however, additional information was provided on such studies narratively.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-05-11 22:11:05 +1200" MODIFIED_BY="Anne Lawson">
<P>In case of missing data in the included studies, we contacted the original investigators by e-mail or post to request relevant missing information. If we did not receive a reply, we sent a reminder to the authors two weeks later. Furthermore, we contacted the members of the CGF group to ask if they know any of the authors personally or have contact details.</P>
<P>We reported the data according to intention-to-treat (ITT) where possible. We reported live birth and ongoing pregnancy as a single outcome (i.e. live birth or ongoing pregnancy due to non-reporting of live birth data by some studies who reported data on ongoing pregnancy). However, where a study reported data on both outcomes, we only included data for live birth in the analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-05-10 20:40:12 +1200" MODIFIED_BY="Anne Lawson">
<P>Before any meta-analysis was done, we judged whether there was sufficient similarity between the eligible studies in their design and clinical characteristics to ensure that pooling was valid. We assessed statistical heterogeneity in the results of trials using the Chi<SUP>2 </SUP>test. A low P value (or a large Chi<SUP>2 </SUP>statistic relative to its degree of freedom) potentially provides evidence of heterogeneity of intervention effects and shows that results are not influenced by chance alone (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).<BR/>We used the I<SUP>2</SUP> statistic to assess the impact of the heterogeneity on the meta-analysis. We interpreted the result of the I<SUP>2</SUP> statistic as follows:</P>
<UL>
<LI>0% to 40%: might not be important;</LI>
<LI>30% to 60%: may represent moderate heterogeneity;</LI>
<LI>50% to 90%: may represent substantial heterogeneity; and</LI>
<LI>75% to 100%: considerable heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</LI>
</UL>
<P>If we found marked clinical or statistical heterogeneity (I<SUP>2</SUP> more than 50%), we explored reasons for this heterogeneity using a sensitivity analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-05-10 20:40:55 +1200" MODIFIED_BY="Anne Lawson">
<P>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. If there were 10 or more studies in an analysis, we intended to use a funnel plot to explore the possibility of small-study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies), but, due to the small number of studies per analysis, this was not possible.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-05-10 20:41:08 +1200" MODIFIED_BY="Anne Lawson">
<P>We carried out statistical analysis using Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used fixed-effect meta-analysis for combining data where studies were sufficiently similar.</P>
<P>Comparisons were grouped separately by type of pretreatment (COCP, progesterone, oestrogen) and type of comparator (no pretreatment or alternative pretreatment) and the primary analysis was subgrouped by type of downregulation (antagonist or agonist).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-05-11 23:47:46 +1200" MODIFIED_BY="Anne Lawson">
<P>Where data were available, we subgrouped the data to determine the separate evidence within the following subgroups.</P>
<UL>
<LI>Types of downregulating agents:</LI>
<UL>
<LI>GnRH agonist in study group versus GnRH agonist in control group;</LI>
<LI>GnRH antagonist in study group versus GnRH antagonist in control group;</LI>
<LI>GnRH antagonist in study group versus GnRH agonist in control group;</LI>
<LI>GnRH agonist in study group versus GnRH antagonist in control group.</LI>
</UL>
<LI>Women who were low responders (i.e. who responded poorly to controlled ovarian hyperstimulation).</LI>
</UL>
<P>Where we detected substantial heterogeneity (I<SUP>2</SUP> greater than 50%), we explored possible explanations in sensitivity analyses. We took any statistical heterogeneity into consideration when interpreting the results especially if there were any variations in the direction of effect estimates.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-05-11 23:48:08 +1200" MODIFIED_BY="Anne Lawson">
<P>We intended to conduct sensitivity analysis for the primary outcomes (live births or ongoing pregnancies and pregnancy losses) to determine whether the conclusions were robust to the choice of statistical model (fixed versus random) or summary effect measure (OR or risk ratio).</P>
<SUBSECTION>
<HEADING LEVEL="3">Overall quality of the body of evidence: 'Summary of findings' table</HEADING>
<P>We prepared 'Summary of findings' tables using GRADEpro (<LINK REF="REF-GRADEpro-GDT-2014" TYPE="REFERENCE">GRADEpro GDT 2014</LINK>) and Cochrane methods. These tables evaluated the overall quality of the body of evidence for the main review outcomes:</P>
<UL>
<LI>live birth or ongoing pregnancy;</LI>
<LI>pregnancy loss;</LI>
<LI>multiple pregnancy;</LI>
<LI>OHSS.</LI>
</UL>
<P>The tables evaluated the main review comparisons:</P>
<UL>
<LI>COCP compared to no pretreatment;</LI>
<LI>progestogen compared to no pretreatment;</LI>
<LI>oestrogen compared to no pretreatment.</LI>
</UL>
<P>We assessed the quality of the evidence using GRADE criteria: risk of bias, consistency of effect, imprecision, indirectness and publication bias). Two review authors (ROA, AL) independently made judgements about evidence quality (high, moderate, low or very low) and resolved disagreements by discussion. Judgements were justified, documented and incorporated into reporting of results for each outcome.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<P>After searching the electronic databases, we found 1792 studies: 609 studies in the GF specialized register of controlled trials, 166 studies in CENTRAL, 511 studies in MEDLINE, 463 studies in Embase, 19 studies in CINAHL and 24 studies in PsycINFO. After removing the duplicates and searching other resources, there were 1528 studies left. We retrieved 137 full-text articles of which 29 studies (42 references) were included and 87 studies (95 references) were excluded. For further details on included/excluded studies, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies </LINK>and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables. The process involved in the screening and selection of eligible studies for inclusion is shown in the PRISMA flow chart (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-08-09 08:45:15 +1200" MODIFIED_BY="[Empty name]">
<P>Nine of the included studies were identified from the searches carried out in 2015 and 2016 (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>). The remaining 20 studies were identified from the previous updates of the review.</P>
<P>The following is a summary of the methods, participants, interventions and outcomes of the included studies. Full details of these domains (for each study separately) are in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Methods</HEADING>
<P>We included 29 trials, with 4702 women randomized to treatment (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>; <LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>; <LINK REF="STD-Tan-2001" TYPE="STUDY">Tan 2001</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>). Two of the included studies were three-arm parallel RCTs (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>), one was a four-arm RCT (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>), and the remaining 26 studies were two-arm parallel RCTs.</P>
<P>The largest trials were <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK> (504 women), <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK> (472 women), <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK> (442 women), <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK> (351 women), <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK> (298 women), <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK> (228 women), <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK> (220 women) and <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK> (210 women). The remainder included fewer than 200 women. Only one study used a cross-over design and reported pre-cross-over data (<LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>). The remaining 28 trials used a parallel design. Four studies were conducted in multiple centres (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>).</P>
<P>The trials took place in (or authors came from): Argentina (<LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>); France (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-1996" TYPE="STUDY">Cédrin-Durnerin 1996</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>); UK (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>); Canada (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Tan-2001" TYPE="STUDY">Tan 2001</LINK>); UK and Canada (<LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>); USA (<LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>); USA and Europe (<LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>); Austria (<LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>); Belgium (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>); Brazil (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>); China (<LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>); Iran (<LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>); South Korea (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>); Taiwan (<LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>); Australia, Denmark, Jordan and Norway (<LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>); the Netherlands and Belgium (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>); Spain (<LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>); Poland (<LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>); Egypt, Iran, the Netherlands, Belgium, France and Austria (<LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>).</P>
<P>Of the 29 included studies, 13 performed and adhered to a power calculation (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>; <LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>). Seven studies did not adhere to a power calculation (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>), and in other studies this was unclear because there was only an abstract available or it was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Inclusion criteria</HEADING>
<P>Of the 29 studies, 25 RCTs included women with a regular IVF/ICSI indication while four RCTs included women who had special indications for IVF: one trial included women who were low responders (i.e. women who respond poorly to controlled ovarian hyperstimulation (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>)); one included women with limited ovarian reserve (<LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>); one included women with PCOS (<LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>); and another one included women with an ovarian cyst of over 5 mm in diameter or an endometrial thickness of over 5 mm and serum oestradiol concentration greater than 100 pmol/L after 14 days of GnRH agonist treatment (<LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>).</P>
<P>Twenty-one studies mentioned an age limit as an inclusion criteria. Eight studies only included women aged 38 years or less (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>). Nine studies only included women aged 39 years or less (<LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>). One study included women less than 40 years (<LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>). The other three studies used age limits above 40 years of age: one study used an upper limit of 41 years of age (<LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>), one study an upper limit of 42 years of age (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-1996" TYPE="STUDY">Cédrin-Durnerin 1996</LINK>), and one study used an upper limit of 44 years of age (<LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>). Six of these 21 studies defined lower limits of 18 years of age (<LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>).</P>
<P>Other common inclusion criteria were the presence of regular menstrual cycles (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>), and a body mass index (BMI) between 18 kg/m<SUP>2</SUP> and 25 kg/m<SUP>2</SUP> (<LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>), or less than 30 kg/m<SUP>2</SUP> (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Exclusion criteria</HEADING>
<P>Nine studies excluded women with an evidence of poor response. Two studies defined poor response as any previous ART cycles with less than three oocytes (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>), <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK> also excluded women if they had a history of three or more consecutive ART cycles without a clinical pregnancy. One study defined poor response as development of fewer than four follicles in previous IVF or ICSI cycles (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>). Three studies defined poor response as fewer than five oocytes in a previous IVF attempt or fewer than five follicles in a spontaneous cycle (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>), and one study defined poor response as more than three unsuccessful controlled ovarian stimulation cycles or a history of low or no ovarian response during FSH/hMG (<LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>). Two studies did not mention how they defined poor response to ovarian stimulation (<LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>).</P>
<P>Other common exclusion criteria were: a high baseline serum FSH level (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>), evidence of ovarian cysts or endometrioma (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>), and PCOS (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Three of the 29 studies had more than two study arms and were used in more than one comparison (four arms: <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; three arms: <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Combined oral contraceptive pill versus placebo or no pretreatment</HEADING>
<P>In 17 trials (with 19 comparisons), the study group received pretreatment with a COCP, while the control group received no pretreatment. None of these studies used a placebo in the control group. Ten trials used ethinyl oestradiol as the oestrogen component in a daily dose of 30 &#956;g (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>); seven trials used desogestrel 150 &#956;g daily (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>); three trials used levonorgestrel 150 &#956;g daily as the progestogen component (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>); one trial used Diane-35, which contained ethinyl oestradiol 35 &#956;g and cyproterone acetate 2 mg (<LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>); and two trials used a combination of ethinyl oestradiol 20 &#956;g and levonorgestrel 100 &#956;g (<LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>). For other studies, there were not enough data available on the type of COCP used.</P>
<P>The starting days of pretreatment in 10 of the trials varied from cycle day one to five. Five studies started COCP pretreatment on cycle day one (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>); two studies started the pretreatment on cycle day two or three (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>); one study started the pretreatment on a variable cycle day from one to five (<LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>); and one study started the pretreatment on cycle day five (<LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>). There were not enough data available from five trials on the start day of pretreatment (<LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>).</P>
<P>The duration of pretreatment in the 17 trials varied from 12 days to three consecutive cycles. Five studies used a fixed duration of 14 days of pretreatment (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>), or 21 days of pretreatment (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>); five studies used a variable duration of pretreatment of 12 to 16 days (<LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>), 14 to 21 days (<LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>), 14 to 25 days (<LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>), and 14 to 28 days (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>). Three other studies used a variable duration of around two or three weeks minimum to around four weeks maximum (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>, 15 to 21 days; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>, 18 to 28 days; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>, 21 to 28 days). <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK> used the longest pretreatment duration of three consecutive cycles.<BR/>
</P>
<P>Two studies used agonists in both treatment groups. One study used buserelin acetate (long protocol) (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>) and one used a depot of triptorelin acetate (<LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>).</P>
<P>Ten studies used antagonists in both treatment groups. Four studies used ganirelix acetate (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>); three studies used cetrorelix acetate (<LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>); one study used antide (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>); one study, a three-arm parallel RCT, used cerotide in two of the treatment arms and a GnRH agonist in the second control arm (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>), and one study did not mention which GnRH antagonist was used (<LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>).</P>
<P>Four trials used an antagonist in the study group and an agonist in the control group. Two trials used cetrorelix acetate as antagonist and buserelin acetate as agonist (<LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>), and one used ganirelix acetate as antagonist and nafarelin acetate as agonist (<LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>). The other study did not mention which antagonists and agonists were used (<LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Progestogen versus placebo or no pretreatment</HEADING>
<P>In seven trials, the study group was given a pretreatment with a progestogen, while the control group received placebo (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>), or no pretreatment (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>). Four studies used norethisterone 10 mg daily (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>), one study used medroxyprogesterone acetate 10 mg daily (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>), and one study used ethynodiol acetate 4 mg daily (<LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>). Another study used a single injection of 100 mg, but did not mention what type of progestogen they used (<LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>).</P>
<P>The starting days of pretreatment in all seven trials varied from cycle day one to 19. Two studies started the pretreatment with progestogen on cycle day one (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>), two studies on cycle day 15 (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>), one study on cycle day 16 or 17 (<LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>), and one study on cycle day 19 (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>). There were not enough data available from one study on the start day of pretreatment (<LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>).</P>
<P>The duration of progestogen pretreatment varied from one to 21 days. In one study, the women received one single injection (<LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>). One study used a duration of pretreatment of five days (<LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>), one study used seven days (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>), and one study used eight days (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>). Two trials used a variable duration of 10 to 15 days (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>), and one trial used 11 to 17 days (<LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>).</P>
<P>Six trials used an agonist in both treatment groups. Three studies used buserelin acetate (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>), one study used triptorelin (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-1996" TYPE="STUDY">Cédrin-Durnerin 1996</LINK>), one study used leuprolide acetate (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>), and one study used dTRP6-LHRH (<LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>).</P>
<P>One trial used an antagonist (ganirelix acetate) in both treatment groups (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>).</P>
<P>One trial did not use GnRH analogues for pituitary desensitisation. Women that participated in this study only received pure FSH and hMG (<LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Oestrogen versus placebo or no pretreatment</HEADING>
<P>In five trials, the study group was given a pretreatment with oestrogen, while the control group received no pretreatment. Three studies used 17&#946;-oestradiol (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>), and two studies used oestradiol valerate (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>). All these studies used 4 mg daily.</P>
<P>The starting days of pretreatment varied from cycle day 15 to 21. One study started the pretreatment on cycle day 20 (<LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>), and two on cycle day 21 (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>). One study started pretreatment seven days before the presumed onset of menses and administered up to the next Thursday after the occurrence of menstrual bleeding (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>). One remaining study started the pretreatment 10 days before the presumed menses (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>).</P>
<P>The duration of pretreatment varied from 10 to 17 days. In two studies the duration varied from 7 to 15 days (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>). Three studies used a fixed duration of pretreatment of 10 days (<LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>), 11 days (<LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>), and 14 days (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>).</P>
<P>Three trials used an antagonist in both treatment groups, one trial used ganirelix acetate (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>), one trial used cetrorelix acetate (<LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>), and one trial did not report the name of the antagonist (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>).</P>
<P>Two trials used an antagonist in the intervention group and an agonist in the control group, one trial used ganirelix acetate in the intervention group and nafarelin acetate in the control group (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>), and one study used cetrotide in the intervention group and triptoreline in the control group (<LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combined oral contraceptive pill versus progestogen</HEADING>
<P>There was only one study that compared COCP with progestogen (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>). The women in the COCP group received ethinyl oestradiol 30 &#956;g plus desogestrel 150 &#956;g daily and the women in the progestogen group received norethisterone 10 mg daily. This study started the COCP pretreatment on cycle day two or three with a duration of 15 to 21 days. The progestogen pretreatment was started on cycle day 15 with a duration of 10 to 15 days. Both groups received the GnRH antagonist, ganirelix acetate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combined oral contraceptive pill versus oestrogen</HEADING>
<P>Four trials compared a pretreatment of COCP with a pretreatment of oestrogen. One trial used ethinyl oestradiol 30 &#956;g plus desogestrel 150 &#956;g daily as a COCP and micronised 17&#946;-oestradiol 4 mg daily as oestrogen pretreatment (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>). The COCP pretreatment started on cycle day two or three with a duration of 15 to 21 days. The oestrogen pretreatment started 10 days before the presumed menses with a duration of 10 to 15 days and both groups received the GnRH antagonist, ganirelix acetate. Another study used ethinyl oestradiol 30 &#956;g plus levonorgestrel 150 &#956;g daily as a COCP and oestradiol valerate 4 mg daily as oestrogen pretreatment (<LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>). The COCP pretreatment started on cycle day one or two and continued for 12 to 16 days. The oestrogen pretreatment started from day 20 of menstrual cycle for five to 12 days until the day before starting stimulation and both groups received the GnRH antagonist, ganirelix acetate. One study used ethinyl oestradiol plus desogestrel as COCP starting from day two to four of the cycle but their doses were not reported (<LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>). In the control group, women were pretreated with oral oestradiol 2 mg twice daily from the day 20 of the natural cycle to day one to four of the new cycle. Both groups received the GnRH agonist, triptorelin. One study did not mention which COCP was used, but used ethinyl oestradiol 2 mg as an oestrogen pretreatment (<LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>). This study only described that the oestrogen pretreatment was administered in the luteal phase of the preparation cycle, but did not report the exact starting days and durations of pretreatment. The COCP group received the GnRH agonist, leuprolide acetate, and the oestrogen group received the GnRH antagonist, ganirelix acetate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Progestogen versus oestrogen</HEADING>
<P>There was only one study that compared progestogen with oestrogen (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>). The women in the progestogen group received norethisterone 10 mg daily and the women in the oestrogen group received micronised 17&#946;-oestradiol 4 mg daily. This study started the progestogen pretreatment on cycle day 15 with a duration of 10 to 15 days. The oestrogen pretreatment started 10 days before the presumed menses with also a duration of 10 to 15 days. Both groups received the GnRH antagonist, ganirelix acetate.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<P>Fifteen studies reported the number of live births or ongoing pregnancies (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>). Three studies defined ongoing pregnancy as a positive heart activity at a gestational age of 12 weeks (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>). One study used the same definition but did not mention when they performed the ultrasound scan (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>). Two studies defined ongoing pregnancy as a pregnancy developing beyond 12 weeks (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>), and one study defined ongoing pregnancy as a pregnancy assessed by ultrasound at 12 to 16 weeks or later (<LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>). The remaining studies did not mention how they assessed ongoing pregnancy (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>).</P>
<P>Ten studies reported the number of pregnancy losses. One study described this as the proportion of women with initially positive hCG in whom pregnancy failed to develop beyond 12 weeks of gestation (<LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>). The other nine studies did not describe a definition (<LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>Twenty-one studies reported the number of clinical pregnancies. Three studies defined clinical pregnancy as the presence of one or more foetal hearts confirmed with ultrasound, performed at least four weeks after embryo transfer (<LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK> or from six weeks after embryo transfer (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>). Two other studies used the same definition, but one of these also included the foetal sacs without heart activity (<LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>), and the other performed the ultrasound scan at seven weeks after embryo transfer (<LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>). One study defined clinical pregnancy as the presence of one or more intrauterine sacs confirmed with ultrasound, at a gestational age of six weeks (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>). In one study, we used a positive pregnancy test with evidence of a gestational sac to define clinical pregnancy, because no clinical or ongoing pregnancy rate was available (<LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>). One study defined clinical pregnancy as the evidence of a clinical gestational sac (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>). In the other 12 studies, it was unclear how they defined this outcome (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>; <LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>). If no clinical pregnancy rates were reported, we used the ongoing pregnancy rates (if available) for our analysis.</P>
<P>Ten studies reported the number of oocytes retrieved (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>). One study only mentioned the number of cumulus-oocyte complexes (<LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>), and two studies mentioned the number of mature oocytes or follicles (<LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>), but we assumed that this meant the same as the number of oocytes retrieved and, therefore, we pooled the data of these studies.</P>
<P>Thirteen studies reported the number of days of gonadotrophin treatment (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>).</P>
<P>Thirteen studies reported the amount of gonadotrophins administered (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>). Two studies reported the amount of gonadotrophins administered in the number of ampoules used, but we could not use these data in our analysis (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse outcomes</HEADING>
<P>Six studies reported the number of women with ovarian cysts. In one study, we used the number of functional ovarian cysts with a diameter of 10 mm or more, measured after one week of GnRH agonist treatment (<LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>). Three studies defined an ovarian cyst as an intraovarian sonolucent structure with a mean diameter of 14 mm or more, measured after seven days (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>) or eight days (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>) of pituitary suppression, or on a day not specified (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>). One study did not mention how they defined ovarian cyst formation and when they measured this (<LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>). One study only reported cyst formation as a reason for cycle cancellation, but it was unclear if there were more cysts formed that did not lead to cycle cancellation (<LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>). We did not use these data in our analysis.</P>
<P>Six studies reported the number of multiple pregnancies. One study defined multiple pregnancies as multiple clinical pregnancies (<LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>). One study described the number of ongoing or live born twin pregnancies (<LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>). Four studies did not describe when the number of multiple pregnancies was measured (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>).</P>
<P>Five studies reported the number of women with OHSS. Two study used the WHO classification criteria to diagnose OHSS and divided the women in categories of mild (grade I), moderate (grade II) or severe (grade III) (<LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>); the other three studies did not mention how they diagnosed OHSS (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>).</P>
<P>Six studies did not contribute data to the analyses: two of these studies reported 'per cycle' data and the numbers of cycles were not equivalent to the numbers of participants (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>); outcomes reported included clinical pregnancy rate, number of days of GnRH agonist and number of oocytes retrieved. One study reported outcome data in denominators other than 'per woman' such as 'per cycle', 'per embryo transfer' (<LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>), outcomes reported included clinical pregnancy, number of oocyte retrieved, multiple pregnancy, duration of stimulation days. Three studies had no available outcome data relevant to the review (<LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>; <LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>; <LINK REF="STD-Tan-2001" TYPE="STUDY">Tan 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-08-09 08:45:27 +1200" MODIFIED_BY="[Empty name]">
<P>A total of 86 studies that described pretreatments with COCPs, progestogens or oestrogens were not eligible for inclusion for various reasons. Some of these studies had multiple reasons for exclusion, but we reported the most important reason. Full details of reasons for exclusion can be found in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<UL>
<LI>Twenty studies did not randomise their participants using standardized randomization procedures such as a computer or a random number table (<LINK REF="STD-Benadiva-1988" TYPE="STUDY">Benadiva 1988</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-1995" TYPE="STUDY">Cédrin-rDurnerin 1995</LINK>; <LINK REF="STD-Cohen-1987" TYPE="STUDY">Cohen 1987</LINK>; <LINK REF="STD-Copperman-2003" TYPE="STUDY">Copperman 2003</LINK>; <LINK REF="STD-Couzinet-1995" TYPE="STUDY">Couzinet 1995</LINK>; <LINK REF="STD-Ditkoff-1997" TYPE="STUDY">Ditkoff 1997</LINK>; <LINK REF="STD-Forman-1991" TYPE="STUDY">Forman 1991</LINK>; <LINK REF="STD-Frydman-1986" TYPE="STUDY">Frydman 1986</LINK>; <LINK REF="STD-Galera-2004" TYPE="STUDY">Galera 2004</LINK>; <LINK REF="STD-Godin-2003" TYPE="STUDY">Godin 2003</LINK>; <LINK REF="STD-Gonen-1990" TYPE="STUDY">Gonen 1990</LINK>; <LINK REF="STD-Lindheim-1996" TYPE="STUDY">Lindheim 1996</LINK>; <LINK REF="STD-Neal-1993" TYPE="STUDY">Neal 1993</LINK>; <LINK REF="STD-Palomba-2008" TYPE="STUDY">Palomba 2008</LINK>; <LINK REF="STD-Schoolcraft-1997" TYPE="STUDY">Schoolcraft 1997</LINK>; <LINK REF="STD-Surrey-1989" TYPE="STUDY">Surrey 1989</LINK>; <LINK REF="STD-Tarlatzis-1993" TYPE="STUDY">Tarlatzis 1993</LINK>; <LINK REF="STD-Wang-2016" TYPE="STUDY">Wang 2016</LINK>; <LINK REF="STD-Weisman-1989" TYPE="STUDY">Weisman 1989</LINK>; <LINK REF="STD-Yokota-2006" TYPE="STUDY">Yokota 2006</LINK>).</LI>
<LI>Twenty-four studies used a retrospective design (<LINK REF="STD-al_x002d_Mizyen-2000" TYPE="STUDY">al-Mizyen 2000</LINK>; <LINK REF="STD-Bellver-2007" TYPE="STUDY">Bellver 2007</LINK>; <LINK REF="STD-Bendikson-2006" TYPE="STUDY">Bendikson 2006</LINK>; <LINK REF="STD-Biljan-1998c" TYPE="STUDY">Biljan 1998c</LINK>; <LINK REF="STD-Chung-2006" TYPE="STUDY">Chung 2006</LINK>; <LINK REF="STD-Damario-1997" TYPE="STUDY">Damario 1997</LINK>; <LINK REF="STD-Dickey-2001" TYPE="STUDY">Dickey 2001</LINK>; <LINK REF="STD-Duvan-2008" TYPE="STUDY">Duvan 2008</LINK>; <LINK REF="STD-Frederick-2004" TYPE="STUDY">Frederick 2004</LINK>; <LINK REF="STD-Gonzalez-1995" TYPE="STUDY">Gonzalez 1995</LINK>; <LINK REF="STD-Keltz-2007" TYPE="STUDY">Keltz 2007</LINK>; <LINK REF="STD-Kovacs-2001" TYPE="STUDY">Kovacs 2001</LINK>; <LINK REF="STD-Leondires-1999" TYPE="STUDY">Leondires 1999</LINK>; <LINK REF="STD-Loutradis-2003" TYPE="STUDY">Loutradis 2003</LINK>; <LINK REF="STD-Min-2005" TYPE="STUDY">Min 2005</LINK>; <LINK REF="STD-Mirkin-2003" TYPE="STUDY">Mirkin 2003</LINK>; <LINK REF="STD-Pados-1995" TYPE="STUDY">Pados 1995</LINK>; <LINK REF="STD-Pinkas-2008" TYPE="STUDY">Pinkas 2008</LINK>; <LINK REF="STD-Ramsewak-2005" TYPE="STUDY">Ramsewak 2005</LINK>; <LINK REF="STD-Talebian-2004" TYPE="STUDY">Talebian 2004</LINK>; <LINK REF="STD-Talebian-2007" TYPE="STUDY">Talebian 2007</LINK>; <LINK REF="STD-Wei-2016" TYPE="STUDY">Wei 2016</LINK>; <LINK REF="STD-Yoshida-2005" TYPE="STUDY">Yoshida 2005</LINK>; <LINK REF="STD-Zhao-2008" TYPE="STUDY">Zhao 2008</LINK>).</LI>
<LI>In five studies, participants served as their own controls in previous cycles (<LINK REF="STD-Branigan-1998" TYPE="STUDY">Branigan 1998</LINK>; <LINK REF="STD-Fanchin-2003b" TYPE="STUDY">Fanchin 2003b</LINK>; <LINK REF="STD-Fisch-1996" TYPE="STUDY">Fisch 1996</LINK>; <LINK REF="STD-Mulangi-1997" TYPE="STUDY">Mulangi 1997</LINK>; <LINK REF="STD-Surrey-1998" TYPE="STUDY">Surrey 1998</LINK>).</LI>
<LI>There was insufficient information in five studies to determine their true randomization status (<LINK REF="STD-Aghahosseini-2011" TYPE="STUDY">Aghahosseini 2011</LINK>; <LINK REF="STD-Bakas-2014" TYPE="STUDY">Bakas 2014</LINK>; <LINK REF="STD-Davar-2014" TYPE="STUDY">Davar 2014</LINK>; <LINK REF="STD-Engels-2011" TYPE="STUDY">Engels 2011</LINK>; <LINK REF="STD-Merviel-2015" TYPE="STUDY">Merviel 2015</LINK>).</LI>
<LI>Three studies used a cross-over design and there were no available pre-cross-over data (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-1996" TYPE="STUDY">Cédrin-Durnerin 1996</LINK>; <LINK REF="STD-Fanchin-2001" TYPE="STUDY">Fanchin 2001</LINK>; <LINK REF="STD-Wang-2008" TYPE="STUDY">Wang 2008</LINK>).</LI>
<LI>Eight studies used a single-arm design (<LINK REF="STD-Brodt-1993" TYPE="STUDY">Brodt 1993</LINK>; <LINK REF="STD-De-Ziegler-1999" TYPE="STUDY">De Ziegler 1999</LINK>; <LINK REF="STD-Gerli-1989" TYPE="STUDY">Gerli 1989</LINK>; <LINK REF="STD-Hugues-1992" TYPE="STUDY">Hugues 1992</LINK>; <LINK REF="STD-Meldrum-2002" TYPE="STUDY">Meldrum 2002</LINK>; <LINK REF="STD-Meldrum-2008" TYPE="STUDY">Meldrum 2008</LINK>; <LINK REF="STD-Sanghvi-2002" TYPE="STUDY">Sanghvi 2002</LINK>; <LINK REF="STD-Tehraninejad-2010" TYPE="STUDY">Tehraninejad 2010</LINK>).</LI>
<LI>Nine studies compared two (or more) different dosages, timings or ways of administration of the same pretreatment (<LINK REF="STD-Davy-2004" TYPE="STUDY">Davy 2004</LINK>; <LINK REF="STD-Gomez-2000" TYPE="STUDY">Gomez 2000</LINK>; <LINK REF="STD-Haydardedeoglu-2012" TYPE="STUDY">Haydardedeoglu 2012</LINK>; <LINK REF="STD-Karande-2004" TYPE="STUDY">Karande 2004</LINK>; <LINK REF="STD-Kreiner-2007" TYPE="STUDY">Kreiner 2007</LINK>; <LINK REF="STD-Lewin-2002" TYPE="STUDY">Lewin 2002</LINK>; <LINK REF="STD-Liu-2011" TYPE="STUDY">Liu 2011</LINK>; <LINK REF="STD-Mashiach-1989" TYPE="STUDY">Mashiach 1989</LINK>; <LINK REF="STD-Russell-1997" TYPE="STUDY">Russell 1997</LINK>).</LI>
<LI>Two studies used interventions that were administered for luteal phase support and not for pretreatment (<LINK REF="STD-Ghanem-2015" TYPE="STUDY">Ghanem 2015</LINK>; <LINK REF="STD-Rashidi-2011" TYPE="STUDY">Rashidi 2011</LINK>).</LI>
<LI>In three studies, women only received ovarian stimulation, but no embryo transfer was performed as part of an ART cycle (<LINK REF="STD-Anderson-1990" TYPE="STUDY">Anderson 1990</LINK>; <LINK REF="STD-Letterie-2000" TYPE="STUDY">Letterie 2000</LINK>; <LINK REF="STD-Steinkampf-1991" TYPE="STUDY">Steinkampf 1991</LINK>).</LI>
<LI>In two studies, the women were oocyte donors (<LINK REF="STD-Doody-2001" TYPE="STUDY">Doody 2001</LINK>; <LINK REF="STD-Martinez-2006" TYPE="STUDY">Martinez 2006</LINK>).</LI>
<LI>In one study, the women had premature ovarian failure (<LINK REF="STD-Tartagni-2007" TYPE="STUDY">Tartagni 2007</LINK>).</LI>
<LI>In two studies, pretreatment was not stopped before oocyte retrieval, but continued to be used as luteal phase support (<LINK REF="STD-Greco-2016" TYPE="STUDY">Greco 2016</LINK>; <LINK REF="STD-Jung-2000" TYPE="STUDY">Jung 2000</LINK>).</LI>
<LI>In one study, the main comparison was mild versus standard stimulation (with pretreatment in one group) (<LINK REF="STD-Youssef-2017" TYPE="STUDY">Youssef 2017</LINK>).</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-08-09 08:45:28 +1200" MODIFIED_BY="[Empty name]">
<P>A complete overview of classification of risk of bias domains can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2017-08-09 08:45:28 +1200" MODIFIED_BY="[Empty name]">
<P>Eighteen studies were at low risk of random sequence generation: 13 of these studies used computer generated random numbers to randomise the women (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>), four studies used a table of random numbers (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>), and one study accomplished the randomization by tossing a coin (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>). In the remaining 11 studies, there was insufficient information on the methods used in random sequence generation; they were thus rated at unclear risk of bias with respect to random sequence generation.</P>
<P>If randomization is not done correctly, there might be a difference in baseline characteristics between the women in the treatment groups. This may influence the outcomes measured in the trial. Therefore, it is important that the method of randomization is reported. Due to the high number of included studies that did not report the method of randomization (15/33 studies), there might be a higher risk of bias.</P>
<P>Fourteen studies were at low risk of allocation concealment: eight studies used sealed envelopes to conceal the allocation (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>); in five studies the allocation was done by a third party (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>, hospital pharmacy and numbered bottles; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>, clinic nurses and sealed envelopes; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>, independent person; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>, independent person from independent monitoring company; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>, central remote allocation); one study centralised the randomization process (<LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>).</P>
<P>Two studies were classified at high risk of allocation concealment, because they reported that the sequence of allocation was not concealed (<LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>). In the remaining 14 studies, there was insufficient information to make a conclusive judgement with respect to allocation concealment and these were rated at unclear risk of bias in this domain.</P>
<P>Most of the outcomes of this review were objectively assessed; thus a poorly designed allocation concealment method is not likely to have a big influence on these outcomes. For example, the number of live births is not likely to be influenced by the clinician if he or she knows which treatment the woman receives. However, some outcomes, such as OHSS, are diagnosed on clinical symptoms and so there might be a more important risk of bias when the clinician was aware of the treatment assigned to each woman. Nevertheless, outcomes that are objectively assessed may be influenced indirectly if allocation is not concealed.</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-05-22 15:48:22 +1200" MODIFIED_BY="Helen E Nagels">
<P>One study was at low risk of blinding because it was described as double blind and placebo controlled (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>).</P>
<P>In 20 studies, there was insufficient information with respect to blinding of clinicians, participants and outcome assessors; these studies were assessed at unclear risk with regard to blinding (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>; <LINK REF="STD-Tan-2001" TYPE="STUDY">Tan 2001</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>).</P>
<P>The remaining eight studies were at high risk of bias because they were described as either open label or not blinded with personnel and participants having knowledge of the treatment allocation.</P>
<P>Poor blinding is less likely to influence the objective outcomes such as live birth, but it might have a bigger influence on the diagnosis of OHSS.<BR/>
</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-08-09 08:45:28 +1200" MODIFIED_BY="[Empty name]">
<P>Of the 29 studies, 13 were at low risk of attrition bias (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>). In these trials, the proportions of, and reasons for, withdrawals were balanced between the treatment groups or data were analyzed using an ITT basis where all women randomized at baseline were included in the analysis.</P>
<P>In 10 studies, there were insufficient information with respect to the proportions of, and reasons for, withdrawals or losses to follow-up and data were not analyzed on an ITT basis; these studies were rated at unclear risk of attrition bias (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hugues-1994" TYPE="STUDY">Hugues 1994</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>; <LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>; <LINK REF="STD-Tan-2001" TYPE="STUDY">Tan 2001</LINK>).</P>
<P>The remaining six studies were at high risk of attrition bias because the proportions of, and reasons for, withdrawals were not balanced between the treatment groups and data were not analyzed by ITT.</P>
<P>Incomplete outcome data can bias the results of our review, especially with regard to adverse outcomes. For example, a study might have withdrawals due to OHSS that they do not report. Also imbalances in reasons for withdrawal can occur because of differences in interventions between the study group and control group. For example, when there are more withdrawals due to OHSS in the control group, this can be in favour of the intervention used in the study group. The risk of bias might increase if authors do not report this.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-05-22 15:49:32 +1200" MODIFIED_BY="Helen E Nagels">
<P>We were unable to retrieve the protocol of any of the included studies to examine whether all prespecified outcomes were reported. However, we examined the Methods sections of the studies to determine whether outcomes planed in the Methods section were eventually reported. In this regard, we classified 16 studies at low risk of selective reporting because these trials reported data on all the outcomes mentioned in the 'Methods' section of their publication (<LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Porrati-2010" TYPE="STUDY">Porrati 2010</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>). In two studies, there was insufficient information in the 'Methods' sections to make a conclusive judgement with respect to selective reporting of outcomes; therefore, they were rated at unclear risk of reporting bias (<LINK REF="STD-Raoofi-2008" TYPE="STUDY">Raoofi 2008</LINK>; <LINK REF="STD-Vilela-2011" TYPE="STUDY">Vilela 2011</LINK>). In the remaining 11 studies, there was evidence of selective reporting as data were not reported on all the outcomes pre-specified in the protocol or Methods section.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-05-22 15:49:40 +1200" MODIFIED_BY="Helen E Nagels">
<P>For other potential sources of bias, we examined the baseline demographic characteristics of participants, such as age and BMI, to determine whether there was substantial imbalance in baseline demographic characteristics between the treatment groups. In this regard, 22 studies were at low risk of bias in this domain because of the absence of substantial imbalance between in baseline demographic characteristics between the treatment groups (<LINK REF="STD-Aston-1995" TYPE="STUDY">Aston 1995</LINK>; <LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>; <LINK REF="STD-Blockeel-2012" TYPE="STUDY">Blockeel 2012</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Fanchin-2003" TYPE="STUDY">Fanchin 2003</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Lukaszuk-2015" TYPE="STUDY">Lukaszuk 2015</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>; <LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>).</P>
<P>The remaining seven studies were rated as being at unclear risk due to insufficient information to make a conclusive judgement with respect to baseline demographic characteristics in the treatment groups.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-08-09 08:45:30 +1200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Combined oral contraceptive pill versus no pretreatment</HEADING>
<P>Eight studies compared COCP versus no pretreatment (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Garcia_x002d_Velasco-2011" TYPE="STUDY">Garcia-Velasco 2011</LINK>; <LINK REF="STD-Huirne-2006c" TYPE="STUDY">Huirne 2006c</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Nyboe-Andersen-2011" TYPE="STUDY">Nyboe Andersen 2011</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.1. Live birth or ongoing pregnancy</HEADING>
<P>See <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>There was a lower rate of live birth or ongoing pregnancy in women pretreated with COCP compared with no pretreatment (OR 0.74, 95% CI 0.58 to 0.95; 6 RCTs; 1335 women; I<SUP>2</SUP> = 0%; moderate quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following no pretreatment was assumed to be 27%, the chance following pretreatment with COCP would be between 18% and 26%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2. Combined oral contraceptive pill plus antagonist versus agonist</HEADING>
<P>There was no clear evidence of a difference between the two treatment groups in live birth or ongoing pregnancy rates (OR 0.89, 95% CI 0.64 to 1.25; 4 RCTs; 724 women; I<SUP>2</SUP> = 0%; moderate quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following no pretreatment was assumed to be 24%, the chance following pretreatment with COCP would be between 16% and 26%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</HEADING>
<P>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 1.71, 95% CI 0.61 to 4.79; 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</HEADING>
<P>Among women with low response, there was insufficient evidence to determine whether there was a difference between the two treatment groups in live birth or ongoing pregnancy rates (OR 1.13, 95% CI 0.43 to 2.98; 1 RCT; 80 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2. Pregnancy loss</HEADING>
<P>See <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> and <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>There was no clear evidence of a difference between the groups in rates of pregnancy loss (OR 1.36, 95% CI 0.82 to 2.26; 5 RCTs; 868 women; I<SUP>2</SUP> = 0%; moderate quality evidence). The evidence suggested that if the risk of a pregnancy loss following no pretreatment was assumed to be 6%, the risk following pretreatment with COCP would be between 5% and 13%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2. Combined oral contraceptive pill plus antagonist versus agonist</HEADING>
<P>There were fewer pregnancy losses recorded in women who had COCP pretreatment than in those who had no pretreatment (OR 0.40, 95% CI 0.22 to 0.72; 5 RCTs; 780 women; I<SUP>2</SUP> = 18%; moderate quality evidence). The evidence suggested that if the risk of a pregnancy loss following no pretreatment was assumed to be 10%, the risk following pretreatment with COCP would be between 3% and 8%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</HEADING>
<P>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 2.05, 95% CI 0.18 to 23.59; 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</HEADING>
<P>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 1.00, 95% CI 0.13 to 7.47; 1 RCT; 80 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3. Clinical pregnancy rate</HEADING>
<P>See <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>There was no clear evidence of a difference between the two treatment groups in clinical pregnancy rates (OR 0.85, 95% CI 0.63 to 1.15; 5 RCTs; 740 women; I<SUP>2</SUP> = 76%). The presence of substantial heterogeneity was explored in sensitivity analysis and there was no change in the evidence using a random-effects model (OR 0.86, 95% CI 0.39 to 1.91) or risk ratio (RR) (RR 0.90, 95% CI 0.73 to 1.11).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.2. Combined oral contraceptive pill plus antagonist versus agonist</HEADING>
<P>There was no clear evidence of a difference between the two treatment groups in clinical pregnancy rates (OR 0.84, 95% CI 0.59 to 1.20; 4 RCTs; 546 women; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</HEADING>
<P>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in rates of clinical pregnancy (OR 1.85, 95% CI 0.69 to 4.97; 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</HEADING>
<P>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in rates of clinical pregnancy (OR 1.12, 95% CI 0.44 to 2.83); 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.5. Combined oral contraceptive pill plus agonist versus agonist</HEADING>
<P>Two studies reported this comparison, but neither reported data suitable for analysis. One (<LINK REF="STD-Biljan-1998b" TYPE="STUDY">Biljan 1998b</LINK>) reported per-cycle data and found no evidence of a difference between the groups. A second study reported a pregnancy rate of 9% in the study group and 11% in the control group, but did not report the number of women per group (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1310230121512767760158845370374&amp;format=REVMAN#STD-Raoofi-2008">Raoofi 2008</A>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4. Multiple pregnancy rate</HEADING>
<P>See <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.4.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 2.21, 95% CI 0.53 to 9.26; 2 RCTs; 125 women; I<SUP>2</SUP> = 0%; low quality evidence). The evidence suggested that if the risk of multiple pregnancy following no pretreatment was assumed to be 5%, the risk following pretreatment with COCP would be between 3% and 31%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.2. Combined oral contraceptive pill plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 1.36, 95% CI 0.85 to 2.19; 4 RCTs; 546 women; I<SUP>2</SUP> = 0%; moderate quality evidence). The evidence suggested that if the risk of multiple pregnancy following no pretreatment was assumed to be 5%, the risk following pretreatment with COCP would be between 4% and 10%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</HEADING>
<P>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rate (OR 2.11, 95% CI 0.36 to 12.24; 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</HEADING>
<P>Among women with low response, there was insufficient evidence to determine whether there was a difference between the groups in the multiple pregnancy rate (OR 1.37, 95% CI 0.29 to 6.56; 1 RCT; 80 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5. Ovarian hyperstimulation syndrome rate</HEADING>
<P>See <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.5.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in OHSS rates (OR 0.98, 95% CI 0.28 to 3.40; 2 RCTs; 642 women; I<SUP>2</SUP> = 0%, low quality evidence).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.2. Combined oral contraceptive pill plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in OHSS rates (OR 0.63, 95% CI 0.20 to 1.96; 2 RCTs; 290 women; I<SUP>2 </SUP>= 0%, low quality evidence).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6. Number of oocytes retrieved</HEADING>
<P>See <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.6.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>There was no clear evidence of a difference between the groups in the mean number of oocytes retrieved (MD 0.44, 95% CI -0.11 to 0.99; 6 RCTs; 1077 women; I<SUP>2</SUP> = 59%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.2. Combined oral contraceptive pill plus antagonist versus agonist</HEADING>
<P>There was no clear evidence of a difference between the two treatment groups in the mean number of oocytes retrieved (MD 0.07, 95% CI -0.67 to 0.81; 4 RCTs; 552 women; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</HEADING>
<P>Among women with low response, there was no clear evidence of a difference between the groups in the mean number of oocytes retrieved (MD 0.70, 95% CI -0.11 to 1.51; 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</HEADING>
<P>Among women with low response, there was no evidence of a difference between the groups in the number of oocytes retrieved (MD 0.10, 95% CI -0.75 to 0.95; 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.5. Combined oral contraceptive pill plus agonist versus agonist</HEADING>
<P>Two studies looked at the number of oocytes retrieved, but the data were unsuitable for analysis. The first study reported a median of 11 oocytes retrieved (range seven to 19) in the study group (51 cycles) and a median of 10 oocytes retrieved (range seven to 15) in the control group (51 cycles) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876&amp;format=REVMAN#STD-Biljan-1998a">Biljan 1998a</A>). The second study reported a mean number of oocytes retrieved of approximately 5 (± 3) in the study group and 5 (± 6) in the control group, but did not report the number of women or cycles in each treatment group (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876&amp;format=REVMAN#STD-Raoofi-2008">Raoofi 2008)</A>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7. Days of gonadotrophin treatment</HEADING>
<P>See <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.7.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>Six RCTs reported days of gonadotrophin treatment but data were unsuitable for pooling due to extreme statistical heterogeneity (I<SUP>2</SUP> = 95%) with differing directions of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.2. Combined oral contraceptive pill plus antagonist versus agonist</HEADING>
<P>Four RCTs reported days of gonadotrophin treatment but data were unsuitable for pooling due to extreme statistical heterogeneity (I<SUP>2</SUP> = 95%) with differing directions of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</HEADING>
<P>Among women with low response, there was no evidence of a difference between the groups in the mean days of gonadotrophin treatment (MD 0.10 days, 95% CI -0.47 to 0.67; 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</HEADING>
<P>Among women with low response, the mean number of days of gonadotrophin treatment was lower in women who had COCP treatment than in women who received no COCP pretreatment (MD -1.40 days, 95% CI -2.02 to -0.78; 1 RCT; n = 80).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.5. Combined oral contraceptive pill plus agonist versus agonist</HEADING>
<P>Only one study reported on the number of days of gonadotrophin treatment (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876&amp;format=REVMAN#STD-Biljan-1998a">Biljan 1998a</A>). This study found a median of 10 days (range nine to 11) in the study group (51 cycles) and a median of 12 days (range 11 to 12) in the control group (51 cycles). The data were unsuitable for analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8. Amount of gonadotrophins administered</HEADING>
<P>See <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.8.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>More gonadotrophins were administered to the group who received pretreatment with a COCP than in the group who did not (MD 190.10 IU/L, 95% CI 134.91 to 245.28; 7 RCTs; 1275 women; I<SUP>2</SUP> = 88%). Sensitivity analysis using a random-effects model did not change the statistical significance of this finding (MD 306.84 IU/L, 95% CI 112.13 to 501.56).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.2. Combined oral contraceptive pill plus antagonist versus agonist</HEADING>
<P>Three RCTs reported the amount of gonadotrophins but data were unsuitable for pooling due to extreme statistical heterogeneity (I<SUP>2</SUP> = 94%) with differing directions of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.3. Combined oral contraceptive pill plus antagonist versus antagonist, low response</HEADING>
<P>Among women with low response, there was no clear evidence of a difference between the two treatment groups in the mean amount of gonadotrophin administered (MD 20.00 IU/L, 95% CI -165.39 to 205.39; 1 RCT; 80 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.4. Combined oral contraceptive pill plus antagonist versus agonist, low response</HEADING>
<P>Among women with low response, the mean amount of gonadotrophin administered in the COCP group was lower than in the group who were not pretreated (MD -349.00, 95% CI -537.92 to -160.08; 1 RCT; 80 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.9. Ovarian cyst formation rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.9.1. Combined oral contraceptive pill plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the number of women with ovarian cyst formation (OR 0.47, 95% CI 0.08 to 2.75; 1 RCT; 64 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9.2. Combined oral contraceptive pill plus agonist versus agonist</HEADING>
<P>Two studies reported on cyst formation, but the data were unsuitable for analysis. The first study found that there was no cyst formation in the intervention group (51 cycles) and cysts in 27 women in the control group (51 cycles) (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876&amp;format=REVMAN#STD-Biljan-1998a">Biljan 1998a</A>). This result was statistically significant according to the authors (OR 0.07, 95% CI 0.03 to 0.16; P &lt; 0.0001). <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1508111100480486471830377071876&amp;format=REVMAN#STD-Raoofi-2008">Raoofi 2008</A> reported no women with cyst formation in either group.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Progestogen versus placebo or no pretreatment</HEADING>
<P>Four studies compared progestogen versus placebo or no treatment (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Ditkoff-1996" TYPE="STUDY">Ditkoff 1996</LINK>; <LINK REF="STD-Engmann-1999" TYPE="STUDY">Engmann 1999</LINK>; <LINK REF="STD-Salat_x002d_Baroux-1988" TYPE="STUDY">Salat-Baroux 1988</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.1. Live birth or ongoing pregnancy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1.1. Progestogen plus agonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 1.35, 95% CI 0.69 to 2.65; 2 RCTs; 222 women; I<SUP>2</SUP> = 24%; low quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following placebo or no pretreatment was assumed to be 17%, the chance following pretreatment with progestogen would be between 12% and 35%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.2. Progestogen plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.67, 95% CI 0.18 to 2.54; 1 RCT; 47 women; low quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following placebo or no pretreatment was assumed to be 25%, the chance following pretreatment with progestogen would be between 3% and 76%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.3. Progestogen plus gonadotrophins versus gonadotrophins</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.63, 95% CI 0.09 to 4.23; 1 RCT; 42 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2. Pregnancy loss</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2.1. Progestogen plus agonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 2.26, 95% CI 0.67 to 7.55; 2 RCTs; 222 women; I<SUP>2</SUP> = 0%; low quality evidence). The evidence suggested that if the risk of a pregnancy loss following placebo or no pretreatment was assumed to be 4%, the risk following pretreatment with progestogen would be between 2% and 22%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.2. Progestogen plus antagonist versus antagonist</HEADING>
<P>The only study in this subgroup did not report on the number of pregnancy losses (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>), but we calculated this number by subtracting the number of live births from the number of clinical pregnancies. There was no evidence of a difference in rates of pregnancy losses between the two treatment groups (OR 0.36, 95% CI 0.06 to 2.09; 1 RCT; 47 women; low quality evidence). The evidence suggested that if the risk of a pregnancy loss following placebo or no pretreatment was assumed to be 25%, the risk following pretreatment with progestogen would be between 1% and 67%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.3. Progestogen plus gonadotrophins versus gonadotrophins</HEADING>
<P>The only trial in this subgroup found one pregnancy loss in each treatment group. Thus, there was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 1.00, 95% CI 0.06 to 17.12; 1 RCT; 42 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3. Clinical pregnancy rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3.1. Progestogen plus agonist versus agonist</HEADING>
<P>We pooled results of three studies. In one of these studies, we used the number of positive pregnancy tests, because there were no data on clinical pregnancy rate. There was evidence of a difference in clinical pregnancy rates between the two treatment groups, with more clinical pregnancies obtained in the group pretreated with a progestogen (OR 1.99, 95% CI 1.20 to 3.28; 3 RCTs; 374 women; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.2. Progestogen plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.52, 95% CI 0.16 to 1.71; 1 RCT; 47 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3.3. Progestogen plus gonadotrophins versus gonadotrophins</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.71, 95% CI 0.14 to 3.64; 1 RCT; 42 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4. Multiple pregnancy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.4.1. Progestogen plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 1.05, 95% CI 0.06 to 17.76; 1 RCT; 47 women; low quality evidence).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5. Ovarian hyperstimulation syndrome rate</HEADING>
<P>None of the studies reported on the number of women with OHSS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6. Number of oocytes retrieved</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.6.1. Progestogen plus agonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD -0.52, 95% CI -2.07 to 1.02; 2 RCTs; 222 women; I<SUP>2</SUP> = 15%). There was one other study that reported the mean number of oocytes retrieved, but because this was analyzed per cycle (instead of per woman randomized), we were unable to include the data (<LINK REF="STD-Shaker-1995" TYPE="STUDY">Shaker 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.2. Progestogen plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD 2.70, 95% CI -0.98 to 6.38; 1 RCT; 47 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.3. Progestogen plus gonadotrophins versus gonadotrophins</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD 0.00, 95% CI -0.57 to 0.57; 1 RCT; 29 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7. Days of gonadotrophin treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.7.1. Progestogen plus agonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean days of gonadotrophin treatment (MD 0.11 days, 95% CI -0.30 to 0.52; 2 RCTs; 222 women; I<SUP>2</SUP> = 88%). The presence of substantial heterogeneity was explored in sensitivity analysis using a random-effects model and there was no substantial change in the evidence (MD 0.10, 95% CI -1.07 to 1.28).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8. Amount of gonadotrophins administered</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.8.1. Progestogen plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the amount of gonadotrophin administered (MD 276.00 IU/L, 95% CI -75.53 to 627.53; 1 RCT; 47 women).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.9. Ovarian cyst formation rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.9.1. Progestogen plus agonist versus agonist</HEADING>
<P>Fewer women had ovarian cyst formation in the group pretreated with a progestogen compared with those who had no progestogen pretreatment (OR 0.16, 95% CI 0.08 to 0.32; 3 RCTs; 374 women; I<SUP>2</SUP> = 1%).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Oestrogen versus no pretreatment</HEADING>
<P>Four studies compared oestrogen versus no pretreatment (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2012" TYPE="STUDY">Cédrin-Durnerin 2012</LINK>; <LINK REF="STD-Franco-Jr-2003" TYPE="STUDY">Franco Jr 2003</LINK>; <LINK REF="STD-Ye-2009" TYPE="STUDY">Ye 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.1. Live birth or ongoing pregnancy</HEADING>
<P>See <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">3.1.1. Oestrogen plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.79, 95% CI 0.53 to 1.17; 2 RCTs; 502 women; I<SUP>2</SUP> = 29%; low quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following no pretreatment was assumed to be 30%, the chance following pretreatment with oestrogen would be between 19% and 35%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.1.2. Oestrogen plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.88, 95% CI 0.51 to 1.50; 2 RCTs; 242 women; I<SUP>2</SUP> = 0%; very low quality evidence). The evidence suggested that if the chance of a live birth or ongoing pregnancy following no pretreatment was assumed to be 35%, the chance following pretreatment with progestogen would be between 22% and 45%.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2. Pregnancy loss</HEADING>
<P>See <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK> and <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">3.2.1. Oestrogen plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 0.16, 95% CI 0.02 to 1.47; 1 RCT; 49 women; very low quality evidence). The evidence suggested that if the risk of a pregnancy loss following no pretreatment was assumed to be 13%, the risk following pretreatment with oestrogen would be between 1% and 71%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.2. Oestrogen plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy losses (OR 1.59, 95% CI 0.62 to 4.06; 1 RCT; 220 women; very low quality evidence). The evidence suggested that if the risk of a pregnancy loss following no pretreatment was assumed to be 7%, the risk following pretreatment with oestrogen would be between 5% and 24%.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3. Clinical pregnancy rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3.1. Oestrogen plus antagonist versus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.91, 95% CI 0.66 to 1.24; 4 RCTs; 688 women; I<SUP>2</SUP> = 50%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3.2. Oestrogen plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.76, 95% CI 0.45 to 1.27; 2 RCTs; 242 women; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4. Multiple pregnancy rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.4.1. Oestrogen plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 2.24, 95% CI 0.09 to 53.59; 1 RCT; 22 women; very low quality evidence).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5. Ovarian hyperstimulation syndrome rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.5.1. Oestrogen plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in OHSS rates (OR 1.54, 95% CI 0.25 to 9.42; 1 RCT; 220 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6. Number of oocytes retrieved</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.6.1. Oestrogen plus antagonist versus antagonist</HEADING>
<P>More oocytes were retrieved in the group pretreated with oestrogen than in the no pretreatment group (MD 2.23, 95% CI 0.71 to 3.75; 2 RCTs; 139 women; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6.2. Oestrogen plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the number of oocytes retrieved (MD 0.40, 95% CI -4.47 to 5.27; 1 RCT; 22 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7. Days of gonadotrophin treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.7.1. Oestrogen plus antagonist versus antagonist</HEADING>
<P>Women who were pretreated with oestrogen had more days of gonadotrophin treatment compared to those who did not receive pretreatment (MD 0.83 days, 95% CI 0.58 to 1.08; 2 RCTs; 529 women; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7.2. Oestrogen plus antagonist versus agonist</HEADING>
<P>Women pretreated with oestrogen had fewer days of gonadotrophin treatment than those who did not receive oestrogen pretreatment (MD -2.50 days, 95% CI -4.07 to -0.93; 1 RCT; 22 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.8. Amount of gonadotrophins administered</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.8.1. Oestrogen plus antagonist versus antagonist</HEADING>
<P>There was a higher total dose of gonadotrophin administered to women who were pretreated with oestrogen than to those who did not receive pretreatment (MD 168.38 IU/L, 95% CI ; 3 RCTs; 111.53 to 225.17, 668 women; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.8.2. Oestrogen plus antagonist versus agonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the amount of gonadotrophin administered (MD -16.00 IU/L, 95% CI -470.12 to 438.12; 1 RCT; 22 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.9. Ovarian cyst formation rate</HEADING>
<P>None of the studies reported ovarian cyst formation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Combined oral contraceptive pill versus progestogen</HEADING>
<P>One trial compared COCP versus progestogen (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>). This trial used a GnRH antagonist in both treatment groups.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.1. Live birth or ongoing pregnancy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 0.60, 95% CI 0.12 to 2.89; 1 RCT; 44 women; very low quality evidence).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2. Pregnancy loss</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.2.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 1.11, 95% CI 0.14 to 8.64; 1 RCT; 44 women)</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3. Clinical pregnancy rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.3.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in clinical pregnancy rates (OR 0.71, 95% CI 0.19 to 2.73; 1 RCT; 44 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4. Multiple pregnancy rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.4.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in multiple pregnancy rates (OR 2.32, 95% CI 0.19 to 27.59; 1 RCT; 44 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5. Ovarian hyperstimulation syndrome rate</HEADING>
<P>None of the studies reported OHSS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.6. Number of oocytes retrieved</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.6.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD 1.40, 95% CI -3.24 to 6.04; 1 RCT; 44 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.7. Days of gonadotrophin treatment</HEADING>
<P>None of the studies reported days of gonadotrophin treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.8. Amount of gonadotrophins administered</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.8.1. Combined oral contraceptive pill plus antagonist versus progestogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean quantity of gonadotrophin administered (MD 164.00 IU/L, 95% CI -249.03 to 577.03; 1 RCT; 44 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.9. Ovarian cyst formation rate</HEADING>
<P>None of the studies reported ovarian cyst formation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Combined oral contraceptive pill versus oestrogen</HEADING>
<P>Three trials compared COCP versus oestrogen (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Daly-2002" TYPE="STUDY">Daly 2002</LINK>; <LINK REF="STD-Hauzman-2013" TYPE="STUDY">Hauzman 2013</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.1. Live birth or ongoing pregnancy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in live birth or ongoing pregnancy rates (OR 1.11, 95% CI 0.54 to 2.29; 2 RCTs; 146 women; I<SUP>2</SUP> = 0%; very low quality evidence). This finding was sensitive to the choice of statistical model, and was no longer statistically significant when a sensitivity analysis was conducted to examine the effect of calculating the RR rather than OR (RR 0.15, 95% CI 0.02 to 1.08).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.1.2. Combined oral contraceptive pill plus agonist versus oestrogen plus antagonist</HEADING>
<P>There was a lower rate of live birth or ongoing pregnancy in women pretreated with COCP than in those who received oestrogen pretreatment (OR 0.08, 95% CI 0.01 to 0.79; 1 RCT; 25 women; very low quality evidence).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.2. Pregnancy loss</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.2.1. Combined oral contraceptive pill plus agonist versus oestrogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in rates of pregnancy loss (OR 1.09, 95% CI 0.06 to 19.63; 1 RCT; 25 women; very low quality evidence).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.3. Clinical pregnancy rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.3.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in rates of clinical pregnancy (OR 1.19, 95% CI 0.60 to 2.37; 2 RCTs; 146 women; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.2. Combined oral contraceptive pill plus agonist versus oestrogen plus antagonist</HEADING>
<P>There was a higher rate of clinical pregnancy in women pretreated with oestrogen than in those who received COCP pretreatment (OR 0.13, 95% CI 0.02 to 0.82; 1 RCT; 25 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.4. Multiple pregnancy rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.4.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There were no data on multiple pregnancies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.5. Ovarian hyperstimulation syndrome rate</HEADING>
<P>None of the studies reported OHSS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.6. Number of oocytes retrieved</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.6.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD 0.90, 95% CI -3.59 to 5.39; 1 RCT; 46 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.7. Days of gonadotrophin treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.7.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was no clear evidence of a difference in the number of days of gonadotrophin treatment between the two treatment groups (MD -0.60 days, 95% CI -1.23 to 0.03; 1 RCT; 100 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.8. Amount of gonadotrophins administered</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.8.1. Combined oral contraceptive pill plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the amount of gonadotrophin administered (MD 181.56 IU/L, 95% CI -344.73 to 707.86; 2 RCTs; 146 women; I<SUP>2</SUP> = 59%). There was no change in the evidence on sensitivity analysis using a random-effects model (MD 113.73 IU/L, 95% CI -383.62 to 611.08).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.9. Ovarian cyst formation rate</HEADING>
<P>None of the studies reported ovarian cyst formation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Progestogen versus oestrogen</HEADING>
<P>One trial compared progestogen versus oestrogen (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>). This trial used a GnRH antagonist in both treatment groups.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.1. Live birth or ongoing pregnancy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1.1. Progestogen plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in rates of live birth or ongoing pregnancy (OR 2.04, 95% CI 0.43 to 9.70; 1 RCT; 48 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.2. Pregnancy loss</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.2.1. Progestogen plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There were no pregnancy losses (1 RCT; 48 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.3. Clinical pregnancy rate</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.3.1. Progestogen plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was no evidence of a difference in clinical pregnancy rates between the two treatment groups (OR 2.30, 95% CI 0.57 to 9.22; 1 RCT; 48 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.4. Multiple pregnancy rate</HEADING>
<P>There were no multiple pregnancies (1 RCT; 48 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.5. Ovarian hyperstimulation syndrome rate</HEADING>
<P>The study did not report OHSS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.6. Number of oocytes retrieved</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.6.1. Progestogen plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean number of oocytes retrieved (MD -0.50, 95% CI -4.55 to 3.55; 1 RCT; 48 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.7. Days of gonadotrophin treatment</HEADING>
<P>The study did not report days of gonadotrophin treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.8. Amount of gonadotrophins administered</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.8.1. Progestogen plus antagonist versus oestrogen plus antagonist</HEADING>
<P>There was insufficient evidence to determine whether there was a difference between the groups in the mean quantity of gonadotrophin administered (MD 310.00 IU/L, 95% CI -32.30 to 652.30; 1 RCT; 48 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.9. Ovarian cyst formation rate</HEADING>
<P>The study did not report ovarian cyst formation.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-08-09 08:45:30 +1200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-05-22 15:52:52 +1200" MODIFIED_BY="Helen E Nagels">
<P>This is the second update of a Cochrane Review that aimed to determine whether pretreatment with a COCP, a progestogen or an oestrogen in ovarian stimulation protocols affects outcomes in subfertile couples undergoing any form of ART. The first update was conducted in 2009.</P>
<SUBSECTION>
<HEADING LEVEL="3">Combined oral contraceptive pill versus no pretreatment</HEADING>
<P>When COCP was compared with no pretreatment in antagonist cycles, there was a lower rate of live births or ongoing pregnancies in the pretreatment group. However, there was no clear evidence of a difference between the two groups in the rates of pregnancy losses, ovarian cyst formation, multiple pregnancies and OHSS.</P>
<P>When COCP in antagonist cycles was compared with no pretreatment in agonist cycles, there was no evidence of a difference between the two groups in rates of live births or ongoing pregnancies. With respect to adverse effects, there was a lower rate of pregnancy loss in the pretreatment group while there was no clear evidence of a difference between the two groups in rates of ovarian cyst formation, multiple pregnancy or OHSS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Progestogen versus no pretreatment</HEADING>
<P>When progestogen was compared with no pretreatment, with the same type of cycle (antagonist, agonist or gonadotrophins) in both groups, there was no clear evidence of a difference between the groups in rates of live births or ongoing pregnancies, pregnancy losses or multiple pregnancies. However, there was a lower rate of ovarian cyst formation among the progestogen pretreatment group that used agonist cycles in both groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oestrogen versus no pretreatment</HEADING>
<P>When oestrogen in antagonist cycles was compared with no pretreatment in either antagonist or agonist cycles, there was no clear evidence of a difference between the groups in rates of live births or ongoing pregnancies, or in rates of pregnancy loss, multiple pregnancy or OHSS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Head-to-head comparisons</HEADING>
<P>We compared COCP with progestogen and oestrogen plus progestogen with oestrogen, in all cases with an antagonist cycle in both groups. We compared COCP in an agonist cycle with oestrogen in an antagonist cycle. The evidence was scant but there was no clear evidence of a difference between the groups in rates of live births or ongoing pregnancies or pregnancy losses or other adverse events except in the small study comparing COCP in an agonist cycle versus oestrogen in an antagonist cycle, which reported lower rates of live birth or ongoing pregnancy in women in the COCP group.</P>
<P>Overall, the evidence was insufficient to conclude whether or not pretreatment with COCPs, progestogens or oestrogens in ovarian stimulation resulted in better fertility outcomes. More studies are required for evidence-based decision making regarding ART protocols. Besides this, there are a few other important aspects to consider when deciding if a pretreatment with a COCP, a progestogen or an oestrogen should be given. First, a pretreatment with one of these drugs may result in a longer duration and a higher amount of gonadotrophin treatment with considerable financial implications. Second, a pretreatment with one of these drugs means the need for a longer duration of the IVF/ICSI cycle and this might be a burden to the woman. In addition, if pretreatment with COCP, progestogen or oestrogen is given, this should be clearly explained to the woman, because the need for OCPs might be difficult to understand for some women trying to get pregnant.</P>
<P>Our finding that pretreatment with progestogen in agonist cycles has a positive effect on clinical pregnancy rates is surprising, since pretreatment with a COCP seems to yield lower clinical pregnancy rates. We also found that pretreatment with progestogen results in the formation of fewer ovarian cysts. This is important, since ovarian cysts have a negative effect on the pregnancy rate, because ART cycles have to be cancelled. However, only one study that used a COCP pretreatment reported on ovarian cyst formation and this study also found a substantial difference in favour of the COCP group. Unless more research is done on the underlying mechanism that could explain these effects, no implications for practice can be suggested.</P>
<P>If it is confirmed that pretreatment with progestogens results in a better IVF/ICSI outcome, this could be clinically and financially important. The administration of progestogen is easy, appears to be safe for the woman and it is less expensive than COCP pretreatment.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-08-09 08:45:30 +1200" MODIFIED_BY="[Empty name]">
<P>Although we were able to include 29 studies across six comparisons, many did not report on the primary outcomes of live births or ongoing pregnancies and pregnancy loss. Using subgroups of different GnRH antagonist and agonist protocols also limited the ability to pool data. There were also limited data for many of the secondary outcomes and almost all the other adverse events.</P>
<P>This review included women with PCOS, but there was only one study of 56 randomized women that included a diagnosis of PCOS (<LINK REF="STD-Hwang-2004" TYPE="STUDY">Hwang 2004</LINK>). Eleven other studies used PCOS or ovarian cysts as an exclusion criteria. These studies randomized 2012 women, so almost half of all the women in this review were not diagnosed with PCOS. Because of the small proportion of women with PCOS included in this review, results might be less applicable to this group of women.</P>
<P>With regard to poor responders, only one of the included studies used poor response to ovarian stimulation as an inclusion criterion in 120 women (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>). Therefore, the outcomes of this review might not be applicable to women with a history of poor response to controlled ovarian stimulation.</P>
<P>In this review, we included 29 studies with 4701 women. These studies were included in six main comparisons each comprising different subgroups. However, most of the subgroups were reported in single trials. Also, some of the review's outcome measures were not reported in some of the comparisons because of the few number of studies in each subgroup. Thus reaching a robust conclusion regarding the objective of this review was difficult.<BR/>
</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-05-24 11:42:16 +1200" MODIFIED_BY="[Empty name]">
<P>The overall quality of the evidence for the main outcomes ranged from very low to moderate. The main limitations of the evidence were risk of bias (associated with poor reporting of study methods) and imprecision. Most of the studies did not describe their methods in adequate detail and many were at high or unclear risk of attrition bias or selective reporting. In several cases, important clinical outcomes or usable data were not reported.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-05-11 23:43:34 +1200" MODIFIED_BY="Anne Lawson">
<P>A strength of this review was the grouping of the studies into subgroups regarding the type of agent used for downregulation (GnRH agonist or antagonist). Nonetheless, there was still some substantial heterogeneity in a few of the statistically significant outcomes, such as the number of days of gonadotrophin administration, but this may be explained by differences in treatment protocols between studies. The combination of live birth and ongoing pregnancy as a single outcome might have given the impression of higher live birth rates than the actual results, as some ongoing pregnancies could have ended in late abortion or intrauterine foetal death. However, there was no presence of significant heterogeneity between studies involved in such combinations.</P>
<P>Furthermore, we were unable to construct a funnel plot, due to the small number of studies in each subgroup. Therefore, we could not examine if publication bias was present.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-05-23 13:56:56 +1200" MODIFIED_BY="Helen E Nagels">
<P>To our knowledge, there is one systematic review on COCP pretreatment available (<LINK REF="REF-Griesinger-2008" TYPE="REFERENCE">Griesinger 2008</LINK>). The review investigated the effect of COCP pretreatment in a GnRH antagonist cycle versus no pretreatment, and included four studies (<LINK REF="STD-C_x00e9_drin_x002d_Durnerin-2007" TYPE="STUDY">Cédrin-Durnerin 2007</LINK>; <LINK REF="STD-Huirne-2006a" TYPE="STUDY">Huirne 2006a</LINK>; <LINK REF="STD-Kolibianakis-2006" TYPE="STUDY">Kolibianakis 2006</LINK>; <LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>). All of these studies are also included in our review, but we have included two more studies .<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Obruca-2002" TYPE="STUDY">Obruca 2002</LINK>). Due to a lack of data, despite contacting the author, or differences in treatment protocols, we were unable to pool their results. Because the systematic review of Dr Griesinger included the same studies and investigated almost the same outcomes, it is not surprising that we reach the same conclusions. In his review, Dr Griesinger found no significant effects on ongoing pregnancies. Also, he found a significant difference in favour of the control group with regard to the number of days and amount of gonadotrophin administration.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-05-25 13:43:29 +1200" MODIFIED_BY="Helen E Nagels">
<IMPLICATIONS_PRACTICE MODIFIED="2017-05-25 13:43:29 +1200" MODIFIED_BY="Helen E Nagels">
<P>Among women undergoing ovarian stimulation in antagonist protocols, COCP pretreatment was associated with a lower rate of live birth or ongoing pregnancy than no pretreatment. There was insufficient evidence to determine whether rates of live birth or ongoing pregnancy were influenced by pretreatment with progestogens or oestrogens, or by COCP pretreatment using other stimulation protocols. Findings on adverse events were inconclusive, except that progesterone pretreatment may reduce the risk of ovarian cysts in agonist cycles, and COCP in antagonist cycles may reduce the risk of pregnancy loss compared with no pretreatment in agonist cycles.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-05-11 01:56:57 +1200" MODIFIED_BY="Anne Lawson">
<P>More and larger trials that randomise subfertile women undergoing pretreatments with COCP, progestogen or oestrogen in gonadotrophin-releasing hormone analogue plus gonadotrophin in in vitro fertilisation/intra-cytoplasmic sperm injection cycles are needed. Pretreatments with COCP or progestogen should be of particular interest for further research because of their clinical importance. Research should also focus more on assessment of outcomes that are of interest to subfertile women and clinicians; these outcomes include number of live births, formation of ovarian cysts, pregnancy losses and the number of women with ovarian hyperstimulation syndrome. Furthermore, research on women with low response is necessary, because evidence in this area is scant.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-05-11 01:59:09 +1200" MODIFIED_BY="Anne Lawson">
<P>For the 2017 review:</P>
<P>We thank Dr Julie Brown for assistance with screening, selection and data extraction during 2015. We also wish to acknowledge the contributions of Brechtje Smulders and Sanne van Oirschot to previous versions of this review.</P>
<P>For the 2009 review:</P>
<P>We would like to thank He Haojie, Bolarinde Ola, Pan LIngya and Li Shangwei, the authors of the original protocol.</P>
<P>We are also grateful to Marian Showell, the Information Specialist of the CGF group, for developing the search strategy and to Jane Clarke, the Review Group Co-ordinator of the MDSG and to Vanessa Jordan, NZ Cochrane fellow, for answering our questions.</P>
<P>Furthermore, we would like to thank Dr G Griesinger for kindly supplying us with information on the trials that he included in his review.</P>
<P>Also thanks to Dr JG Franco Jr, Dr EC Ditkoff, Dr I Cédrin-Durnerin, Dr CH Kim and M Grynberg (on behalf of Dr R Fanchin) for sending us more data on their studies.</P>
<P>We would like to thank all the members of the MDSG for their assistance in contacting the authors from the included trials. Special thanks to S Dias and X Zhu for their help with articles in languages other than English.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]">
<P>LR was the first author of a randomized trial about oral contraceptive pretreatment (<LINK REF="STD-Rombauts-2006" TYPE="STUDY">Rombauts 2006</LINK>). This study was sponsored by Organon/Schering Plough. He was not involved in selection of that study or in extraction and interpretation of data from it. He is a minority shareholder in an IVF unit that has received research grants from MSD, Merck-Serono and Ferring. He has received educational grants from MSD, Merck-Serono and Ferring and provided consultancy services and board membership to Ferring Australia.</P>
<P>ROA, AL, CF and JK have no interests to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]">
<P>
<B>For the 2017 update:</B>
</P>
<P>ROA: selected studies, extracted and analyzed data, contacted authors of trials and drafted the results, discussion and authors' conclusions of the review.</P>
<P>AL: selected studies, extracted and analyzed data, and contributed to the discussion and conclusions.</P>
<P>CF: acted as third review author to resolve differences, acted as a clinical expert and commented on the review.</P>
<P>LR: acted as a clinical expert and commented on the review.</P>
<P>JK: acted as a clinical expert and commented on the review.</P>
<P>
<B>For the 2009 update:</B>
</P>
<P>Brechtje Smulders and Sanne van Oirschot contributed equally to the review.</P>
<P>Brechtje Smulders drafted the Background and Objectives of the review, and performed the search, selected the studies, extracted and analyzed the data, contacted the authors of trials and drafted the Results, Discussion and Authors' conclusions of the review together with Sanne M van Oirschot. BS also drafted half of the tables of Characteristics of included studies and drafted Table 1, Table 2 and Table 3.</P>
<P>Sanne M van Oirschot drafted the Methods of the review, and performed the search, selected the studies, extracted and analyzed the data, contacted the authors of trials and drafted the Results, Discussion and Authors' conclusions of the review together with Brechtje Smulders. SvO also drafted half of the tables of Characteristics of included studies and all the tables of Characteristics of excluded studies.</P>
<P>Cindy Farquhar helped to solve differences of opinion as a third review author, commented on the review and helped with drafting the Discussion and Authors' conclusions of the review.</P>
<P>Luk Rombauts acted as a clinical expert and commented on the review.</P>
<P>Jan Kremer acted as a clinical expert and commented on the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]">
<P>The biggest change between the protocol and the review is the formation of different subgroups. In the protocol, we described that we would perform subgroup analyses on women's age; poor response; agonist long, short and ultra-short protocol; and the duration of pretreatment. After examining the included studies, we decided it would make more sense to perform subgroup analyses on the type of GnRH analogue used in the treatment cycles. After this, we could not perform any more subgroup analysis on the planned regimens, because there were not enough studies per subgroup. Furthermore, we did not perform any sensitivity analyses due to the small number of included studies per subgroup.</P>
<P>Other minor changes to this review included: the exclusion of oocyte donors as participants, we rewrote the interventions to make them more understandable, we changed the outcome 'ovarian cysts per woman randomized' to 'number of women with ovarian cysts' and we removed a few items of data extraction because we thought they were less important. We were unable to perform a funnel plot because of the limited number of included studies to each subgroup.</P>
<P>We combined live births and ongoing pregnancies as one outcome measure in the review against two separate outcome measures in the protocol.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-08-09 02:34:44 +0100" MODIFIED_BY="Jane Marjoribanks">
<STUDIES MODIFIED="2017-07-26 09:21:37 +1200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-05-24 10:10:42 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aston-1995" MODIFIED="2009-01-05 12:01:10 +1300" MODIFIED_BY="[Empty name]" NAME="Aston 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-01-05 12:01:10 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aston K, Arthur I, Masson GM, Jenkins JM</AU>
<TI>Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<VL>102</VL>
<PG>835-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755310"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755309"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biljan-1998b" MODIFIED="2017-05-11 22:27:36 +1200" MODIFIED_BY="Anne Lawson" NAME="Biljan 1998b" YEAR="1998">
<REFERENCE MODIFIED="2009-01-05 12:02:02 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL</AU>
<TI>Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates</TI>
<SO>Fertility and Sterility</SO>
<YR>1998</YR>
<VL>70</VL>
<NO>6</NO>
<PG>1063-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755312"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-28 12:13:59 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F</AU>
<TI>Prospective randomized trial on effect of pre-treatment with an oral contraceptive (OC) on the length of time required for pituitary suppression by gonadotropin releasing hormone agonist (GnRH-a) and subsequent implantation and pregnancy rates</TI>
<SO>Fertility and Sterility</SO>
<YR>1998</YR>
<VL>Suppl 1, 70</VL>
<NO>3</NO>
<PG>S133</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755313"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755311"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blockeel-2012" MODIFIED="2017-05-11 22:12:50 +1200" MODIFIED_BY="Anne Lawson" NAME="Blockeel 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-05-11 22:12:50 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blockeel C, Engels S, de Vos M, Haentjens P, Polyzos NP, Stoop D, et al</AU>
<TI>Oestradiol valerate pretreatment in GnRH antagonist cycles: a randomised controlled trial</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2012</YR>
<VL>24</VL>
<PG>272-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755315"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755314"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-C_x00e9_drin_x002d_Durnerin-2007" MODIFIED="2017-05-10 06:28:36 +1200" MODIFIED_BY="Anne Lawson" NAME="Cédrin-Durnerin 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-01-28 13:42:14 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cédrin-Durnerin I, Bständig B, Parneix I, Bied-Damon V, Avril C, Decanter C, et al</AU>
<TI>Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol</TI>
<SO>Human Reproduction</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>1</NO>
<PG>109-16</PG>
<MD>Multicenter Study</MD>
<IDENTIFIERS MODIFIED="2009-01-28 13:42:14 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755320"/><IDENTIFIER MODIFIED="2009-01-28 13:42:14 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humrep/de1340"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:28:36 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hugues JN, Cédrin-Durnerin I, Bständig B, Parneix I, Bied-Damon V, Avril C, et al</AU>
<TI>Consequences of different steroid pre-treatments on the hormonal profile and on the antral follicular count prior to an IVF antagonist protocol</TI>
<SO>21st Annual Meeting of the ESHRE; 2005 Jun 19-22; Copenhagen, Denmark</SO>
<YR>2005</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755321"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755319"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-C_x00e9_drin_x002d_Durnerin-2012" MODIFIED="2017-05-11 22:13:22 +1200" MODIFIED_BY="Anne Lawson" NAME="Cédrin-Durnerin 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-05-11 22:13:22 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cédrin-Durnerin I, Guivarc'h-Leveque A, Hugues J-N</AU>
<TI>Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomised trial</TI>
<SO>Fertility and Sterility</SO>
<YR>2012</YR>
<VL>97</VL>
<NO>6</NO>
<PG>1359-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755323"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755322"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daly-2002" MODIFIED="2009-01-28 12:13:13 +1300" MODIFIED_BY="[Empty name]" NAME="Daly 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-28 12:13:13 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Daly DC, Daly CL, Mayo D, Jacobs A</AU>
<TI>Oocyte recruitment in IVF patients with limited ovarian reserve (LOR), maximizing quality of oocytes and embryos</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>Suppl 1, 78</VL>
<NO>3</NO>
<PG>S148-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755325"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755324"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ditkoff-1996" MODIFIED="2009-01-05 12:11:39 +1300" MODIFIED_BY="[Empty name]" NAME="Ditkoff 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-01-05 12:11:39 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ditkoff EC, Sauer MV</AU>
<TI>A combination of norethindrone acetate and leuprolide acetate blocks the gonadotrophin-releasing hormone agonistic response and minimizes cyst formation during ovarian stimulation</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>5</NO>
<PG>1035-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755327"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755326"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engmann-1999" MODIFIED="2017-05-10 06:29:44 +1200" MODIFIED_BY="Anne Lawson" NAME="Engmann 1999" YEAR="1999">
<REFERENCE MODIFIED="2017-05-10 06:29:09 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engmann L, Maconochie N, Bekir J, Tan SL</AU>
<TI>A prospective randomized study to assess the effect of progestogen therapy during pituitary desensitization with GnRH agonist in the prevention of functional ovarian cyst formation. Abstracts from ASRM/CFAS Conjoint Annual Meeting. Toronto, Canada, 1999</TI>
<SO>Fertility and Sterility</SO>
<YR>1999</YR>
<VL>72</VL>
<NO>3, Suppl 1</NO>
<PG>S10-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755329"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:29:20 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engmann L, Maconochie N, Bekir J, Tan SL</AU>
<TI>Progestogen therapy during pituitary desensitization with gonadotropin-releasing hormone agonist prevents functional ovarian cyst formation: a prospective, randomized study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>181</VL>
<NO>3</NO>
<PG>576-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755330"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:29:44 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Engmann L, Maconochie N, Tan SL, Bekir J</AU>
<TI>Progestogen therapy during pituitary desensitization with GnRH agonist prevents functional ovarian cyst formation - a prospective randomized study</TI>
<SO>Human Fertility</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>190-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755331"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755328"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fanchin-2003" MODIFIED="2017-05-11 22:28:26 +1200" MODIFIED_BY="Anne Lawson" NAME="Fanchin 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-05-10 06:35:02 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R</AU>
<SO>Luteal estradiol administration coordinates FSH-induced follicular growth and improves the outcome of GnRH antagonist COH protocols. 19th Annual meeting of the ESHRE; 2003 Jun 29-Jul 2; Madrid, Spain, 2003</SO>
<YR>2003</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755335"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-28 13:43:44 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R</AU>
<TI>Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>12</NO>
<PG>2698-703</PG>
<IDENTIFIERS MODIFIED="2009-01-28 13:43:44 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755336"/><IDENTIFIER MODIFIED="2009-01-28 13:43:44 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humrep/deg516"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755334"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franco-Jr-2003" MODIFIED="2017-05-12 00:23:29 +1200" MODIFIED_BY="Anne Lawson" NAME="Franco Jr 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-05-12 00:23:29 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franco JG Jr, Baruffi RLR, Petersen CG, Mauri AL, Felipe V, Contart P</AU>
<TI>Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I - estradiol + Ganirelix versus II - Nafarelin)</TI>
<TO>Comparação da estimulação ovariana com FSH recombinante após protocolo de 2<SUP>a</SUP> fase com análogos do GnRH (I - estradiol + Ganirelix versus II - Nafarelin)</TO>
<SO>Jornal Brasileiro de Reproducao Assistida</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>26-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755338"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755337"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Velasco-2011" MODIFIED="2017-05-12 00:24:26 +1200" MODIFIED_BY="Anne Lawson" NAME="Garcia-Velasco 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-05-10 06:35:53 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Velasco JA, Bermejo A, Ruiz F, Martinez-Salazar J, Requena A, Pellicer A</AU>
<TI>Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial</TI>
<SO>Fertility and Sterility</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>3</NO>
<PG>590-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755341"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-12 00:24:26 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Velasco JA, Bermejo A, Ruiz-Flores F, Martinez-Salazar J, Requena A, Pellicer A</AU>
<TI>Cycle scheduling with oral contraceptive pills in GnRH antagonist protocol vs long protocol: a randomized, controlled trial</TI>
<SO>Fertility and Sterility</SO>
<YR>2010</YR>
<VL>94 Suppl 1</VL>
<NO>4</NO>
<PG>S28 Abstract no. O-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755340"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755339"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hauzman-2013" MODIFIED="2015-08-07 11:12:42 +1200" MODIFIED_BY="[Empty name]" NAME="Hauzman 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-08-07 11:12:42 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauzman EE, Zapata A, Bermejo A, Iglesias C, Pellicer A, Garcia-Velasco J</AU>
<TI>Cycle scheduling for in vitro fertilisation with oral contraceptive pills versus oral estradiol valerate: a randomised controlled trial</TI>
<SO>Reproductive Biology and Endocrinology</SO>
<YR>2013</YR>
<VL>11</VL>
<PG>96</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755343"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755342"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hugues-1994" MODIFIED="2009-01-28 13:40:22 +1300" MODIFIED_BY="[Empty name]" NAME="Hugues 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-01-28 13:40:22 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hugues JN, Cédrin-Durnerin I, Hervé F, Huet-Pecqueux L, Santarelli J</AU>
<TI>Incidence of preprogrammed norethisterone on the intensity of 'flare up' (flush) caused by GnRH agonist according to the IVF protocol [poster]</TI>
<TO>Incidence d'une préprogrammation par la noréthistérone sur la qualité du flare-up induit par un agoniste du GnRH en protocole court de FIV</TO>
<SO>Contraception, Fertilite, Sexualite</SO>
<YR>1994</YR>
<VL>22</VL>
<NO>5</NO>
<PG>331</PG>
<IDENTIFIERS MODIFIED="2009-01-28 13:40:22 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755345"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755344"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huirne-2006a" MODIFIED="2017-05-11 22:30:06 +1200" MODIFIED_BY="Anne Lawson" NAME="Huirne 2006a" YEAR="2006">
<REFERENCE MODIFIED="2009-01-28 13:45:26 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huirne JAF, van Loenen ACD, Donnez J, Pirard C, Homburg R, Schats R, et al</AU>
<TI>Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>2</NO>
<PG>235-45</PG>
<IDENTIFIERS MODIFIED="2009-01-28 13:45:12 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755349"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:37:00 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Van Loenen ACD, Huirne JAF, Schats R, Donnez J, Lambalk CB</AU>
<TI>An open-label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH-antagonist in patients undergoing ART (IVF-ICSI) treatment</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17 Abstract Book 1</VL>
<PG>144-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755350"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755348"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huirne-2006c" MODIFIED="2017-05-11 22:29:30 +1200" MODIFIED_BY="Anne Lawson" NAME="Huirne 2006c" YEAR="2006">
<REFERENCE MODIFIED="2009-01-28 13:41:07 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huirne JA, Hugues JN, Pirard C, Fischl F, Sage JC, Pouly JL, et al</AU>
<TI>Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1408-15</PG>
<IDENTIFIERS MODIFIED="2009-01-28 13:41:07 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755347"/><IDENTIFIER MODIFIED="2009-01-28 13:41:07 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humrep/de1030"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755346"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hwang-2004" MODIFIED="2009-01-28 13:47:34 +1300" MODIFIED_BY="[Empty name]" NAME="Hwang 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-28 13:47:34 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, et al</AU>
<TI>Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study</TI>
<SO>Human Reproduction</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>9</NO>
<PG>1993-2000</PG>
<IDENTIFIERS MODIFIED="2009-01-28 13:47:28 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755352"/><IDENTIFIER MODIFIED="2009-01-28 13:47:28 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humrep/deh375"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755351"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011" MODIFIED="2017-05-24 10:10:42 +1200" MODIFIED_BY="[Empty name]" NAME="Kim 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-05-10 06:37:25 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim C-H, Jeon G-H, Cheon Y-P, Jeon I, Kim S-H, Chae H-D, et al</AU>
<TI>Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection</TI>
<SO>Fertility and Sterility</SO>
<YR>2009</YR>
<VL>92</VL>
<NO>5</NO>
<PG>1758-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755355"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-24 10:10:42 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kim C-H, You R-M, Kang H-J, Ahn J-W, Lee J-I, Kim S-H, et al</AU>
<TI>GnRH antagonist multiple dose protocol with oral contraceptive pill pre-treatment in poor responders undergoing IVF/ICSI</TI>
<SO>Clinical and Experimental Reproductive Medicine</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>4</NO>
<PG>228-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755354"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:40:25 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kim CH, Lee HA, Lee JW, Lee YJ, Nah HY, Hong SH, et al</AU>
<TI>The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]</TI>
<SO>Human Reproduction</SO>
<YR>2005</YR>
<VL>20 Suppl 1</VL>
<PG>i105-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755356"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755353"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolibianakis-2006" MODIFIED="2017-05-10 06:40:52 +1200" MODIFIED_BY="Anne Lawson" NAME="Kolibianakis 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-05-10 06:40:52 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Kolibianakis EM, Albano C, Tournaye H, Camus M, Van Steirteghem A, Devroey P</AU>
<TI>Pre-treatment with oral contraceptive pill affects adversely implantation rate in IVF/ICSI cycles stimulated with rec-FSH and GnRH antagonists</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>80</VL>
<NO>Suppl 3</NO>
<PG>S67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755358"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-28 13:54:26 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P</AU>
<TI>Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>2</NO>
<PG>352-7</PG>
<IDENTIFIERS MODIFIED="2009-01-28 13:54:26 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755359"/><IDENTIFIER MODIFIED="2009-01-28 13:54:26 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humrep/dei348"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755357"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lukaszuk-2015" MODIFIED="2017-05-10 06:41:16 +1200" MODIFIED_BY="Anne Lawson" NAME="Lukaszuk 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-10 06:41:16 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lukaszuk K, Liss J, Kunicki M, Kuczynski W, Pastuszek E, Jakiel G, et al</AU>
<TI>Estradiol valerate pretreatment in short protocol GNRH-agonist cycles versus combined pretreatment with oral contraceptive pills in long protocol GNRH-agonist cycles: a randomised controlled trial</TI>
<SO>BioMed Research International</SO>
<YR>2015</YR>
<VL>2015</VL>
<PG>1-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755361"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755360"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nyboe-Andersen-2011" MODIFIED="2017-05-10 06:44:14 +1200" MODIFIED_BY="Anne Lawson" NAME="Nyboe Andersen 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-05-10 06:41:40 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broekmans JF, Verweij PJM, Eijkemans MJC, Mannaerts NMJL, Witjes H</AU>
<TI>Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol</TI>
<SO>Human Reproduction</SO>
<YR>2014</YR>
<VL>29</VL>
<NO>8</NO>
<PG>1688-97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755364"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:41:53 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nyboe Andersen A, Witjes H, Gordon K, Mannaerts B</AU>
<TI>Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pretreatment</TI>
<SO>Human Reproduction</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>12</NO>
<PG>3413-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755365"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:44:14 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tavmergen E, von Mauw, Witjes H, Mannaerts B</AU>
<SO>Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling. 25th Annual Meeting of ESHRE; 2009 28 Jun-1 Jul; Amsterdam, the Netherlands</SO>
<YR>2009</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755363"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755362"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Obruca-2002" MODIFIED="2017-05-11 22:15:17 +1200" MODIFIED_BY="Anne Lawson" NAME="Obruca 2002" YEAR="2001">
<REFERENCE MODIFIED="2017-05-10 06:44:23 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Obruca A, Fischl F, Huber J</AU>
<TI>Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17 Abstract Book 1</VL>
<PG>89</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755367"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755366"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porrati-2010" MODIFIED="2017-05-10 06:44:45 +1200" MODIFIED_BY="Anne Lawson" NAME="Porrati 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-05-10 06:44:45 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porrati L, Vilela M, Viglierchio MI, Valcarcel A, Lombardi E, Marconi G</AU>
<TI>Oral contraceptive pretreatment achieves better pregnancy rates in IVF antagonists GnRH flexible protocols: a prospective randomized study</TI>
<SO>Human Reproduction</SO>
<YR>2010</YR>
<VL>25 Suppl 1</VL>
<NO>6</NO>
<PG>i102 Abstract no. O-259</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755369"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755368"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raoofi-2008" MODIFIED="2009-01-05 12:44:58 +1300" MODIFIED_BY="[Empty name]" NAME="Raoofi 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-01-05 12:44:58 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raoofi Z, Aflatoonian A</AU>
<TI>Ovarian cysts formation during depot formulation of GnRH-a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in ART cycles</TI>
<SO>Iranian Journal of Pharmaceutical Research</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>2</NO>
<PG>109-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755371"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755370"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rombauts-2006" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Rombauts 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rombauts L, Healy D, Norman RJ, Speirs A, Watkins B, Yovich J, et al</AU>
<TI>A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>1</NO>
<PG>95-103</PG>
<IDENTIFIERS MODIFIED="2009-01-28 13:55:42 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755373"/><IDENTIFIER MODIFIED="2009-01-28 13:55:42 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humrep/dei302"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755372"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salat_x002d_Baroux-1988" MODIFIED="2009-01-05 12:49:25 +1300" MODIFIED_BY="[Empty name]" NAME="Salat-Baroux 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-01-05 12:49:25 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salat-Baroux J, Antoine JM, Alvarez S, Cornet D, Tibi C, Mandelbaum J, et al</AU>
<TI>Programmed ovulation induction and oocyte retrieval for in vitro fertilization</TI>
<SO>Journal of In Vitro Fertilization and Embryo Transfer</SO>
<YR>1988</YR>
<VL>5</VL>
<NO>3</NO>
<PG>153-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755375"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755374"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaker-1995" MODIFIED="2009-01-05 12:49:49 +1300" MODIFIED_BY="[Empty name]" NAME="Shaker 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-01-05 12:49:49 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaker AG, Pittrof R, Zaidi J, Bekir J, Kyei-Mensah A, Tan SL</AU>
<TI>Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin-releasing hormone agonist in in vitro fertilization - a prospective randomized study</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>64</VL>
<NO>4</NO>
<PG>791-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755377"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755376"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2001" MODIFIED="2017-05-10 06:45:24 +1200" MODIFIED_BY="Anne Lawson" NAME="Tan 2001" YEAR="">
<REFERENCE MODIFIED="2017-05-10 06:45:24 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tan SL, Biljan M</AU>
<TI>Fixed scheduling of long protocol of GNRH agonists - use of oral contraceptive (OC) or progestogen pre-treatment</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2001</YR>
<VL>15 Suppl 2</VL>
<PG>31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755379"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755378"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Vilela-2011" MODIFIED="2015-08-07 11:18:51 +1200" MODIFIED_BY="[Empty name]" NAME="Vilela 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-08-07 11:18:51 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Vilela M, Marconi M, Zappacosta MP, Porrati L, Valcarcel A, Marconi G</AU>
<TI>Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilisation (IVF) antagonists GnRH flexible protocols: a prospective randomised study</TI>
<SO>Fertility and Sterility</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>3 (supplement)</NO>
<PG>S252, P-492</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755381"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755380"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ye-2009" MODIFIED="2017-05-10 06:47:13 +1200" MODIFIED_BY="Anne Lawson" NAME="Ye 2009" YEAR="2009">
<REFERENCE MODIFIED="2017-05-10 06:47:13 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ye H, Huang G-N, Zeng P-H, Pei L</AU>
<TI>IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2009</YR>
<VL>26</VL>
<NO>2-3</NO>
<PG>105-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755385"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755384"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-07-26 09:21:37 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aghahosseini-2011" MODIFIED="2017-05-10 06:47:45 +1200" MODIFIED_BY="Anne Lawson" NAME="Aghahosseini 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-05-10 06:47:45 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aghahosseini M, Aleyassin A, Khodaverdi S, Esfahani F, Mohammadbeigi R, Movahedi S, et al</AU>
<TI>Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2011</YR>
<VL>28</VL>
<PG>785-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755389"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-22 11:17:32 +1200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-06-22 11:17:32 +1200" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755388"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-al_x002d_Mizyen-2000" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="al-Mizyen 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>al-Mizyen E, Sabatini L, Lower AM, Wilson CMY, al-Shawaf T, Grudzinskas JG</AU>
<TI>Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF-ET?</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>3</NO>
<PG>140-6</PG>
<MD>Clinical Trial</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755391"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755390"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1990" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Anderson 1990" YEAR="1990">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson RE, Stein AL, Paulson RJ, Stanczyk FZ, Vijod AG, Lobo RA</AU>
<TI>Effects of norethindrone on gonadotropin and ovarian-steroid secretion when used for cycle programming during in vitro fertilization</TI>
<SO>Fertility and Sterility</SO>
<YR>1990</YR>
<VL>54</VL>
<NO>1</NO>
<PG>96-101</PG>
<IDENTIFIERS MODIFIED="2009-01-28 14:07:56 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755393"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755392"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakas-2014" MODIFIED="2017-04-06 16:06:56 +1200" MODIFIED_BY="[Empty name]" NAME="Bakas 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-04-06 16:06:56 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bakas P, Hassiakos D, Grigoriadis C, Vlahos NF, Liapis A, Creatsas G</AU>
<TI>Effect of a low dose combined oral contraceptive pill on the hormonal profile and cycle outcome following COS with a GnRH antagonist protocol in women over 35 years old</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2014</YR>
<VL>30</VL>
<NO>11</NO>
<PG>825-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755395"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755394"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellver-2007" MODIFIED="2009-01-05 14:18:10 +1300" MODIFIED_BY="[Empty name]" NAME="Bellver 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-01-05 14:18:10 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellver J, Albert C, Labarta E, Pellicer A</AU>
<TI>Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pill pretreatment</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>87</VL>
<NO>5</NO>
<PG>1098-101</PG>
<IDENTIFIERS MODIFIED="2009-01-05 14:18:01 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755397"/><IDENTIFIER MODIFIED="2009-01-05 14:18:00 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.fertnstert.2006.08.098"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755396"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benadiva-1988" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Benadiva 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benadiva CA, Ben-Rafael Z, Blasco L, Tureck R, Mastroianni LJ, Flickinger GL</AU>
<TI>Ovarian response to human menopausal gonadotropin following suppression with oral contraceptives</TI>
<SO>Fertility and Sterility</SO>
<YR>1988</YR>
<VL>50</VL>
<NO>3</NO>
<PG>516-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755399"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755398"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bendikson-2006" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Bendikson 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bendikson K, Milki AA, Speck-Zulak A, Westphal LM</AU>
<TI>Comparison of GnRH antagonist cycles with and without oral contraceptive pretreatment in potential poor prognosis patients</TI>
<SO>Clinical and Experimental Obstetrics and Gynecology</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>3</NO>
<PG>145-7</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755401"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755400"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biljan-1998c" MODIFIED="2017-05-11 22:27:33 +1200" MODIFIED_BY="Anne Lawson" NAME="Biljan 1998c" YEAR="1998">
<REFERENCE MODIFIED="2009-01-05 14:22:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL</AU>
<TI>Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>10</NO>
<PG>599-604</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755403"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755402"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branigan-1998" MODIFIED="2009-01-28 14:11:43 +1300" MODIFIED_BY="[Empty name]" NAME="Branigan 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-01-28 14:11:43 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Branigan EF, Estes MA</AU>
<TI>Treatment of high responders with oral contraceptive pills (OC) before ovarian hyperstimulation for IVF</TI>
<SO>Fertility and Sterility</SO>
<YR>1998</YR>
<VL>69</VL>
<NO>3</NO>
<PG>599</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755405"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755404"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brodt-1993" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Brodt 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodt J, Taubert HD</AU>
<TI>Planned ovarian stimulation with preadministered contraceptives in an in-vitro fertilization program</TI>
<TO>Programmierte ovarielle stimulation mittels ovulationshemmer-vorbehandlung in einem in vitro fertilisations(IVF)-programm</TO>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>1993</YR>
<VL>254</VL>
<NO>1-4</NO>
<PG>246-8</PG>
<MD>Proceedings Paper</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755407"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755406"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-C_x00e9_drin_x002d_Durnerin-1995" MODIFIED="2009-07-23 08:31:53 +1200" MODIFIED_BY="[Empty name]" NAME="Cédrin-Durnerin 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-01-05 14:26:20 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cédrin-Durnerin I, Hervé F, Huet-Pecqueux L, Kottler ML, Hugues JN</AU>
<TI>Progestogen pretreatment in the short-term protocol does not affect the prognostic value of the oestradiol flare-up in response to a GnRH agonist</TI>
<SO>Human Reproduction</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>11</NO>
<PG>2904-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755409"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755408"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-C_x00e9_drin_x002d_Durnerin-1996" MODIFIED="2017-05-11 22:17:10 +1200" MODIFIED_BY="Anne Lawson" NAME="Cédrin-Durnerin 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-08-11 16:29:48 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cédrin-Durnerin I, Bulwa S, Hervé F, Martin-Pont B, Uzan M, Hugues JN</AU>
<TI>The hormonal flare-up following gonadotrophin-releasing hormone agonist administration is influenced by a progestogen pretreatment</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1859-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755317"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-11 22:17:10 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cédrin-Durnerin I, Bulwa S, Hervé F, Pecqueux L, Uzan M, Hugues JN</AU>
<TI>Influence of norethisterone pretreatment on the initial flare-up induced by a gonadotrophin-releasing hormone agonist in a short protocol for IVF</TI>
<SO>Human Reproduction</SO>
<YR>1995</YR>
<VL>10 Abstract Book 2</VL>
<PG>116</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755318"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755316"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chung-2006" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Chung 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chung MT, Tsai YC, Chen SH, Loo TC, Tang HH, Lin LY</AU>
<TI>Influence of pituitary suppression with triphasic or monophasic oral contraceptives on the outcome of in vitro fertilization and embryo transfer</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2006</YR>
<VL>23</VL>
<PG>343-6</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS MODIFIED="2009-01-05 14:29:16 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755411"/><IDENTIFIER MODIFIED="2009-01-05 14:29:16 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s10815-006-9056-y"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755410"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1987" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Cohen 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J, Debache C, Solal P, Serkine AM, Achard B, Boujenah A, et al</AU>
<TI>Results of planned in-vitro fertilization programming through the pre-administration of the oestrogen-progesterone combined pill</TI>
<SO>Human Reproduction</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>1</NO>
<PG>7-9</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755413"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755412"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Copperman-2003" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Copperman 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Copperman AB, Mukherjee T, Sandler B, Grunfeld L, Bergh PA, Scott RT</AU>
<TI>Pre-treatment with oral contraceptive pill improves outcome in IVF cycles of poor-responders using the GnRH antagonist</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>Suppl 3, 80</VL>
<PG>S108</PG>
<MD>Meeting abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755415"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755414"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Couzinet-1995" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Couzinet 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Couzinet B, Young J, Brailly S, Chanson P, Schaison G</AU>
<TI>Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhoea</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1995</YR>
<VL>80</VL>
<NO>7</NO>
<PG>2102-7</PG>
<MD>Clinical Trial</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755417"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755416"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Damario-1997" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Damario 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z</AU>
<TI>Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients</TI>
<SO>Human Reproduction</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>11</NO>
<PG>2359-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755419"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755418"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davar-2014" MODIFIED="2017-05-10 06:50:03 +1200" MODIFIED_BY="Anne Lawson" NAME="Davar 2014" YEAR="2013">
<REFERENCE MODIFIED="2017-05-10 06:50:03 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davar R, Rahsepar M, Rahmani E</AU>
<TI>Outcome of a trial to identify predicative factors for ovarian response in a GnRH antagonist protocol with or without oral contraceptive scheduling</TI>
<SO>Iranian Journal of Reproductive Medicine</SO>
<YR>2014</YR>
<VL>12 Suppl 1</VL>
<NO>6</NO>
<PG>71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755421"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755420"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davy-2004" MODIFIED="2017-05-10 06:50:23 +1200" MODIFIED_BY="Anne Lawson" NAME="Davy 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-05-10 06:50:15 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Davy C, Guibert J, Blanchet V, Nataf E, Olivennes F</AU>
<TI>The 'wash out' period do not create asynchrony of the follicle cohort when contraceptive pill is used to program GnRH antagonist IVF cycles</TI>
<SO>Human Reproduction</SO>
<YR>2004</YR>
<VL>19 Suppl 1</VL>
<PG>i5-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755423"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:50:23 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Olivennes F Sr, Davy C, Guibert J, Nataf E, Blanchet V</AU>
<TI>Asynchrony of the follicle cohort is not induced by the &#8220;wash out&#8221; period when contraceptive pill is used to program GnRH antagonist IVF cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>Suppl 2, 82</VL>
<PG>S234</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755424"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755422"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Ziegler-1999" MODIFIED="2009-01-05 14:37:03 +1300" MODIFIED_BY="[Empty name]" NAME="De Ziegler 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-05 14:37:03 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Ziegler D, Brioschi PA, Benchaa C, Campana A, Ditesheim PJ, Fanchin R, et al</AU>
<TI>Programming ovulation in the menstrual cycle by a simple innovative approach: back to the future of assisted reproduction</TI>
<SO>Fertility and Sterility</SO>
<YR>1999</YR>
<VL>72</VL>
<NO>1</NO>
<PG>77-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755426"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755425"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dickey-2001" MODIFIED="2009-01-28 14:29:36 +1300" MODIFIED_BY="[Empty name]" NAME="Dickey 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-28 14:29:36 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Dickey RP, Sartor BM, Taylor SN, Lu PY, Rye PH, Pyrzak R</AU>
<TI>Oral contraceptives, not GnRH suppression, may be responsible for very low endogenous LH during IVF cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>Suppl 3, 76</VL>
<NO>3</NO>
<PG>S237</PG>
<MD>Meeting Abstract: P375</MD>
<IDENTIFIERS MODIFIED="2009-01-05 14:41:47 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755428"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755427"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ditkoff-1997" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Ditkoff 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ditkoff EC, Prosser R, Zimmermann RC, Lindheim S, Sauer MV</AU>
<TI>The addition of norethindrone acetate to leuprolide acetate for ovarian suppression has no adverse effect on ovarian stimulation</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>2</NO>
<PG>92-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755430"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755429"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doody-2001" MODIFIED="2009-01-28 14:30:41 +1300" MODIFIED_BY="[Empty name]" NAME="Doody 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-28 14:30:41 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Doody KJ, Langley M, Marek D, Doody K</AU>
<TI>Oral contraceptive pre-treatment for IVF cycles employing recombinant FSH and a GnRH antagonist</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>Suppl 1, 76</VL>
<NO>3</NO>
<PG>S236</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755432"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755431"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duvan-2008" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Duvan 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duvan CI, Berker B, Turhan NO, Satiroglu H</AU>
<TI>Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2008</YR>
<VL>25</VL>
<PG>89-93</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS MODIFIED="2009-01-05 14:44:24 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755434"/><IDENTIFIER MODIFIED="2009-01-05 14:44:24 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s10815-008-9203-8"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755433"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engels-2011" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Engels 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engels S, Blockeel C, Haentjens P, De Vos M, Camus M, Devroey P</AU>
<TI>How to avoid oocyte retrievals during weekend days using a GnRH antagonist protocol? A randomised controlled trial</TI>
<SO>Human Reproduction</SO>
<YR>2011</YR>
<VL>26 Suppl 1</VL>
<PG>i308 Abstract no: P-480</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755436"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755435"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fanchin-2001" MODIFIED="2016-08-16 10:39:16 +1200" MODIFIED_BY="[Empty name]" NAME="Fanchin 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-08-16 10:39:16 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Fanchin R, Schonauer L, Cunha Filho J, Kadoch I, Cohen Bacrie P, Frydman R</AU>
<TI>Luteal E2 administration reduces size and improves homogeneity of selectable follicles on cycle-day 3: bases for novel controlled ovarian hyperstimulation (COH) concepts</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>Suppl 1, 76</VL>
<NO>3</NO>
<PG>S90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755333"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755332"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fanchin-2003b" MODIFIED="2017-05-10 06:51:55 +1200" MODIFIED_BY="Anne Lawson" NAME="Fanchin 2003b" YEAR="2002">
<REFERENCE MODIFIED="2017-05-10 06:51:55 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fanchin R, Cunha Filho J, Schonauer L, Kadoch I, Cohen Bacri P, Frydman R</AU>
<TI>Co-ordination of early antral follicles by luteal estradiol administration: basis for novel controlled ovarian hyperstimulation</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17 Abstract Book 1</VL>
<PG>88-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755438"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-05 09:16:59 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R</AU>
<TI>Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>79</VL>
<NO>2</NO>
<PG>316-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755439"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755437"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feichtinger-1991" MODIFIED="2017-05-11 22:18:26 +1200" MODIFIED_BY="Anne Lawson" NAME="Feichtinger 1991" YEAR="">
<REFERENCE MODIFIED="2017-05-11 22:18:26 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feichtinger W, Babor P, Herczeg KM, Heyda M, Hoffmann R, Plockinger B, et al</AU>
<TI>Side effects of oral contraceptives in the first treatment cycle</TI>
<SO>Weiner Medizinische Wochenschrift</SO>
<YR>1991</YR>
<VL>141</VL>
<NO>18-19</NO>
<PG>412-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755441"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755440"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisch-1996" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Fisch 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisch B, Royburt M, Pinkas H, Avrech OM, Goldman GA, Bar J, et al</AU>
<TI>Augmentation of low ovarian response to superovulation before in vitro fertilization following priming with contraceptive pills</TI>
<SO>Israel Journal of Medical Sciences</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>12</NO>
<PG>1172-6</PG>
<MD>Clinical Trial</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755443"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755442"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forman-1991" MODIFIED="2009-01-05 14:50:48 +1300" MODIFIED_BY="[Empty name]" NAME="Forman 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-01-05 14:50:48 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forman RG, Demouzon J, Feinstein MC, Testart J, Frydman R</AU>
<TI>Studies on the influence of gonadotrophin-levels in the early follicular phase on the ovarian response to stimulation</TI>
<SO>Human Reproduction</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>1</NO>
<PG>113-7</PG>
<IDENTIFIERS MODIFIED="2009-01-05 14:50:48 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755445"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755444"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frederick-2004" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Frederick 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frederick J, DaCosta V, Wynter S, Reid M, Frederick C, McKenzie C</AU>
<TI>Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation</TI>
<SO>West Indian Medical Journal</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>1</NO>
<PG>39-43</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755447"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755446"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frydman-1986" MODIFIED="2017-05-12 00:28:40 +1200" MODIFIED_BY="Anne Lawson" NAME="Frydman 1986" YEAR="1986">
<REFERENCE MODIFIED="2017-05-12 00:28:40 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frydman R, Forman R, Rainhorn JD, Belaisch-Allart J, Hazout A, Testart J</AU>
<TI>A new approach to follicular stimulation for in vitro fertilization: programmed oocyte retrieval</TI>
<SO>Fertility and Sterility</SO>
<YR>1986</YR>
<VL>46</VL>
<NO>4</NO>
<PG>657-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755449"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755448"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galera-2004" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Galera 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Galera F, Verdu V, Villafañex V, Garijo E, Rayward J, Bajo JM</AU>
<TI>Comparison of plasmatic steroid levels with and without previous oral contraceptive administration in GnRH antagonist IVF cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>Suppl 2, 82</VL>
<PG>S32</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755451"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755450"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerli-1989" MODIFIED="2009-01-05 14:55:30 +1300" MODIFIED_BY="[Empty name]" NAME="Gerli 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-01-05 14:55:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerli S, Remohi J, Partrizio P, Borrero C, Balmaceda JP, Silber SJ, et al</AU>
<TI>Programming of ovarian stimulation with norethindrone acetate in IVF/GIFT cycles</TI>
<SO>Human Reproduction</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>7</NO>
<PG>746-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755453"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755452"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghanem-2015" MODIFIED="2016-09-02 15:03:10 +1200" MODIFIED_BY="[Empty name]" NAME="Ghanem 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-09-02 15:03:10 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghanem M, Bediary MH, Helal AS, et al</AU>
<TI>Is adding estradiole (E2) to progesterone (P) luteal support in high responder long GnRH agonist ICSI cycles detrimental to outcome? Randomised controlled trial (RCT)</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>2015</YR>
<VL>104 Suppl</VL>
<NO>3</NO>
<PG>e224</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755455"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755454"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godin-2003" MODIFIED="2017-05-11 22:19:08 +1200" MODIFIED_BY="Anne Lawson" NAME="Godin 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-05-11 22:19:08 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godin PA, Gaspard O, Jouan C, Thonon F, Hincourt N, Ravet S, et al</AU>
<TI>Importance of estradiol priming in in-vitro maturation cycles</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18 Suppl 1</VL>
<PG>153</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755457"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755456"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez-2000" MODIFIED="2017-05-11 22:19:19 +1200" MODIFIED_BY="Anne Lawson" NAME="Gomez 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-05-11 22:19:19 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez E, Ballesteros A, Landeras J, Munoz M, Martinez MC</AU>
<TI>Preparation of endometrium with oral oestradiol valerate versus transdermal oestradiol for cryopreserved embryo transfer: a prospective randomized study</TI>
<SO>Human Reproduction</SO>
<YR>2000</YR>
<VL>15</VL>
<PG>175-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755459"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755458"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonen-1990" MODIFIED="2009-01-05 14:58:25 +1300" MODIFIED_BY="[Empty name]" NAME="Gonen 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-01-05 14:58:25 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonen Y, Jacobson W, Casper RF</AU>
<TI>Gonadotropin suppression with oral contraceptives before in vitro fertilization</TI>
<SO>Fertility and Sterility</SO>
<YR>1990</YR>
<VL>53</VL>
<NO>2</NO>
<PG>282-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755461"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755460"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-1995" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Gonzalez 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez P, Maloul S, Ciuffardi I, Frederick JL, Balmaceda JP, Asch RH</AU>
<TI>The use of progestins for programming assisted reproductive cycles and gonadotropin-releasing hormone agonist flare-up protocols in older patients</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>63</VL>
<NO>2</NO>
<PG>249-51</PG>
<MD>Clinical Trial</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755463"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755462"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greco-2016" MODIFIED="2017-05-10 06:56:25 +1200" MODIFIED_BY="Anne Lawson" NAME="Greco 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-10 06:56:25 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greco E, Litwicka K, Arrivi C, Varricchio MT, Caragia A, Greco A, et al</AU>
<TI>The endometrial preparation for frozen-thawed euploidblastocyst transfer: a prospective randomized trial comparing clinical results from natural modified cycle and exogenous hormone stimulation with GnRH agonist</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2016</YR>
<VL>33</VL>
<PG>873-84</PG>
<IDENTIFIERS MODIFIED="2017-01-31 13:36:00 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5670895"/><IDENTIFIER MODIFIED="2017-01-31 13:36:00 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s10815-016-0736-y"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5670894"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guivarc_x0027_h_x002d_Lev_x00ea_que-2009" MODIFIED="2017-07-26 09:21:37 +1200" MODIFIED_BY="[Empty name]" NAME="Guivarc'h-Levêque 2009" YEAR="2009">
<REFERENCE MODIFIED="2017-07-26 09:21:37 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guivarc&#8217;h-Levêque A, Arvis P, Bouchet J-L, Broux P-L, Moy L, Priou G, et al</AU>
<TI>Efficiency of antagonist IVF cycle programming by estrogens</TI>
<TO>Efficacité de la programmation des cycles FIV en antagonistes par les estrogènes</TO>
<SO>Gynécologie Obstétrique &amp; Fertilité</SO>
<YR>2010</YR>
<VL>38</VL>
<PG>18-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6484747"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6484746"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haydardedeoglu-2012" MODIFIED="2017-05-10 06:56:38 +1200" MODIFIED_BY="Anne Lawson" NAME="Haydardedeoglu 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-05-10 06:56:38 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haydardedeoglu B, Kilicdag EB, Parlakgummus AH, Zeyneloglu HB</AU>
<TI>IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist protocol in women with PCOS: a randomised trial</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>2012</YR>
<VL>286</VL>
<PG>763-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755465"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755464"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hugues-1992" MODIFIED="2009-01-05 15:01:09 +1300" MODIFIED_BY="[Empty name]" NAME="Hugues 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-01-05 15:01:09 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hugues JN, Attalah M, Hervé F, Martin-Pont B, Kottler ML, Santarelli J</AU>
<TI>Effects of short-term GnRH agonist - human menopausal gonadotropin stimulation in patients pre-treated with progestogen</TI>
<SO>Human Reproduction</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1079-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755467"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755466"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-2000" MODIFIED="2009-01-08 14:58:42 +1300" MODIFIED_BY="[Empty name]" NAME="Jung 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-08 14:58:42 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jung H, Roh HK</AU>
<TI>The effects of E2 supplementation from the early proliferative phase to the late secretory phase of the endometrium in hMG-stimulated IVF-ET</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2000</YR>
<VL>17</VL>
<NO>1</NO>
<PG>28-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755469"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755468"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karande-2004" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Karande 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Karande VC, Latash WDZ, Birkenkamp T, Cavanaugh J, Melone K, Hazlett D</AU>
<TI>Preliminary report of a prospective randomized controlled trial comparing the use of NuvaRing® to Desogen® in in vitro fertilization cycles with ganirelix acetate</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>Suppl 2, 82</VL>
<PG>S31-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755471"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755470"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keltz-2007" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Keltz 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keltz MD, Gera PS, Skorupski J, Stein DE</AU>
<TI>Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>88</VL>
<NO>2</NO>
<PG>350-3</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS MODIFIED="2009-01-05 15:04:36 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755473"/><IDENTIFIER MODIFIED="2009-01-05 15:04:36 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.fertnstert.2006.11.123"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-28 14:44:15 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Keltz MD, Sharma P, Stein DE</AU>
<TI>Comparison of FSH flare in poor responders undergoing in vitro fertilization (IVF) with and without prior oral contraceptive suppression</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>80</VL>
<PG>S107</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755474"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755472"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kovacs-2001" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Kovacs 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kovacs P, Barg PE, Witt BR</AU>
<TI>Hypothalamic-pituitary suppression with oral contraceptive pills does not improve outcome in poor responder patients undergoing in vitro fertilization-embryo transfer cycles</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>7</NO>
<PG>391-4</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755476"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755475"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kreiner-2007" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Kreiner 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kreiner D, diLandro R, Moschella J</AU>
<TI>Study of IVF success with pituitary suppression prior to follistim/HMG stimulation in ganirelix cycles using oral contraceptives and estrace</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>2007</YR>
<VL>Vol 88 Suppl 1</VL>
<PG>284, abstract no. 534</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755478"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755477"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leondires-1999" MODIFIED="2009-01-05 15:07:59 +1300" MODIFIED_BY="[Empty name]" NAME="Leondires 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-05 15:07:59 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leondires MP, Escalpes M, Segars JH, Scott RT, Miller BT</AU>
<TI>Microdose follicular phase gonadotropin-releasing hormone agonist (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization</TI>
<SO>Fertility and Sterility</SO>
<YR>1999</YR>
<VL>72</VL>
<NO>6</NO>
<PG>1018-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755480"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755479"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Letterie-2000" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Letterie 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Letterie GS</AU>
<TI>Inhibition of gonadotropin surge by a brief mid-cycle regimen of ethinyl estradiol and norethindrone: possible role in in vitro fertilization</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>1</NO>
<PG>1-4</PG>
<MD>Clinical Trial</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755482"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755481"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewin-2002" MODIFIED="2017-05-10 06:57:39 +1200" MODIFIED_BY="Anne Lawson" NAME="Lewin 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-28 14:46:49 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lewin A, Fatum M, Shufaro Y, Simon A, Reubinoff B, Laufer N, et al</AU>
<TI>Artificial endometrial preparation for frozen-thawed embryo transfer using oral oestradiol and a new low-dose vaginal progesterone preparation: Endometrin tablets</TI>
<SO>Human Reproduction</SO>
<YR>2001</YR>
<VL>Suppl 1, 16</VL>
<PG>152</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755484"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-10 06:57:39 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewin A, Pisov G, Turgeman R, Fatum M, Shufaro Y, Simon A, et al</AU>
<TI>Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>2</NO>
<PG>131-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755485"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755483"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindheim-1996" MODIFIED="2009-01-05 15:08:49 +1300" MODIFIED_BY="[Empty name]" NAME="Lindheim 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-01-05 15:08:49 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindheim SR, Barad DH, Witt B, Ditkoff E, Sauer MV</AU>
<TI>Short-term gonadotropin suppression with oral contraceptives benefits poor responders prior to controlled ovarian hyperstimulation</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>9</NO>
<PG>745-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755487"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755486"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2011" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Liu 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu KE, Alhajri M, Greenblatt E</AU>
<TI>A randomized controlled trial of NuvaRing versus combined oral contraceptive pills for pretreatment in in vitro fertilization cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>3</NO>
<PG>605-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755489"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755488"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loutradis-2003" MODIFIED="2009-01-05 15:10:46 +1300" MODIFIED_BY="[Empty name]" NAME="Loutradis 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 15:10:46 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loutradis D, Stefanidis K, Drakakis P, Kallianidis K, El Sheikh A, Milingos S, et al</AU>
<TI>Does pre-treatment with micronized progesterone affect the ovarian response to a gonadotropin releasing hormone agonist flare-up protocol?</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>2</NO>
<PG>101-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755491"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755490"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-2006" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Martinez 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, et al</AU>
<TI>A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>8</NO>
<PG>2121-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755493"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755492"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mashiach-1989" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Mashiach 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-01-28 14:49:51 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mashiach S, Dor J, Goldenberg M, Shalev J, Blankstein J, Rudake E, et al</AU>
<TI>Protocols for induction of ovulation - the concept of programmed cycles</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1988</YR>
<VL>541</VL>
<PG>37-45</PG>
<IDENTIFIERS MODIFIED="2009-01-28 14:49:46 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755495"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mashiach S, Dor J, Goldenberg M, Shalev J, Levran D, Rudak E, et al</AU>
<TI>Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization</TI>
<SO>Gynecological Endocrinology</SO>
<YR>1989</YR>
<VL>3</VL>
<NO>2</NO>
<PG>107-15</PG>
<MD>Clinical Trial</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755496"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755494"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meldrum-2002" MODIFIED="2009-01-28 14:50:45 +1300" MODIFIED_BY="[Empty name]" NAME="Meldrum 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-28 14:50:45 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Meldrum D, Scott R, Levy MJ, Alper M, Noyes N</AU>
<TI>A pilot study to assess oral contraceptive (OC) pretreatment in women undergoing controlled ovarian hyperstimulation (COH) in ganirelix acetate cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>Suppl 1, 78</VL>
<NO>3</NO>
<PG>S176</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755498"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755497"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meldrum-2008" MODIFIED="2009-01-05 15:16:04 +1300" MODIFIED_BY="[Empty name]" NAME="Meldrum 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-01-05 15:16:04 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meldrum DR, Cassidenti DL, Rosen GF, Yee B, Wisot AL</AU>
<TI>Oral contraceptive pretreatment and half dose of ganirelix does not excessively suppress LH and may be an excellent choice for scheduling IUI cycles</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2008</YR>
<VL>25</VL>
<PG>417-20</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:15:56 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755500"/><IDENTIFIER MODIFIED="2009-01-05 15:15:56 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s10815-008-9244-z"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755499"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merviel-2015" MODIFIED="2017-05-12 00:31:52 +1200" MODIFIED_BY="Anne Lawson" NAME="Merviel 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-05-10 06:58:46 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merviel P, Cabry-Goubet R, Lourdel E, Devaux A, Belhadri-Mansouri N, Copin H, et al</AU>
<TI>Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy</TI>
<SO>Reproductive Health</SO>
<YR>2015</YR>
<VL>12</VL>
<PG>52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755502"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-12 00:31:52 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scheffler F, Merviel P, Lourdel E, et al</AU>
<TI>Contraceptive pill and gonadotropin-releasing hormone (GnRH) flare-up agonist versus GnRH antagonist protocol in poor responders: lessons to a prospective study</TI>
<SO>Human Reproduction</SO>
<YR>2015</YR>
<VL>30 Suppl</VL>
<PG>i295 Abstract no: p-410</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755503"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755501"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Min-2005" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Min 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Min JK, Claman P</AU>
<TI>Oral contraceptive (OC) pre-treatment does not influence oocyte yield in poor responders undergoing gonadotropin releasing hormone (GnRH) antagonist cycles for in vitro fertilization (IVF)</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>Suppl 1, 84</VL>
<PG>S45-6</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755505"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755504"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mirkin-2003" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Mirkin 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mirkin S, Stadtmauer LA, Gibbons WE, Oehninger S</AU>
<TI>Clinical and endocrine impact of pretreatment with oral contraceptive pills in poor responders undergoing IVF with a combination of microdose flare leuprolide acetate and high dose gonadotropins</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>Suppl 3, 80</VL>
<PG>S190-1</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755507"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755506"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulangi-1997" MODIFIED="2009-01-28 14:55:57 +1300" MODIFIED_BY="[Empty name]" NAME="Mulangi 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-01-28 14:55:57 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mulangi AS, Nelson-White TM, Racowsky C, Gelety TJ</AU>
<TI>Follicular phase endocrine response to oral contraceptives (OCs) followed by gonadotropin releasing hormone agonist (GnRHa) for down-regulation prior to controlled ovarian hyperstimulation (COH) for the purpose of IVF</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>Suppl 1, 68</VL>
<PG>S6</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:22:10 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755509"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755508"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neal-1993" MODIFIED="2017-05-23 13:09:57 +1200" MODIFIED_BY="Helen E Nagels" NAME="Neal 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-05-23 13:09:57 +1200" MODIFIED_BY="Helen E Nagels" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neal GS, Sultan KM, Liu HC, Davis OK, Rosenwaks Z</AU>
<TI>A dual approach to ovarian suppression using oral contraceptive pills and leuprolide acetate in high responder patients undergoing IVF</TI>
<SO>Fertility and Sterility</SO>
<YR>1993</YR>
<VL>60</VL>
<NO>5</NO>
<PG>S111</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755511"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755510"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pados-1995" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Pados 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pados G, Tarlatzis BC, Bontis J, Lagos S, Papadimas J, Spanos E, et al</AU>
<TI>Evaluation of different ovarian stimulation protocols for in vitro fertilization</TI>
<SO>Gynecological Endocrinology</SO>
<YR>1995</YR>
<VL>9</VL>
<PG>103-12</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS MODIFIED="2009-01-05 15:28:36 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755513"/><IDENTIFIER MODIFIED="2009-01-05 15:28:36 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.3109/09513599509160198"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755512"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palomba-2008" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Palomba 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palomba S, Falbo A, Orio F, Russo T, Tolino A, Zullo F</AU>
<TI>Pretreatment with oral contraceptives in infertile anovulatory patients with polycystic ovary syndrome who receive gonadotropins for controlled ovarian stimulation</TI>
<SO>Fertility and Sterility</SO>
<YR>2008</YR>
<VL>89</VL>
<NO>6</NO>
<PG>1838-42</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:31:30 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755515"/><IDENTIFIER MODIFIED="2009-01-05 15:31:30 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.fertnstert.2007.05.035"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755514"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pinkas-2008" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Pinkas 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinkas H, Sapir O, Avrech OM, Ben-Haroush A, Ashkenzi J, Fisch B, et al</AU>
<TI>The effect of oral contraceptive pill for cycle scheduling prior to GnRH-antagonist protocol on IVF cycle parameters and pregnancy outcome</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2008</YR>
<VL>25</VL>
<PG>29-33</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:33:42 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755517"/><IDENTIFIER MODIFIED="2009-01-05 15:33:42 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s10815-007-9189-7"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755516"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramsewak-2005" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Ramsewak 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramsewak SS, Duffy S, Taylor J, Woodward B</AU>
<TI>The oral contraceptive pill effectively permits cycle batching for an intermittent in vitro fertilization programme in Trinidad and Tobago</TI>
<SO>West Indian Medical Journal</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>2</NO>
<PG>127-9</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755519"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755518"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rashidi-2011" MODIFIED="2017-05-10 07:01:26 +1200" MODIFIED_BY="Anne Lawson" NAME="Rashidi 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-05-10 07:01:26 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rashidi B, Nasiri R, Rahmanpour H, Shahrokh Tehraninejad E, Deldar M</AU>
<TI>Luteal phase estradiol versus luteal phase GnRH antagonist administration: their effects on antral follicular size coordination and basal hormonal levels</TI>
<SO>Iranian Journal of Reproductive Medicine</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>4</NO>
<PG>315-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755521"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755520"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-1997" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Russell 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell JB, Knezevich KM, Fabian KF, Dickson JA</AU>
<TI>Unstimulated immature oocyte retrieval: early versus mid follicular endometrial priming</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>67</VL>
<NO>4</NO>
<PG>616-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755523"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755522"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanghvi-2002" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Sanghvi 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sanghvi A, Noyes N, Krey LC</AU>
<TI>An oral contraceptive (OCP) microdose flare leuprolide acetate (LA) stimulation protocol is useful for poor prognosis patients undergoing in vitro fertilization (IVF)</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>Suppl 1, 78</VL>
<PG>S149</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755525"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755524"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoolcraft-1997" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Schoolcraft 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L</AU>
<TI>Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>67</VL>
<NO>1</NO>
<PG>93-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755527"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755526"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinkampf-1991" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Steinkampf 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinkampf MP, Hammond KR, Blackwell RE</AU>
<TI>Effect of estrogen/progestin administration on the ovarian response to gonadotropins: a randomized, prospective study</TI>
<SO>Fertility and Sterility</SO>
<YR>1991</YR>
<VL>55</VL>
<NO>3</NO>
<PG>642-3</PG>
<MD>Clinical Trial</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755529"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755528"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Surrey-1989" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Surrey 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Surrey ES, Cedars MI</AU>
<TI>The effect of gonadotropin suppression on the induction of ovulation in premature ovarian failure patients</TI>
<SO>Fertility and Sterility</SO>
<YR>1989</YR>
<VL>52</VL>
<NO>1</NO>
<PG>36-41</PG>
<MD>Research Support, Non-U.S. Gov't</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755531"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755530"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Surrey-1998" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Surrey 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW</AU>
<TI>Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization</TI>
<SO>Fertility and Sterility</SO>
<YR>1998</YR>
<VL>69</VL>
<NO>3</NO>
<PG>419-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755533"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755532"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talebian-2004" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Talebian 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Talebian S, Krey LC, Noyes N</AU>
<TI>Use of oral contraceptives with GnRH antagonists and recombinant gonadotropins in IVF cycles have no deleterious effect on pregnancy outcome</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>Suppl 2, 82</VL>
<PG>S234</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755535"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755534"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talebian-2007" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Talebian 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Talebian S, Krey LC, Reh A, Granguly N, Liu M, Noyes N</AU>
<TI>Oral contraceptive (OC) pre-treatment in GnRH antagonist (ANT) cycles is a reasonable option to control the timing of IVF cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>Suppl 1, 88</VL>
<PG>S291</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755537"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755536"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarlatzis-1993" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Tarlatzis 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarlatzis BC, Pazaitou K, Bili H, Bontis J, Papadimas J, Lagos S, et al</AU>
<TI>Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction</TI>
<SO>Human Reproduction</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>10</NO>
<PG>1612-6</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755539"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755538"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tartagni-2007" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Tartagni 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G</AU>
<TI>Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>87</VL>
<NO>4</NO>
<PG>858-61</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:43:07 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755541"/><IDENTIFIER MODIFIED="2009-01-05 15:43:07 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.fertnstert.2006.08.086"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755540"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tehraninejad-2010" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Tehraninejad 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tehraninejad ES, Nasiri R, Rashidi B, Haghollahi F, Ataie M</AU>
<TI>Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients</TI>
<SO>Archives of Gynecology &amp; Obstetrics</SO>
<YR>2010</YR>
<VL>282</VL>
<NO>3</NO>
<PG>319-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755543"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755542"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008" MODIFIED="2016-08-11 15:21:20 +1200" MODIFIED_BY="[Empty name]" NAME="Wang 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-08-11 15:21:20 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang B, Sun HX, Hu YL, Chen H, Zhang NY</AU>
<TI>Application of GnRH-antagonist to IVF-ET for patients with poor ovarian response</TI>
<SO>National Journal of Andrology [Zhonghua Nan Ke Xue]</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>5</NO>
<PG>423-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755383"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755382"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2016" MODIFIED="2017-05-10 07:04:16 +1200" MODIFIED_BY="Anne Lawson" NAME="Wang 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-10 07:04:16 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y</AU>
<TI>Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF a double-blind randomized crossover clinical trial</TI>
<SO>Medicine</SO>
<YR>2016</YR>
<VL>95</VL>
<NO>9</NO>
<PG>1-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5670897"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5670896"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2016" MODIFIED="2017-05-10 07:04:31 +1200" MODIFIED_BY="Anne Lawson" NAME="Wei 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-10 07:04:31 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei D, Shi Y, Li J, Wang Z, Zhang L, Sun Y, et al</AU>
<TI>Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome</TI>
<SO>Human Reproduction</SO>
<YR>2016</YR>
<VL>32</VL>
<NO>2</NO>
<PG>1-8</PG>
<IDENTIFIERS MODIFIED="2017-01-31 14:01:46 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5670899"/><IDENTIFIER MODIFIED="2017-01-31 14:01:46 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humrep/dew325"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5670898"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisman-1989" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Weisman 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisman Z, Dirnfeld M, Lissak A, Sorokin Y, Abramovici H</AU>
<TI>Oral contraceptive pills and follicular fluid hormones in an in vitro fertilization program</TI>
<SO>Fertility and Sterility</SO>
<YR>1989</YR>
<VL>52</VL>
<NO>3</NO>
<PG>451-3</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755545"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755544"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yokota-2006" MODIFIED="2017-05-11 22:22:38 +1200" MODIFIED_BY="Anne Lawson" NAME="Yokota 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-05-11 22:22:38 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yokota Y, Yokota M, Yokota H, Makita M, Sato S, Araki Y</AU>
<TI>A novel procedure for improving pregnancy rates in frequent repeated IVF failure: estrogen rebound combined with GnRH agonist flare</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21 Suppl 1</VL>
<PG>i130-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755547"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755546"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshida-2005" MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" NAME="Yoshida 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Yoshida A, Kakinuma M, Matsuba T, Seida K, Suzuki H, Tanaka M</AU>
<TI>Effectiveness of using estradiol-GnRH antagonist protocol with unsuccessful oral contraceptive pill-GnRH antagonist protocol cases (full term pregnancies had not resulted) in in-vitro fertilization (IVF) cycles</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>Suppl 1, 84</VL>
<PG>S45</PG>
<MD>Meeting Abstract</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755549"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755548"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Youssef-2017" MODIFIED="2017-05-12 01:04:19 +1200" MODIFIED_BY="Anne Lawson" NAME="Youssef 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-05-12 01:04:19 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Youssef M, van Wely M, Al-Inany H, Madani T, Jahangiri N, Khodabakhshi S, et al</AU>
<TI>A mild ovarian stimulation in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial</TI>
<SO>Human Reproduction</SO>
<YR>2017</YR>
<VL>32</VL>
<NO>1</NO>
<PG>112-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5670900"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-05-12 00:35:41 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Youssef M, van Wely M, Al-Inany H, Madani T, Jahangiri N, Khodabakhshi S, et al</AU>
<TI>Mild versus standard ovarian stimulation in poor responder women undergoing IVF and ICSI (prima) - multicenter randomised controlled study</TI>
<SO>Human Reproduction</SO>
<YR>2014</YR>
<VL>29</VL>
<PG>i50-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755387"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755386"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2008" MODIFIED="2017-05-10 07:06:29 +1200" MODIFIED_BY="Anne Lawson" NAME="Zhao 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-05-10 07:06:29 +1200" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao JZ, Lin XH, Huang XF, Lin JJ, Lin WQ, Ye BL</AU>
<TI>Effect of desogestrel and ethinyl estradiol pretreatment in superovulation cycles with short protocol</TI>
<SO>Chinese Journal of Obstetrics and Gynecology [Zhonghua Fu Chan Ke Za Zhi]</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>2</NO>
<PG>102-5</PG>
<MD>English Abstract; Journal Article</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2755551"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2755550"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-03-01 11:47:49 +1300" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2016-03-01 11:48:54 +1300" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-05-23 13:24:38 +1200" MODIFIED_BY="Helen E Nagels">
<ADDITIONAL_REFERENCES MODIFIED="2017-05-12 01:06:21 +1200" MODIFIED_BY="Anne Lawson">
<REFERENCE ID="REF-Al_x002d_Inany-2016" MODIFIED="2017-04-07 11:46:32 +1200" MODIFIED_BY="[Empty name]" NAME="Al-Inany 2016" TYPE="COCHRANE_REVIEW">
<AU>Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ</AU>
<TI>Gonadotrophin-releasing hormone antagonists for assisted reproductive technology</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2016</YR>
<NO>4</NO>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2017-04-07 11:46:32 +1200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-07 11:46:32 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001750.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arowojolu-2007" MODIFIED="2009-01-28 15:44:27 +1300" MODIFIED_BY="[Empty name]" NAME="Arowojolu 2007" TYPE="COCHRANE_REVIEW">
<AU>Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE</AU>
<TI>Combined oral contraceptive pills for treatment of acne</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-01-28 15:44:27 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-28 15:44:12 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004425.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Awadalla-1987" MODIFIED="2008-12-19 13:45:03 +1300" MODIFIED_BY="jane clarke" NAME="Awadalla 1987" TYPE="JOURNAL_ARTICLE">
<AU>Awadalla SG, Friedman CI, Chin NW, Dodds W, Park JM, Kim MH</AU>
<TI>Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins</TI>
<SO>Fertility and Sterility</SO>
<YR>1987</YR>
<VL>48</VL>
<NO>5</NO>
<PG>811-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barmat-2005" MODIFIED="2009-01-28 15:46:02 +1300" MODIFIED_BY="[Empty name]" NAME="Barmat 2005" TYPE="JOURNAL_ARTICLE">
<AU>Barmat LI, Chantilis SJ, Hurst BS, Dickey RP</AU>
<TI>A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/ recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/ rFSH in women pretreated with oral contraceptives before in vitro fertilization</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>83</VL>
<NO>2</NO>
<PG>321-30</PG>
<IDENTIFIERS MODIFIED="2009-01-28 15:46:02 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-28 15:46:02 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.fertnstert.2004.06.076"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Biljan-1998a" MODIFIED="2017-05-11 22:26:56 +1200" MODIFIED_BY="Anne Lawson" NAME="Biljan 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL</AU>
<TI>Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates</TI>
<SO>Fertility and Sterility</SO>
<YR>1998</YR>
<VL>70</VL>
<NO>6</NO>
<PG>1063-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1979" MODIFIED="2008-12-19 13:46:38 +1300" MODIFIED_BY="jane clarke" NAME="Cohen 1979" TYPE="JOURNAL_ARTICLE">
<AU>Cohen BL, Katz M</AU>
<TI>Pituitary and ovarian function in women receiving hormonal contraception</TI>
<SO>Contraception</SO>
<YR>1979</YR>
<VL>20</VL>
<NO>5</NO>
<PG>475-87</PG>
<IDENTIFIERS MODIFIED="2008-11-11 13:59:57 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-De-Ziegler-1998" MODIFIED="2008-12-19 13:47:13 +1300" MODIFIED_BY="jane clarke" NAME="De Ziegler 1998" TYPE="JOURNAL_ARTICLE">
<AU>De Ziegler D, Jaaskelainen AS, Brioschi PA, Fanchin R, Bulletti C</AU>
<TI>Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH)</TI>
<SO>Human Reproduction</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>3</NO>
<PG>561-4</PG>
<IDENTIFIERS MODIFIED="2008-11-17 16:52:16 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dodson-1989" MODIFIED="2008-12-19 13:47:20 +1300" MODIFIED_BY="jane clarke" NAME="Dodson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Dodson WC</AU>
<TI>Role of gonadotropin releasing hormone agonists in ovulation induction</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1989</YR>
<VL>34</VL>
<NO>1</NO>
<PG>76-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EndNote" MODIFIED="2017-05-10 07:12:19 +1200" MODIFIED_BY="Anne Lawson" NAME="EndNote" TYPE="COMPUTER_PROGRAM">
<TI>EndNote</TI>
<YR>2008</YR>
<EN>X1</EN>
<PB>Thomson Reuters</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erkkola-2007" MODIFIED="2008-12-19 13:47:37 +1300" MODIFIED_BY="jane clarke" NAME="Erkkola 2007" TYPE="JOURNAL_ARTICLE">
<AU>Erkkola R</AU>
<TI>Recent advances in hormonal contraception</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>19</VL>
<PG>547-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESHRE-2016" MODIFIED="2017-05-12 01:06:21 +1200" MODIFIED_BY="Anne Lawson" NAME="ESHRE 2016" TYPE="JOURNAL_ARTICLE">
<AU>European Society of Human Reproduction and Embryology</AU>
<TI>32nd annual meeting of the European Society of Human Reproduction and Embryology. Helsinki, Finland 2016</TI>
<SO>Human Reproduction</SO>
<YR>2016</YR>
<VL>31 Suppl 1</VL>
<PG>Abstract book</PG>
<PB>Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaspard-1984" MODIFIED="2008-12-19 13:47:43 +1300" MODIFIED_BY="jane clarke" NAME="Gaspard 1984" TYPE="JOURNAL_ARTICLE">
<AU>Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier J</AU>
<TI>Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel</TI>
<SO>Contraception</SO>
<YR>1984</YR>
<VL>29</VL>
<NO>4</NO>
<PG>305-18</PG>
<MD>Comparative Study</MD>
<IDENTIFIERS MODIFIED="2008-11-11 14:00:11 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2014" MODIFIED="2017-05-11 22:24:09 +1200" MODIFIED_BY="Anne Lawson" NAME="GRADEpro GDT 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>accessed prior to 28 October 2016</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griesinger-2008" MODIFIED="2009-01-28 15:25:46 +1300" MODIFIED_BY="[Empty name]" NAME="Griesinger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM</AU>
<TI>Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis</TI>
<SO>Fertility and Sterility</SO>
<YR>2008</YR>
<VL>90</VL>
<NO>4</NO>
<PG>1055-63</PG>
<IDENTIFIERS MODIFIED="2009-01-28 15:25:46 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-28 15:25:46 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.fertnstert.2007.07.1354"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Griffin-2002" MODIFIED="2017-05-10 07:18:47 +1200" MODIFIED_BY="Anne Lawson" NAME="Griffin 2002" TYPE="OTHER">
<AU>Griffin PD, Rowe PJ, Vayena E, editor(s)</AU>
<TI>Medical, ethical and social aspects of assisted reproduction</TI>
<SO>Current practices and controversies in assisted reproduction: report of a WHO meeting. Geneva, Switzerland: World Health Organization</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2008-11-12 11:29:29 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-11-12 11:29:29 +1300" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISBN 92 4 159030 0"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harwood-2007" MODIFIED="2009-01-28 15:48:55 +1300" MODIFIED_BY="[Empty name]" NAME="Harwood 2007" TYPE="JOURNAL_ARTICLE">
<AU>Harwood K, Vuguin P, DiMartino-Nardi J</AU>
<TI>Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth</TI>
<SO>Hormone Research</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>5</NO>
<PG>209-17</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2009-01-28 15:48:55 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-28 15:48:55 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1159/000101538"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-05-10 07:20:32 +1200" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS MODIFIED="2008-11-26 13:26:47 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Huirne-2006b" MODIFIED="2017-05-11 22:30:18 +1200" MODIFIED_BY="Anne Lawson" NAME="Huirne 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Huirne JA, Hugues JN, Pirard C, Fischl F, Sage JC, Pouly JL, et al</AU>
<TI>Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1408-15</PG>
<IDENTIFIERS MODIFIED="2009-01-28 15:49:56 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-28 15:49:56 +1300" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="10.1093/humrep/del030"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Irvine-1999" MODIFIED="2008-12-19 13:50:18 +1300" MODIFIED_BY="jane clarke" NAME="Irvine 1999" TYPE="JOURNAL_ARTICLE">
<AU>Irvine GA, Cameron IT</AU>
<TI>Medical management of dysfunctional uterine bleeding</TI>
<SO>Best Practice and Research in Clinical Obstetrics and Gynaecology</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>2</NO>
<PG>189-202</PG>
<IDENTIFIERS MODIFIED="2008-11-17 16:54:16 +1300" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Le-Nestour-1993" MODIFIED="2008-12-19 13:50:42 +1300" MODIFIED_BY="jane clarke" NAME="Le Nestour 1993" TYPE="JOURNAL_ARTICLE">
<AU>Le Nestour E, Marraoui J, Lahlou N, Roger M, De Ziegler D, Bouchard P</AU>
<TI>Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1993</YR>
<VL>77</VL>
<NO>2</NO>
<PG>439-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MDSG-Module-2008" MODIFIED="2017-05-10 07:23:33 +1200" MODIFIED_BY="Anne Lawson" NAME="MDSG Module 2008" TYPE="OTHER">
<AU>Farquhar C, Clarke J, Lethaby A, Thomas J, Proctor M, Barlow D, et al</AU>
<TI>Cochrane Menstrual Disorders and Subfertility Group, About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>Available at www.thecochranelibrary.com</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2017-05-10 07:29:28 +1200" MODIFIED_BY="Anne Lawson" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group</AU>
<TI>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>2535</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moudgal-1985" MODIFIED="2017-05-10 07:29:42 +1200" MODIFIED_BY="Anne Lawson" NAME="Moudgal 1985" TYPE="JOURNAL_ARTICLE">
<AU>Moudgal RN, Jagannadha Rao A, Murthy GSRC, Neelakanta R, Banavar SR, Kotagi SG, et al</AU>
<TI>Effect of intranasal administration of norethisterone and progesterone on pituitary and gonadal function in adult male and female bonnet monkeys (<I>Macaca radiata</I>)</TI>
<SO>Fertility and Sterility</SO>
<YR>1985</YR>
<VL>44</VL>
<NO>1</NO>
<PG>120-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pandian-2005" MODIFIED="2009-01-28 15:53:06 +1300" MODIFIED_BY="[Empty name]" NAME="Pandian 2005" TYPE="COCHRANE_REVIEW">
<AU>Pandian Z, Bhattacharya S, Vale L, Templeton A</AU>
<TI>In vitro fertilisation for unexplained subfertility</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-01-28 15:53:06 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-28 15:53:06 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003357.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-10-28 12:03:30 +1300" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5 (RevMan 5)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN" MODIFIED="2017-05-10 07:30:13 +1200" MODIFIED_BY="Anne Lawson" NAME="SIGN" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network</AU>
<TI>Search filters</TI>
<SO>www.sign.ac.uk/methodology/filters.html#random</SO>
<YR>(accessed 18 November 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarlatzis-2006" MODIFIED="2009-01-28 15:54:05 +1300" MODIFIED_BY="[Empty name]" NAME="Tarlatzis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P</AU>
<TI>GnRH antagonists in ovarian stimulation for IVF</TI>
<SO>Human Reproduction Update</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>4</NO>
<PG>333-40</PG>
<IDENTIFIERS MODIFIED="2009-01-28 15:54:05 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-28 15:54:05 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humupd/dml001"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Wely-2003" MODIFIED="2009-01-28 15:54:14 +1300" MODIFIED_BY="[Empty name]" NAME="Van Wely 2003" TYPE="COCHRANE_REVIEW">
<AU>Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F</AU>
<TI>Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-01-28 15:54:14 +1300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-28 15:41:45 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003973"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-05-23 13:24:38 +1200" MODIFIED_BY="Helen E Nagels">
<REFERENCE ID="REF-Smulders-2006" MODIFIED="2017-05-23 13:22:19 +1200" MODIFIED_BY="Helen E Nagels" NAME="Smulders 2006" TYPE="COCHRANE_REVIEW">
<AU>Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JAM</AU>
<TI>Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2017-05-23 13:22:19 +1200" MODIFIED_BY="Helen E Nagels"><IDENTIFIER MODIFIED="2017-05-23 13:22:19 +1200" MODIFIED_BY="Helen E Nagels" TYPE="DOI" VALUE="10.1002/14651858.CD006109"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smulders-2010" MODIFIED="2017-05-23 13:24:38 +1200" MODIFIED_BY="Helen E Nagels" NAME="Smulders 2010" TYPE="COCHRANE_REVIEW">
<AU>Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JAM</AU>
<TI>Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-05-23 13:24:38 +1200" MODIFIED_BY="Helen E Nagels"><IDENTIFIER MODIFIED="2017-05-23 13:24:38 +1200" MODIFIED_BY="Helen E Nagels" TYPE="DOI" VALUE="10.1002/14651858.CD006109.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aston-1995">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 152 (77 in intervention group; 75 in control group).</P>
<P>Number of withdrawals: 8 (1 in intervention group due to endometrioma; 7 in control group: 5 due to endometrioma or cysts and 2 chose not to proceed).</P>
<P>Number of women analyzed: 144.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 21:26:20 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: UK.</P>
<P>Inclusion criteria: women planning to have an IVF cycle on the Southampton (UK) IVF programme.</P>
<P>Exclusion criteria: endometrioma or ovarian cyst seen on vaginal ultrasound scan on day 19 of the menstrual cycle (after recruitment).</P>
<P>Mean age ± SD: intervention group: 33.8 ± 4.1 years; control group: 33.5 ± 3.5 years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:04:15 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: medroxyprogesterone acetate (10 mg/day) on cycle days 19-25 + GnRH agonist (buserelin acetate, nasal administration 200 &#956;g 3 times daily) from cycle day 21 + hMG 4 ampoules/day (75 IU FSH and 75 IU LH per ampoule) from day 4 of ensuing menses.</P>
<P>Control: placebo on cycle days 19-25 + GnRH agonist (buserelin acetate, 200 &#956;g nasal administration, 3 times daily) from cycle day 21 + hMG 4 ampoules/day (75 IU FSH and 75 IU LH per ampoule) from day 4 of ensuing menses.</P>
<P>Both hMG and GnRH agonist continued until hCG injection (10,000 IU, IM), administered when leading 3 follicles reached diameter of &#8805; 18 mm and serum oestradiol &gt; 300 pmol/L for every follicle &gt; 14 mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:27:06 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Cyst development: intraovarian sonolucent structure with a mean diameter &gt; 14 mm, measured after 12 days of pituitary suppression.</LI>
<LI>Clinical pregnancy rates: not defined.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 02:13:56 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biljan-1998b">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]">
<P>Academic centre, parallel group study.</P>
<P>Number of women randomized: 83 women undergoing 102 cycles (51 cycles in each group; number of women per group not reported).</P>
<P>Number of withdrawals: not reported.</P>
<P>Number of women analyzed: only number of cycles analyzed reported (102 cycles).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-12 00:07:06 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: Canada.</P>
<P>Inclusion criteria: women who were receiving a long protocol of pituitary suppression in the early follicular phase as a part of IVF-ET treatment.</P>
<P>Exclusion criteria: not reported.</P>
<P>Median age (range): intervention group: 35.2 years (32.5-39.1); control group: 33.7 years (31.6-38.3).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 20:47:53 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP on cycle days 1-14 + GnRH agonist (buserelin acetate, long protocol 500 &#956;g/day) started on cycle day 14 + hMG (75 IU FSH and 75 IU LH) or pure FSH (75 IU) started after achievement of pituitary suppression.</P>
<P>Control: GnRH agonist (buserelin acetate, long protocol 500 &#956;g/day) started on cycle day 2 + hMG (75 IU FSH and 75 IU LH) or pure FSH (75 IU) started after achievement of pituitary suppression.</P>
<P>If no pituitary suppression (serum oestradiol &lt; 40 pg/mL) achieved after 14 days of GnRH agonist administration, dosage of buserelin acetate increased to 500 &#956;g twice daily + administration of an IM injection of progesterone 100 mg.</P>
<P>Both hMG/FSH and GnRH agonist continued until hCG injection, administered when &#8805; 3 follicles reach a mean diameter of &#8805; 18 mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 23:43:38 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Clinical pregnancy rate per cycle started: presence of &#8805; 1 foetal heart beats confirmed with ultrasound performed at least 4 weeks after embryo transfer.</LI>
<LI>Number of women with a cyst: intraovarian sonolucent structure with a mean diameter of &gt; 14 mm, measured after 7 days of pituitary suppression.</LI>
<LI>Number of days of GnRHa treatment.</LI>
<LI>Number of days of gonadotrophin treatment.</LI>
<LI>Total quantity of gonadotrophin administered: measured in ampoules.</LI>
<LI>Number of follicles.</LI>
<LI>Number of oocytes collected/fertilised.</LI>
<LI>Number of embryos replaced.</LI>
<LI>Implantation rate.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no.</P>
<P>No per-woman data reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blockeel-2012">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 86 (44 in intervention group; 42 in control group).</P>
<P>Number of withdrawals: 14 (9 in intervention group due to cyst development, protocol violation, insufficient ovarian response, did not undergo treatment, did not receive embryo transfer; 5 in control group due to insufficient ovarian response, did not receive embryo transfer).</P>
<P>Number of women analyzed (for pregnancy outcome): 72 (35 in intervention group; 37 in control group).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 20:36:45 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Belgium.</P>
<P>Inclusion criteria: women aged &#8804; 36 years, BMI 18-29 kg/m<SUP>2</SUP>, underwent a first or second treatment cycle of IVF with ICSI, serum FSH on day 3 of the menstrual cycle &lt; 12 IU/L, normal ultrasound scan regular ovulatory menstrual cycle of 21 to 35 days.</P>
<P>Exclusion criteria: oocyte donors, women with endometriosis &#8805; grade 3, endocrine or metabolic abnormalities, PCOS or previous history of poor ovarian response (defined as development of &lt; 4 follicles in previous IVF or ICSI cycle).</P>
<P>Mean age ± SD: intervention group: 29.2 ± 3.0 years; control group: 30.2 ± 3.0 years.</P>
<P>Setting: assisted reproduction programme in Belgium.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:34:01 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: oestradiol valerate (2 × 2 mg/day) during 6-10 consecutive days (from cycle day 25 onwards) prior to start of rFSH stimulation so that the first day of stimulation occurred between Friday and Sunday.</P>
<P>Control: no pretreatment; standard GnRH antagonist protocol.</P>
<P>Both groups received rFSH (150 IU) and on day 6 of stimulation GnRH antagonist protocol (ganirelix 0.25 mg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:33:08 +1200" MODIFIED_BY="Anne Lawson">
<P>Primary:</P>
<UL>
<LI>Number of women undergoing oocyte retrieval during weekend days.</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Mean number of COCP in each treatment group.</LI>
<LI>Number of oocytes.</LI>
<LI>Duration of stimulation.</LI>
<LI>Total cumulative dose of rFSH used.</LI>
<LI>Pregnancy rate.</LI>
<LI>Basal hormone serum values.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 02:31:27 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation: not reported.</P>
<P>ITT analysis: not reported.</P>
<P>Objective of the study was to assess the ability of oestradiol to control the oocyte retrieval of GnRH antagonist cycles prior to COS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]">
<P>Multicentre (6 IVF centres), parallel group study.</P>
<P>Number of women randomized: 93 (21 in COCP group; 23 in progestogen group; 25 in oestrogen group; 24 in control group).</P>
<P>Number of withdrawals: 3 in oestrogen group (1 did not start any treatment, 1 due to an ovarian cyst and 1 due to major protocol violation).</P>
<P>Number of women analyzed: 90.</P>
<P>Duration of study: 10 months of recruitment.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 21:27:49 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: France.</P>
<P>Inclusion criteria: regular normo-ovulatory cycles (28-35 days), aged &lt; 38 years, BMI 18-30.</P>
<P>Exclusion criteria: high levels of baseline serum FSH or oestradiol, &lt; 5 follicles at the antral follicular count performed on day 3 of a spontaneous cycle, history of high (&gt; 20 oocytes) or low (&lt; 5 oocytes) ovarian response in a previous IVF attempt.</P>
<P>Mean age ± SD: COCP group: 30.8 ± 4.6 years; progestogen group: 32.9 ± 2.5 years; oestrogen group: 31.8 ± 3.2 years; control group: 31.2 ± 4.3 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:06:53 +1200" MODIFIED_BY="Anne Lawson">
<P>COCP group: COCP (ethinyl oestradiol 30 &#956;g + desogestrel 150 &#956;g daily), started cycle day 2 or 3 for 15-21 days (stopped on a Sunday) + rFSH (recombinant follitropin beta 150-300 IU/day), started post-treatment day 5 + GnRH antagonist (ganirelix acetate 0.25 mg/day), started when leading follicle reached 14 mm in diameter.</P>
<P>Progestogen group: norethisterone 10 mg/day, started cycle day 15 for 10-15 days (stopped on a Sunday) + rFSH (recombinant follitropin beta 150-300 IU/day), started post-treatment day 5 + GnRH antagonist (ganirelix acetate 0.25 mg/day), started when leading follicle reached 14 mm in diameter.</P>
<P>Oestrogen group: micronised 17-&#946;E<SUB>2</SUB> (2 mg twice daily), 10-15 days, started 10 days before the presumed menses (stopped on a Sunday) + rFSH (recombinant follitropin beta 150-300 IU/day), started post-treatment day 5 + GnRH antagonist (ganirelix acetate 0.25 mg/day), started when leading follicle reached 14 mm in diameter.</P>
<P>Control group: rFSH (recombinant follitropin beta 150-300 IU/day), started day 3 after spontaneous menses + GnRH antagonist (ganirelix acetate 0.25 mg/day), started when leading follicle reached 14 mm in diameter.</P>
<P>rFSH dose according to age, BMI and previous responses to stimulation; after 5 days of treatment dose adjustment according to ovarian response.</P>
<P>Both rFSH and GnRH antagonist were continued until hCG injection (10,000 IU), administered when &#8805; 3 mature (of &#8805; 17 mm diameter) follicles were obtained.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-12 00:57:38 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Number of live births.</LI>
<LI>Number of positive pregnancy tests.</LI>
<LI>Clinical pregnancy rate: not defined.</LI>
<LI>Ongoing pregnancy rate: pregnancy developing beyond 12 weeks.</LI>
<LI>Multiple pregnancy rate: not defined.</LI>
<LI>Hormonal profiles during the 5-day washout period.</LI>
<LI>Follicular growth.</LI>
<LI>Antagonist duration.</LI>
<LI>Pretreatment duration.</LI>
<LI>Number of retrievals.</LI>
<LI>FSH dose.</LI>
<LI>Transferred embryos.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 02:53:11 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: no.</P>
<P>ITT analysis performed: no (not for oestrogen group).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:35 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:35 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 472 (238 in intervention group; 234 in control group).</P>
<P>Number of withdrawals: 19 (5 in intervention group due to spontaneous pregnancy, discontinuation and no periods; 14 in control group due to spontaneous pregnancy, discontinuation, ovarian cyst and protocol change).</P>
<P>Number of women analyzed: 453 (233 in intervention group; 220 in control group).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-12 00:07:52 +1200" MODIFIED_BY="Anne Lawson">
<P>Country France.</P>
<P>Inclusion criteria: regular normo-ovulatory cycles (28-35 days), aged &lt; 38 years, BMI 18-30 kg/m<SUP>2</SUP> and first or second IVF/ICSI attempt.</P>
<P>Exclusion criteria: high basal levels of serum FSH (&gt; 12 IU/L) or oestradiol (&gt; 80 pg/mL), &lt; 5 follicles at the antral follicular count performed on day 3 of a spontaneous cycle or history of high (&gt; 20 oocytes) or low (&lt; 5 oocytes) ovarian response in earlier IVF attempt.</P>
<P>Mean age ± SD: intervention group: 31.1 ± 3.6 years; control group: 31.2 ± 3.7 years.</P>
<P>Setting: 10 private or university-based centres in France.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:34:14 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: oral 17 &#946;-oestradiol (4 mg; 2 mg x 2/day) started 7 days before the presumed onset of menses and administered up to the next Thursday after the occurrence of menstrual bleeding.</P>
<P>Control: no pretreatment.</P>
<P>Ovarian stimulation started on Friday in intervention group and on cycle day 2 after spontaneous menses in control group. Followed by GnRH antagonists on day 6, then hCG.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:27:37 +1200" MODIFIED_BY="Anne Lawson">
<P>Primary: </P>
<UL>
<LI>Number of retrieved oocytes.</LI>
</UL>
<P>Secondary: </P>
<UL>
<LI>Consumption of gonadotropins.</LI>
<LI>Duration of treatment.</LI>
<LI>Implantation and pregnancy rates.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 02:43:27 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation for sample size (225 women per group).</P>
<P>ITT analysis not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:36 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daly-2002">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:36 +1200" MODIFIED_BY="[Empty name]">
<P>Cross-over study.</P>
<P>Number of women randomized: 25 (13 intervention group; 12 in control group).</P>
<P>Number of withdrawals: not reported.</P>
<P>Number of women analyzed: unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 21:28:10 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: USA.</P>
<P>Inclusion criteria: women, aged &lt; 41 years, who were anticipated to have limited ovarian reserve based on transvaginal ultrasound showing limited follicles on cycle day 2-3 or hormonal values (inhibin B, FSH, oestradiol).<BR/>Exclusion criteria: not reported.</P>
<P>Mean age: not reported.</P>
<P>Poor response: yes ("limited ovarian reserve").</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:07:20 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP + GnRH agonist (leuprolide acetate, microdose) + hMG (300 IU FSH + 75 IU LH). Timing of administration of COCP, hMG and GnRH agonist not reported.</P>
<P>Control: oestradiol (2 mg) in the luteal phase of the preparation cycle + FSH (300 IU), started cycle day 2 + GnRH antagonist (ganirelix acetate) started in late follicular phase + hMG (375 IU FSH + 150 IU LH), timing not reported.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:28:14 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Ongoing pregnancy: a viable pregnancy, method of assessment not reported.</LI>
<LI>Clinical pregnancy: not defined.</LI>
<LI>Number of mature oocytes.</LI>
<LI>Number of good embryos.</LI>
<LI>Implantation rate.</LI>
<LI>Cancellation rate.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 02:57:53 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: unclear.</P>
<P>ITT analysis performed: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:36 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ditkoff-1996">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:36 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 105 (47 in intervention group; 58 in control group).</P>
<P>Number of withdrawals: 0.</P>
<P>Number of women analyzed: 105.</P>
<P>Length of follow-up: until end of treatment cycle.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 21:07:40 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: USA.</P>
<P>Inclusion criteria: day 3 FSH values &lt; 15 mIU/mL.</P>
<P>Exclusion criteria: not reported.</P>
<P>Mean age ± SD: intervention: 36.7 ± 4.8 years; control: 35.8 ± 4.57 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:08:34 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: norethindrone acetate (10 mg/day PO) on cycle days 1-8 + GnRH agonist (leuprolide acetate, 1 mg/day, SC), started cycle day 1 + hMG (225 IU/day IM), started when serum oestradiol level was &lt; 30 pg/mL.<BR/>2) GnRH agonist (leuprolide acetate 1 mg/day, SC), started cycle day 1 + hMG (225 IU/day, IM), started when serum oestradiol level was &lt; 30 pg/mL.</P>
<P>Both hMG and GnRH agonist are continued until hCG injection (10,000 IU, IM), administered when the leading follicles reached a diameter of &#8805; 18 mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 23:43:42 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Number of deliveries/ongoing pregnancies; positive foetal heart activity on ultrasound.</LI>
<LI>Number of clinical pregnancies; evidence of a clinical gestational sac.</LI>
<LI>Days until suppression.</LI>
<LI>Number of cysts cycles; intraovarian sonolucent structure with a mean diameter &gt; 14 mm, measured after 8 days of pituitary suppression.</LI>
<LI>Number of oocytes retrieved.</LI>
<LI>Days of ovarian stimulation.</LI>
<LI>Number of ampoules of hMG.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 03:02:09 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: no.</P>
<P>ITT analysis performed: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:37 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Engmann-1999">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:37 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women recruited: 123.</P>
<P>Number of women excluded: 6 (2 due to ovarian cysts &#8805; 15 mm, 2 due to raised early follicular phase serum FSH, 2 did not undergo IVF).</P>
<P>Number of women randomized: 117 (63 in intervention group; 54 in control group).</P>
<P>Number of withdrawals: 1 (in intervention group, due to violation of the study protocol).</P>
<P>Number of women analyzed: 116.</P>
<P>Duration of study: 1 year of recruitment.</P>
<P>Source of funding: Schering Health Care Limited, West Sussex, UK, supplied the norethindrone.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 21:32:28 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: UK and Canada.</P>
<P>Inclusion criteria: aged 18-44 years at time of screening, duration of infertility &#8805; 1 year, early follicular phase serum FSH &#8804; 11.0 IU/L, good physical and mental health, suitability for the long-term buserelin protocol for desensitisation.</P>
<P>Exclusion criteria: endometrioma of the ovary, ovarian cysts (&#8805; 15 mm) in the early follicular phase, known contraindications to the use of progestogen, GnRH agonists or hMG.</P>
<P>Mean age ± SD: intervention group: 35.3 ± 4.3 years; control group: 33.8 ± 5.5 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:34:56 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: norethindrone (10 mg on cycle day 1 and 5 mg twice daily on cycle day 2-5) + GnRH agonist (buserelin acetate 500 &#956;g/day, SC, long protocol), started on cycle day 2 (dose adjustment after pituitary suppression to 200 &#956;g/day) + hMG (Normegon, 75 IU FSH 2-5 ampoules/day) or rFSH<I>,</I> started when serum oestradiol &#8804; 150 pmol/L.</P>
<P>Control: GnRH agonist (buserelin acetate 500 &#956;g/day, SC, long protocol) started on cycle day 2 (dose adjustment after pituitary suppression to 200 &#956;g/day) + hMG (Normegon, 75 IU FSH 2-5 ampoules/day) or rFSH<I>,</I> started when serum oestradiol &#8804; 150 pmol/L.</P>
<P>Pituitary suppression achieved when there was an absence of follicular activity and endometrial thickness &lt; 5 mm.</P>
<P>hMG or rFSH dose according to woman's age, previous response, basal serum FSH levels and PCOS.</P>
<P>Both hMG/rFSH and GnRH agonist continued until hCG injection (10,000 IU, IM), administered when 2 or 3 leading follicles &#8805; 18 mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:28:29 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Incidence of functional ovarian cysts (&#8805; 10 mm, measured after 1 week of GnRH agonist).</LI>
<LI>Number of days required to achieve pituitary desensitisation.</LI>
<LI>Number of hospital visits before ovarian stimulation.</LI>
<LI>Number of preovulatory follicles and mature oocytes.</LI>
<LI>Fertilisation rate.</LI>
<LI>Number of good-quality embryos produced and transferred.</LI>
<LI>Implantation rate.</LI>
<LI>Clinical pregnancy rate: positive pregnancy test with evidence of a gestational sac.</LI>
<LI>Amount of gonadotrophins administered: measured in ampoules.</LI>
<LI>Pregnancy loss.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 03:10:15 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fanchin-2003">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:37 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 100 (number of women per group not reported).</P>
<P>Number of withdrawals: 10 (4 due to personal reasons and 6 due to major protocol violation).</P>
<P>Number of women analyzed: 90 (47 in intervention group; 43 in control group).</P>
<P>Duration of study: 1 IVF-ET cycle, from day 20 of the previous cycle to day of hCG administration (information obtained from contact person).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 21:28:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: France.</P>
<P>Inclusion criteria: aged &#8804; 38 years; regular, ovulatory menstrual cycles every 25-35 days; both ovaries present; no current or past diseases affecting ovaries or gonadotrophin or sex steroid secretion, clearance or excretion; BMI 18-27 kg/m<SUP>2</SUP>; no hormone therapy during the past 6 weeks; adequate visualisation of both ovaries in transvaginal ultrasound scans.</P>
<P>Exclusion criteria: not reported.</P>
<P>Median age (range): intervention group: 33 (26-38) years; control group: 33 (25-38) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:11:05 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: micronised 17&#946;-E<SUB>2 </SUB>(4 mg/day, PO), started cycle day 20 until day 2 of the next cycle + rFSH (225 IU/day, SC) on cycle days 3-7 + GnRH antagonist (cetrorelix acetate 3 mg single dose, SC) when &#8805; 1 follicle &gt; 13 mm in diameter.</P>
<P>Control: rFSH (225 IU/day SC) on cycle days 3-7 + GnRH antagonist (cetrorelix acetate 3 mg single dose, SC) when &#8805; 1 follicle &gt; 13 mm in diameter.</P>
<P>rFSH dose adjustments according to follicle growth determined by serum oestradiol levels and ultrasound monitoring.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 23:43:45 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Days of GnRH antagonist administration.</LI>
<LI>Day of hCG administration.</LI>
<LI>Dose of gonadotrophins.</LI>
<LI>Number of mature follicles.</LI>
<LI>Number of embryos transferred.</LI>
<LI>Clinical pregnancy rates per cycle (cycles equivalent to number of participants); presence of a gestational sac with foetal heart activity at 6 weeks on ultrasound scan.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no</P>
<P>Our data analysis in this review includes 90 women with full follow-up. We did not include all randomized women because it is unclear how many women were randomized to each group before dropouts.</P>
<P>The study publication reports very low measures of variability which can be to be assumed SEs and which we have converted to SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franco-Jr-2003">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women recruited: 22.</P>
<P>Number of women randomized: 22 (16 in intervention group; 6 in control group).</P>
<P>Number of withdrawals: 1 (both in intervention group, due to spontaneous pregnancies).</P>
<P>Number of women analyzed: 20.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 21:32:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: Brazil.</P>
<P>Inclusion criteria: women without specific ovulatory dysfunction, aged &#8804; 37 years, who would be submitted to ovarian stimulation.</P>
<P>Exclusion criteria: not reported.</P>
<P>Mean age ± SD: intervention group: 32.2 ± 2.1 years; control group: 31.8 ± 1.9 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-12 00:08:05 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: oestradiol valerate (4 mg/day) for 14 days, started cycle day 21 + rFSH (150-300 IU) (fixed dose for 5 days), started post-treatment day 1 + GnRH antagonist (ganirelix acetate 0.25 mg/day), started when follicular diameter &#8805; 15 mm.</P>
<P>Control: GnRH agonist (nafarelin acetate 200 &#956;g twice daily, nasal), started cycle day 21 + rFSH (150-300 IU) (fixed dose for 5 days), started stimulation day 14.</P>
<P>Both rFSH and GnRH analogues continued until hCG injection (5000-10,000 IU), administered when &#8805; 2 follicles were &#8805; 17 mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 23:43:49 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Clinical pregnancy rate: &#8805; 1 foetal heart beats confirmed with ultrasound, performed at least 4 weeks after embryo transfer.</LI>
<LI>Ovarian cyst: intraovarian sonolucent structure with mean diameter of &gt; 14 mm, time of measurement not reported.</LI>
<LI>OHSS: not defined.</LI>
<LI>Values of LH, oestradiol, progesterone.</LI>
<LI>Dose of FSH.</LI>
<LI>Number of collected oocytes.</LI>
<LI>Number of oocytes in metaphase II.</LI>
<LI>Fertilisation rate.</LI>
<LI>Number of transferred embryos.</LI>
<LI>Embryo implantation rate.</LI>
<LI>Gestation rate per embryo transfer.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 03:24:41 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: no.</P>
<P>ITT analysis performed: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Velasco-2011">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]">
<P>2-arm parallel RCT.</P>
<P>Number of women randomized: 228 (115 in intervention; 113 in control).</P>
<P>Withdrawals: not reported.</P>
<P>Number of women analyzed: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 20:37:59 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Spain.</P>
<P>Inclusion criteria: regular cycle women under 39 years, &lt; 3 previous IVF attempts.</P>
<P>Exclusion criteria: previous low response to COH, ovarian surgery or PCOS.</P>
<P>Mean age: intervention group: 34.1 years; control group: 33.7 years.</P>
<P>Setting: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-12 00:09:20 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP (ethinyl oestradiol 30 &#956;g + desogestrel 150 &#956;g) for 12-16 days and COH started on day 5 post COCP using GnRH antagonist.</P>
<P>Control: GnRH agonist long protocol from days 20-22 of the previous cycle.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:29:21 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Duration of stimulation.</LI>
<LI>FSH used.</LI>
<LI>Number of oocyte retrieved.</LI>
<LI>Miscarriage rate.</LI>
<LI>Multiple pregnancy rate.</LI>
<LI>Ongoing pregnancy.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 03:43:44 +1200" MODIFIED_BY="Anne Lawson">
<P>Duration of stimulation, FSH used and number of oocyte retrieved were continuous variables.</P>
<P>Power calculation was not reported.</P>
<P>ITT analysis: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hauzman-2013">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 100 (50 in each group).</P>
<P>Number of withdrawals: 16 (7 in intervention group; 9 in control group).</P>
<P>Number of women analyzed: 100 (ITT analysis).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 03:46:32 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Spain.</P>
<P>Inclusion criteria: aged 18-38 years, regular normo-ovulatory menstrual cycles (26-35 days), BMI &lt; 30 kg/m<SUP>2</SUP>, normal cycle day 3 basal serum hormone levels (FSH &lt; 10 IU/L and oestradiol &lt; 60 pg/mL) and &lt; 3 previous IVF/ICSI attempts.</P>
<P>Exclusion criteria: previous ovarian surgery, low ovarian response (cancellation of cycle due to poor follicular development after &#8805; 7 days of gonadotropin stimulation or &lt; 5 oocytes retrieved) in previous IVF/ICSI cycle and PCOS.</P>
<P>Mean age ± SD: intervention group: 33.9 ± 3.4 years; control group: 34.5 ± 3.1 years.</P>
<P>Setting: single hospital clinic in Madrid, Spain.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:35:05 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP: (ethinyl oestradiol 30 &#956;g + levonorgestrel 150 &#956;g) on day 1 or 2 of cycle prior to IVF/ICSI and continued for 12-16 days, with stimulation starting 5 days after stopping pretreatment.</P>
<P>Control: (oestradiol valerate 4 mg/day (2 mg × 2)) from day 20 of menstrual cycle for 5-12 days until the day before starting stimulation.</P>
<P>In both groups, GnRH antagonist (ganirelix 0.25 mg/day) started when the leading follicle reached 13 mm in diameter and ovarian triggering performed with rhCG (250 &#956;g) (when 2 leading follicles reached &#8805; 17 mm mean diameter).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:29:30 +1200" MODIFIED_BY="Anne Lawson">
<P>Primary: </P>
<UL>
<LI>Ongoing pregnancy rate.</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Implantation rate.</LI>
<LI>Clinical pregnancy rate.</LI>
<LI>Miscarriage rate.</LI>
<LI>Live birth rate.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 03:50:07 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation for sample size: yes but not achieved because this was a single-centre study.</P>
<P>ITT analysis: yes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hugues-1994">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 45 (20 in intervention group; 25 in control group).</P>
<P>Number of withdrawals: not reported.</P>
<P>Number of women analyzed: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 07:48:17 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: France.</P>
<P>Inclusion criteria: not reported.</P>
<P>Exclusion criteria: not reported.</P>
<P>Mean age: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:13:19 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: norethisterone (10 mg/day) for 10-15 days + GnRH agonist (DTRP6-LHRH 100 &#956;g/day).</P>
<P>Control: GnRH agonist (DTRP6-LHRH 100 &#956;g/day).</P>
<P>Timing of treatments not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:29:37 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Oestradiol and progestogen levels.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 07:49:13 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: unclear.</P>
<P>ITT analysis performed: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:40 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huirne-2006a">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:40 +1200" MODIFIED_BY="[Empty name]">
<P>Academic, multicentre, parallel group study.</P>
<P>Number of women randomized: 64 (32 in each group).</P>
<P>Number of withdrawals: 1 (in intervention group, due to unwillingness to take OCP).</P>
<P>Number of women analyzed: 63.</P>
<P>Source of funding: Serono Geneva supplied the antide.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 08:08:08 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: the Netherlands and Belgium.</P>
<P>Inclusion criteria: regular IVF or ICSI indication (i.e. idiopathic infertility after 6 unsuccessful IUIs, infertility based on a male or tubal factor); spontaneous, regular ovulatory menstrual cycle; 2 ovaries and a normal uterine cavity; aged 18-38 years.</P>
<P>Exclusion criteria: FSH &#8805; 12 IU/L on cycle day 2-4; BMI &gt; 30 kg/m<SUP>2</SUP>; abnormal gynaecological bleeding; extrauterine pregnancy within the last 3 months; previous ART cycles with &lt; 3 oocytes or severe OHSS; any contraindication to receive gonadotrophins or OCP; PCOS.</P>
<P>Mean age ± SD: intervention group: 32.3 ± 4.0 years; control group: 33.3 ± 3.8 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 23:51:44 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP (ethinyl oestradiol 30 &#956;g + levonorgestrel 150 &#956;g) for 14-28 days, started cycle day 2 or 3 + rFSH (150-300 IU), started post-treatment day 2 or 3 (= stimulation day 1) + GnRH antagonist (antide 0.5 mg/mL daily), started stimulation day 6.</P>
<P>Control: rFSH (150-300 IU), started on cycle days 2 or 3 (= stimulation day 1) + GnRH antagonist (antide 0.5 mg/mL daily), started on stimulation day 6.</P>
<P>rFSH dose adjustments after 5 days of stimulation (up to a maximum of 450 IU), according to number and size of oocytes and risk for OHSS.</P>
<P>Both rFSH and GnRH antagonist were continued until hCG injection (6500 IU), administered when &#8805; 1 follicle reached a diameter &#8805; 18 mm + &#8805; 2 follicles reached a diameter &#8805; 16 mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:29:51 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Ongoing pregnancy rate: positive heart activity at gestational age of 12 weeks.</LI>
<LI>Clinical pregnancy rate: presence of &#8805; 1 intrauterine sac confirmed with ultrasound at gestational age of 6 weeks.</LI>
<LI>Number of oocytes retrieved.</LI>
<LI>Ovarian cysts: not defined.</LI>
<LI>Number and size of follicles.</LI>
<LI>Cumulative dose of rFSH.</LI>
<LI>Duration of r-FSH treatment.</LI>
<LI>Implantation rates.</LI>
<LI>Serum hormone concentrations.</LI>
<LI>Endometrial thickness.</LI>
<LI>Bleeding pattern.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 08:11:41 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:41 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huirne-2006c">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:41 +1200" MODIFIED_BY="[Empty name]">
<P>Multicentre (8 IVF centres), parallel group study.</P>
<P>Number of women recruited: 216.</P>
<P>Number of women excluded: 34 (reasons not reported).</P>
<P>Number of women randomized: 182 (91 in each group).</P>
<P>Number of withdrawals: 22 (10 in intervention group: 1 due to hepatitis B, 1 due to non-compliance, 1 due to personal reasons, 2 due to insufficient follicular response, 1 due to conversion to IUI, 1 due to absence of mature oocytes, 3 due to absence of viable embryos; 12 in control group: 2 due to spontaneous pregnancy, 3 due to failure of desensitisation, 1 due to personal reasons, 1 due to stimulation failure, 3 due to absence of 'mature' oocytes, 2 due to failure of fertilisation).</P>
<P>Number of women analyzed: 182.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 07:56:32 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: the Netherlands, Belgium, France and Austria.</P>
<P>Inclusion criteria: regular IVF/ICSI indication, male partner with viable sperm in the ejaculate, aged 18-39 years.</P>
<P>Exclusion criteria: any previous ART cycles with &lt; 3 oocytes or &#8805; 3 consecutive ART cycles without a clinical pregnancy, any contraindication to ART, gonadotrophins or OCPs, significant systemic disease.</P>
<P>Mean age ± SD: intervention group: 32.8 ± 3.8 years; control group: 32.2 ± 4.2 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:35:13 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP (ethinyl oestradiol 30 &#956;g + levonorgestrel 150 &#956;g daily), started within 5 days of onset of menses for 21-28 days (stop on a Sunday) + r-hFSH (150-225 IU/day), started post-treatment day 5 (= stimulation day 1) + GnRH antagonist (cetrorelix acetate 0.25 mg/day, SC), started stimulation day 6.</P>
<P>Control: GnRH agonist (buserelin acetate 500 &#956;g/day, SC), started cycle day 18-22 (reducing dose to 200 &#956;g/day when downregulation was achieved) + r-hFSH (150-225 IU/day), started when downregulation was achieved.</P>
<P>After 5 days of r-hFSH treatment, the dose could be adjusted by steps of 75 IU (maximal dose 450 IU/day), according to the ovarian response.</P>
<P>Both rhFSH and GnRH analogues were continued until hCG injection, administered when the largest follicle reached a mean diameter &#8805; 18 mm and &#8805; 2 other follicles had a mean diameter &#8805; 16 mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 23:43:53 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Ongoing pregnancy rate: positive heart activity at a gestational age of 12 weeks.</LI>
<LI>Clinical pregnancy rate: presence of &#8805; 1 foetal sacs with or without heart activity confirmed with ultrasound, performed at least 4 weeks after embryo transfer.</LI>
<LI>Numbers of oocytes retrieved per woman.</LI>
<LI>Multiple clinical pregnancies.</LI>
<LI>Total number of oocyte retrievals performed on weekends or public holidays.</LI>
<LI>Cancellation rate.</LI>
<LI>Drug requirements.</LI>
<LI>Total number of (good quality) embryos.</LI>
<LI>Implantation rate.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 08:01:17 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:41 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hwang-2004">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:41 +1200" MODIFIED_BY="[Empty name]">
<P>Single-centre, parallel group study.</P>
<P>Number of women recruited: 60.</P>
<P>Number of women excluded: 4 (2 refused to participate, 2 did not meet inclusion criteria).</P>
<P>Number of women randomized: 56 (27 in intervention group; 29 in control group).</P>
<P>Number of withdrawals: 7 (2 in intervention group: 1 due to poor ovarian response, 1 due to personal reasons; 5 in control group: 2 due to inadequate ovarian response, 3 due to risk of severe OHSS).</P>
<P>Number of women analyzed: 49.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 08:19:49 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Taiwan.</P>
<P>Inclusion criteria: PCOS.</P>
<P>Exclusion criteria: diagnosis of congenital adrenal hyperplasia, Cushing's syndrome, androgen-producing tumours, hyperprolactinaemia or thyroid dysfunction; aged &gt; 38 years; serum FSH levels &gt; 12 mIU/mL.</P>
<P>Mean age ± SD: intervention group: 31.4 ± 3.5 years; control group: 31.7 ± 3.7 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:16:19 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP (Diane-35, oral) on cycle days 5-25 for 3 consecutive cycles + GnRH antagonist (cetrorelix acetate 0.25 mg single dose, SC on post-treatment day 3; 0.125 mg/day on post-treatment days 4-9; and 0.25 mg/day started post-treatment day 10 + hMG 150 IU/day), started post-treatment day 4.</P>
<P>Control: GnRH agonist (buserelin acetate 500 &#956;g/day, long protocol) started day 3 of induced or spontaneous menstruation, and 250 &#956;g/day started day of ensuing pituitary downregulation + hMG (150 IU/day) for 6 days started when pituitary downregulation was achieved.</P>
<P>hMG dose can be adjusted according to woman's follicular response.</P>
<P>Pituitary downregulation achieved when serum oestradiol levels &lt; 50 pg/mL and there was an absence of ovarian cysts &gt; 10 mm in diameter.</P>
<P>Both GnRH analogues and hMG were continued until hCG injection (10,000 IU, IM), administered when &#8805; 2 follicles reached 18 mm in diameter with adequate oestradiol response.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 23:43:57 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Fertilisation.</LI>
<LI>Clinical pregnancy: presence of &#8805; 1 foetal heart beat confirmed with ultrasound, performed 7 weeks after embryo transfer.</LI>
<LI>Implantation rates.</LI>
<LI>Serum LH and testosterone status upon starting and during hMG administration.</LI>
<LI>Total days and amount of gonadotrophins administered: measured in ampoules.</LI>
<LI>Pregnancy loss.</LI>
<LI>Multiple pregnancy rate: ongoing or live born.</LI>
<LI>OHSS: not defined.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 08:24:13 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 120.</P>
<P>Number of withdrawals: 0.</P>
<P>Number of women analyzed: 120.</P>
<P>Duration of study: 1 cycle.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 08:28:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: South Korea.</P>
<P>120 poor responders (repeated day 3 levels of FSH &gt; 8.5 mIU/mL or antral follicle count &#8804; 5, or both). 40 in each group.</P>
<P>Inclusion criteria: not clearly stated.</P>
<P>Exclusion criteria: PCOS (Rotterdam criteria).</P>
<P>Mean age ± SD: group 1: 36.7 ± 3.1 years; group 2: 35.9 ± 2.8 years; group 3: 36.4 ± 3.3 years.</P>
<P>Setting: university-based infertility clinic, Seoul. Korea.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 23:51:48 +1200" MODIFIED_BY="Anne Lawson">
<P>Pretreatment was ethinyl oestradiol 0.03 mg and levonorgestrel 0,15 mg for 21 days in the cycle preceding COS.</P>
<P>Group 1: GnRH antagonist multiple dose protocol after OCP pretreatment. Ovarian stimulation started 5 days after OCP discontinued using rFSH (225 IU/day, dose adjusted every 3-4 days). Cerotide (0.25 mg) started when lead follicle was 14 mm diameter and continued until day of hCG injection.</P>
<P>Group 2 GnRH antagonist multiple dose protocol without OCP pretreatment. Ovarian stimulation started on cycle day 3 using rFSH (225 IU/day, dose adjusted every 3-4 days). Cerotide (0.25 mg) started when lead follicle was 14 mm diameter and continued until day of hCG injection.</P>
<P>Group 3: GnRH agonist luteal low-dose long protocol without OCP pretreatment. Daily injection of decapeptyl (0.1 mg) started from mid-luteal phase and continued until menses followed by a dose reduction to 0.05 mg daily and continued until day of hCG injection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:30:22 +1200" MODIFIED_BY="Anne Lawson">
<P>Primary:</P>
<UL>
<LI>Number of mature oocytes retrieved.</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Total amount and days of rFSH.</LI>
<LI>Number of fertilised oocytes and grade I and II embryos.</LI>
<LI>Implantation rate ongoing pregnancy rate.</LI>
<LI>Clinical pregnancy rate per cycle and live birth rate per cycle.</LI>
<LI>Miscarriage rate.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 08:32:33 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation: yes.</P>
<P>ITT analysis: yes.</P>
<P>Earlier publications were Kim 2005 and Kim 2009.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolibianakis-2006">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Academic, single centre, parallel group study.</P>
<P>Number of women randomized: 504 (250 in intervention group; 254 in control group).</P>
<P>Number of withdrawals: 79 (36 in intervention group: 28 due to personal reasons, 6 due to abnormal steroid levels, 2 due to spontaneous pregnancy; 43 in control group: 31 due to personal reasons, 10 due to abnormal steroid levels, 2 due to spontaneous pregnancy).</P>
<P>Number of women analyzed: 425.</P>
<P>Duration of study: 3 years of recruitment.</P>
<P>Source of funding: the Fund for Scientific Research Flanders.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 20:38:45 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Belgium.</P>
<P>Inclusion criteria: aged &lt; 39 years, &#8804; 3 previous ART attempts, BMI 18-29 kg/m<SUP>2</SUP>, FSH &lt; 10 IU/L, LH &lt; 10 IU/L.</P>
<P>Exclusion criteria: polycystic ovaries, endometriosis &gt; stage II, poor response to ovarian stimulation</P>
<P>Mean age ± SD: intervention group: 31.2 ± 0.3 years; control group: 31.5 ± 0.3 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 23:51:53 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP (ethinyl oestradiol 30 &#956;g + desogestrel 150 &#956;g) for 14 days, started cycle day 1 + rFSH (200 IU/day) (fixed dose), started post-treatment day 5 + GnRH antagonist (ganirelix acetate).</P>
<P>Control: rFSH (200 IU/day) (fixed dose), started cycle day 2 + GnRH antagonist (ganirelix acetate).</P>
<P>Timing of GnRH antagonist not reported.</P>
<P>Both rFSH and GnRH antagonist continued until hCG injection (10,000 IU), administered when &#8805; 3 follicles &#8805; 17 mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:30:30 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Ongoing pregnancies per started cycles equivalent to number of participants): developing beyond 12 weeks.</LI>
<LI>Stimulation length.</LI>
<LI>Gonadotrophin consumption.</LI>
<LI>Early pregnancy loss: proportion of women with initially positive hCG in whom pregnancy failed to develop before 12 weeks of gestation.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 18:32:24 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lukaszuk-2015">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>2-arm parallel multicentre RCT.</P>
<P>Number of women randomized: 298 (154 in intervention group; 144 in control group).</P>
<P>Withdrawals: not reported.</P>
<P>Number of women analyzed: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 20:39:17 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Poland.</P>
<P>Inclusion criteria: women aged &lt; 40 years, AMH &gt; 0.6 ng/mL, BMI 18-29 kg/m<SUP>2</SUP>, and undergoing a first or second treatment cycle of IVF with ICSI.</P>
<P>Exclusion criteria: presence of endometriosis and pre-implantation diagnosis cycles.</P>
<P>Mean age ± SD: intervention group: 32.5 ± 3.97; control group: 32.5 ± 2.96 years.</P>
<P>BMI (mean ± SD): intervention group: 22.2 ± 1.3 kg/m<SUP>2</SUP>; control group: 22.4 ± 1.1 kg/m<SUP>2</SUP>.</P>
<P>Setting: infertility clinics, 2 centres.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:18:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: OCP pretreatment: pretreated with COCP (Ovulastan, Adamed, Pabianice, Poland) from day 2-4 of the cycle. Beginning from the day 14 of cycle, pituitary was suppressed by administering triptorelin (0.1 mg) every 2 days; treatment continued for 2 weeks. Ovarian stimulation started with gonadotropin injections (150-225 IU/day) starting from days 2-4 of cycle and continued with a daily dose of triptorelin (0.1 mg) until hCG injection was administered 36 hours before retrieval.</P>
<P>Control: oestradiol pretreatment: pretreated with oral oestradiol (2 mg twice daily) from day 20 of natural cycle until the day 1-4 of the new cycle. Ovarian stimulation started with hMG injections (150-225 IU/day) starting from days 2-4 of cycle, 2 days after discontinuation of oestradiol administration, and continued with a daily dose of triptorelin (0.1 mg) until the hCG injection 5000 IU was administered 36 hours before retrieval.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:30:36 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Clinical pregnancy.</LI>
<LI>Number of oocyte retrieved.</LI>
<LI>Multiple pregnancy.</LI>
<LI>Duration of stimulation days.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>All outcomes were measured in denominators other than "per woman randomized."</P>
<P>Power calculation was performed.</P>
<P>No, outcome measured in denominators other than "per woman randomized."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nyboe-Andersen-2011">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group multicentre study.</P>
<P>Number of women randomized: 442 (223 in intervention group; 219 in control group).</P>
<P>Number of withdrawals: 34 (14 in intervention group; 20 in the control group due to adverse events, withdrawal of consent, spontaneous pregnancy and "other" reasons).</P>
<P>Number of women analyzed: 408 (209 in intervention group; 199 in control group).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 18:44:23 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: multicentre (USA, Europe).</P>
<P>Inclusion criteria: aged 18-39 years, BMI &#8804; 32 kg/m<SUP>2</SUP>, menstrual cycle length 24-35 days, access to ejaculatory sperm, indication for COS and IVF or ICSI or IVF plus ICSI and scheduled for first COS cycle.</P>
<P>Exclusion criteria: history of endocrine abnormality, &lt; 2 ovaries or any other ovarian abnormality, presence of unilateral or bilateral hydrosalpinx, clinically relevant pathology affecting the uterine cavity, fibroids &#8805; 5 cm, history of recurrent miscarriage (&#8805; 3), with or without FSH or LH levels &gt; 12 IU/L in the early follicular phase.</P>
<P>Mean age ± SD: intervention group: 31.8 ± 3.7 years; control group: 31.6 ± 4.1 years.</P>
<P>Setting: 8 centres in USA, 6 centres in Europe (Denmark, Germany, Spain and Turkey).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 23:51:57 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP pretreatment: Marvelon (ethinyl oestradiol 30 &#956;g + desogestrel 150 &#956;g) for 14-21 days. Women started daily rFSH 5 days after stopping COCP pretreatment provided a withdrawal bleed occurred.</P>
<P>Control: no pretreatment: daily rFSH on day 2 or 3 of the next menstrual cycle.</P>
<P>In both groups, a single SC injection of rFSH (200 IU) started on stimulation day 1 and continued daily up to and including day of triggering of final oocyte maturation by urinary hCG. Maximum total duration of stimulation 19 days. Starting on day 5 of stimulation, all women received ganirelix (0.25 mg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:30:48 +1200" MODIFIED_BY="Anne Lawson">
<P>Primary: </P>
<UL>
<LI>Number of oocytes obtained.</LI>
</UL>
<P>Secondary:</P>
<UL>
<LI>Number of follicles &#8805; 11 mm at day 8.</LI>
<LI>Number of follicles &#8805; 11 mm at day of hCG.</LI>
</UL>
<P>Other: </P>
<UL>
<LI>Duration of stimulation.</LI>
<LI>Total rFSH dose.</LI>
<LI>Number of embryos.</LI>
<LI>Number of embryos transferred.</LI>
<LI>Implantation rate.</LI>
<LI>Clinical pregnancy rate.</LI>
<LI>Ongoing pregnancy rate.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Power calculation for sample size: yes (200 women per group with an additional 20 to compensate for discontinuation).</P>
<P>ITT analysis: modified: all randomized women who received at least 1 dose of rFSH.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Obruca-2002">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 150 (75 in each group).</P>
<P>Number of withdrawals: not reported.</P>
<P>Number of women analyzed: unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 20:39:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: Austria.</P>
<P>Inclusion criteria: women undergoing COS and IVF.</P>
<P>Exclusion criteria: not reported.</P>
<P>Mean age: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:20:14 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP (ethinyl oestradiol 30 &#956;g + desogestrel 150 &#956;g daily), started cycle day 1 for 18-28 days (stopped on a Sunday) + rFSH (150 IU/day), started post-treatment day 5 (= stimulation day 1) + GnRH antagonist (cetrorelix acetate 0.25 mg/day), started stimulation day 6.</P>
<P>Control: rFSH 150 IU/day, started cycle day 3 (= stimulation day 1) + GnRH antagonist (cetrorelix acetate 0.25 mg/day), started stimulation day 6.</P>
<P>Both rFSH and GnRH antagonist continued until final follicular maturation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:30:54 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Number of cancelled cycles.</LI>
<LI>Number of oocytes.</LI>
<LI>Number of transferred embryos.</LI>
<LI>Clinical pregnancy rate; not defined.</LI>
<LI>Number of weekend oocyte retrievals.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 18:51:25 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: unclear.</P>
<P>ITT analysis performed: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Porrati-2010">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>2-arm parallel group study.</P>
<P>Number of women randomized: 150 women (75 in each group).</P>
<P>Number of withdrawals: 4 women in intervention group; 3 in control group did not have embryo transfer.</P>
<P>Number of women analyzed: 71 in intervention group; 72 in control group.</P>
<P>Duration of study: 1 year of recruitment.</P>
<P>Source of funding: Yazd IVF Centre, Yazd, Iran.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 18:54:02 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: Argentina.</P>
<P>Inclusion criteria: aged &lt; 39 years, first IVF attempt, baseline FSH &lt; 12 mlU/mL.</P>
<P>Exclusion criteria: PCOS, prior ovarian surgery and TESE needing.</P>
<P>Mean age: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-12 00:14:48 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP group: April® (ethinyl oestradiol 20 &#956;g + levonorgestrel 100 &#956;g) for 21 days in preceding cycle and follicular development induced using rFSH (200 IU/day) from menstrual cycle day 2-3.</P>
<P>Control: rFSH (200 IU/day) from menstrual cycle day 2-3.</P>
<P>Both groups received GnRH antagonist (cetrorelix 0.25 mg, SC) in flexible protocol starting when the leading follicle reached 14 mm continuing daily until the day of hCG administration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:31:00 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Dose of gonadotrophin administered.</LI>
<LI>Days of gonadotrophin treatment.</LI>
<LI>Clinical pregnancy.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 18:56:35 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation not reported.</P>
<P>ITT: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raoofi-2008">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Academic, single-centre, parallel group study.</P>
<P>Number of women randomized: 54 women (number of women per group not reported).</P>
<P>Number of withdrawals: 3 women excluded due to incomplete data.</P>
<P>Number of women analyzed: 51.</P>
<P>Duration of study: 1 year of recruitment.</P>
<P>Source of funding: Yazd IVF Centre, Yazd, Iran.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 18:59:09 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Iran.</P>
<P>Inclusion criteria: women undergoing IVF and ICSI.</P>
<P>Exclusion criteria: not reported.</P>
<P>Mean age ± SD: intervention: 31.48 ± 5.82 years; control: 35.27 ± 4.13 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 23:52:02 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP (ethinyl oestradiol 30 &#956;g + desogestrel 150 &#956;g), on cycle days 1-14 + GnRH agonist (triptorelin acetate depot 3.75 mg, IM) single dose on post-treatment day 1 + hMG (FSH 75 IU + LH 75 IU), started post-treatment day 2.</P>
<P>Control: GnRH agonist (triptorelin acetate depot 3.75 mg, IM) single dose on cycle day 1 + hMG (FSH 75 IU + LH 75 IU), started cycle day 1.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 23:44:01 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Cyst formation &gt; 28 mm: measured 7 and 14 days after pituitary suppression.</LI>
<LI>Number of follicles.</LI>
<LI>Number of oocytes retrieved.</LI>
<LI>Implantation rate.</LI>
<LI>Clinical pregnancy rate: presence of &#8805; 1 foetal heart beats confirmed with ultrasound performed &#8805; 4 weeks after embryo transfer.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 19:02:34 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: no.</P>
<P>ITT analysis performed: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rombauts-2006">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Multicentre (10 IVF centres), parallel group study.</P>
<P>Number of women randomized: 351 (117 in each group).</P>
<P>Number of withdrawals: 19 (5 due to spontaneous pregnancy: 2 in COCP group; 3 in GnRH antagonist group). Other reasons not reported.</P>
<P>Number of women analyzed: 332 (111 in COCP group; 110 in GnRH antagonist group; 111 in GnRH agonist group).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-12 01:02:04 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Australia, Denmark, Jordan and Norway.<BR/>Inclusion criteria: healthy women of infertile couples, aged 18-39 years, BMI 18-29 kg/m<SUP>2</SUP>, bodyweight &#8804; 90 kg, normal menstrual cycle with a range of 24-35 days and intra-individual variation of ± 3 days.</P>
<P>Exclusion criteria: contraindications for the use of gonadotrophins, endocrine abnormalities (e.g. PCOS), &gt; 3 unsuccessful COS cycles, history of low or no ovarian response during FSH/hMG treatment, clinically relevant abnormal laboratory values (including hormones) or medical examination findings.</P>
<P>Mean age ± SD: COCP group: 32.7 ± 3.9 years; GnRH antagonist group: 32.1 ± 3.7 years; GnRH agonist group: 32.2 ± 4.0 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:23:17 +1200" MODIFIED_BY="Anne Lawson">
<P>COCP group: COCP (ethinyl oestradiol 30 &#956;g + desogestrel 150 &#956;g daily), started cycle day 1 for 14-28 days (depending on the planned started of rFSH treatment) + rFSH (follitropin beta 200 IU/day, SC), started post-treatment day 2 (= stimulation day 1) + GnRH antagonist (ganirelix acetate 0.25 mg/day, SC), started stimulation day 5 or 6.</P>
<P>GnRH antagonist: rFSH (follitropin beta 200 IU/day, SC), started cycle day 2 or 3 (= stimulation day 1) + GnRH antagonist (ganirelix acetate 0.25 mg/day, SC), started stimulation day 5 or 6.</P>
<P>GnRH agonist: nafarelin acetate (0.8 mg/day, intranasal), started cycle day 21-24 + rFSH (follitropin beta 200 IU/day, SC), started when downregulation (i.e. serum oestradiol &#8804; 50 pg/mL) achieved after 2-4 weeks of GnRH agonist treatment).</P>
<P>After 5-6 days of rFSH treatment, dose could be adjusted depending on the ovarian response as assessed by ultrasound.</P>
<P>rFSH and GnRH analogues are both continued until hCG injection (10,000 IU, SC or IM), administered when &#8805; 3 follicles &#8805; 17 mm in diameter, or &#8805; 1 follicle &#8805; 20 mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-12 00:18:15 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Ongoing pregnancy rate: assessed by ultrasound at &#8805; 12-16 weeks.</LI>
<LI>Number of cumulus-oocyte complexes.</LI>
<LI>Number of grade 1 or 2 embryos.</LI>
<LI>Number and size of follicles.</LI>
<LI>Serum hormone values.</LI>
<LI>Duration of rFSH treatment.</LI>
<LI>Total rFSH dose.</LI>
<LI>Number of good-quality embryos.</LI>
<LI>Implantation rate.</LI>
<LI>Incidences of LH rises.</LI>
<LI>Pregnancy loss.</LI>
<LI>OHSS: according to WHO classification.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 19:11:11 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: yes.</P>
<P>ITT analysis performed: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salat_x002d_Baroux-1988">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>4 study arms (A1+A2 and B1+B2), of which we can only include 2 study arms (A2 and B2).</P>
<P>Number of women randomized: 42 (21 in intervention group (A2); 21 in control group (B2)).</P>
<P>Number of withdrawals: 13 (8 in intervention group (A2): 3 due to poorly followed treatment, 1 due to inadequate response, 2 due to spontaneous ovulation, 2 due to other reasons; 5 in control group (B2): 1 due to ovarian cyst, 4 due to inadequate response).</P>
<P>Number of women analyzed: 29.</P>
<P>Duration of study: 7 months of recruitment.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 19:14:56 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: France.</P>
<P>Inclusion criteria: infertile women scheduled for IVF treatment, aged &lt; 38 years.</P>
<P>Exclusion criteria: not reported.</P>
<P>Mean age ± SD: intervention group (A1+A2): 32.8 ± 0.7 years; control group (B1+B2): 31.7 ± 0.5 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:24:02 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention (A2): progestogen (ethynodiol acetate 2 mg twice daily) for 11-17 days, started cycle day 15 + pure FSH 4 ampoules on post-treatment days 6-7 and 2 ampoules on post-treatment days 8-9 + hMG (FSH 75 IU + LH 75 IU) 2 ampoules on post-treatment days 10-11.</P>
<P>Control (B2): pure FSH 4 ampoules on cycle days 2-3 and 2 ampoules on cycle days 4-5 + hMG (FSH 75 IU + LH 75 IU) when needed.</P>
<P>FSH and GnRH agonist both continued until hCG injection (10,000 IU), administration depending on follicular maturity.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:31:18 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Clinical pregnancy rate: not defined.</LI>
<LI>Pregnancy loss.</LI>
<LI>Day of hCG.</LI>
<LI>Values of oestradiol and P on day of hCG.</LI>
<LI>Number of oocytes recovered, cleaved or replaced.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 19:17:10 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: no.</P>
<P>ITT analysis performed: no.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaker-1995">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 49 (number per group not reported; 22 cycles in intervention group; 29 cycles in control group) but total number of cycles not the same as total number of women randomized.</P>
<P>Number of withdrawals: 11 cycles (3 in intervention group: 2 due to poor response, 1 due to failure of embryo cleavage; 8 in control group: 3 due to conversion to IUI, 1 due to poor response, 2 due to failed fertilisation, 2 due to risk of OHSS).</P>
<P>Number of women analyzed: unclear.</P>
<P>Duration of study: 8 months of recruitment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 20:19:24 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: UK.</P>
<P>Inclusion criteria: women who underwent IVF treatment cycles and had an ovarian cyst &gt; 15 mm in diameter or an endometrial thickness &gt; 5 mm and serum oestradiol concentration &gt; 100 pmol/L after 14 days of GnRH agonist (buserelin acetate) treatment</P>
<P>Exclusion criteria: relevant uterine or ovarian pathology.</P>
<P>Mean age ± SEM: intervention group: 36.0 ± 0.86 years; control group: 35.72 ± 0.69 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:36:01 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: GnRH agonist (buserelin acetate 500 &#956;g/day) started cycle day 2 or 3 + progestogen (100 mg IM single dose) on cycle day 16 or 17 + hMG, started when serum oestradiol concentration &#8804; 100 pmol/L.</P>
<P>Control: GnRH agonist (buserelin acetate 500 &#956;g/day), started cycle day 2 or 3 + hMG, started when serum oestradiol concentration &#8804; 100 pmol/L.</P>
<P>hMG start dose according to women's age, baseline serum FSH level, response to stimulation in previous treatment cycles.</P>
<P>hMG and GnRH agonist both continued until hCG injection (10,000 IU), administered when 3 follicles &#8805; 18 mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:31:24 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Clinical pregnancy rate: not defined.</LI>
<LI>Serum oestradiol levels on day of recruitment.</LI>
<LI>Number of days of hMG administration.</LI>
<LI>Number of days of GnRH agonist.</LI>
<LI>Endometrial thickness.</LI>
<LI>Mean diameter of ovarian cyst on day of recruitment and 6 days later.</LI>
<LI>Total number of hMG ampoules.</LI>
<LI>Number of follicles.</LI>
<LI>Number of oocytes retrieved.</LI>
<LI>Number of embryos transferred.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 19:23:11 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: no.</P>
<P>ITT analysis performed: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tan-2001">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 117 (number per group not reported).</P>
<P>Number of withdrawals: not reported.</P>
<P>Number of women analyzed: unclear.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 19:24:08 +1200" MODIFIED_BY="Anne Lawson">
<P>Country of authors: Canada.</P>
<P>Inclusion criteria: not reported.</P>
<P>Exclusion criteria: not reported.</P>
<P>Mean age: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 19:24:32 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: progestogen (norethindrone) for 5 days, started cycle day 1 + GnRH agonist, start cycle day 2.</P>
<P>Control: GnRH agonist. Timing of treatment not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:31:29 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Cyst formation.</LI>
<LI>Time required to achieve pituitary suppression.</LI>
<LI>Implantation rate.</LI>
<LI>Pregnancy rate.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 19:24:47 +1200" MODIFIED_BY="Anne Lawson">
<P>Power calculation performed: unclear.</P>
<P>ITT analysis used: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vilela-2011">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 210 (105 to each group).</P>
<P>Number of withdrawals: 5 (4 in intervention group; 1 in control group).</P>
<P>Number of women analyzed: not clear; assumed 205.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 19:26:04 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: Argentina.</P>
<P>Inclusion criteria: aged &#8804; 39 years, first IVF attempt, basal FSH &#8804; 12 mIU/mL.</P>
<P>Exclusion criteria: PCOS, prior ovarian surgery, "TESE needing."</P>
<P>Mean age: not reported.</P>
<P>Setting: assume single fertility centre in Buenos Aires, Argentina.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-12 00:19:26 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: COCP (ethinyl oestradiol 0.02 mg + levonorgestrel 0.1 mg) for 14/25 days in the preceding cycle.</P>
<P>Control: no pretreatment.</P>
<P>All women stimulated with rFSH (200 IU/day) from menstrual cycle day 2 or 3, hMG (225 UI/day) from day 4 and GnRH antagonist (cetrorelix 0.25 mg) in a flexible protocol starting with 14 mm leading follicle continuing both daily until the day of hCG. Oocyte maturation was triggered by rhCG (250 &#956;g). Embryo transfer performed 3 days later.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:31:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Primary: </P>
<UL>
<LI>Clinical pregnancy rate.</LI>
</UL>
<P>Other: </P>
<UL>
<LI>Total gonadotropin stimulation days.</LI>
<LI>Fertilisation rate.</LI>
<LI>Implantation rate.</LI>
<LI>Number of oocytes retrieved.</LI>
<LI>Total number of embryos achieved.</LI>
<LI>Embryo quality rate.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-11 19:28:50 +1200" MODIFIED_BY="Anne Lawson">
<P>Abstract with minimal data reported.</P>
<P>Power calculation for sample size: not reported.</P>
<P>ITT analysis: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-08-09 08:45:43 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ye-2009">
<CHAR_METHODS MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]">
<P>Parallel group study.</P>
<P>Number of women randomized: 220 (109 in intervention group; 111 in control group).</P>
<P>Number of withdrawals: none reported.</P>
<P>Number of women analyzed: 208 cycles (103 in intervention group; 105 in control group) and numbers of cycles were equivalent to numbers of participants.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-11 20:40:16 +1200" MODIFIED_BY="Anne Lawson">
<P>Country: China.</P>
<P>Inclusion criteria: aged 25-35 years; BMI 18-25 kg/m<SUP>2</SUP>; number of previous IVF cycles &lt; 3, and no previous poor response to ovarian stimulation (poor ovarian response characterised by cancellation of the cycle due to either poor follicular development or &#8804; 4 cumulus-oocyte-complexes collected at oocyte retrieval); normal ovulatory cycles (25-35 days); both ovaries present and normal uterus; no hormone therapy within the past 3 months; no current or past diseases affecting ovaries, gonadotrophin, sex steroid secretion, clearance or excretion.</P>
<P>Exclusion criteria: not explicitly reported.</P>
<P>Age range: 25-35 years.</P>
<P>Setting: IVF centre, China.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-11 21:26:01 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention: oral oestradiol valerate (4 mg/day) preceding the IVF cycle from day 21 until day 2 of next cycle before GnRH antagonist protocol.</P>
<P>Control: standard long GnRH agonist protocol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-11 21:31:44 +1200" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Number of oocytes collected.</LI>
<LI>MII oocytes.</LI>
<LI>Fertilisation.</LI>
<LI>Implantation.</LI>
<LI>Live birth.</LI>
<LI>Early pregnancy rate.</LI>
<LI>Clinical pregnancy rate.</LI>
<LI>OHSS rate.</LI>
<LI>Hormone profiles.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-08-09 08:45:43 +1200" MODIFIED_BY="[Empty name]">
<P>Outcomes measured as per 'embryo transfer cycle' but numbers of cycles transferred were equivalent to numbers of women randomized.</P>
<P>Power calculation for sample size: not reported.</P>
<P>ITT analysis: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>17-&#946;E<SUB>2</SUB>: 17-beta oestradiol; AMH: anti-mullerian hormone; BMI: body mass index; COCP: combined oral contraceptive pill; COH: controlled ovarian hyperstimulation; COS: controlled ovarian stimulation; FSH: follicle-stimulating hormone; rFSH: recombinant follicle-stimulating hormone; GnRH: gonadotrophin-releasing hormone; GnRHa: gonadotrophin-releasing hormone analogue; hMG: human menopausal gonadotrophin; IM: intramuscular; ITT: intention to treat; IU: international unit; IUI: intrauterine insemination; IVF: in vitro fertilisation; IVF-ET: in vitro fertilisation with embryo transfer; LH: luteinising hormone; OCP: oral contraceptive pill; OHSS: ovarian hyperstimulation syndrome; PCOS: polycystic ovary syndrome; PO: per os (oral); rhCG: recombinant human chorionic gonadotropin; SC: subcutaneous; SD: standard deviation; SEM: standardized mean difference; TESE: testicular epididymal sperm extraction; WHO: World Health Organization.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-07-14 16:40:53 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:41:15 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Aghahosseini-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:41:15 +1200" MODIFIED_BY="Anne Lawson">
<P>Randomisation status unknown.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:06 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-al_x002d_Mizyen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:06 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:07 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Anderson-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:07 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Women only received controlled ovarian stimulation, but no embryo transfer as part of an ART cycle.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:43:11 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Bakas-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:43:11 +1200" MODIFIED_BY="Anne Lawson">
<P>Did not state that allocation randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:28 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Bellver-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:28 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:29 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Benadiva-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:29 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:29 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Bendikson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:29 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:43:18 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Biljan-1998c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:43:18 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study. Each woman served as her own control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:30 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Branigan-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:30 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Each woman served as her own control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:31 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Brodt-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:31 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Single arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 23:10:16 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Chung-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 23:10:16 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
<P>Monophasic OCP vs triphasic OCP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:32 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Cohen-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:32 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:32 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Copperman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:32 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:43:58 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Couzinet-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:43:58 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Naltrexone used in treatment protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:33 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:33 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:44:07 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:44:07 +1200" MODIFIED_BY="Anne Lawson">
<P>Cross-over design with no pre-cross-over data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:33 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Damario-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:33 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:44:22 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Davar-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:44:22 +1200" MODIFIED_BY="Anne Lawson">
<P>RCT status unclear. Number of women randomised at baseline not stated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:44:32 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Davy-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:44:32 +1200" MODIFIED_BY="Anne Lawson">
<P>Compared different durations of COCP pretreatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:34 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-De-Ziegler-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:34 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Open single-arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:34 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Dickey-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:34 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:35 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Ditkoff-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:35 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-12 00:20:16 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Doody-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-12 00:20:16 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Women were oocyte donors. Compared different durations of COCP pretreatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:36 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Duvan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:45:12 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Engels-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:45:12 +1200" MODIFIED_BY="Anne Lawson">
<P>Number of women randomised or analysed in each treatment group not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:45:18 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fanchin-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:45:18 +1200" MODIFIED_BY="Anne Lawson">
<P>Cross-over design with no pre-cross-over data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:45:25 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fanchin-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:45:25 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Each woman served as her own control. Women only received controlled ovarian stimulation, but no embryo transfer as part of an ART cycle.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:45:42 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Feichtinger-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:45:42 +1200" MODIFIED_BY="Anne Lawson">
<P>Randomised comparison of different types of COCP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:36 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fisch-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Each woman served as her own control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:37 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Forman-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:37 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:37 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Frederick-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:37 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:38 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Frydman-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:38 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:38 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Galera-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:38 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:39 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gerli-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:39 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Single-arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:45:51 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Ghanem-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:45:51 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention not relevant: luteal phase support.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:39 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Godin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:39 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:45:56 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gomez-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:45:56 +1200" MODIFIED_BY="Anne Lawson">
<P>Compared 2 different ways of administration of oestrogen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:39 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gonen-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:39 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Clomiphene citrate used in treatment protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:40 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gonzalez-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:40 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:46:10 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Greco-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:46:10 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention not relevant: OCP used for endometrial preparation before embryo transfer and used as luteal phase support.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-14 16:40:53 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guivarc_x0027_h_x002d_Lev_x00ea_que-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-14 16:40:53 +1200" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:46:17 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Haydardedeoglu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:46:17 +1200" MODIFIED_BY="Anne Lawson">
<P>Both groups received COCP pretreatment, no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:40 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Hugues-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:40 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Single-arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:46:26 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Jung-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:46:26 +1200" MODIFIED_BY="Anne Lawson">
<P>Oestrogen pretreatment not stopped before oocyte retrieval, but also used as luteal phase support.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:46:36 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Karande-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:46:36 +1200" MODIFIED_BY="Anne Lawson">
<P>Compared 2 different ways of administration of a combined contraceptive (Nuvaring vs oral Desogen).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:41 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Keltz-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:41 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:41 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Kovacs-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:41 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:46:47 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Kreiner-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:46:47 +1200" MODIFIED_BY="Anne Lawson">
<P>Interventions not relevant (OCP vs OCP).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:41 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Leondires-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:41 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:47:16 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Letterie-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:47:16 +1200" MODIFIED_BY="Anne Lawson">
<P>Women only received oestrogen plus progestogen, but no gonadotrophins or GnRH analogues as part of an ART cycle. Compared 2 different timings of administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:47:22 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Lewin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:47:22 +1200" MODIFIED_BY="Anne Lawson">
<P>Compared 2 different doses of oestrogen treatment for endometrial preparation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:42 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Lindheim-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:42 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:47:31 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Liu-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:47:31 +1200" MODIFIED_BY="Anne Lawson">
<P>Interventions not relevant (OCP vs Nuvaring with similar contents as OCP).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:42 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Loutradis-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:42 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:47:46 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Martinez-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:47:46 +1200" MODIFIED_BY="Anne Lawson">
<P>Women were oocyte donors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:47:54 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Mashiach-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:47:54 +1200" MODIFIED_BY="Anne Lawson">
<P>Compared different durations of COCP pretreatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:43 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Meldrum-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:43 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Open-label single-arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:43 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Meldrum-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:43 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Open-label single-arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-26 17:15:30 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Merviel-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]">
<P>Alternate randomisation was used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:43 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Min-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:43 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:44 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Mirkin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:44 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-12 00:21:14 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Mulangi-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-12 00:21:14 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Each woman served as her own control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:45 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Neal-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:45 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:48:17 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Pados-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:48:17 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
<P>Prednisolone used in treatment protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:46 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Palomba-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:46 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:46 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Pinkas-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:46 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:46 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Ramsewak-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:46 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:48:23 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Rashidi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:48:23 +1200" MODIFIED_BY="Anne Lawson">
<P>Intervention not relevant: luteal phase support.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:48:26 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Russell-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:48:26 +1200" MODIFIED_BY="Anne Lawson">
<P>Compared different doses and timings of oestrogen pretreatments.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:47 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Sanghvi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:47 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study. Single-arm study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:47 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Schoolcraft-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:47 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 20:00:11 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinkampf-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 20:00:11 +1200" MODIFIED_BY="[Empty name]">
<P>Women only received ovulation induction, no embryo transfer as part of an ART cycle.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:48 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Surrey-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:48 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:48 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Surrey-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:48 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Each woman served as her own control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:49 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Talebian-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:49 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:49 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Talebian-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:49 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:49 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Tarlatzis-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:49 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:48:49 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Tartagni-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:48:49 +1200" MODIFIED_BY="Anne Lawson">
<P>Women had premature ovarian failure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:48:53 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Tehraninejad-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:48:53 +1200" MODIFIED_BY="Anne Lawson">
<P>Interventions not relevant (OCP vs OCP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:48:59 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Wang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:48:59 +1200" MODIFIED_BY="Anne Lawson">
<P>Cross-over design with no pre-cross-over data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:49:10 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Wang-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:49:10 +1200" MODIFIED_BY="Anne Lawson">
<P>Not a true RCT: randomisation according to alternate number allocation; intervention not relevant: co-administration of medroxyprogesterone acetate with the stimulation agent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:49:15 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Wei-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:49:15 +1200" MODIFIED_BY="Anne Lawson">
<P>Design not relevant: retrospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:50 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Weisman-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:50 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:50 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Yokota-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:50 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:42:51 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Yoshida-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:42:51 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:49:35 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Youssef-2017">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:49:35 +1200" MODIFIED_BY="Anne Lawson">
<P>Not relevant: compared mild vs standard stimulation (with pretreatment in the mild group).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-11 19:49:38 +1200" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Zhao-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-11 19:49:38 +1200" MODIFIED_BY="Anne Lawson">
<P>Not an RCT. Retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ART: assisted reproductive technique; COCP: combined oral contraceptive pill; OCP: oral contraceptive pill; GnRH: gonadotrophin-releasing hormone; RCT: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-03-01 11:47:49 +1300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-03-01 11:48:54 +1300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aston-1995">
<DESCRIPTION>
<P>Quote: "The hospital pharmacy randomized to contain placebo or progestogen."<BR/>Method of randomization not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biljan-1998b">
<DESCRIPTION>
<P>Quote: "They were randomized in two groups by drawing sealed envelopes that contained randomly generated numbers."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blockeel-2012">
<DESCRIPTION>
<P>Computer-generated randomization list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:41:53 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007">
<DESCRIPTION>
<P>Quote: "Random allocation sequence was generated from a table of random numbers... Randomization was stratified by centre..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:43:30 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012">
<DESCRIPTION>
<P>Table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:44:15 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Daly-2002">
<DESCRIPTION>
<P>"Randomized," method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:04 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Ditkoff-1996">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned by tossing a coin to one of two groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:37 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engmann-1999">
<DESCRIPTION>
<P>Quote: "Eligible patients were randomly assigned in a ratio of 1:1 by means of computer-generated random numbers. To ensure similar distributions of age in the two groups, separate randomization schedules were drawn up for women &lt; 40 years old and women &#8805; 40 years old by use of stratified randomised blocks."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:15 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Fanchin-2003">
<DESCRIPTION>
<P>Quote: "Women randomly received...", "...according to a computer-generated, blocked randomization list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franco-Jr-2003">
<DESCRIPTION>
<P>Randomisation by drawing lots after constructing a table of distribution.<BR/>2:1 randomization (intervention:control).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:43:51 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Velasco-2011">
<DESCRIPTION>
<P>Computer-generated list with consecutive inclusion.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:50:14 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hauzman-2013">
<DESCRIPTION>
<P>Computer-generated random number list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:44:20 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hugues-1994">
<DESCRIPTION>
<P>"Randomised," method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:41 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huirne-2006a">
<DESCRIPTION>
<P>Quote: "64 patients were randomly allocated according to a computer-generated, blocked randomization list. The randomization was stratified by centre."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:32 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huirne-2006c">
<DESCRIPTION>
<P>Quote: "182 were randomly allocated to...", "The treatment assigned to each patient was determined according to a computer-generated concealed randomization list. Randomization was performed by centre."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:44 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hwang-2004">
<DESCRIPTION>
<P>Quote: "Randomization was done by opening sealed envelopes containing computer-generated block randomization numbers with a block size of 10."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:57 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>Quote: "Computer generated lists."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:43:08 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kolibianakis-2006">
<DESCRIPTION>
<P>Quote: "Randomized on the basis of a computer-generated list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lukaszuk-2015">
<DESCRIPTION>
<P>Randomisation using "block randomization software."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:48:44 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Nyboe-Andersen-2011">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:44:32 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Obruca-2002">
<DESCRIPTION>
<P>"Randomized," method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:56:43 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Porrati-2010">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:44:33 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raoofi-2008">
<DESCRIPTION>
<P>"Randomized allocation method," method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:43:29 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Rombauts-2006">
<DESCRIPTION>
<P>Quote: "The subjects were randomly assigned..." "To improve balance, the randomization of subjects to treatment was stratified for type of infertility (primary or secondary), IVF or ICSI, centre, and age."</P>
<P>Method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:44:33 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Salat_x002d_Baroux-1988">
<DESCRIPTION>
<P>"Randomized," method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:43:40 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Shaker-1995">
<DESCRIPTION>
<P>Quote: "Randomization was done by drawing sequentially labelled sealed envelops, each containing a number obtained from a table of random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:24:50 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2001">
<DESCRIPTION>
<P>Method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:28:59 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Vilela-2011">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:43:49 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Ye-2009">
<DESCRIPTION>
<P>"Randomization allocation sequence was generated from a table of computer-generated random numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:41:44 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Aston-1995">
<DESCRIPTION>
<P>Quote: "The hospital pharmacy provided a series of consecutively numbered bottles."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:19:56 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Biljan-1998b">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:39:00 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Blockeel-2012">
<DESCRIPTION>
<P>Consecutive sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:35 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007">
<DESCRIPTION>
<P>Quote: "Random allocation sequence was concealed to each physician who enrolled and randomised patients."</P>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:43:34 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012">
<DESCRIPTION>
<P>Authors stated allocation concealed by sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:58:02 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Daly-2002">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:37 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ditkoff-1996">
<DESCRIPTION>
<P>Centralised randomization process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:10 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Engmann-1999">
<DESCRIPTION>
<P>Quote: "Selection into the groups (and of administration of the appropriate treatment protocol) was performed by the clinic nurses by using a series of consecutively numbered sealed envelopes (one for each age group)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:17 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Fanchin-2003">
<DESCRIPTION>
<P>Quote: "Treatment allocation was decided by an independent person."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:25:09 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Franco-Jr-2003">
<DESCRIPTION>
<P>After drawing lots, clinicians and participants could see in the table to which treatment they were assigned to.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:43:57 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Velasco-2011">
<DESCRIPTION>
<P>Opaque consecutively numbered envelopes with assignment under nurse control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:50:17 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hauzman-2013">
<DESCRIPTION>
<P>Consecutively numbered opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 07:49:17 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hugues-1994">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:38 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huirne-2006a">
<DESCRIPTION>
<P>Quote: "Treatment allocation was decided by an independent person from an independent monitoring company..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:44:24 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Huirne-2006c">
<DESCRIPTION>
<P>"Concealed randomization list," method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 08:24:34 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hwang-2004">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:43:02 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>Quote: "The sequence of allocation to the three groups was provided to the investigating physicians."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kolibianakis-2006">
<DESCRIPTION>
<P>Quote: "... randomized at the outpatient clinic by the treating physician." "The sequence of allocation was not concealed and thus it was possible for the treating physician to be aware of the next treatment to be allocated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:40:45 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Lukaszuk-2015">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:48:52 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Nyboe-Andersen-2011">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:51:30 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Obruca-2002">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:56:45 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Porrati-2010">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:02:41 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raoofi-2008">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:43:30 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Rombauts-2006">
<DESCRIPTION>
<P>Quote: "...by central remote allocation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:17:14 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Salat_x002d_Baroux-1988">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:23:16 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Shaker-1995">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:24:50 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2001">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:29:02 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Vilela-2011">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:40:21 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Ye-2009">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2017-05-11 23:59:59 +1200" MODIFIED_BY="Anne Lawson" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 02:13:13 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Aston-1995">
<DESCRIPTION>
<P>Double blind.<BR/>Women in control group received a placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 02:19:57 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Biljan-1998b">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 02:39:05 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Blockeel-2012">
<DESCRIPTION>
<P>Blinding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 20:41:55 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007">
<DESCRIPTION>
<P>Quote: "This study was not blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 02:43:36 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012">
<DESCRIPTION>
<P>Blinding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 02:58:03 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Daly-2002">
<DESCRIPTION>
<P>Unblinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 03:02:16 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Ditkoff-1996">
<DESCRIPTION>
<P>No blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 20:42:12 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Engmann-1999">
<DESCRIPTION>
<P>Quote: "Although the patient could guess her treatment status, treatment allocation was not recorded in the clinical notes, and all clinicians were blinded to the status of study participants until the trial was over."</P>
<P>However, no information on outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 03:16:43 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fanchin-2003">
<DESCRIPTION>
<P>No blinding, information obtained from contact person.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 03:25:16 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Franco-Jr-2003">
<DESCRIPTION>
<P>Insufficient information to make a conclusive judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 03:44:00 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Velasco-2011">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 23:59:59 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hauzman-2013">
<DESCRIPTION>
<P>Although personnel involved in data collection and data analysis blinded it was not reported whether other personnel and participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 07:49:18 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hugues-1994">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 08:12:07 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Huirne-2006a">
<DESCRIPTION>
<P>Open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 08:01:34 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Huirne-2006c">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 20:42:45 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Hwang-2004">
<DESCRIPTION>
<P>Quote: "The laboratory staff were blinded to the stimulation protocol."</P>
<P>Unclear if treating physicians were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 08:34:54 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 18:32:39 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Kolibianakis-2006">
<DESCRIPTION>
<P>Treating physician not blinded as this was the person to allocate the participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 18:41:03 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Lukaszuk-2015">
<DESCRIPTION>
<P>Only doctors who retrieved oocytes and embryologists were blinded to treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nyboe-Andersen-2011">
<DESCRIPTION>
<P>Study reported as open label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 18:51:31 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Obruca-2002">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 18:56:46 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Porrati-2010">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 19:02:43 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raoofi-2008">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 19:11:57 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Rombauts-2006">
<DESCRIPTION>
<P>Open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 19:17:14 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Salat_x002d_Baroux-1988">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 19:23:17 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Shaker-1995">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 19:24:51 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2001">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 19:29:08 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Vilela-2011">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-11 19:40:30 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Ye-2009">
<DESCRIPTION>
<P>"This study was not blind."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aston-1995">
<DESCRIPTION>
<P>Proportions of withdrawals not balanced between the 2 treatment groups (1 in intervention group; 5 in control group) and data were not analyzed on ITT basis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-08-11 09:22:48 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biljan-1998b">
<DESCRIPTION>
<P>Numbers and reasons for withdrawals not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blockeel-2012">
<DESCRIPTION>
<P>Reasons for, and proportions of, withdrawals balanced between the 2 treatment groups and data were analyzed on the basis of ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 02:53:34 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007">
<DESCRIPTION>
<P>Reasons for withdrawals and proportions of withdrawals not clearly stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:36 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012">
<DESCRIPTION>
<P>Reasons for withdrawals and proportions of withdrawals not balanced between groups and data not analyzed on the basis of ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-14 15:39:54 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daly-2002">
<DESCRIPTION>
<P>Only abstract available. Numbers and reasons for withdrawals not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 03:02:16 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Ditkoff-1996">
<DESCRIPTION>
<P>No withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 03:10:52 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Engmann-1999">
<DESCRIPTION>
<P>Proportions of withdrawals fairly balanced between the 2 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fanchin-2003">
<DESCRIPTION>
<P>Unclear how many withdrew in each group and data not analyzed on the basis of ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Franco-Jr-2003">
<DESCRIPTION>
<P>There was imbalance in the proportions of withdrawals between the 2 groups and data analyzed on the basis of ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 03:44:05 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Garcia_x002d_Velasco-2011">
<DESCRIPTION>
<P>Proportions of withdrawals and reasons for withdrawals not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:39 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hauzman-2013">
<DESCRIPTION>
<P>Reasons for withdrawals and proportions of withdrawals were fairly balanced between groups and data were analyzed on the basis of ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-14 15:58:48 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hugues-1994">
<DESCRIPTION>
<P>Numbers and reasons of withdrawals not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-23 13:57:08 +1200" MODIFIED_BY="Helen E Nagels" RESULT="YES" STUDY_ID="STD-Huirne-2006a">
<DESCRIPTION>
<P>Proportions of withdrawals were fairly balanced between groups (3% in intervention group vs 0% in control group).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:41 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huirne-2006c">
<DESCRIPTION>
<P>All women randomized were included in final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:41 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hwang-2004">
<DESCRIPTION>
<P>Reasons for withdrawals and proportions of withdrawals were not balanced between groups and data were not analyzed on the basis of ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>In groups 1 and 3 there were no losses, withdrawals or cancellations. In group 2, 1 cycle was cancelled before embryo transfer; all women randomized were included in data analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 18:33:00 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kolibianakis-2006">
<DESCRIPTION>
<P>Reasons for withdrawals and proportions of withdrawals fairly balanced between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 18:41:08 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Lukaszuk-2015">
<DESCRIPTION>
<P>No information reported on reasons for withdrawals and proportion of withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 18:48:59 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Nyboe-Andersen-2011">
<DESCRIPTION>
<P>Minimal (&lt; 10%) discontinuations and balanced between groups with similar reasons given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-14 16:40:50 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Obruca-2002">
<DESCRIPTION>
<P>Number and reasons for withdrawals not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 18:56:53 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Porrati-2010">
<DESCRIPTION>
<P>Proportions of exclusion and reason for exclusion similar between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 19:02:45 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raoofi-2008">
<DESCRIPTION>
<P>No information on reasons for withdrawals and proportions of withdrawals per treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 19:12:06 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Rombauts-2006">
<DESCRIPTION>
<P>Proportions of withdrawals fairly balanced between groups although reasons for withdrawals were not completely reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:42 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salat_x002d_Baroux-1988">
<DESCRIPTION>
<P>Proportions of, and reasons for, withdrawals not balanced between groups and data not analyzed on the basis of ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 19:23:23 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Shaker-1995">
<DESCRIPTION>
<P>Reasons for withdrawals and proportions of participants who withdrew not reported per treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 19:24:52 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2001">
<DESCRIPTION>
<P>No data reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-11 19:29:23 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Vilela-2011">
<DESCRIPTION>
<P>Proportions of withdrawals fairly balanced between groups although reasons for withdrawals not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-08-09 08:45:43 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ye-2009">
<DESCRIPTION>
<P>No withdrawals reported, cycle cancellation (number of cycles were equivalent to numbers of women randomized) similar between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-05-12 00:13:13 +1200" MODIFIED_BY="Anne Lawson" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aston-1995">
<DESCRIPTION>
<P>All planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Biljan-1998b">
<DESCRIPTION>
<P>All planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:39:33 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Blockeel-2012">
<DESCRIPTION>
<P>All prespecified outcomes reported,</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:53:38 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007">
<DESCRIPTION>
<P>Some planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:43:50 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012">
<DESCRIPTION>
<P>All prespecified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:58:17 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Daly-2002">
<DESCRIPTION>
<P>Data on all planned outcomes reported. Pre-cross-over data on primary outcome reported, but on some secondary outcomes (implantation rate, mature oocytes, good embryos) only post-cross-over data reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ditkoff-1996">
<DESCRIPTION>
<P>All planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 12:01:59 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engmann-1999">
<DESCRIPTION>
<P>Data on all planned outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fanchin-2003">
<DESCRIPTION>
<P>All planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Franco-Jr-2003">
<DESCRIPTION>
<P>All planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:44:09 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Velasco-2011">
<DESCRIPTION>
<P>All prespecified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:50:50 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hauzman-2013">
<DESCRIPTION>
<P>All prespecified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hugues-1994">
<DESCRIPTION>
<P>All planned outcomes not reported. No data on pregnancy rates.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-14 16:15:39 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huirne-2006a">
<DESCRIPTION>
<P>Data on all planned outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-09 15:54:03 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huirne-2006c">
<DESCRIPTION>
<P>Data on all planned outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 08:25:01 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hwang-2004">
<DESCRIPTION>
<P>Data on all planned outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 08:35:12 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>All outcomes listed were reported although multiple pregnancy was reported it is not listed a priori.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-14 16:38:20 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolibianakis-2006">
<DESCRIPTION>
<P>Data on all planned outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-12 00:13:13 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lukaszuk-2015">
<DESCRIPTION>
<P>Important outcome measures were prespecified in the methods section and data were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:49:00 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Nyboe-Andersen-2011">
<DESCRIPTION>
<P>All prespecified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Obruca-2002">
<DESCRIPTION>
<P>All planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:57:32 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Porrati-2010">
<DESCRIPTION>
<P>All reported outcomes pre-specified in the methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raoofi-2008">
<DESCRIPTION>
<P>All planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-03 15:37:59 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rombauts-2006">
<DESCRIPTION>
<P>Data on all planned outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Salat_x002d_Baroux-1988">
<DESCRIPTION>
<P>All planned outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-15 12:03:12 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shaker-1995">
<DESCRIPTION>
<P>Data on all planned outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:24:54 +1200" MODIFIED_BY="Anne Lawson" RESULT="NO" STUDY_ID="STD-Tan-2001">
<DESCRIPTION>
<P>All prespecified outcomes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:29:24 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Vilela-2011">
<DESCRIPTION>
<P>Outcome data not clearly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:40:56 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Ye-2009">
<DESCRIPTION>
<P>All prespecified outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-05-11 20:43:25 +1200" MODIFIED_BY="Anne Lawson" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:41:45 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Aston-1995">
<DESCRIPTION>
<P>Quote: "No difference was seen between the study group and control group in the indication of IVF and age."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:18:43 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Biljan-1998b">
<DESCRIPTION>
<P>No significant difference in baseline characteristics between groups with regard to age, cause of infertility, number of previous attempts, and oestradiol, FSH or LH level.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:39:39 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Blockeel-2012">
<DESCRIPTION>
<P>Groups comparable at baseline,</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:53:41 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007">
<DESCRIPTION>
<P>No significant baseline imbalance with regard to age and BMI.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 02:43:51 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012">
<DESCRIPTION>
<P>Groups balanced at baseline with respect to demographic characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-16 12:28:03 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daly-2002">
<DESCRIPTION>
<P>No data on baseline characteristics reported.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:42:05 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Ditkoff-1996">
<DESCRIPTION>
<P>Quote: "The various infertility diagnoses were distributed equally between the control and study groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-14 16:20:03 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engmann-1999">
<DESCRIPTION>
<P>No significant baseline imbalance between groups with regard to age, duration of infertility, previous attempts, baseline serum FSH, polycystic ovaries and cause of infertility.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:18:59 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Fanchin-2003">
<DESCRIPTION>
<P>No difference in baseline characteristics with regard to age, indication for IVF-ET, duration of infertility, rank of the current IVF-ET attempt, menstrual cycle length, day 3 serum FSH and oestradiol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franco-Jr-2003">
<DESCRIPTION>
<P>No significant difference in baseline characteristics with regard to age. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:44:22 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Velasco-2011">
<DESCRIPTION>
<P>Groups comparable at baseline with regard to demographic characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 03:50:58 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hauzman-2013">
<DESCRIPTION>
<P>Groups balanced at baseline with respect to demographic characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hugues-1994">
<DESCRIPTION>
<P>Baseline demographic characteristics not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-14 16:22:38 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huirne-2006a">
<DESCRIPTION>
<P>No significant differences in baseline characteristics with regard to age, BMI, cycle length, primary infertility, smoking habits, duration of infertility, type of infertility and antral follicle count.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 08:02:19 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Huirne-2006c">
<DESCRIPTION>
<P>No significant difference in baseline characteristics with regard to age, race, duration of infertility, cause of infertility, smoking habits, primary infertility, number of previous ART attempts, number of follicles, endometrial thickness, FSH levels and oestradiol levels.</P>
<P>P value of BMI was 0.04.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-16 12:34:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hwang-2004">
<DESCRIPTION>
<P>No significant difference in baseline characteristics with regard to age, duration of infertility, BMI and hormonal levels.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 08:35:19 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>Groups similar at baseline with respect to demographic characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-14 16:39:40 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolibianakis-2006">
<DESCRIPTION>
<P>No significant differences in baseline characteristics with regard to age, BMI, primary/secondary infertility, duration of infertility, number of previous IVF trials, indication for treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:41:25 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Lukaszuk-2015">
<DESCRIPTION>
<P>Demographic and infertility characteristics similar between the two groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:49:06 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Nyboe-Andersen-2011">
<DESCRIPTION>
<P>Groups appeared balanced at baseline with respect to age, BMI, age at menarche, duration of infertility, cycle length, alcohol use and smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-16 12:37:30 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Obruca-2002">
<DESCRIPTION>
<P>No data on baseline characteristics reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 18:57:33 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Porrati-2010">
<DESCRIPTION>
<P>Insufficient information to make a conclusive judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 20:43:25 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Raoofi-2008">
<DESCRIPTION>
<P>Number of women per group not reported.</P>
<P>Quote: "The etiology and duration of infertility were equally distributed among the groups." No table of demographic characteristics available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:12:11 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Rombauts-2006">
<DESCRIPTION>
<P>No differences in baseline characteristics with regard to age, BMI, height and weight.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:17:50 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Salat_x002d_Baroux-1988">
<DESCRIPTION>
<P>Baseline demographic characteristics balanced between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:23:35 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Shaker-1995">
<DESCRIPTION>
<P>No significant differences in baseline characteristics between groups with regard to age, length of infertility, number of previous IVF cycles and cause of infertility.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:24:57 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2001">
<DESCRIPTION>
<P>Insufficient information to make a conclusive judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:29:31 +1200" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Vilela-2011">
<DESCRIPTION>
<P>Not clear whether groups were comparable at baseline with respect to demographic characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-11 19:41:01 +1200" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Ye-2009">
<DESCRIPTION>
<P>Groups comparable at baseline with respect to demographic characteristics.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-05-12 00:21:49 +1200" MODIFIED_BY="Anne Lawson">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-05-12 00:21:49 +1200" MODIFIED_BY="Anne Lawson" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-05-11 19:50:38 +1200" MODIFIED_BY="Anne Lawson">Combined oral contraceptive pill compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Combined oral contraceptive pill compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> women undergoing ART</P>
<P>
<B>Settings: </B>ART clinic</P>
<P>
<B>Intervention:</B> COCP</P>
<P>
<B>Comparison: </B>no pretreatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk<SUP>1</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No p</B>retreat<B>ment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>COCP</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth or ongoing pregnancy </B>
</P>
<P>
<B>(COCP + Ant vs Ant)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>270 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>215 per 1000</B>
<BR/>(177 to 260)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.74 </B>
<BR/>(0.58 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1335<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth or ongoing pregnancy</B>
</P>
<P>
<B>(COCP + Ant vs Ag)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>296 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>273 per 1000</B>
<BR/>(212 to 345)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.89</B>
<BR/>(0.64 to 1.25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>724<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pregnancy loss </B>
</P>
<P>
<B>(COCP + Ant vs Ant)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>64 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>85 per 1000</B>
<BR/>(53 to 134)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.36 </B>
<BR/>(0.82 to 2.26)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>868<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pregnancy loss</B>
</P>
<P>
<B>(COCP + Ant vs Ag)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>103 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
<BR/>(25 to 76)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.40 </B>
<BR/>(0.22 to 0.72)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>780<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Multiple pregnancy rate (COCP + Ant vs Ant)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>47 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>98 per 1000</B>
<BR/>(25 to 313)</P>
</TD>
<TD>
<P>
<B>OR 2.21 </B>
<BR/>(0.53 to 9.26)</P>
</TD>
<TD>
<P>125<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Multiple pregnancy rate (COCP + Ant vs Ag)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>147 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>189 per 1000</B>
<BR/>(127 to 273)</P>
</TD>
<TD>
<P>
<B>OR 1.36 </B>
<BR/>(0.85 to 2.19)</P>
</TD>
<TD>
<P>546<BR/>(4 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>OHSS rate</B>
</P>
<P>
<B>(COCP + Ant vs Ant)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>16 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>16 per 1000</B>
</P>
<P>(4 to 52)</P>
</TD>
<TD>
<P>
<B>OR 0.98</B>
</P>
<P>(0.28 to 3.40)</P>
</TD>
<TD>
<P>642</P>
<P>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>OHSS rate</B>
</P>
<P>
<B>(COCP + Ant vs Ag)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>55 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>35 per 1000</B>
</P>
<P>(11 to 102)</P>
</TD>
<TD>
<P>
<B>OR 0.63</B>
</P>
<P>(0.20 to 1.96)</P>
</TD>
<TD>
<P>290</P>
<P>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>Ag:</B> agonist; <B>Ant:</B> antagonist; <B>ART:</B> assisted reproductive techniques; <B>COCP:</B> combined oral contraceptive pill; <B>CI:</B> confidence interval; <B>OHSS:</B> ovarian hyperstimulation syndrome; <B>OR:</B> odds ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Mean baseline risk of control group.<BR/>
<SUP>2</SUP> Downgraded one level for serious risk of bias due to poor reporting of sequence generation and allocation concealment.<BR/>
<SUP>3</SUP> Downgraded one level for serious imprecision: effect estimate with wide confidence intervals or low event rate (or both).<BR/>
<SUP>4</SUP> Downgraded two levels for very serious imprecision: small sample size or very low event rate, and effect estimate with wide confidence intervals.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-05-11 22:42:04 +1200" MODIFIED_BY="Anne Lawson" NO="2" READONLY="YES">
<TITLE MODIFIED="2017-05-10 19:04:09 +1200" MODIFIED_BY="Anne Lawson">Progestogen compared to placebo or no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Progestogen compared to placebo or no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> ovarian stimulation protocols for women undergoing ART</P>
<P>
<B>Settings:</B>
</P>
<P>
<B>Intervention:</B> progestogen</P>
<P>
<B>Comparison: </B>placebo or no pretreatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk<SUP>1</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo or no p</B>retreat<B>ment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prog</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth or ongoing pregnancy </B>
</P>
<P>
<B>(Prog + Ag vs Ag)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>170 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>217 per 1000</B>
<BR/>(124 to 352)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.35 </B>
<BR/>(0.69 to 2.65)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>222<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth or ongoing pregnancy (Prog + Ant vs Ant)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>292 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>217 per 1000</B>
<BR/>(69 to 512)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.67 </B>
<BR/>(0.18 to 2.54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pregnancy loss</B>
</P>
<P>
<B>(Prog + Ag vs Ag)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>78 per 1000</B>
<BR/>(24 to 220)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 2.26 </B>
<BR/>(0.67 to 7.55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>222<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pregnancy loss </B>
</P>
<P>
<B>(Prog + Ant vs Ant)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>208 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>86 per 1000</B>
<BR/>(16 to 354)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.36 </B>
<BR/>(0.06 to 2.09)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Multiple pregnancy rate</B>
</P>
<P>
<B>(Prog + Ag vs Ag)</B>
</P>
</TD>
<TD COLSPAN="4" ROWSPAN="1" VALIGN="TOP">
<P>No data available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Multiple pregnancy rate</B>
</P>
<P>
<B>(Prog + Ant vs Ant)</B>
</P>
</TD>
<TD>
<P>
<B>42 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>44 per 1000</B>
<BR/>(3 to 438)</P>
</TD>
<TD>
<P>
<B>OR 1.05 </B>
<BR/>(0.06 to 17.76)</P>
</TD>
<TD>
<P>47<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low</B>
<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>OHSS rate</B>
</P>
<P>
<B>(Prog + Ag vs Ag)</B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>No data available</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>OHSS rate</B>
</P>
<P>
<B>(Prog + Ant vs Ant)</B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>No data available</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>Ag:</B> agonist; <B>Ant:</B> antagonist; <B>ART:</B> assisted reproductive techniques; <B>CI:</B> confidence interval; <B>OHSS:</B> ovarian hyperstimulation syndrome; <B>OR:</B> odds ratio; <B>Prog:</B> progestogen.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Mean baseline risk of control group.<BR/>
<SUP>2</SUP> Downgraded two levels for very serious imprecision: small sample size and effect estimate with wide confidence intervals.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2017-05-11 22:42:26 +1200" MODIFIED_BY="Anne Lawson" NO="3" READONLY="YES">
<TITLE MODIFIED="2017-05-10 19:04:22 +1200" MODIFIED_BY="Anne Lawson">Oestrogen compared to no pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>Oestrogen<B> compared to no p</B>retreat<B>ment for ovarian stimulation protocols for women undergoing assisted reproductive techniques</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> ovarian stimulation protocols for women undergoing ART</P>
<P>
<B>Settings:</B>
</P>
<P>
<B>Intervention:</B> oestrogen</P>
<P>
<B>Comparison: </B>no pretreatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk<SUP>1</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No p</B>retreat<B>ment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Oestr</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth or ongoing pregnancy </B>
</P>
<P>
<B>(Oestr + Ant vs Ant)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>299 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>252 per 1000</B>
<BR/>(184 to 333)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.79 </B>
<BR/>(0.53 to 1.17)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>502<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth or ongoing pregnancy </B>
</P>
<P>
<B>(Oestr + Ant vs Ag)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>350 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>322 per 1000</B>
<BR/>(215 to 447)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.88 </B>
<BR/>(0.51 to 1.5)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>242<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pregnancy loss</B>
</P>
<P>
<B>(Oestr + Ant vs Ant)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>208 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
<BR/>(5 to 279)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.16 </B>
<BR/>(0.02 to 1.47)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pregnancy loss</B>
</P>
<P>
<B>(Oestr + Ant vs Ag)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>72 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
<BR/>(46 to 240)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.59 </B>
<BR/>(0.62 to 4.06)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>220<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Multiple pregnancy rate</B>
</P>
<P>
<B>(Oestr + Ant vs Ant)</B>
</P>
</TD>
<TD COLSPAN="4" ROWSPAN="1" VALIGN="TOP">
<P>No data available</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Multiple pregnancy rate</B>
</P>
<P>
<B>(Oestr + Ant vs Ag)</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Not calculable - see comment</P>
</TD>
<TD>
<P>
<B>OR 2.24 </B>
<BR/>(0.09 to 53.59)</P>
</TD>
<TD>
<P>22<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD>
<P>Only 2 events (both in oestrogen group)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>OHSS rate</B>
</P>
<P>
<B>(Oestr + Ant vs Ant)</B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>No data available</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>OHSS rate</B>
</P>
<P>
<B>(Oestr + Ant vs Ag)</B>
</P>
</TD>
<TD>
<P>18 per 1000</P>
</TD>
<TD>
<P>27 per 1000</P>
<P>(5 to 147)</P>
</TD>
<TD>
<P>OR 1.54</P>
<P>(0.25 to 9.42)</P>
</TD>
<TD>
<P>220</P>
<P>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>Very low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>Ag:</B> agonist; <B>Ant:</B> antagonist; <B>ART:</B> assisted reproductive techniques; <B>CI:</B> confidence interval; <B>Oestr:</B> oestrogen; <B>OHSS:</B> ovarian hyperstimulation syndrome; <B>OR:</B> odds ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Mean baseline risk of control group.<BR/>
<SUP>2</SUP> Downgraded one level for serious imprecision: effect estimate with wide confidence intervals.<BR/>
<SUP>3</SUP> Downgraded one level for serious risk of bias due to poor reporting on allocation concealment or high attrition (or both).<BR/>
<SUP>4</SUP> Downgraded two levels for very serious imprecision: small sample size and effect estimate with wide confidence intervals.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-09-27 13:16:49 +1300" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-07-26 09:13:15 +1200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-07-14 15:22:16 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Combined oral contraceptive pill (COCP) versus no pretreatment (Rx)</NAME>
<DICH_OUTCOME CHI2="8.516652931399156" CI_END="1.002099654250018" CI_START="0.6810081517179009" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8260980773358284" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="306" I2="0.0" I2_Q="7.9957913969928045" ID="CMP-001.01" LOG_CI_END="9.109122885576868E-4" LOG_CI_START="-0.1668476895190595" LOG_EFFECT_SIZE="-0.08296838861525088" METHOD="MH" MODIFIED="2017-05-24 10:22:04 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6664107170183995" P_Q="0.3531472148073189" P_Z="0.0525404164650986" Q="3.260720401329493" RANDOM="NO" SCALE="17.71" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1112" TOTAL_2="1107" WEIGHT="400.0" Z="1.9386791710114397">
<NAME>Live birth or ongoing pregnancy</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.536642032131379" CI_END="0.9527750857312354" CI_START="0.5752981978491101" DF="5" EFFECT_SIZE="0.7403578795263215" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="180" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.021009607812970506" LOG_CI_START="-0.24010698642194192" LOG_EFFECT_SIZE="-0.13055829711745617" MODIFIED="2017-05-24 10:22:04 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.474995931839886" P_Z="0.01949893961147003" STUDIES="6" TAU2="0.0" TOTAL_1="669" TOTAL_2="666" WEIGHT="100.00000000000001" Z="2.3358523215358615">
<NAME>COCP + antagonist (Ant) vs Ant</NAME>
<DICH_DATA CI_END="1.825305034161824" CI_START="0.08975606623564518" EFFECT_SIZE="0.40476190476190477" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2613354515779543" LOG_CI_START="-1.0469361896172074" LOG_EFFECT_SIZE="-0.3928003690196265" MODIFIED="2017-04-05 13:26:04 +1200" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.7684852380871062" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="24" VAR="0.5905695611577964" WEIGHT="3.9791224779684025"/>
<DICH_DATA CI_END="1.6015303258325488" CI_START="0.11468622630812386" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.20453516667579472" LOG_CI_START="-0.9404887372649836" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2016-09-02 17:15:26 +1200" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.6725927091345493" STUDY_ID="STD-Huirne-2006a" TOTAL_1="32" TOTAL_2="32" VAR="0.4523809523809524" WEIGHT="4.973903097460504"/>
<DICH_DATA CI_END="4.794005633681151" CI_START="0.6130104415308116" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.6806985400595873" LOG_CI_START="-0.2125321279928514" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2017-05-24 10:22:04 +1200" MODIFIED_BY="[Empty name]" ORDER="637" O_E="0.0" SE="0.5246881159771194" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.27529761904761907" WEIGHT="3.9791224779684025"/>
<DICH_DATA CI_END="1.2642390697739914" CI_START="0.5431327001140889" EFFECT_SIZE="0.828643216080402" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="60" LOG_CI_END="0.10182920754297504" LOG_CI_START="-0.2650940490733507" LOG_EFFECT_SIZE="-0.08163242076518785" MODIFIED="2016-09-02 17:15:35 +1200" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.2155325372358429" STUDY_ID="STD-Kolibianakis-2006" TOTAL_1="250" TOTAL_2="254" VAR="0.04645427460732001" WEIGHT="33.66689511546395"/>
<DICH_DATA CI_END="0.9828521479999914" CI_START="0.4217926309785677" EFFECT_SIZE="0.6438631790744467" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="71" LOG_CI_END="-0.007511808858814639" LOG_CI_START="-0.37490101196803766" LOG_EFFECT_SIZE="-0.19120641041342615" MODIFIED="2016-09-02 17:15:46 +1200" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.2158062365122431" STUDY_ID="STD-Nyboe-Andersen-2011" TOTAL_1="209" TOTAL_2="199" VAR="0.0465723317175782" WEIGHT="38.08449332467307"/>
<DICH_DATA CI_END="1.3814321339001365" CI_START="0.3769841208636895" EFFECT_SIZE="0.7216494845360825" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" LOG_CI_END="0.1403295540396067" LOG_CI_START="-0.42367694254358274" LOG_EFFECT_SIZE="-0.14167369425198803" MODIFIED="2017-04-05 13:26:22 +1200" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.3313002079701504" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" VAR="0.10975982780106493" WEIGHT="15.316463506465679"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7298835843269506" CI_END="1.2452378733554046" CI_START="0.6380571078439081" DF="3" EFFECT_SIZE="0.8913657364128644" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.09525232108462532" LOG_CI_START="-0.19514044900369137" LOG_EFFECT_SIZE="-0.049944063959533054" MODIFIED="2017-05-23 13:31:50 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="0.8661535510830526" P_Z="0.5001965911590653" STUDIES="4" TAU2="0.0" TOTAL_1="363" TOTAL_2="361" WEIGHT="100.0" Z="0.6741804664935634">
<NAME>COCP + Ant vs agonist (Ag)</NAME>
<DICH_DATA CI_END="1.5195097378363995" CI_START="0.5355841032534275" EFFECT_SIZE="0.902122641509434" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="53" LOG_CI_END="0.1817034876177141" LOG_CI_START="-0.2711723218239065" LOG_EFFECT_SIZE="-0.044734417103096204" MODIFIED="2016-09-02 17:14:19 +1200" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.2660214922374195" STUDY_ID="STD-Garcia_x002d_Velasco-2011" TOTAL_1="115" TOTAL_2="113" VAR="0.07076743433222345" WEIGHT="40.85226408953038"/>
<DICH_DATA CI_END="2.107479785231373" CI_START="0.47450039948554645" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.32376341760066035" LOG_CI_START="-0.3237634176006603" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-09-02 17:14:19 +1200" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.38036046830678455" STUDY_ID="STD-Huirne-2006c" TOTAL_1="91" TOTAL_2="91" VAR="0.14467408585055644" WEIGHT="18.980357459075428"/>
<DICH_DATA CI_END="2.977621904051725" CI_START="0.42873358388304234" EFFECT_SIZE="1.12987012987013" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.4738695505656434" LOG_CI_START="-0.36781249567336993" LOG_EFFECT_SIZE="0.05302852744613667" MODIFIED="2017-04-05 13:26:30 +1200" MODIFIED_BY="[Empty name]" ORDER="638" O_E="0.0" SE="0.49440820035412" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.24443946857739962" WEIGHT="10.571968578357833"/>
<DICH_DATA CI_END="1.3814321339001365" CI_START="0.3769841208636895" EFFECT_SIZE="0.7216494845360825" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" LOG_CI_END="0.1403295540396067" LOG_CI_START="-0.42367694254358274" LOG_EFFECT_SIZE="-0.14167369425198803" MODIFIED="2017-05-23 13:31:50 +1200" MODIFIED_BY="Helen E Nagels" ORDER="89" O_E="0.0" SE="0.3313002079701504" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" VAR="0.10975982780106493" WEIGHT="29.59540987303636">
<FOOTNOTE>Includes 2 spontaneous pregnancies in the COCP group</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7909274605017564E-31" CI_END="4.794005633681152" CI_START="0.6130104415308117" DF="0" EFFECT_SIZE="1.7142857142857144" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="100.0" ID="CMP-001.01.03" LOG_CI_END="0.6806985400595874" LOG_CI_START="-0.21253212799285132" LOG_EFFECT_SIZE="0.23408320603336802" MODIFIED="2017-04-05 13:27:20 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.30429323355668203" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.0272702665066493">
<NAME>COCP + Ant vs Ant, low response</NAME>
<DICH_DATA CI_END="4.794005633681151" CI_START="0.6130104415308116" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.6806985400595873" LOG_CI_START="-0.2125321279928514" LOG_EFFECT_SIZE="0.23408320603336796" MODIFIED="2017-04-05 13:27:20 +1200" MODIFIED_BY="[Empty name]" ORDER="639" O_E="0.0" SE="0.5246881159771194" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.27529761904761907" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.977621904051725" CI_START="0.42873358388304234" DF="0" EFFECT_SIZE="1.12987012987013" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.4738695505656434" LOG_CI_START="-0.36781249567336993" LOG_EFFECT_SIZE="0.05302852744613667" MODIFIED="2017-04-05 13:27:26 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8049334711513855" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.24696737779317543">
<NAME>COCP + Ant vs Ag, low response</NAME>
<DICH_DATA CI_END="2.977621904051725" CI_START="0.42873358388304234" EFFECT_SIZE="1.12987012987013" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.4738695505656434" LOG_CI_START="-0.36781249567336993" LOG_EFFECT_SIZE="0.05302852744613667" MODIFIED="2017-04-05 13:27:26 +1200" MODIFIED_BY="[Empty name]" ORDER="640" O_E="0.0" SE="0.49440820035412" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.24443946857739962" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.6097403544706" CI_END="1.1542835090081092" CI_START="0.5636904961101742" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8066341449781145" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="73" I2="33.773799197051915" I2_Q="70.5517599944276" ID="CMP-001.02" LOG_CI_END="0.0623124910343802" LOG_CI_START="-0.24895928737548825" LOG_EFFECT_SIZE="-0.09332339817055402" METHOD="MH" MODIFIED="2017-05-23 13:33:56 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="0.11996117385246075" P_Q="0.017038846777988836" P_Z="0.2398962215736098" Q="10.187366034208901" RANDOM="NO" SCALE="678.31" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="871" TOTAL_2="937" WEIGHT="400.0" Z="1.1752462768296899">
<NAME>Pregnancy loss</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.926330606761115" CI_END="2.258718835971905" CI_START="0.8165026346444852" DF="4" EFFECT_SIZE="1.358031619842552" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.35386217355623634" LOG_CI_START="-0.08804240956820013" LOG_EFFECT_SIZE="0.13290988199401813" MODIFIED="2017-04-07 11:58:33 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.41606788692384933" P_Z="0.23840571157826906" STUDIES="5" TAU2="0.0" TOTAL_1="401" TOTAL_2="467" WEIGHT="100.00000000000001" Z="1.1789811278078102">
<NAME>COCP + Ant vs Ant</NAME>
<DICH_DATA CI_END="2.322191824172889" CI_START="0.06890042344240374" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3658980916897468" LOG_CI_START="-1.161778109033822" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2017-04-07 11:58:33 +1200" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.8973645624241782" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="24" VAR="0.8052631578947367" WEIGHT="16.49515222358993">
<FOOTNOTE>Calculated from the number of clinical pregnancies minus the number of live births</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.1822007657582394" CI_START="0.18700958381377564" EFFECT_SIZE="0.7714285714285715" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.5027275759109512" LOG_CI_START="-0.7281361362935279" LOG_EFFECT_SIZE="-0.11270428019128831" MODIFIED="2009-02-03 11:56:27 +1300" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.723015437422551" STUDY_ID="STD-Huirne-2006a" TOTAL_1="32" TOTAL_2="32" VAR="0.5227513227513227" WEIGHT="17.09201628431193">
<FOOTNOTE>Calculated from the number of positive pregnancy tests minus the number of ongoing pregnancies.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="23.589411635381268" CI_START="0.1786096433440727" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3727171088934862" LOG_CI_START="-0.7480950967461457" LOG_EFFECT_SIZE="0.3123110060736703" MODIFIED="2017-04-05 14:02:31 +1200" MODIFIED_BY="[Empty name]" ORDER="628" O_E="0.0" SE="1.2457755877824503" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="1.5519568151147096" WEIGHT="3.711409250307734"/>
<DICH_DATA CI_END="3.561179254923292" CI_START="0.9883942899720286" EFFECT_SIZE="1.8761261261261262" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" LOG_CI_END="0.5515938347988532" LOG_CI_START="-0.005069772214517671" LOG_EFFECT_SIZE="0.27326203129216775" MODIFIED="2009-01-09 09:49:57 +1300" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.32698695828894936" STUDY_ID="STD-Kolibianakis-2006" TOTAL_1="250" TOTAL_2="254" VAR="0.10692047089105912" WEIGHT="55.06652321258593"/>
<DICH_DATA CI_END="6.553053753904233" CI_START="0.06782249331918719" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.8164437304356504" LOG_CI_START="-1.168626248547013" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2017-04-05 14:02:37 +1200" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="1.1660399319092882" STUDY_ID="STD-Rombauts-2006" TOTAL_1="58" TOTAL_2="117" VAR="1.3596491228070176" WEIGHT="7.634899029204481"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.849591549783607" CI_END="0.7162673279037279" CI_START="0.22325241047558098" DF="4" EFFECT_SIZE="0.3998854929844425" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="40" I2="17.51882691690843" ID="CMP-001.02.02" LOG_CI_END="-0.1449248584668656" LOG_CI_START="-0.651203843299026" LOG_EFFECT_SIZE="-0.39806435088294584" MODIFIED="2017-04-06 16:33:07 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.30308167225610194" P_Z="0.0020557152153140453" STUDIES="5" TAU2="0.0" TOTAL_1="390" TOTAL_2="390" WEIGHT="100.0" Z="3.0820627149615336">
<NAME>COCP + Ant vs Ag</NAME>
<DICH_DATA CI_END="0.7101134365181849" CI_START="0.10444082166622047" EFFECT_SIZE="0.2723322066634476" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.14867226970515482" LOG_CI_START="-0.9811297201150658" LOG_EFFECT_SIZE="-0.5649009949101104" MODIFIED="2016-03-01 11:26:55 +1300" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.4889896271016196" STUDY_ID="STD-Garcia_x002d_Velasco-2011" TOTAL_1="115" TOTAL_2="113" VAR="0.239110855412981" WEIGHT="47.170331055409974"/>
<DICH_DATA CI_END="2.0776932781119686" CI_START="0.2933677650290507" EFFECT_SIZE="0.7807228915662651" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3175814347248004" LOG_CI_START="-0.5325876077357615" LOG_EFFECT_SIZE="-0.10750308650548057" MODIFIED="2009-02-03 11:50:27 +1300" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.4993935039459665" STUDY_ID="STD-Huirne-2006c" TOTAL_1="91" TOTAL_2="91" VAR="0.24939387178343003" WEIGHT="23.682654365958427">
<FOOTNOTE>Calculated from the number of positive pregnancy tests minus the number of live births.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.078255420629009" CI_START="0.044354929672908786" EFFECT_SIZE="0.5192307692307693" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7837789460629444" LOG_CI_START="-1.353058105014568" LOG_EFFECT_SIZE="-0.2846395794758118" MODIFIED="2017-04-06 16:33:07 +1200" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="1.2551886613169254" STUDY_ID="STD-Hwang-2004" TOTAL_1="27" TOTAL_2="29" VAR="1.5754985754985755" WEIGHT="4.822130828731295"/>
<DICH_DATA CI_END="7.469892581126037" CI_START="0.13387073363366314" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8733143565999179" LOG_CI_START="-0.8733143565999179" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-05 14:02:49 +1200" MODIFIED_BY="[Empty name]" ORDER="629" O_E="0.0" SE="1.025978352085154" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="1.0526315789473684" WEIGHT="4.9334107709327855"/>
<DICH_DATA CI_END="1.1107057115087968" CI_START="0.0035388919231500934" EFFECT_SIZE="0.0626950354609929" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.045599005117219774" LOG_CI_START="-2.4511327004018333" LOG_EFFECT_SIZE="-1.2027668476423068" MODIFIED="2017-04-05 14:02:59 +1200" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.4665925628431578" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" VAR="2.1508937453868615" WEIGHT="19.39147297896752"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.589411635381282" CI_START="0.17860964334407264" DF="0" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.3727171088934864" LOG_CI_START="-0.7480950967461458" LOG_EFFECT_SIZE="0.3123110060736703" MODIFIED="2016-11-22 15:53:10 +1300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5637712877187138" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.5772489636301865">
<NAME>COCP + Ant vs Ant, low response</NAME>
<DICH_DATA CI_END="23.589411635381268" CI_START="0.1786096433440727" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3727171088934862" LOG_CI_START="-0.7480950967461457" LOG_EFFECT_SIZE="0.3123110060736703" MODIFIED="2016-11-22 15:53:10 +1300" MODIFIED_BY="[Empty name]" ORDER="630" O_E="0.0" SE="1.2457755877824503" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="1.5519568151147096" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.469892581126037" CI_START="0.13387073363366314" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.8733143565999179" LOG_CI_START="-0.8733143565999179" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-11-22 15:53:38 +1300" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.0">
<NAME>COCP + Ant vs Ag, low response</NAME>
<DICH_DATA CI_END="7.469892581126037" CI_START="0.13387073363366314" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8733143565999179" LOG_CI_START="-0.8733143565999179" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-11-22 15:53:38 +1300" MODIFIED_BY="[Empty name]" ORDER="631" O_E="0.0" SE="1.025978352085154" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="1.0526315789473684" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.385663785145134" CI_END="1.1133794455110932" CI_START="0.7178880052698857" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8940255864607288" ESTIMABLE="YES" EVENTS_1="245" EVENTS_2="261" I2="50.94591912534672" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.04664319938199423" LOG_CI_START="-0.1439433029541537" LOG_EFFECT_SIZE="-0.04865005178607974" METHOD="MH" MODIFIED="2017-07-14 15:22:16 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.025808927525657777" P_Q="0.4663333692837437" P_Z="0.3170104875523825" Q="2.549941919241731" RANDOM="NO" SCALE="24.9" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="726" TOTAL_2="720" WEIGHT="400.0" Z="1.000620171711285">
<NAME>Clinical pregnancy rate</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.93475868709517" CI_END="1.1516697138721088" CI_START="0.625181603141655" DF="4" EFFECT_SIZE="0.8485297390240699" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="130" I2="76.37994096102398" ID="CMP-001.03.01" LOG_CI_END="0.06132794609280483" LOG_CI_START="-0.20399381019798168" LOG_EFFECT_SIZE="-0.07133293205258841" MODIFIED="2017-04-05 14:03:33 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0019901933231706304" P_Z="0.2919332804076833" STUDIES="5" TAU2="0.0" TOTAL_1="373" TOTAL_2="367" WEIGHT="100.00000000000001" Z="1.0538900366805024">
<NAME>COCP + Ant vs Ant</NAME>
<DICH_DATA CI_END="1.3359383434314458" CI_START="0.1020974658689305" EFFECT_SIZE="0.3693181818181818" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.12578641493189316" LOG_CI_START="-0.9909850372744817" LOG_EFFECT_SIZE="-0.43259931117129424" MODIFIED="2017-04-05 14:03:26 +1200" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.6559970791338692" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="24" VAR="0.4303321678321678" WEIGHT="8.742203149881858">
<FOOTNOTE>Data obtained from Dr. Cédrin-Durnerin</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.8467721366452235" CI_START="0.06694757650886135" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.07223344104034042" LOG_CI_START="-1.1742651397554607" LOG_EFFECT_SIZE="-0.6232492903979004" MODIFIED="2016-11-22 13:33:18 +1300" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.6473388749701496" STUDY_ID="STD-Huirne-2006a" TOTAL_1="32" TOTAL_2="32" VAR="0.419047619047619" WEIGHT="11.73491758045221"/>
<DICH_DATA CI_END="4.973246306606301" CI_START="0.6916840728074554" EFFECT_SIZE="1.8547008547008548" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.696639968773955" LOG_CI_START="-0.16009222456921923" LOG_EFFECT_SIZE="0.26827387210236786" MODIFIED="2017-04-05 14:03:33 +1200" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="0.5032487312625338" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.25325928551735" WEIGHT="6.5380255091090875"/>
<DICH_DATA CI_END="0.9828521479999914" CI_START="0.4217926309785677" EFFECT_SIZE="0.6438631790744467" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="71" LOG_CI_END="-0.007511808858814639" LOG_CI_START="-0.37490101196803766" LOG_EFFECT_SIZE="-0.19120641041342615" MODIFIED="2015-07-31 12:37:40 +1200" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.2158062365122431" STUDY_ID="STD-Nyboe-Andersen-2011" TOTAL_1="209" TOTAL_2="199" VAR="0.0465723317175782" WEIGHT="59.90176882570704"/>
<DICH_DATA CI_END="4.198571741419756" CI_START="1.1015203268728369" EFFECT_SIZE="2.150537634408602" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="27" LOG_CI_END="0.6231015784189573" LOG_CI_START="0.041992515801134736" LOG_EFFECT_SIZE="0.33254704711004607" MODIFIED="2016-06-22 14:39:03 +1200" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.34134633991796115" STUDY_ID="STD-Porrati-2010" TOTAL_1="71" TOTAL_2="72" VAR="0.11651732377538829" WEIGHT="13.083084934849817"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9258406511761486" CI_END="1.2042518644365843" CI_START="0.5874215204753256" DF="3" EFFECT_SIZE="0.8410728037706272" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="109" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.08071732736670299" LOG_CI_START="-0.23105014693055254" LOG_EFFECT_SIZE="-0.07516640978192478" MODIFIED="2017-04-05 14:03:40 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8191879557822647" P_Z="0.3446152508033178" STUDIES="4" TAU2="0.0" TOTAL_1="273" TOTAL_2="273" WEIGHT="99.99999999999999" Z="0.9450854766157283">
<NAME>COCP + Ant vs Ag</NAME>
<DICH_DATA CI_END="1.2243489881574163" CI_START="0.4313194235992347" EFFECT_SIZE="0.7266949152542372" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="64" LOG_CI_END="0.08790522665605494" LOG_CI_START="-0.36520098383868954" LOG_EFFECT_SIZE="-0.1386478785913173" MODIFIED="2015-08-10 16:44:18 +1200" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.2661568309565281" STUDY_ID="STD-Garcia_x002d_Velasco-2011" TOTAL_1="115" TOTAL_2="113" VAR="0.07083945866482186" WEIGHT="50.918347281633665"/>
<DICH_DATA CI_END="1.661706884726553" CI_START="0.4122309637330064" EFFECT_SIZE="0.8276515151515151" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.22055441922396618" LOG_CI_START="-0.384859390350747" LOG_EFFECT_SIZE="-0.08215248556339043" MODIFIED="2009-02-03 14:58:17 +1300" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.3556230685908764" STUDY_ID="STD-Huirne-2006c" TOTAL_1="91" TOTAL_2="91" VAR="0.12646776691399117" WEIGHT="26.758449777450057"/>
<DICH_DATA CI_END="3.3369110206401933" CI_START="0.37433870437972805" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.5233446262651681" LOG_CI_START="-0.426735267116058" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.5580816323434531" STUDY_ID="STD-Hwang-2004" TOTAL_1="27" TOTAL_2="29" VAR="0.3114551083591331" WEIGHT="9.333360796743156"/>
<DICH_DATA CI_END="2.826848219478887" CI_START="0.4424331995542842" EFFECT_SIZE="1.1183431952662721" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.45130249076317225" LOG_CI_START="-0.35415229164403106" LOG_EFFECT_SIZE="0.04857509955957058" MODIFIED="2017-04-05 14:03:40 +1200" MODIFIED_BY="[Empty name]" ORDER="634" O_E="0.0" SE="0.4731281262514667" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.22385022385022385" WEIGHT="12.98984214417312"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.973246306606302" CI_START="0.6916840728074553" DF="0" EFFECT_SIZE="1.8547008547008548" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.6966399687739551" LOG_CI_START="-0.16009222456921932" LOG_EFFECT_SIZE="0.26827387210236786" MODIFIED="2017-04-05 14:03:49 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.21964549242575548" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="99.99999999999999" Z="1.2274713881403718">
<NAME>COCP + Ant vs Ant, low response</NAME>
<DICH_DATA CI_END="4.973246306606301" CI_START="0.6916840728074554" EFFECT_SIZE="1.8547008547008548" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.696639968773955" LOG_CI_START="-0.16009222456921923" LOG_EFFECT_SIZE="0.26827387210236786" MODIFIED="2017-04-05 14:03:49 +1200" MODIFIED_BY="[Empty name]" ORDER="635" O_E="0.0" SE="0.5032487312625338" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.25325928551735" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.826848219478887" CI_START="0.4424331995542841" DF="0" EFFECT_SIZE="1.1183431952662721" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.45130249076317225" LOG_CI_START="-0.3541522916440311" LOG_EFFECT_SIZE="0.04857509955957058" MODIFIED="2017-04-05 14:03:56 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8131209662552291" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.2364017143151656">
<NAME>COCP + Ant vs Ag, low response</NAME>
<DICH_DATA CI_END="2.826848219478887" CI_START="0.4424331995542842" EFFECT_SIZE="1.1183431952662721" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.45130249076317225" LOG_CI_START="-0.35415229164403106" LOG_EFFECT_SIZE="0.04857509955957058" MODIFIED="2017-04-05 14:03:56 +1200" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="0.4731281262514667" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.22385022385022385" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2102311927109177" CI_END="2.2184674846481496" CI_START="0.9601159960938366" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4594471963126128" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.3460530677871374" LOG_CI_START="-0.01767629464767619" LOG_EFFECT_SIZE="0.1641883865697306" METHOD="MH" MODIFIED="2017-05-23 13:34:38 +1200" MODIFIED_BY="Helen E Nagels" NO="4" P_CHI2="0.9906894201026615" P_Q="0.9004535393732929" P_Z="0.07681618176071613" Q="0.5823818488257315" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="414" TOTAL_2="417" WEIGHT="400.0" Z="1.7694657489417536">
<NAME>Multiple pregnancy rate</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.007818396751235338" CI_END="9.264371212547967" CI_START="0.5272318351209189" DF="1" EFFECT_SIZE="2.2100840336134455" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.9668159484053054" LOG_CI_START="-0.2779983742108511" LOG_EFFECT_SIZE="0.34440878709722716" MODIFIED="2017-04-05 14:10:16 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.929541516314915" P_Z="0.2781230690430331" STUDIES="2" TAU2="0.0" TOTAL_1="61" TOTAL_2="64" WEIGHT="100.0" Z="1.08454539187984">
<NAME>COCP + Ant vs Ant</NAME>
<DICH_DATA CI_END="28.799753696982513" CI_START="0.20352590187219138" EFFECT_SIZE="2.4210526315789473" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4593887735752455" LOG_CI_START="-0.6913803121177554" LOG_EFFECT_SIZE="0.3840042307287451" MODIFIED="2017-04-05 14:10:08 +1200" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="1.263372407414747" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="24" VAR="1.5961098398169336" WEIGHT="31.932773109243698">
<FOOTNOTE>Data obtained from Dr. Griesinger</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="12.240362467683132" CI_START="0.3641060577432701" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0877942785435182" LOG_CI_START="-0.43877209551651" LOG_EFFECT_SIZE="0.3245110915135041" MODIFIED="2017-04-05 14:10:16 +1200" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="0.8967126447482838" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.804093567251462" WEIGHT="68.0672268907563"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6236150293299934" CI_END="2.185345971743693" CI_START="0.8465544520500771" DF="3" EFFECT_SIZE="1.360152330310589" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="40" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.33952020182126746" LOG_CI_START="-0.07234510197995998" LOG_EFFECT_SIZE="0.13358754992065375" MODIFIED="2017-04-05 14:10:45 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.89100561495433" P_Z="0.20357947901917128" STUDIES="4" TAU2="0.0" TOTAL_1="273" TOTAL_2="273" WEIGHT="100.0" Z="1.271419486958239">
<NAME>COCP + Ant vs Ag</NAME>
<DICH_DATA CI_END="2.633722916061223" CI_START="0.8388697295608728" EFFECT_SIZE="1.486388384754991" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="29" LOG_CI_END="0.4205700825637073" LOG_CI_START="-0.07630547674644036" LOG_EFFECT_SIZE="0.17213230290863346" MODIFIED="2016-03-01 11:32:00 +1300" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.2918671631124668" STUDY_ID="STD-Garcia_x002d_Velasco-2011" TOTAL_1="115" TOTAL_2="113" VAR="0.0851864409033193" WEIGHT="65.79939785696921"/>
<DICH_DATA CI_END="4.1292993022125914" CI_START="0.3569810645863818" EFFECT_SIZE="1.2141176470588235" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6158763627943926" LOG_CI_START="-0.44735481964059287" LOG_EFFECT_SIZE="0.08426077157689982" MODIFIED="2017-04-05 14:10:23 +1200" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.6245472596415453" STUDY_ID="STD-Huirne-2006c" TOTAL_1="91" TOTAL_2="91" VAR="0.3900592795257638" WEIGHT="15.895080005236027">
<FOOTNOTE>'Multiple clinical pregnancies'</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.505437709753353" CI_START="0.1066957623385781" EFFECT_SIZE="0.6933333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6537369896982692" LOG_CI_START="-0.9718528292120708" LOG_EFFECT_SIZE="-0.15905791975690087" MODIFIED="2017-04-05 14:10:36 +1200" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.9548795064273145" STUDY_ID="STD-Hwang-2004" TOTAL_1="27" TOTAL_2="29" VAR="0.9117948717948717" WEIGHT="9.116295885355957">
<FOOTNOTE>Data obtained from text. In the study group 2 ongoing. In the control group 1 live birth and 2 ongoing</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.558551916981211" CI_START="0.28633072906334456" EFFECT_SIZE="1.3703703703703705" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8168079607343389" LOG_CI_START="-0.5431320409183235" LOG_EFFECT_SIZE="0.1368379599080077" MODIFIED="2017-04-05 14:10:45 +1200" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="0.7988354887823513" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.6381381381381381" WEIGHT="9.189226252438806"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.240362467683132" CI_START="0.3641060577432701" DF="0" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="1.0877942785435182" LOG_CI_START="-0.43877209551651" LOG_EFFECT_SIZE="0.3245110915135041" MODIFIED="2017-04-05 14:10:51 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4046857791178067" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.8332818837856041">
<NAME>COCP + Ant vs Ant, low response</NAME>
<DICH_DATA CI_END="12.240362467683132" CI_START="0.3641060577432701" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0877942785435182" LOG_CI_START="-0.43877209551651" LOG_EFFECT_SIZE="0.3245110915135041" MODIFIED="2017-04-05 14:10:51 +1200" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.8967126447482838" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.804093567251462" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.5585519169812105" CI_START="0.2863307290633446" DF="0" EFFECT_SIZE="1.3703703703703705" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.8168079607343388" LOG_CI_START="-0.5431320409183233" LOG_EFFECT_SIZE="0.1368379599080077" MODIFIED="2017-04-05 14:10:59 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6932669585841411" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.00000000000001" Z="0.3944254493752739">
<NAME>COCP + Ant vs Ag, low response</NAME>
<DICH_DATA CI_END="6.558551916981211" CI_START="0.28633072906334456" EFFECT_SIZE="1.3703703703703705" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8168079607343389" LOG_CI_START="-0.5431320409183235" LOG_EFFECT_SIZE="0.1368379599080077" MODIFIED="2017-04-05 14:10:59 +1200" MODIFIED_BY="[Empty name]" ORDER="644" O_E="0.0" SE="0.7988354887823513" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" VAR="0.6381381381381381" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0955566468799023" CI_END="1.7656537988732635" CI_START="0.33056554735845967" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7639792631152262" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.24690555316097987" LOG_CI_START="-0.48074241202230406" LOG_EFFECT_SIZE="-0.11691842943066207" METHOD="MH" MODIFIED="2017-05-23 13:34:50 +1200" MODIFIED_BY="Helen E Nagels" NO="5" P_CHI2="0.7781468645029684" P_Q="0.6069845455175" P_Z="0.528790258824315" Q="0.2645894919821326" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="470" TOTAL_2="462" WEIGHT="200.0" Z="0.6298537803383112">
<NAME>Ovarian hyperstimulation syndrome rate</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.451189060582844" CI_END="3.3984701892664906" CI_START="0.2799825965406443" DF="1" EFFECT_SIZE="0.9754550260554338" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.5312834647264731" LOG_CI_START="-0.5528689631623005" LOG_EFFECT_SIZE="-0.010792749217913646" MODIFIED="2017-04-05 14:11:05 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.501770856218462" P_Z="0.9688721105517079" STUDIES="2" TAU2="0.0" TOTAL_1="326" TOTAL_2="316" WEIGHT="100.0" Z="0.03902292559078007">
<NAME>COCP + Ant vs Ant</NAME>
<DICH_DATA CI_END="3.818113717132346" CI_START="0.10436144279644818" EFFECT_SIZE="0.6312399355877617" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5818488590989291" LOG_CI_START="-0.9814599254111751" LOG_EFFECT_SIZE="-0.19980553315612293" MODIFIED="2015-08-03 14:02:07 +1200" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.9182953185245234" STUDY_ID="STD-Nyboe-Andersen-2011" TOTAL_1="209" TOTAL_2="199" VAR="0.8432662920240559" WEIGHT="60.96971527830224"/>
<DICH_DATA CI_END="9.226201463186513" CI_START="0.24816787532120954" EFFECT_SIZE="1.513157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9650229336230977" LOG_CI_START="-0.6052544374774571" LOG_EFFECT_SIZE="0.1798842480728203" MODIFIED="2017-04-05 14:11:05 +1200" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.9223887007828141" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" VAR="0.8508009153318077" WEIGHT="39.030284721697754"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.39824916793081305" CI_END="1.961739982744447" CI_START="0.19952329935895086" DF="1" EFFECT_SIZE="0.6256299496040318" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.29264144364399586" LOG_CI_START="-0.7000063822218939" LOG_EFFECT_SIZE="-0.20368246928894898" MODIFIED="2017-04-05 14:11:17 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.527995257524309" P_Z="0.4212039908792613" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="146" WEIGHT="100.0" Z="0.8043342133758129">
<NAME>COCP + Ant vs Ag</NAME>
<DICH_DATA CI_END="8.256653867248701" CI_START="0.14126788148728225" EFFECT_SIZE="1.08" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9168040786258553" LOG_CI_START="-0.8499565676519558" LOG_EFFECT_SIZE="0.03342375548694973" MODIFIED="2017-04-05 14:11:11 +1200" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="1.0378039492298325" STUDY_ID="STD-Hwang-2004" TOTAL_1="27" TOTAL_2="29" VAR="1.077037037037037" WEIGHT="23.398128149748022">
<FOOTNOTE>Calculated from rates</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.9947441449571146" CI_START="0.11881986772903116" EFFECT_SIZE="0.4868421052631579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2998871989906169" LOG_CI_START="-0.9251109354182095" LOG_EFFECT_SIZE="-0.31261186821379633" MODIFIED="2017-04-05 14:11:17 +1200" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.7195699679903063" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" VAR="0.5177809388335703" WEIGHT="76.60187185025198"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.53" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="890" TOTAL_2="899" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of oocytes retrieved</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.255621092583537" CI_START="-0.055621092583537646" EFFECT_SIZE="4.1" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="9.9" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="8.3" SD_2="5.4" SE="2.1202538033160536" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="24" WEIGHT="0.0"/>
<CONT_DATA CI_END="6.416165532378836" CI_START="0.1838344676211654" EFFECT_SIZE="3.3000000000000007" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="10.2" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="6.7" SD_2="6.0" SE="1.58990958862446" STUDY_ID="STD-Huirne-2006a" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0"/>
<CONT_DATA CI_END="3.195366522898748" CI_START="-2.195366522898748" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="10.9" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="116" SD_1="7.3" SD_2="10.9" SE="1.3752122713271544" STUDY_ID="STD-Huirne-2006c" TOTAL_1="91" TOTAL_2="91" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.9308993381179813" CI_START="-4.530899338117983" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="17.6" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="117" SD_1="6.4" SD_2="5.9" SE="1.648448320276752" STUDY_ID="STD-Hwang-2004" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.5134440865016867" CI_START="-0.11344408650168636" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.2" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="624" SD_1="2.0" SD_2="1.7" SE="0.4150301193889427" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.9548903676127474" CI_START="-0.7548903676127463" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.8" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="625" SD_1="2.0" SD_2="1.9" SE="0.43617656975128777" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.5134440865016867" CI_START="-0.11344408650168636" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.2" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="626" SD_1="2.0" SD_2="1.7" SE="0.4150301193889427" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0">
<FOOTNOTE>Kim 2011 is a 3-arm parallel RCT: total was halved for the intervention group</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.9548903676127474" CI_START="-0.7548903676127463" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.8" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="627" SD_1="2.0" SD_2="1.9" SE="0.43617656975128777" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.042993970402783" CI_START="-1.8429939704027802" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="13.2" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="101" SD_1="7.7" SD_2="8.8" SE="0.736234941960635" STUDY_ID="STD-Kolibianakis-2006" TOTAL_1="250" TOTAL_2="254" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.5882066466405369" CI_START="-1.588206646640537" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="6.3" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="102" SD_1="3.4" SD_2="3.4" SE="0.5552176750308536" STUDY_ID="STD-Obruca-2002" TOTAL_1="75" TOTAL_2="75" WEIGHT="0.0"/>
<CONT_DATA CI_END="3.573319941340393" CI_START="-0.3733199413403936" EFFECT_SIZE="1.5999999999999996" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="11.5" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="7.8" SD_2="7.6" SE="1.0068143888896373" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.3172356852551115" CI_START="-1.917235685255113" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="12.9" MODIFIED="2017-07-14 15:22:05 +1200" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="7.8" SD_2="8.7" SE="1.0802421380982492" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2017-05-11 21:39:01 +1200" MODIFIED_BY="Anne Lawson" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="21.94" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="966" TOTAL_2="976" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days of gonadotrophin treatment</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="5" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" MODIFIED="2017-04-05 14:08:49 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="6" TAU2="0.0" TOTAL_1="611" TOTAL_2="619" WEIGHT="0.0" Z="0.0">
<NAME>COCP + Ant vs Ant</NAME>
<CONT_DATA CI_END="3.8147227718726806" CI_START="1.98527722812732" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="8.7" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="2.1" SD_2="1.6" SE="0.46670386756486176" STUDY_ID="STD-Huirne-2006a" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.6697396513747778" CI_START="-0.46973965137477847" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="9.8" MODIFIED="2017-04-05 14:07:21 +1200" MODIFIED_BY="[Empty name]" ORDER="620" SD_1="1.3" SD_2="1.3" SE="0.2906888370749727" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.9492259377970454" CI_START="0.25077406220295384" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="9.1" MODIFIED="2017-04-05 14:08:49 +1200" MODIFIED_BY="[Empty name]" ORDER="108" SD_1="2.0" SD_2="2.0" SE="0.1781797729711849" STUDY_ID="STD-Kolibianakis-2006" TOTAL_1="250" TOTAL_2="254" WEIGHT="0.0">
<FOOTNOTE>Data obtained from Dr. Griesinger</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.5108195877145334" CI_START="-0.5108195877145334" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="10.3" MEAN_2="10.3" MODIFIED="2016-08-18 18:05:41 +1200" MODIFIED_BY="[Empty name]" ORDER="185" SD_1="1.7" SD_2="1.4" SE="0.26062702771265855" STUDY_ID="STD-Porrati-2010" TOTAL_1="71" TOTAL_2="72" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.7500883191932566" CI_START="1.8499116808067415" EFFECT_SIZE="2.299999999999999" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="9.4" MODIFIED="2017-04-05 14:08:15 +1200" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="1.9" SD_2="1.6" SE="0.22964111725699896" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.26948068251745905" CI_START="-0.6694806825174576" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="10.6" MODIFIED="2015-08-02 12:48:19 +1200" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="1.9" SD_2="1.5" SE="0.23953536198657835" STUDY_ID="STD-Vilela-2011" TOTAL_1="101" TOTAL_2="104" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="3" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.02" MODIFIED="2017-04-05 14:08:22 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="275" TOTAL_2="277" WEIGHT="0.0" Z="0.0">
<NAME>COCP + Ant vs Ag</NAME>
<CONT_DATA CI_END="0.29481333099236173" CI_START="-0.6948133309923639" EFFECT_SIZE="-0.20000000000000107" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="10.3" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="1.8" SD_2="1.6" SE="0.2524604201380164" STUDY_ID="STD-Huirne-2006c" TOTAL_1="91" TOTAL_2="91" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.2263056888832755" CI_START="-2.0263056888832764" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="10.8" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="2.1" SD_2="2.2" SE="0.5746563190790399" STUDY_ID="STD-Hwang-2004" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.7848709941497061" CI_START="-2.0151290058502944" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="11.3" MODIFIED="2017-04-05 14:07:58 +1200" MODIFIED_BY="[Empty name]" ORDER="621" SD_1="1.3" SD_2="1.5" SE="0.3138470965295043" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.8619679414498913" CI_START="0.9380320585501059" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="10.3" MODIFIED="2017-04-05 14:08:22 +1200" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="1.9" SD_2="1.7" SE="0.23570226039551584" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.03" MODIFIED="2017-04-05 14:08:29 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>COCP + Ant vs Ant, low response</NAME>
<CONT_DATA CI_END="0.6697396513747778" CI_START="-0.46973965137477847" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="9.8" MODIFIED="2017-04-05 14:08:29 +1200" MODIFIED_BY="[Empty name]" ORDER="622" SD_1="1.3" SD_2="1.3" SE="0.2906888370749727" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.04" MODIFIED="2017-04-05 14:08:39 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>COCP + Ant vs Ag, low response</NAME>
<CONT_DATA CI_END="-0.7848709941497061" CI_START="-2.0151290058502944" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="11.3" MODIFIED="2017-04-05 14:08:39 +1200" MODIFIED_BY="[Empty name]" ORDER="623" SD_1="1.3" SD_2="1.5" SE="0.3138470965295043" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="117.37541330986461" CI_END="163.27598200864966" CI_START="70.26229996273344" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="116.76914098569155" ESTIMABLE="YES" I2="90.62836100865468" I2_Q="91.31655285856662" ID="CMP-001.08" MODIFIED="2017-05-23 13:35:34 +1200" MODIFIED_BY="Helen E Nagels" NO="8" P_CHI2="0.0" P_Q="1.5174590450861558E-7" P_Z="8.607336997445121E-7" Q="34.5484915280407" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="960" TOTAL_2="971" UNITS="IU/L" WEIGHT="400.0" Z="4.9210676494810075">
<NAME>Amount of gonadotrophins administered</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="50.42063183935654" CI_END="245.28253497792517" CI_START="134.91034331129813" DF="6" EFFECT_SIZE="190.09643914461165" ESTIMABLE="YES" I2="88.10010945694533" ID="CMP-001.08.01" MODIFIED="2017-04-05 14:09:25 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.8712184569078545E-9" P_Z="1.4644784894203286E-11" STUDIES="7" TAU2="0.0" TOTAL_1="632" TOTAL_2="643" WEIGHT="100.0" Z="6.751377655670956">
<NAME>COCP + Ant vs Ant</NAME>
<CONT_DATA CI_END="819.7573677066075" CI_START="60.24263229339243" EFFECT_SIZE="440.0" ESTIMABLE="YES" MEAN_1="2174.0" MEAN_2="1734.0" MODIFIED="2017-04-05 14:09:00 +1200" MODIFIED_BY="[Empty name]" ORDER="111" SD_1="723.0" SD_2="551.0" SE="193.75731937019518" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="24" WEIGHT="2.1117715015443306"/>
<CONT_DATA CI_END="1463.6784544142197" CI_START="552.3215455857802" EFFECT_SIZE="1008.0" ESTIMABLE="YES" MEAN_1="2958.0" MEAN_2="1950.0" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="112" SD_1="1162.0" SD_2="616.0" SE="232.4932794727624" STUDY_ID="STD-Huirne-2006a" TOTAL_1="32" TOTAL_2="32" WEIGHT="1.466703581334352"/>
<CONT_DATA CI_END="205.38503537054982" CI_START="-165.38503537054982" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="2925.0" MEAN_2="2905.0" MODIFIED="2017-04-05 14:09:09 +1200" MODIFIED_BY="[Empty name]" ORDER="616" SD_1="424.0" SD_2="422.0" SE="94.58593975850745" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="8.861556141486995"/>
<CONT_DATA CI_END="194.84883216359074" CI_START="55.15116783640926" EFFECT_SIZE="125.0" ESTIMABLE="YES" MEAN_1="1943.0" MEAN_2="1818.0" MODIFIED="2017-04-05 14:09:15 +1200" MODIFIED_BY="[Empty name]" ORDER="114" SD_1="402.0" SD_2="398.0" SE="35.637814120335584" STUDY_ID="STD-Kolibianakis-2006" TOTAL_1="250" TOTAL_2="254" WEIGHT="62.422483452844894">
<FOOTNOTE>Data obtained from Dr. Griesinger</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="335.70335998778216" CI_START="-81.70335998778219" EFFECT_SIZE="127.0" ESTIMABLE="YES" MEAN_1="2360.0" MEAN_2="2233.0" MODIFIED="2016-03-01 15:31:44 +1300" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="748.0" SD_2="499.0" SE="106.48326277115684" STUDY_ID="STD-Porrati-2010" TOTAL_1="71" TOTAL_2="72" WEIGHT="6.991984543982106"/>
<CONT_DATA CI_END="886.2090905695088" CI_START="516.3909094304911" EFFECT_SIZE="701.3" ESTIMABLE="YES" MEAN_1="2667.0" MEAN_2="1965.7" MODIFIED="2017-04-05 14:09:25 +1200" MODIFIED_BY="[Empty name]" ORDER="116" SD_1="880.7" SD_2="515.5" SE="94.34310631626303" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" WEIGHT="8.907233068457474"/>
<CONT_DATA CI_END="342.565946997327" CI_START="-20.56594699732699" EFFECT_SIZE="161.0" ESTIMABLE="YES" MEAN_1="2412.0" MEAN_2="2251.0" MODIFIED="2015-07-31 12:59:09 +1200" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="774.0" SD_2="525.0" SE="92.63738947730468" STUDY_ID="STD-Vilela-2011" TOTAL_1="101" TOTAL_2="104" WEIGHT="9.238267710349852"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="32.40628994246742" CI_END="124.01595552885345" CI_START="-104.08972942801722" DF="2" EFFECT_SIZE="9.963113050418118" ESTIMABLE="YES" I2="93.82835861942016" ID="CMP-001.08.02" MODIFIED="2017-04-05 14:09:38 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.184799432127022E-8" P_Z="0.8640561933645006" STUDIES="3" TAU2="0.0" TOTAL_1="248" TOTAL_2="248" WEIGHT="100.0" Z="0.1712131177827739">
<NAME>COCP + Ant vs Ag</NAME>
<CONT_DATA CI_END="175.92930110511017" CI_START="-235.92930110511017" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="1919.0" MEAN_2="1949.0" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="638.0" SD_2="773.0" SE="105.06790059891621" STUDY_ID="STD-Huirne-2006c" TOTAL_1="91" TOTAL_2="91" WEIGHT="30.674390054606732"/>
<CONT_DATA CI_END="-160.08448138477672" CI_START="-537.9155186152233" EFFECT_SIZE="-349.0" ESTIMABLE="YES" MEAN_1="2925.0" MEAN_2="3274.0" MODIFIED="2017-04-05 14:09:32 +1200" MODIFIED_BY="[Empty name]" ORDER="617" SD_1="424.0" SD_2="438.0" SE="96.38723981938688" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="36.44827315664702"/>
<CONT_DATA CI_END="644.110540814734" CI_START="246.28945918526566" EFFECT_SIZE="445.1999999999998" ESTIMABLE="YES" MEAN_1="2667.0" MEAN_2="2221.8" MODIFIED="2017-04-05 14:09:38 +1200" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="880.7" SD_2="655.3" SE="101.48683464783798" STUDY_ID="STD-Rombauts-2006" TOTAL_1="117" TOTAL_2="117" WEIGHT="32.87733678874625"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="205.38503537054982" CI_START="-165.38503537054982" DF="0" EFFECT_SIZE="20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.03" MODIFIED="2017-04-05 14:09:45 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8325377691614655" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.2114479176404347">
<NAME>COCP + Ant vs Ant, low response</NAME>
<CONT_DATA CI_END="205.38503537054982" CI_START="-165.38503537054982" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="2925.0" MEAN_2="2905.0" MODIFIED="2017-04-05 14:09:45 +1200" MODIFIED_BY="[Empty name]" ORDER="618" SD_1="424.0" SD_2="422.0" SE="94.58593975850745" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-160.08448138477672" CI_START="-537.9155186152233" DF="0" EFFECT_SIZE="-349.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.04" MODIFIED="2017-04-05 14:09:50 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="2.936807414369327E-4" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="3.620811226195148">
<NAME>COCP + Ant vs Ag, low response</NAME>
<CONT_DATA CI_END="-160.08448138477672" CI_START="-537.9155186152233" EFFECT_SIZE="-349.0" ESTIMABLE="YES" MEAN_1="2925.0" MEAN_2="3274.0" MODIFIED="2017-04-05 14:09:50 +1200" MODIFIED_BY="[Empty name]" ORDER="619" SD_1="424.0" SD_2="438.0" SE="96.38723981938688" STUDY_ID="STD-Kim-2011" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.750140075418289" CI_START="0.07918788563693593" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.4393548147146009" LOG_CI_START="-1.1013412527974495" LOG_EFFECT_SIZE="-0.3309932190414244" METHOD="MH" MODIFIED="2017-05-23 13:35:44 +1200" MODIFIED_BY="Helen E Nagels" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.3997140373078879" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.8421320754011661">
<NAME>Ovarian cyst formation rate</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.750140075418289" CI_START="0.07918788563693593" DF="0" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.4393548147146009" LOG_CI_START="-1.1013412527974495" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2016-05-17 10:10:33 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3997140373078879" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="0.8421320754011661">
<NAME>COCP + Ant vs Ant</NAME>
<DICH_DATA CI_END="2.750140075418289" CI_START="0.07918788563693593" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4393548147146009" LOG_CI_START="-1.1013412527974495" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2009-02-04 11:38:15 +1300" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.9050124966251124" STUDY_ID="STD-Huirne-2006a" TOTAL_1="32" TOTAL_2="32" VAR="0.819047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-05-23 13:37:59 +1200" MODIFIED_BY="Helen E Nagels" NO="2">
<NAME>Progestogen versus placebo/no pretreatment (Rx)</NAME>
<DICH_OUTCOME CHI2="2.48766977428288" CI_END="1.950863644274229" CI_START="0.6268286130241909" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1058287174511854" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.29022691541770024" LOG_CI_START="-0.20285118738708682" LOG_EFFECT_SIZE="0.04368786401530671" METHOD="MH" MODIFIED="2017-05-23 13:37:01 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.4775238214204798" P_Q="0.5460335468199315" P_Z="0.7283548987733988" Q="1.210150683097865" RANDOM="NO" SCALE="80.24" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="157" WEIGHT="300.0" Z="0.3473147136099238">
<NAME>Live birth or ongoing pregnancy</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3089393510031027" CI_END="2.65290544472585" CI_START="0.6894073516369763" DF="1" EFFECT_SIZE="1.352380315145027" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" I2="23.60226627508354" ID="CMP-002.01.01" LOG_CI_END="0.4237217710657784" LOG_CI_START="-0.1615240897149173" LOG_EFFECT_SIZE="0.13109884067543054" MODIFIED="2017-05-22 15:21:41 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.2525869087891176" P_Z="0.37989537606202883" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="112" WEIGHT="100.0" Z="0.87808910188972">
<NAME>Progestogen (Prog) + agonist (Ag) vs Ag</NAME>
<DICH_DATA CI_END="2.3939378949728876" CI_START="0.32088412063724164" EFFECT_SIZE="0.8764568764568764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.3791128794787332" LOG_CI_START="-0.4936517739928596" LOG_EFFECT_SIZE="-0.05726944725706321" MODIFIED="2016-09-02 17:30:20 +1200" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.5126662777039245" STUDY_ID="STD-Ditkoff-1996" TOTAL_1="47" TOTAL_2="58" VAR="0.26282671229479737" WEIGHT="55.97336991067545"/>
<DICH_DATA CI_END="5.016136060182554" CI_START="0.7638544812536521" EFFECT_SIZE="1.9574468085106382" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.7003693080031" LOG_CI_START="-0.11698936918342444" LOG_EFFECT_SIZE="0.29168996940983777" MODIFIED="2016-09-02 17:30:20 +1200" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.4801205329700694" STUDY_ID="STD-Engmann-1999" TOTAL_1="63" TOTAL_2="54" VAR="0.23051572617946348" WEIGHT="44.02663008932455"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5387763064284137" CI_START="0.1792554318520908" DF="0" EFFECT_SIZE="0.6746031746031746" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.40462443653201935" LOG_CI_START="-0.7465276753385597" LOG_EFFECT_SIZE="-0.17095161940327014" MODIFIED="2017-05-22 15:21:50 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Z="0.5604803769071038" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.5821281369753123">
<NAME>Prog + antagonist (Ant) vs Ant</NAME>
<DICH_DATA CI_END="2.538776306428414" CI_START="0.17925543185209078" EFFECT_SIZE="0.6746031746031746" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.4046244365320194" LOG_CI_START="-0.7465276753385597" LOG_EFFECT_SIZE="-0.17095161940327014" MODIFIED="2017-04-05 14:12:00 +1200" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.6761924488076329" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="24" VAR="0.4572362278244631" WEIGHT="99.99999999999999">
<FOOTNOTE>Data obtained from Dr. Griesinger</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.230243198790957" CI_START="0.094295279967121" DF="0" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.6263653358991061" LOG_CI_START="-1.0255100457095143" LOG_EFFECT_SIZE="-0.19957235490520417" MODIFIED="2017-05-22 15:21:57 +1200" MODIFIED_BY="Helen E Nagels" NO="3" P_CHI2="1.0" P_Z="0.6357933483779437" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="99.99999999999999" Z="0.47358854339621387">
<NAME>Prog + gonadotrophin (Gon) vs Gon</NAME>
<DICH_DATA CI_END="4.230243198790956" CI_START="0.094295279967121" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.626365335899106" LOG_CI_START="-1.0255100457095143" LOG_EFFECT_SIZE="-0.19957235490520417" MODIFIED="2017-04-05 14:12:06 +1200" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="0.9703197760719181" STUDY_ID="STD-Salat_x002d_Baroux-1988" TOTAL_1="21" TOTAL_2="21" VAR="0.9415204678362572" WEIGHT="99.99999999999999">
<FOOTNOTE>Data obtained from text</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1139495127570607" CI_END="2.8911205768664225" CI_START="0.5016406854121229" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2042855590715869" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="3.6593243496799945" I2_Q="30.068665997931333" ID="CMP-002.02" LOG_CI_END="0.46106620470273457" LOG_CI_START="-0.2996072474296886" LOG_EFFECT_SIZE="0.08072947863652301" METHOD="MH" MODIFIED="2017-05-23 13:37:10 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="0.37438817746335995" P_Q="0.2393154556001612" P_Z="0.6773969357983514" Q="2.859948302917884" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="154" TOTAL_2="157" WEIGHT="300.0" Z="0.416017859371108">
<NAME>Pregnancy loss</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.31529238103041646" CI_END="7.553318815581212" CI_START="0.6742446414301108" DF="1" EFFECT_SIZE="2.2567199065056487" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.8781378160788067" LOG_CI_START="-0.17118249642357913" LOG_EFFECT_SIZE="0.3534776598276138" MODIFIED="2017-04-05 14:12:13 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5744506996762146" P_Z="0.1866746569014318" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="112" WEIGHT="100.0" Z="1.320480456438412">
<NAME>Prog + Ag vs Ag</NAME>
<DICH_DATA CI_END="38.65085224263755" CI_START="0.3907759192276713" EFFECT_SIZE="3.8863636363636362" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5871590744560027" LOG_CI_START="-0.40807220664406985" LOG_EFFECT_SIZE="0.5895434339059664" MODIFIED="2017-04-05 14:12:13 +1200" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="1.172008731072311" STUDY_ID="STD-Ditkoff-1996" TOTAL_1="47" TOTAL_2="58" VAR="1.3736044657097288" WEIGHT="22.282820412933386">
<FOOTNOTE>Calculated from the number of clinical pregnancies minus the number of live births</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.526209851513861" CI_START="0.42547525642510275" EFFECT_SIZE="1.7894736842105263" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8765763234821045" LOG_CI_START="-0.37112569130325207" LOG_EFFECT_SIZE="0.25272531608942617" MODIFIED="2009-01-09 12:18:29 +1300" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.7329063397095005" STUDY_ID="STD-Engmann-1999" TOTAL_1="63" TOTAL_2="54" VAR="0.5371517027863777" WEIGHT="77.71717958706661"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0895431822748964" CI_START="0.06268119165967616" DF="0" EFFECT_SIZE="0.3619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.3200513506554858" LOG_CI_START="-1.2028627555617417" LOG_EFFECT_SIZE="-0.44140570245312793" MODIFIED="2017-04-05 14:12:20 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.25588839907504735" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="1.136162933742412">
<NAME>Prog + Ant vs Ant</NAME>
<DICH_DATA CI_END="2.089543182274896" CI_START="0.06268119165967616" EFFECT_SIZE="0.3619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.32005135065548573" LOG_CI_START="-1.2028627555617417" LOG_EFFECT_SIZE="-0.44140570245312793" MODIFIED="2017-04-05 14:12:20 +1200" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.8945672845384052" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="24" VAR="0.800250626566416" WEIGHT="100.0">
<FOOTNOTE>Calculated from the number of clinical pregnancies minus the number of live births</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.12017599758039" CI_START="0.05841061447857376" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="1.2335082249664329" LOG_CI_START="-1.2335082249664329" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-05 14:12:25 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.0">
<NAME>Prog + Gon vs Gon</NAME>
<DICH_DATA CI_END="17.120175997580382" CI_START="0.058410614478573784" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2335082249664329" LOG_CI_START="-1.2335082249664326" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-04-05 14:12:25 +1200" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="1.4491376746189437" STUDY_ID="STD-Salat_x002d_Baroux-1988" TOTAL_1="21" TOTAL_2="21" VAR="2.0999999999999996" WEIGHT="100.0">
<FOOTNOTE>Data obtained from text, unclear whether follow up was long enough</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.739909061659347" CI_END="2.35087094591283" CI_START="0.9820536142858671" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5194345359880859" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="46" I2="40.65201824822231" I2_Q="60.32058924509132" ID="CMP-002.03" LOG_CI_END="0.37122878862460074" LOG_CI_START="-0.007864801670385205" LOG_EFFECT_SIZE="0.18168199347710776" METHOD="MH" MODIFIED="2017-05-23 13:37:18 +1200" MODIFIED_BY="Helen E Nagels" NO="3" P_CHI2="0.15028809546415278" P_Q="0.08044369637667248" P_Z="0.06029368525902621" Q="5.040397430177521" RANDOM="NO" SCALE="22.76" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="231" TOTAL_2="232" WEIGHT="300.0" Z="1.8786398555432502">
<NAME>Clinical pregnancy rate</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7718871391985058" CI_END="3.278410965255129" CI_START="1.2023154953672008" DF="2" EFFECT_SIZE="1.9853675487697444" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="31" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.5156633936382055" LOG_CI_START="0.08001844430422259" LOG_EFFECT_SIZE="0.297840918971214" MODIFIED="2017-04-05 14:12:31 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4123249691891583" P_Z="0.007362898392155316" STUDIES="3" TAU2="0.0" TOTAL_1="187" TOTAL_2="187" WEIGHT="100.0" Z="2.6799689756456244">
<NAME>Prog + Ag vs Ag</NAME>
<DICH_DATA CI_END="5.958324246204567" CI_START="1.1345471848575708" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" LOG_CI_END="0.7751241334049989" LOG_CI_START="0.05482256253663697" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.42310870827835606" STUDY_ID="STD-Aston-1995" TOTAL_1="77" TOTAL_2="75" VAR="0.17902097902097902" WEIGHT="32.774368283055296"/>
<DICH_DATA CI_END="2.960140956678581" CI_START="0.46346948803978494" EFFECT_SIZE="1.1712962962962963" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.47131239188669405" LOG_CI_START="-0.33397885183692005" LOG_EFFECT_SIZE="0.06866677002488701" MODIFIED="2009-01-27 12:22:46 +1300" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.4730320628191969" STUDY_ID="STD-Ditkoff-1996" TOTAL_1="47" TOTAL_2="58" VAR="0.22375933245498464" WEIGHT="37.265733661273465"/>
<DICH_DATA CI_END="5.667876010364938" CI_START="0.9542073285481801" EFFECT_SIZE="2.3255813953488373" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.7534203411161247" LOG_CI_START="-0.02035725227529767" LOG_EFFECT_SIZE="0.3665315444204135" MODIFIED="2017-04-05 14:12:31 +1200" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.45452078861898243" STUDY_ID="STD-Engmann-1999" TOTAL_1="63" TOTAL_2="54" VAR="0.2065891472868217" WEIGHT="29.959898055671246">
<FOOTNOTE>Positive pregnancy test</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7120684700586346" CI_START="0.15614796180257914" DF="0" EFFECT_SIZE="0.5170454545454546" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.2335211292511925" LOG_CI_START="-0.8064636802373047" LOG_EFFECT_SIZE="-0.2864712754930562" MODIFIED="2017-04-05 14:12:36 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2802436160593661" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="1.0797722763812199">
<NAME>Prog + Ant vs Ant</NAME>
<DICH_DATA CI_END="1.7120684700586346" CI_START="0.15614796180257914" EFFECT_SIZE="0.5170454545454546" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.2335211292511925" LOG_CI_START="-0.8064636802373047" LOG_EFFECT_SIZE="-0.2864712754930562" MODIFIED="2017-04-05 14:12:36 +1200" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.6108922251013763" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="24" VAR="0.37318931068931066" WEIGHT="100.0">
<FOOTNOTE>Data obtained from Dr. Cédrin-Durnerin</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.64115664266137" CI_START="0.13779580511108838" DF="0" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.561239362696684" LOG_CI_START="-0.8607640033633482" LOG_EFFECT_SIZE="-0.14976232033333206" MODIFIED="2009-02-03 14:19:40 +1300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6797250607762886" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="0.4128383393462231">
<NAME>Prog + Gon vs Gon</NAME>
<DICH_DATA CI_END="3.64115664266137" CI_START="0.13779580511108838" EFFECT_SIZE="0.7083333333333334" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.561239362696684" LOG_CI_START="-0.8607640033633482" LOG_EFFECT_SIZE="-0.14976232033333206" MODIFIED="2009-02-03 14:19:40 +1300" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="0.8352918162538489" STUDY_ID="STD-Salat_x002d_Baroux-1988" TOTAL_1="21" TOTAL_2="21" VAR="0.6977124183006536" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="17.764735079976546" CI_START="0.06152499329097864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.2495587353737732" LOG_CI_START="-1.210948424983" LOG_EFFECT_SIZE="0.019305155195386624" METHOD="MH" MODIFIED="2017-05-23 13:37:27 +1200" MODIFIED_BY="Helen E Nagels" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9754643058801493" Q="0.0" RANDOM="NO" SCALE="91.43" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="0.03075578035987319">
<NAME>Multiple pregnancy rate</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.764735079976546" CI_START="0.06152499329097864" DF="0" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="1.2495587353737732" LOG_CI_START="-1.210948424983" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2017-04-05 14:13:24 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9754643058801493" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="0.03075578035987319">
<NAME>Prog + Ant vs Ant</NAME>
<DICH_DATA CI_END="17.764735079976546" CI_START="0.06152499329097864" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2495587353737732" LOG_CI_START="-1.210948424983" LOG_EFFECT_SIZE="0.019305155195386624" MODIFIED="2017-04-05 14:13:24 +1200" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="1.445314085700444" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="24" VAR="2.088932806324111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.6780734794947936" CI_END="0.5239495805069143" CI_START="-0.5355278359908608" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.005789127741973233" ESTIMABLE="YES" I2="18.43556098797491" I2_Q="20.141879106715596" ID="CMP-002.05" MODIFIED="2017-05-23 13:37:35 +1200" MODIFIED_BY="Helen E Nagels" NO="5" P_CHI2="0.2983905249236267" P_Q="0.28586932793706477" P_Z="0.982911404456335" Q="2.504441599211469" RANDOM="NO" SCALE="11.25" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="146" TOTAL_2="152" UNITS="" WEIGHT="300.0" Z="0.02141901601579452">
<NAME>Number of oocytes retrieved</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1736318802833245" CI_END="1.0199362738055031" CI_START="-2.0650718598839855" DF="1" EFFECT_SIZE="-0.5225677930392411" ESTIMABLE="YES" I2="14.794407275423396" ID="CMP-002.05.01" MODIFIED="2017-04-05 14:12:43 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2786562951874618" P_Z="0.5066939030394207" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="112" WEIGHT="100.0" Z="0.6639943944735041">
<NAME>Prog + Ag vs Ag</NAME>
<CONT_DATA CI_END="4.157079071440352" CI_START="-2.1570790714403523" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="13.8" MEAN_2="12.8" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="7.6" SD_2="8.9" SE="1.6107842268240584" STUDY_ID="STD-Ditkoff-1996" TOTAL_1="47" TOTAL_2="58" WEIGHT="23.871610348037944"/>
<CONT_DATA CI_END="0.7678808688498111" CI_START="-2.767880868849811" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="9.4" MODIFIED="2017-04-05 14:12:43 +1200" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="4.7" SD_2="5.0" SE="0.9019966095268228" STUDY_ID="STD-Engmann-1999" TOTAL_1="63" TOTAL_2="54" WEIGHT="76.12838965196205">
<FOOTNOTE>'Mature oocytes'</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.383458366093327" CI_START="-0.9834583660933283" DF="0" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" MODIFIED="2017-04-05 14:12:48 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.15081266084153247" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="1.4366669125327272">
<NAME>Prog + Ant vs Ant</NAME>
<CONT_DATA CI_END="6.383458366093327" CI_START="-0.9834583660933283" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="9.9" MODIFIED="2017-04-05 14:12:48 +1200" MODIFIED_BY="[Empty name]" ORDER="217" SD_1="7.3" SD_2="5.4" SE="1.879350026402514" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5707760135798438" CI_START="-0.5707760135798438" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.03" MODIFIED="2017-04-05 14:12:51 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>Prog + Gon vs Gon</NAME>
<CONT_DATA CI_END="0.5707760135798438" CI_START="-0.5707760135798438" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.9" MODIFIED="2017-04-05 14:12:51 +1200" MODIFIED_BY="[Empty name]" ORDER="392" SD_1="0.9" SD_2="0.6" SE="0.2912176030182453" STUDY_ID="STD-Salat_x002d_Baroux-1988" TOTAL_1="13" TOTAL_2="16" WEIGHT="100.0">
<FOOTNOTE>No ITT</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.186551119754292" CI_END="0.5197202995961688" CI_START="-0.3022054439113719" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10875742784239849" ESTIMABLE="YES" I2="87.7848438814853" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2017-05-23 13:37:44 +1200" MODIFIED_BY="Helen E Nagels" NO="6" P_CHI2="0.0042202409983248534" P_Q="1.0" P_Z="0.6039798070631361" Q="0.0" RANDOM="NO" SCALE="1.95" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="110" TOTAL_2="112" UNITS="" WEIGHT="100.0" Z="0.5186858869090991">
<NAME>Days of gonadotrophin treatment</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.186551119754292" CI_END="0.5197202995961688" CI_START="-0.3022054439113719" DF="1" EFFECT_SIZE="0.10875742784239849" ESTIMABLE="YES" I2="87.7848438814853" ID="CMP-002.06.01" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0042202409983248534" P_Z="0.6039798070631361" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="112" WEIGHT="100.0" Z="0.5186858869090991">
<NAME>Prog + Ag vs Ag</NAME>
<CONT_DATA CI_END="1.2769937034478036" CI_START="0.12300629655219852" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="11.1" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="219" SD_1="1.5" SD_2="1.5" SE="0.2943899520598619" STUDY_ID="STD-Ditkoff-1996" TOTAL_1="47" TOTAL_2="58" WEIGHT="50.729785653533156"/>
<CONT_DATA CI_END="0.085477704883267" CI_START="-1.085477704883267" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="11.7" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="220" SD_1="1.5" SD_2="1.7" SE="0.298718603760804" STUDY_ID="STD-Engmann-1999" TOTAL_1="63" TOTAL_2="54" WEIGHT="49.27021434646684"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="627.5250618741013" CI_START="-75.52506187410125" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="276.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2017-05-23 13:37:52 +1200" MODIFIED_BY="Helen E Nagels" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.12383694791391428" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="24" UNITS="IU/L" WEIGHT="100.0" Z="1.5388662670281994">
<NAME>Amount of gonadotrophins administered</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="627.5250618741013" CI_START="-75.52506187410125" DF="0" EFFECT_SIZE="276.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" MODIFIED="2017-04-05 14:12:59 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12383694791391428" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="1.5388662670281994">
<NAME>Prog + Ant vs Ant</NAME>
<CONT_DATA CI_END="627.5250618741013" CI_START="-75.52506187410125" EFFECT_SIZE="276.0" ESTIMABLE="YES" MEAN_1="2010.0" MEAN_2="1734.0" MODIFIED="2017-04-05 14:12:59 +1200" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="670.0" SD_2="551.0" SE="179.35281701443805" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.0139793222187707" CI_END="0.3229648087029459" CI_START="0.08227372616480239" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.16300772445529677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="52" I2="0.6941144859109045" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-0.49084479723160646" LOG_CI_START="-1.084738833115994" LOG_EFFECT_SIZE="-0.7877918151738001" METHOD="MH" MODIFIED="2017-05-23 13:37:59 +1200" MODIFIED_BY="Helen E Nagels" NO="8" P_CHI2="0.36531717280215437" P_Q="1.0" P_Z="1.9958087435361988E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="187" TOTAL_2="187" WEIGHT="100.0" Z="5.199727533066723">
<NAME>Ovarian cyst formation rate</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0139793222187707" CI_END="0.3229648087029459" CI_START="0.08227372616480239" DF="2" EFFECT_SIZE="0.16300772445529677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="52" I2="0.6941144859109045" ID="CMP-002.08.01" LOG_CI_END="-0.49084479723160646" LOG_CI_START="-1.084738833115994" LOG_EFFECT_SIZE="-0.7877918151738001" MODIFIED="2017-04-05 14:13:08 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36531717280215437" P_Z="1.9958087435361988E-7" STUDIES="3" TAU2="0.0" TOTAL_1="187" TOTAL_2="187" WEIGHT="100.0" Z="5.199727533066723">
<NAME>Prog + Ag vs Ag</NAME>
<DICH_DATA CI_END="0.740263219560287" CI_START="0.08858351355795413" EFFECT_SIZE="0.2560763888888889" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.13061382827392465" LOG_CI_START="-1.0526470979441358" LOG_EFFECT_SIZE="-0.5916304631090302" MODIFIED="2017-04-05 14:13:03 +1200" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.5416069067425764" STUDY_ID="STD-Aston-1995" TOTAL_1="77" TOTAL_2="75" VAR="0.2933380414312618" WEIGHT="30.766341096919607">
<FOOTNOTE>Measured after 12 days of pituitary suppression</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7235938925126533" CI_START="0.05279546957781285" EFFECT_SIZE="0.19545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.14050510745518535" LOG_CI_START="-1.2774033430300542" LOG_EFFECT_SIZE="-0.7089542252426196" MODIFIED="2017-04-05 14:13:06 +1200" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.6678196513137069" STUDY_ID="STD-Ditkoff-1996" TOTAL_1="47" TOTAL_2="58" VAR="0.44598308668076103" WEIGHT="25.516528925619834">
<FOOTNOTE>Measured after 8 days of pituitary suppression</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.28319432817235957" CI_START="0.02179941041756234" EFFECT_SIZE="0.07857142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="21" LOG_CI_END="-0.5479154489628948" LOG_CI_START="-1.661555252077131" LOG_EFFECT_SIZE="-1.104735350520013" MODIFIED="2017-04-05 14:13:08 +1200" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.6541575329552339" STUDY_ID="STD-Engmann-1999" TOTAL_1="63" TOTAL_2="54" VAR="0.4279220779220779" WEIGHT="43.71712997746056">
<FOOTNOTE>Measured after 7 days of pituitary suppression</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-07-26 09:13:15 +1200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Oestrogen versus no pretreatment (Rx)</NAME>
<DICH_OUTCOME CHI2="1.4976108388398979" CI_END="1.1229740441512026" CI_START="0.595249352743251" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8175876545841885" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="114" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.05036971831650853" LOG_CI_START="-0.22530106816195242" LOG_EFFECT_SIZE="-0.08746567492272195" METHOD="MH" MODIFIED="2017-07-14 15:36:00 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6828218859489927" P_Q="0.7573833169751581" P_Z="0.2136001524746054" Q="0.09543082442470574" RANDOM="NO" SCALE="434.47" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="383" TOTAL_2="361" WEIGHT="200.0" Z="1.2437268012468021">
<NAME>Live birth or ongoing pregnancy</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oestrogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4101160200593017" CI_END="1.1675490725612616" CI_START="0.5322853287417793" DF="1" EFFECT_SIZE="0.7883332048762316" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="73" I2="29.08384942978341" ID="CMP-003.01.01" LOG_CI_END="0.06727514319505573" LOG_CI_START="-0.2738555040213033" LOG_EFFECT_SIZE="-0.10329018041312381" MODIFIED="2017-07-14 15:36:00 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23503736346710813" P_Z="0.23526465780504602" STUDIES="2" TAU2="0.0" TOTAL_1="258" TOTAL_2="244" WEIGHT="100.0" Z="1.1869061617203116">
<NAME>Oestrogen (Oestr) + antagonist (Ant) vs Ant</NAME>
<DICH_DATA CI_END="1.4742360606380323" CI_START="0.07439296708714663" EFFECT_SIZE="0.33116883116883117" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.16856703007941587" LOG_CI_START="-1.1284681195564692" LOG_EFFECT_SIZE="-0.4799505447385267" MODIFIED="2017-04-05 14:13:52 +1200" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.761884867323657" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="25" TOTAL_2="24" VAR="0.5804685510567864" WEIGHT="11.201780415430267">
<FOOTNOTE>Data obtained from Dr. Griesinger</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2739527339987857" CI_START="0.5618125205162514" EFFECT_SIZE="0.8460038986354775" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="66" LOG_CI_END="0.10515331517020615" LOG_CI_START="-0.2504085863688173" LOG_EFFECT_SIZE="-0.07262763559930559" MODIFIED="2016-09-02 18:13:05 +1200" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.20885882102382086" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012" TOTAL_1="233" TOTAL_2="220" VAR="0.04362200711946043" WEIGHT="88.79821958456974"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0014469968644155408" CI_END="1.5014374738005973" CI_START="0.5107726733921535" DF="1" EFFECT_SIZE="0.8757244043786221" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="41" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.17650725105462223" LOG_CI_START="-0.2917723457713041" LOG_EFFECT_SIZE="-0.057632547358340974" MODIFIED="2017-05-22 15:20:52 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="0.9696562627664733" P_Z="0.6294954977996058" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="117" WEIGHT="100.0" Z="0.48243706505810946">
<NAME>Oestr + Ant vs agonist (Ag)</NAME>
<DICH_DATA CI_END="6.714988666458291" CI_START="0.12307485865462091" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.8270452840041715" LOG_CI_START="-0.9098306543206216" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2017-04-05 14:13:57 +1200" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="1.0202495238465397" STUDY_ID="STD-Franco-Jr-2003" TOTAL_1="16" TOTAL_2="6" VAR="1.040909090909091" WEIGHT="7.083065035415324">
<FOOTNOTE>Includes 2 spontaneous pregnancies in the study group. Data obtained from Dr. Franco Jr</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.528544701139254" CI_START="0.4988044096588391" EFFECT_SIZE="0.8731808731808732" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.18427814386305236" LOG_CI_START="-0.30206971581491493" LOG_EFFECT_SIZE="-0.05889578597593128" MODIFIED="2016-09-02 18:13:05 +1200" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.28568314023557045" STUDY_ID="STD-Ye-2009" TOTAL_1="109" TOTAL_2="111" VAR="0.08161485661485662" WEIGHT="92.91693496458467"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5673693436781986" CI_END="2.238290677242809" CI_START="0.45121881098780603" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0049670930088166" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" I2="71.96813944224422" I2_Q="71.42891632735294" ID="CMP-003.02" LOG_CI_END="0.3499164858228578" LOG_CI_START="-0.34561280322260757" LOG_EFFECT_SIZE="0.002151841300125103" METHOD="MH" MODIFIED="2017-05-23 13:38:31 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="0.058925748106623876" P_Q="0.061367390730109106" P_Z="0.9903238561068075" Q="3.5000422506107602" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="134" TOTAL_2="135" WEIGHT="200.0" Z="0.012127545209430731">
<NAME>Pregnancy loss</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4721795007510154" CI_START="0.017028796034488695" DF="0" EFFECT_SIZE="0.15833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.16796076613797933" LOG_CI_START="-1.7688160563275712" LOG_EFFECT_SIZE="-0.8004276450947959" MODIFIED="2017-05-22 15:13:50 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.10522781156249299" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="24" WEIGHT="100.00000000000001" Z="1.6200207875462769">
<NAME>Oestr + Ant vs Ant</NAME>
<DICH_DATA CI_END="1.4721795007510154" CI_START="0.017028796034488695" EFFECT_SIZE="0.15833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.16796076613797933" LOG_CI_START="-1.7688160563275712" LOG_EFFECT_SIZE="-0.8004276450947959" MODIFIED="2017-04-05 14:14:05 +1200" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="1.137672292716156" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="25" TOTAL_2="24" VAR="1.294298245614035" WEIGHT="100.00000000000001">
<FOOTNOTE>Calculated from the number of clinical pregnancies minus the number of live births</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.063618800471985" CI_START="0.6243103546026594" DF="0" EFFECT_SIZE="1.592783505154639" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.608912960935223" LOG_CI_START="-0.20459946194600578" LOG_EFFECT_SIZE="0.20215674949460857" MODIFIED="2017-05-22 15:13:59 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Z="0.3300084610663826" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="111" WEIGHT="100.0" Z="0.9740968597328132">
<NAME>Oestr + Ant vs Ag</NAME>
<DICH_DATA CI_END="4.063618800471985" CI_START="0.6243103546026594" EFFECT_SIZE="1.592783505154639" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.608912960935223" LOG_CI_START="-0.20459946194600578" LOG_EFFECT_SIZE="0.20215674949460857" MODIFIED="2016-08-23 11:36:56 +1200" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.4778612241518728" STUDY_ID="STD-Ye-2009" TOTAL_1="109" TOTAL_2="111" VAR="0.22835134954792646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.434362159605399" CI_END="1.129464821804752" CI_START="0.6594316380766292" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8630207631295065" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="181" I2="22.292219866178073" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.052872708975730376" LOG_CI_START="-0.18083022020093442" LOG_EFFECT_SIZE="-0.06397875561260202" METHOD="MH" MODIFIED="2017-05-23 13:38:44 +1200" MODIFIED_BY="Helen E Nagels" NO="3" P_CHI2="0.26621691619088594" P_Q="0.5589881527343783" P_Z="0.28321570881692015" Q="0.3414595129621685" RANDOM="NO" SCALE="407.56" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="477" TOTAL_2="453" WEIGHT="200.0" Z="1.0731235352347532">
<NAME>Clinical pregnancy rate</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oestrogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.030560364563771" CI_END="1.243982437862467" CI_START="0.6609641967201383" DF="3" EFFECT_SIZE="0.9067678053259969" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="116" I2="50.25337914485814" ID="CMP-003.03.01" LOG_CI_END="0.09481424917050774" LOG_CI_START="-0.17982206485324936" LOG_EFFECT_SIZE="-0.04250390784137079" MODIFIED="2017-05-22 15:16:06 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.11013288227881446" P_Z="0.5440732145493303" STUDIES="4" TAU2="0.0" TOTAL_1="352" TOTAL_2="336" WEIGHT="100.0" Z="0.6066650644320113">
<NAME>Oestr + Ant vs Ant</NAME>
<DICH_DATA CI_END="2.441018104416565" CI_START="0.42885062227311554" EFFECT_SIZE="1.0231481481481481" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.3875710004819385" LOG_CI_START="-0.36769395541357897" LOG_EFFECT_SIZE="0.009938522534179796" MODIFIED="2016-08-16 16:29:53 +1200" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.4436463737148544" STUDY_ID="STD-Blockeel-2012" TOTAL_1="44" TOTAL_2="42" VAR="0.19682210491034022" WEIGHT="12.452767738242553"/>
<DICH_DATA CI_END="0.8572647740947767" CI_START="0.05911092411896187" EFFECT_SIZE="0.22510822510822512" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.06688502152063322" LOG_CI_START="-1.228332250994057" LOG_EFFECT_SIZE="-0.6476086362573451" MODIFIED="2017-04-05 14:14:14 +1200" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.6822398518491979" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="25" TOTAL_2="24" VAR="0.4654512154512154" WEIGHT="11.68682369085065">
<FOOTNOTE>Data obtained from Dr. Cédrin-Durnerin</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3250070218472882" CI_START="0.609398747398253" EFFECT_SIZE="0.898586456278764" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="78" LOG_CI_END="0.12221817981354328" LOG_CI_START="-0.21509844279235055" LOG_EFFECT_SIZE="-0.04644013148940364" MODIFIED="2015-07-31 13:16:35 +1200" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.19814145386291326" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012" TOTAL_1="233" TOTAL_2="220" VAR="0.03926003573890898" WEIGHT="66.58886177616529"/>
<DICH_DATA CI_END="4.082737000160269" CI_START="0.6818275891230843" EFFECT_SIZE="1.6684491978609626" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.610951404645524" LOG_CI_START="-0.16632542968163633" LOG_EFFECT_SIZE="0.22231298748194384" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.45657626006615687" STUDY_ID="STD-Fanchin-2003" TOTAL_1="50" TOTAL_2="50" VAR="0.2084618812559989" WEIGHT="9.271546794741516"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03411459511429015" CI_END="1.2654248227606035" CI_START="0.453648515574845" DF="1" EFFECT_SIZE="0.7576662143826324" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="65" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.10223634939151961" LOG_CI_START="-0.34328050587941306" LOG_EFFECT_SIZE="-0.12052207824394676" MODIFIED="2017-05-22 15:16:12 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="0.8534633286017883" P_Z="0.2889506417158797" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="117" WEIGHT="100.00000000000001" Z="1.060426468293335">
<NAME>Oestr + Ant vs Ag</NAME>
<DICH_DATA CI_END="6.714988666458291" CI_START="0.12307485865462091" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.8270452840041715" LOG_CI_START="-0.9098306543206216" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2017-04-05 14:14:21 +1200" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="1.0202495238465397" STUDY_ID="STD-Franco-Jr-2003" TOTAL_1="16" TOTAL_2="6" VAR="1.040909090909091" WEIGHT="5.970149253731344">
<FOOTNOTE>Includes 2 spontaneous pregnancies in the study group</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2721944027309577" CI_START="0.4398555093333909" EFFECT_SIZE="0.7480519480519481" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="63" LOG_CI_END="0.10455348048087965" LOG_CI_START="-0.35668996397941927" LOG_EFFECT_SIZE="-0.1260682417492698" MODIFIED="2016-08-23 11:38:46 +1200" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.27093668246785246" STUDY_ID="STD-Ye-2009" TOTAL_1="109" TOTAL_2="111" VAR="0.0734066859066859" WEIGHT="94.02985074626866"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="53.585157968132364" CI_START="0.0937532220363995" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.2413793103448274" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.7290445153431542" LOG_CI_START="-1.0280137978553552" LOG_EFFECT_SIZE="0.35051535874389944" METHOD="MH" MODIFIED="2017-05-23 13:38:59 +1200" MODIFIED_BY="Helen E Nagels" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6182335530031147" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="6" WEIGHT="100.0" Z="0.4983554217024757">
<NAME>Multiple pregnancies</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="53.585157968132364" CI_START="0.0937532220363995" DF="0" EFFECT_SIZE="2.2413793103448274" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="1.7290445153431542" LOG_CI_START="-1.0280137978553552" LOG_EFFECT_SIZE="0.35051535874389944" MODIFIED="2017-05-22 15:16:27 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.6182335530031147" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="6" WEIGHT="100.0" Z="0.4983554217024757">
<NAME>Oestr + Ant vs Ag</NAME>
<DICH_DATA CI_END="53.585157968132364" CI_START="0.0937532220363995" EFFECT_SIZE="2.2413793103448274" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7290445153431542" LOG_CI_START="-1.0280137978553552" LOG_EFFECT_SIZE="0.35051535874389944" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="1.6195097008315613" STUDY_ID="STD-Franco-Jr-2003" TOTAL_1="16" TOTAL_2="6" VAR="2.622811671087533" WEIGHT="100.0">
<FOOTNOTE>Data obtained from Dr. Franco Jr.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.416222877529359" CI_START="0.25266614483336386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5424528301886793" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.9738767295014352" LOG_CI_START="-0.5974529460383659" LOG_EFFECT_SIZE="0.18821189173153466" METHOD="MH" MODIFIED="2017-05-23 13:39:12 +1200" MODIFIED_BY="Helen E Nagels" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.638695106582654" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="109" TOTAL_2="111" WEIGHT="100.0" Z="0.46952404068768727">
<NAME>Ovarian hyperstimulation syndrome rate</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.416222877529359" CI_START="0.25266614483336386" DF="0" EFFECT_SIZE="1.5424528301886793" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.9738767295014352" LOG_CI_START="-0.5974529460383659" LOG_EFFECT_SIZE="0.18821189173153466" MODIFIED="2017-05-22 15:16:36 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.638695106582654" STUDIES="1" TAU2="0.0" TOTAL_1="109" TOTAL_2="111" WEIGHT="100.0" Z="0.46952404068768727">
<NAME>Oestr + Ant vs Ag</NAME>
<DICH_DATA CI_END="9.416222877529359" CI_START="0.25266614483336386" EFFECT_SIZE="1.5424528301886793" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9738767295014352" LOG_CI_START="-0.5974529460383659" LOG_EFFECT_SIZE="0.18821189173153466" MODIFIED="2016-08-23 11:52:43 +1200" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.9230068296194183" STUDY_ID="STD-Ye-2009" TOTAL_1="109" TOTAL_2="111" VAR="0.8519416075240898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8609274186520728" CI_END="3.5170070663816446" CI_START="0.6130803445515081" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0650437054665765" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2017-07-26 09:12:50 +1200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6502075374787866" P_Q="0.4823982173054957" P_Z="0.00531092941501568" Q="0.4934369129523366" RANDOM="NO" SCALE="8.87" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="88" TOTAL_2="73" UNITS="" WEIGHT="200.0" Z="2.7875436792460357">
<NAME>Number of oocytes retrieved</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oestrogen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.36749050569973607" CI_END="3.748905064061989" CI_START="0.7064576766102366" DF="1" EFFECT_SIZE="2.227681370336113" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" MODIFIED="2017-07-26 09:12:50 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5443756122162524" P_Z="0.004102472072127261" STUDIES="2" TAU2="0.0" TOTAL_1="72" TOTAL_2="67" WEIGHT="100.0" Z="2.8701730540336947">
<NAME>Oestr + Ant vs Ant</NAME>
<CONT_DATA CI_END="6.692367643262067" CI_START="-0.29236764326206854" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="9.9" MODIFIED="2017-07-12 15:32:43 +1200" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="7.0" SD_2="5.4" SE="1.7818529681205462" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="25" TOTAL_2="24" WEIGHT="18.97344752800937"/>
<CONT_DATA CI_END="3.68997157792899" CI_START="0.31002842207101167" EFFECT_SIZE="2.000000000000001" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="7.3" MODIFIED="2017-07-26 09:12:50 +1200" MODIFIED_BY="[Empty name]" ORDER="271" SD_1="4.8" SD_2="3.3" SE="0.8622462408795617" STUDY_ID="STD-Fanchin-2003" TOTAL_1="47" TOTAL_2="43" WEIGHT="81.02655247199063">
<FOOTNOTE>'Mature follicles'</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.267380915103116" CI_START="-4.467380915103115" DF="0" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" MODIFIED="2017-07-14 14:00:14 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8720388265681005" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="6" WEIGHT="100.0" Z="0.16106929116301014">
<NAME>Oestr + Ant vs Ag</NAME>
<CONT_DATA CI_END="5.267380915103116" CI_START="-4.467380915103115" EFFECT_SIZE="0.40000000000000036" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="10.1" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="272" SD_1="6.5" SD_2="4.6" SE="2.483403242863846" STUDY_ID="STD-Franco-Jr-2003" TOTAL_1="16" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.15969346212014" CI_END="0.9926080286658947" CI_START="0.5035515055137252" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7480797670898099" ESTIMABLE="YES" I2="88.34478014181907" I2_Q="94.06540387182332" ID="CMP-003.07" MODIFIED="2017-05-23 13:39:37 +1200" MODIFIED_BY="Helen E Nagels" NO="7" P_CHI2="1.878544822608852E-4" P_Q="4.044685998039199E-5" P_Z="2.0214569928203755E-9" Q="16.85034631509521" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="286" TOTAL_2="265" UNITS="" WEIGHT="200.0" Z="5.996073384764689">
<NAME>Days of gonadotrophin treatment</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.30934714702492966" CI_END="1.0763792569412372" CI_START="0.5812808545735848" DF="1" EFFECT_SIZE="0.828830055757411" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" MODIFIED="2017-05-22 15:19:56 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.5780811846697098" P_Z="5.300571453976686E-11" STUDIES="2" TAU2="0.0" TOTAL_1="270" TOTAL_2="259" WEIGHT="100.0" Z="6.562239146078032">
<NAME>Oestr + Ant vs Ant</NAME>
<CONT_DATA CI_END="1.6520092933051136" CI_START="0.3479907066948865" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="8.6" MODIFIED="2015-07-31 14:27:41 +1200" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="1.4" SD_2="1.5" SE="0.33266391548420254" STUDY_ID="STD-Blockeel-2012" TOTAL_1="37" TOTAL_2="39" WEIGHT="14.415027878705185"/>
<CONT_DATA CI_END="1.0675856210211911" CI_START="0.5324143789788102" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="10.0" MODIFIED="2015-07-31 13:48:23 +1200" MODIFIED_BY="[Empty name]" ORDER="251" SD_1="1.4" SD_2="1.5" SE="0.13652578472455196" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012" TOTAL_1="233" TOTAL_2="220" WEIGHT="85.58497212129481"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.9299885106751402" CI_START="-4.07001148932486" DF="0" EFFECT_SIZE="-2.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" MODIFIED="2017-05-22 15:20:04 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Z="0.0018027542196569766" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="6" WEIGHT="99.99999999999999" Z="3.1209389196617963">
<NAME>Oestr + Ant vs Ag</NAME>
<CONT_DATA CI_END="-0.9299885106751402" CI_START="-4.07001148932486" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="10.3" MEAN_2="12.8" MODIFIED="2017-04-05 14:14:46 +1200" MODIFIED_BY="[Empty name]" ORDER="276" SD_1="1.6" SD_2="1.7" SE="0.801040989379861" STUDY_ID="STD-Franco-Jr-2003" TOTAL_1="16" TOTAL_2="6" WEIGHT="99.99999999999999">
<FOOTNOTE>Data obtained from Dr. Franco Jr</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.596186263196567" CI_END="221.88443252634374" CI_START="109.12437868693092" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="165.50440560663733" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2017-07-26 09:13:15 +1200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6274989944601894" P_Q="0.42983374098386207" P_Z="8.74127108645869E-9" Q="0.62327321767145" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="358" TOTAL_2="332" UNITS="IU/L" WEIGHT="200.0" Z="5.7535033591539015">
<NAME>Amount of gonadotrophins administered</NAME>
<GROUP_LABEL_1>Oestrogen</GROUP_LABEL_1>
<GROUP_LABEL_2>No Rx</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.9729130455251174" CI_END="225.16552583166276" CI_START="111.52625933910271" DF="3" EFFECT_SIZE="168.34589258538273" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" MODIFIED="2017-07-26 09:13:15 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5780477245306224" P_Z="6.360029109961402E-9" STUDIES="4" TAU2="0.0" TOTAL_1="342" TOTAL_2="326" WEIGHT="100.0" Z="5.807004860141379">
<NAME>Oestr + Ant vs Ant</NAME>
<CONT_DATA CI_END="303.1012856117364" CI_START="76.8987143882636" EFFECT_SIZE="190.0" ESTIMABLE="YES" MEAN_1="1485.0" MEAN_2="1295.0" MODIFIED="2015-07-31 14:29:24 +1200" MODIFIED_BY="[Empty name]" ORDER="254" SD_1="249.0" SD_2="254.0" SE="57.70579791458665" STUDY_ID="STD-Blockeel-2012" TOTAL_1="37" TOTAL_2="39" WEIGHT="25.23839709942187"/>
<CONT_DATA CI_END="267.30633917759064" CI_START="-335.30633917759064" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="1700.0" MEAN_2="1734.0" MODIFIED="2017-07-14 14:08:20 +1200" MODIFIED_BY="[Empty name]" ORDER="279" SD_1="524.0" SD_2="551.0" SE="153.7305489051108" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="25" TOTAL_2="24" WEIGHT="3.556151990801906"/>
<CONT_DATA CI_END="237.62015557824589" CI_START="98.37984442175413" EFFECT_SIZE="168.0" ESTIMABLE="YES" MEAN_1="1557.0" MEAN_2="1389.0" MODIFIED="2015-07-31 13:35:06 +1200" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="408.0" SD_2="347.0" SE="35.521140249209054" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2012" TOTAL_1="233" TOTAL_2="220" WEIGHT="66.60807359598608"/>
<CONT_DATA CI_END="475.99846112112374" CI_START="-53.99846112112374" EFFECT_SIZE="211.0" ESTIMABLE="YES" MEAN_1="2674.0" MEAN_2="2463.0" MODIFIED="2017-07-26 09:13:15 +1200" MODIFIED_BY="[Empty name]" ORDER="278" SD_1="623.9" SD_2="655.7" SE="135.20578092832204" STUDY_ID="STD-Fanchin-2003" TOTAL_1="47" TOTAL_2="43" WEIGHT="4.597377313790131"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="438.11848106399486" CI_START="-470.11848106399486" DF="0" EFFECT_SIZE="-16.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.02" MODIFIED="2017-05-22 15:17:06 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Z="0.9449453634337974" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="6" WEIGHT="100.0" Z="0.06905559905680576">
<NAME>Oestr + Ant vs Ag</NAME>
<CONT_DATA CI_END="438.11848106399486" CI_START="-470.11848106399486" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="2500.0" MEAN_2="2516.0" MODIFIED="2016-10-26 17:15:28 +1300" MODIFIED_BY="[Empty name]" ORDER="280" SD_1="484.0" SD_2="484.0" SE="231.6973600770338" STUDY_ID="STD-Franco-Jr-2003" TOTAL_1="16" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-05-23 13:40:56 +1200" MODIFIED_BY="Helen E Nagels" NO="4">
<NAME>Combined oral contraceptive pill (COCP) versus progestogen</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.893828856068592" CI_START="0.12440265748440894" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.46147284293268664" LOG_CI_START="-0.9051703421653994" LOG_EFFECT_SIZE="-0.2218487496163564" METHOD="MH" MODIFIED="2017-05-23 13:40:04 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5245637143029886" Q="0.0" RANDOM="NO" SCALE="501.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.636326385708491">
<NAME>Live birth or ongoing pregnancy</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.893828856068592" CI_START="0.12440265748440894" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.46147284293268664" LOG_CI_START="-0.9051703421653994" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2017-05-22 15:17:20 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.5245637143029886" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.636326385708491">
<NAME>COCP + antagonist (Ant) vs progestogen (Prog) + Ant</NAME>
<DICH_DATA CI_END="2.893828856068592" CI_START="0.12440265748440894" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.46147284293268664" LOG_CI_START="-0.9051703421653994" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2017-04-05 14:15:37 +1200" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.8027729719194864" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="23" VAR="0.6444444444444444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.636049062447508" CI_START="0.1414543432263961" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.9363151009490964" LOG_CI_START="-0.8493837133869158" LOG_EFFECT_SIZE="0.043465693781090345" METHOD="MH" MODIFIED="2017-05-23 13:40:14 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9239852304634593" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.09541496437142553">
<NAME>Pregnancy loss</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.636049062447508" CI_START="0.1414543432263961" DF="0" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.9363151009490964" LOG_CI_START="-0.8493837133869158" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2017-04-05 14:15:46 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9239852304634593" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.09541496437142553">
<NAME>COCP + Ant vs Prog + Ant</NAME>
<DICH_DATA CI_END="8.636049062447508" CI_START="0.1414543432263961" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9363151009490964" LOG_CI_START="-0.8493837133869158" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2017-04-05 14:15:46 +1200" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="1.0489283228926636" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="23" VAR="1.100250626566416" WEIGHT="100.0">
<FOOTNOTE>Calculated from the number of clinical pregnancies minus the number of live births</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.72957185219541" CI_START="0.18691725635369993" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.43609453099268947" LOG_CI_START="-0.7283506023491655" LOG_EFFECT_SIZE="-0.146128035678238" METHOD="MH" MODIFIED="2017-05-23 13:40:24 +1200" MODIFIED_BY="Helen E Nagels" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6227774040004026" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.49191787377559204">
<NAME>Clinical pregnancy rate</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.72957185219541" CI_START="0.18691725635369993" DF="0" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.43609453099268947" LOG_CI_START="-0.7283506023491655" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2017-04-05 14:16:41 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6227774040004026" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.49191787377559204">
<NAME>COCP + Ant vs Prog + Ant</NAME>
<DICH_DATA CI_END="2.72957185219541" CI_START="0.18691725635369993" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.43609453099268947" LOG_CI_START="-0.7283506023491655" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2017-04-05 14:16:41 +1200" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.6840008354213779" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="23" VAR="0.46785714285714286" WEIGHT="100.0">
<FOOTNOTE>Data obtained from Dr. Cédrin-Durnerin</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.58983967029218" CI_START="0.1943788347636237" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.3157894736842106" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="1.4407491767202254" LOG_CI_START="-0.7113510256535084" LOG_EFFECT_SIZE="0.3646990755333585" METHOD="MH" MODIFIED="2017-05-23 13:40:33 +1200" MODIFIED_BY="Helen E Nagels" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5065120202053233" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.6642785986005905">
<NAME>Multiple pregnancy rate</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.58983967029218" CI_START="0.1943788347636237" DF="0" EFFECT_SIZE="2.3157894736842106" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="1.4407491767202254" LOG_CI_START="-0.7113510256535084" LOG_EFFECT_SIZE="0.3646990755333585" MODIFIED="2017-04-05 14:17:06 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5065120202053233" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.6642785986005905">
<NAME>COCP + Ant vs Prog + Ant</NAME>
<DICH_DATA CI_END="27.589839670292168" CI_START="0.19437883476362378" EFFECT_SIZE="2.3157894736842106" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4407491767202252" LOG_CI_START="-0.7113510256535082" LOG_EFFECT_SIZE="0.3646990755333585" MODIFIED="2017-04-05 14:17:06 +1200" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="1.2641543119421432" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="23" VAR="1.5980861244019138" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.037058039919426" CI_START="-3.2370580399194253" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2017-05-23 13:40:46 +1200" MODIFIED_BY="Helen E Nagels" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5540222755618756" Q="0.0" RANDOM="NO" SCALE="8.09" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.5917436345920216">
<NAME>Number of oocytes retrieved</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.037058039919426" CI_START="-3.2370580399194253" DF="0" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.01" MODIFIED="2017-04-05 14:15:54 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5540222755618756" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.5917436345920216">
<NAME>COCP + Ant vs Prog + Ant</NAME>
<CONT_DATA CI_END="6.037058039919426" CI_START="-3.2370580399194253" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="12.6" MODIFIED="2017-04-05 14:15:54 +1200" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="8.3" SD_2="7.3" SE="2.36588941250755" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="577.0330485178063" CI_START="-249.0330485178062" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="164.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2017-05-23 13:40:56 +1200" MODIFIED_BY="Helen E Nagels" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.4364343195201479" Q="0.0" RANDOM="NO" SCALE="902.23" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="23" UNITS="IU/L" WEIGHT="100.0" Z="0.7782285088761162">
<NAME>Amount of gonadotrophins administered</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Progestogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="577.0330485178063" CI_START="-249.0330485178062" DF="0" EFFECT_SIZE="164.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.01" MODIFIED="2017-04-05 14:16:56 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4364343195201479" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0" Z="0.7782285088761162">
<NAME>COCP + Ant vs Prog + Ant</NAME>
<CONT_DATA CI_END="577.0330485178063" CI_START="-249.0330485178062" EFFECT_SIZE="164.0" ESTIMABLE="YES" MEAN_1="2174.0" MEAN_2="2010.0" MODIFIED="2017-04-05 14:16:56 +1200" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="723.0" SD_2="670.0" SE="210.7350195083982" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2017-05-23 13:42:56 +1200" MODIFIED_BY="Helen E Nagels" NO="5">
<NAME>Combined oral contraceptive pill (COCP) versus oestrogen (Oestr)</NAME>
<DICH_OUTCOME CHI2="4.68548045466881" CI_END="1.52761524568903" CI_START="0.41186365838772865" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7932018681888947" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" I2="57.31494305974288" I2_Q="78.21178795259414" ID="CMP-005.01" LOG_CI_END="0.18401398400710559" LOG_CI_START="-0.3852465271937961" LOG_EFFECT_SIZE="-0.1006162715933453" METHOD="MH" MODIFIED="2017-05-23 13:41:24 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.09606423543098086" P_Q="0.03216587228017409" P_Z="0.4884076731532514" Q="4.58963772623583" RANDOM="NO" SCALE="213.7" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="83" TOTAL_2="88" WEIGHT="200.0" Z="0.69284366191373">
<NAME>Live birth or ongoing pregnancy</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.014916820172298034" CI_END="2.2856566699098817" CI_START="0.5381857234740677" DF="1" EFFECT_SIZE="1.1091022443890275" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.3590109952798514" LOG_CI_START="-0.2690678270082907" LOG_EFFECT_SIZE="0.04497158413578037" MODIFIED="2017-05-22 15:10:27 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.9027925540201658" P_Z="0.7789604831819246" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.00000000000001" Z="0.28067396035654074">
<NAME>COCP + antagonist (Ant) vs Oestr + Ant</NAME>
<DICH_DATA CI_END="6.806891684901259" CI_START="0.21945804776170713" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8329488399208969" LOG_CI_START="-0.6586484884830963" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2017-04-05 14:17:25 +1200" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.8761716542303611" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="25" VAR="0.7676767676767675" WEIGHT="16.832917705735664"/>
<DICH_DATA CI_END="2.4106151266862703" CI_START="0.48943749213852794" EFFECT_SIZE="1.0862068965517242" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.38212787744550125" LOG_CI_START="-0.3103027656642124" LOG_EFFECT_SIZE="0.035912555890644446" MODIFIED="2016-09-02 18:16:31 +1200" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.4067371873496086" STUDY_ID="STD-Hauzman-2013" TOTAL_1="50" TOTAL_2="50" VAR="0.1654351395730706" WEIGHT="83.16708229426435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7924492796436386" CI_START="0.007662131045692757" DF="0" EFFECT_SIZE="0.07792207792207792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-0.10102852504182629" LOG_CI_START="-2.11565042453585" LOG_EFFECT_SIZE="-1.1083394747888382" MODIFIED="2017-05-22 15:10:18 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Z="0.031041593746993473" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="2.1565391042118036">
<NAME>COCP + agonist (Ag) vs Oestr + Ant</NAME>
<DICH_DATA CI_END="0.7924492796436386" CI_START="0.007662131045692757" EFFECT_SIZE="0.07792207792207792" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.10102852504182629" LOG_CI_START="-2.11565042453585" LOG_EFFECT_SIZE="-1.1083394747888382" MODIFIED="2016-09-02 18:17:19 +1200" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="1.1833988763020271" STUDY_ID="STD-Daly-2002" TOTAL_1="12" TOTAL_2="13" VAR="1.4004329004329004" WEIGHT="100.0">
<FOOTNOTE>Viable pregnancies</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.629617691588546" CI_START="0.06062688857858191" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.292911841319297" LOG_CI_START="-1.2173347195404975" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" MODIFIED="2017-05-23 13:41:39 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9529445279675898" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.05900951685435583">
<NAME>Pregnancy loss</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oestrogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.629617691588546" CI_START="0.06062688857858191" DF="0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="1.292911841319297" LOG_CI_START="-1.2173347195404975" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2017-05-22 15:18:25 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.9529445279675898" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.05900951685435583">
<NAME>COCP + Ag vs Oestr + Ant</NAME>
<DICH_DATA CI_END="19.629617691588546" CI_START="0.06062688857858191" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.292911841319297" LOG_CI_START="-1.2173347195404975" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-01-19 14:00:39 +1300" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="1.4745312557699224" STUDY_ID="STD-Daly-2002" TOTAL_1="12" TOTAL_2="13" VAR="2.1742424242424243" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.091163165744101" CI_END="1.6182345162662937" CI_START="0.4645065042158885" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8669950738916257" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="36" I2="60.716246270459315" I2_Q="79.31222453915497" ID="CMP-005.03" LOG_CI_END="0.20904146025522133" LOG_CI_START="-0.3330082004533475" LOG_EFFECT_SIZE="-0.06198337009906307" METHOD="MH" MODIFIED="2017-05-23 13:42:07 +1200" MODIFIED_BY="Helen E Nagels" NO="3" P_CHI2="0.0784275135934075" P_Q="0.02790761491774396" P_Z="0.6539773280974983" Q="4.833772494740492" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="83" TOTAL_2="88" WEIGHT="200.0" Z="0.4482437010504711">
<NAME>Clinical pregnancy rate</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23915929225173835" CI_END="2.370064495479437" CI_START="0.5957234990355144" DF="1" EFFECT_SIZE="1.188235294117647" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="28" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.37476016442770377" LOG_CI_START="-0.22495526829100404" LOG_EFFECT_SIZE="0.07490244806834984" MODIFIED="2017-05-22 15:18:37 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.6248140051317446" P_Z="0.6244269798280044" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0" Z="0.48958586875887783">
<NAME>COCP + Ant vs Oestr + Ant</NAME>
<DICH_DATA CI_END="7.113083979428097" CI_START="0.3784083526090203" EFFECT_SIZE="1.640625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.8520579361527805" LOG_CI_START="-0.4220392859806785" LOG_EFFECT_SIZE="0.2150093250860509" MODIFIED="2017-04-05 14:17:38 +1200" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.7484110151641594" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="25" VAR="0.5601190476190476" WEIGHT="18.823529411764707">
<FOOTNOTE>Data obtained from Dr. Cédrin-Durnerin</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.3734446420284794" CI_START="0.4944758728849378" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.37537910673399494" LOG_CI_START="-0.3058548942155711" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2015-07-31 14:36:54 +1200" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.40016022432046533" STUDY_ID="STD-Hauzman-2013" TOTAL_1="50" TOTAL_2="50" VAR="0.16012820512820514" WEIGHT="81.17647058823529"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8233214739870667" CI_START="0.018978006153943044" DF="0" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="-0.08443055711068899" LOG_CI_START="-1.721749416873198" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2017-05-22 15:18:44 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Z="0.03061044118134452" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="2.162100361513817">
<NAME>COCP + Ag vs Oestr + Ant</NAME>
<DICH_DATA CI_END="0.823321473987067" CI_START="0.018978006153943027" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.08443055711068881" LOG_CI_START="-1.7217494168731984" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2009-01-19 13:59:55 +1300" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.9617692030835673" STUDY_ID="STD-Daly-2002" TOTAL_1="12" TOTAL_2="13" VAR="0.925" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.38676648451224" CI_START="-3.586766484512239" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2017-05-23 13:42:21 +1200" MODIFIED_BY="Helen E Nagels" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6942094640812454" Q="0.0" RANDOM="NO" SCALE="15.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="21" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="0.3931489619919037">
<NAME>Number of oocytes retrieved</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours COCP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.38676648451224" CI_START="-3.586766484512239" DF="0" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" MODIFIED="2017-05-22 15:18:52 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.6942094640812454" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="25" WEIGHT="100.0" Z="0.3931489619919037">
<NAME>COCP + Ant vs Oestr + Ant</NAME>
<CONT_DATA CI_END="5.38676648451224" CI_START="-3.586766484512239" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="13.1" MODIFIED="2017-04-05 14:17:45 +1200" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="8.3" SD_2="7.0" SE="2.289208638476666" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.028412258606845264" CI_START="-1.2284122586068444" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2017-05-23 13:42:40 +1200" MODIFIED_BY="Helen E Nagels" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.061296780460093514" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="1.871348584655415">
<NAME>Days of gonadotropin treatment</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oestrogen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.028412258606845264" CI_START="-1.2284122586068444" DF="0" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" MODIFIED="2017-05-22 15:19:02 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.061296780460093514" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="1.871348584655415">
<NAME>COCP + Ant vs Oestr + Ant</NAME>
<CONT_DATA CI_END="0.028412258606845264" CI_START="-1.2284122586068444" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.6" MODIFIED="2015-07-31 14:44:47 +1200" MODIFIED_BY="[Empty name]" ORDER="259" SD_1="1.7" SD_2="1.5" SE="0.32062439083762795" STUDY_ID="STD-Hauzman-2013" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.1783694379022895" CI_END="707.8551895055069" CI_START="-344.73184468706006" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="181.56167240922343" ESTIMABLE="YES" I2="83.81449976323324" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2017-05-23 13:42:56 +1200" MODIFIED_BY="Helen E Nagels" NO="6" P_CHI2="0.012932217689525238" P_Q="1.0" P_Z="0.49894423967056467" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="121749.36142857146" TOTALS="SUB" TOTAL_1="71" TOTAL_2="75" UNITS="IU/L" WEIGHT="100.0" Z="0.6761518569681249">
<NAME>Amount of gonadotrophins administered</NAME>
<GROUP_LABEL_1>COCP</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours COCP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oestrogen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.1783694379022895" CI_END="707.8551895055069" CI_START="-344.73184468706006" DF="1" EFFECT_SIZE="181.56167240922343" ESTIMABLE="YES" I2="83.81449976323324" ID="CMP-005.06.01" MODIFIED="2017-05-22 15:19:25 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.012932217689525238" P_Z="0.49894423967056467" STUDIES="2" TAU2="121749.36142857146" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0" Z="0.6761518569681249">
<NAME>COCP + Ant vs Oestr + Ant</NAME>
<CONT_DATA CI_END="845.2303059704623" CI_START="102.76969402953767" EFFECT_SIZE="474.0" ESTIMABLE="YES" MEAN_1="2174.0" MEAN_2="1700.0" MODIFIED="2017-04-05 14:17:55 +1200" MODIFIED_BY="[Empty name]" ORDER="159" SD_1="723.0" SD_2="524.0" SE="189.40669772438656" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="21" TOTAL_2="25" WEIGHT="45.74428059540323"/>
<CONT_DATA CI_END="141.9352585438965" CI_START="-271.9352585438965" EFFECT_SIZE="-65.0" ESTIMABLE="YES" MEAN_1="1627.0" MEAN_2="1692.0" MODIFIED="2015-07-31 14:38:44 +1200" MODIFIED_BY="[Empty name]" ORDER="258" SD_1="565.0" SD_2="488.0" SE="105.58115362127846" STUDY_ID="STD-Hauzman-2013" TOTAL_1="50" TOTAL_2="50" WEIGHT="54.25571940459677"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2017-05-23 13:43:45 +1200" MODIFIED_BY="Helen E Nagels" NO="6">
<NAME>Progestogen (Prog) versus oestrogen (Oestr)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.703852412242973" CI_START="0.42761572558805033" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.037037037037037" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.9869441826404726" LOG_CI_START="-0.3689463319699594" LOG_EFFECT_SIZE="0.3089989253352566" METHOD="MH" MODIFIED="2017-05-23 13:43:18 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.371682122784598" Q="0.0" RANDOM="NO" SCALE="434.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="0.8933269440161102">
<NAME>Live birth or ongoing pregnancy</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.703852412242973" CI_START="0.42761572558805033" DF="0" EFFECT_SIZE="2.037037037037037" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.9869441826404726" LOG_CI_START="-0.3689463319699594" LOG_EFFECT_SIZE="0.3089989253352566" MODIFIED="2017-05-22 15:08:25 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.371682122784598" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="0.8933269440161102">
<NAME>Prog + antagonist (Ant) vs Oestr + Ant</NAME>
<DICH_DATA CI_END="9.703852412242973" CI_START="0.4276157255880504" EFFECT_SIZE="2.037037037037037" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.9869441826404726" LOG_CI_START="-0.36894633196995935" LOG_EFFECT_SIZE="0.3089989253352566" MODIFIED="2017-04-05 14:18:52 +1200" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.796456800048461" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="25" VAR="0.6343434343434342" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.22181545100135" CI_START="0.5720820150496663" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.296875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.964816426773681" LOG_CI_START="-0.2425417052451032" LOG_EFFECT_SIZE="0.36113736076428893" METHOD="MH" MODIFIED="2017-05-23 13:43:26 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.24099472054929538" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="1.1725041672371699">
<NAME>Clinical pregnancy rate</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.22181545100135" CI_START="0.5720820150496663" DF="0" EFFECT_SIZE="2.296875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.964816426773681" LOG_CI_START="-0.2425417052451032" LOG_EFFECT_SIZE="0.36113736076428893" MODIFIED="2017-05-22 15:08:41 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.24099472054929538" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="1.1725041672371699">
<NAME>Prog + Ant vs Oestr + Ant</NAME>
<DICH_DATA CI_END="9.22181545100135" CI_START="0.5720820150496664" EFFECT_SIZE="2.296875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.964816426773681" LOG_CI_START="-0.24254170524510313" LOG_EFFECT_SIZE="0.36113736076428893" MODIFIED="2017-04-05 14:19:24 +1200" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.7092081432669752" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="25" VAR="0.5029761904761905" WEIGHT="100.0">
<FOOTNOTE>Data obtained from Dr. Cédrin-Durnerin</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.5533630920705894" CI_START="-4.553363092070589" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2017-05-23 13:43:36 +1200" MODIFIED_BY="Helen E Nagels" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8089583101293768" Q="0.0" RANDOM="NO" SCALE="8.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="0.24177009806674402">
<NAME>Number of oocytes retrieved</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oestrogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours progestogen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.5533630920705894" CI_START="-4.553363092070589" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" MODIFIED="2017-05-22 15:08:55 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.8089583101293768" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="0.24177009806674402">
<NAME>Prog + Ant vs Oestr + Ant</NAME>
<CONT_DATA CI_END="3.5533630920705894" CI_START="-4.553363092070589" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="13.1" MODIFIED="2017-04-05 14:19:35 +1200" MODIFIED_BY="[Empty name]" ORDER="239" SD_1="7.3" SD_2="7.0" SE="2.0680803953761395" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="652.2954146188088" CI_START="-32.29541461880882" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="310.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" MODIFIED="2017-05-23 13:43:45 +1200" MODIFIED_BY="Helen E Nagels" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.07589090535442923" Q="0.0" RANDOM="NO" SCALE="699.85" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="25" UNITS="IU/L" WEIGHT="100.0" Z="1.7750422858689103">
<NAME>Amount of gonadotrophins administered</NAME>
<GROUP_LABEL_1>Progestogen</GROUP_LABEL_1>
<GROUP_LABEL_2>Oestrogen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours progestogen</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oestrogen</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="652.2954146188088" CI_START="-32.29541461880882" DF="0" EFFECT_SIZE="310.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.01" MODIFIED="2017-05-22 15:09:11 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Z="0.07589090535442923" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="1.7750422858689103">
<NAME>Prog + Ant vs Oestr + Ant</NAME>
<CONT_DATA CI_END="652.2954146188088" CI_START="-32.29541461880882" EFFECT_SIZE="310.0" ESTIMABLE="YES" MEAN_1="2010.0" MEAN_2="1700.0" MODIFIED="2017-04-05 14:19:42 +1200" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="670.0" SD_2="524.0" SE="174.64372678212015" STUDY_ID="STD-C_x00e9_drin_x002d_Durnerin-2007" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-08-09 08:46:45 +1200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-08-09 08:46:45 +1200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjAAAADnCAMAAAA3i5zjAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-08-09 08:46:45 +1200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVEAAASjCAIAAABIdp6gAACAAElEQVR42uy9z8vrWJ7mqb73P6lV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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-08-09 08:46:42 +1200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study PRISMA flow chart</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAc0AAANxCAYAAACG0uI6AACAAElEQVR42uy9va7jRtq2uwYdd2x3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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-08-09 08:46:45 +1200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Combined oral contraceptive pill (OCP) versus no pretreatment (Rx), outcome: 1.1 Live birth or ongoing pregnancy.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1cAAAMQCAMAAAD8QW8WAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2017-08-09 08:46:45 +1200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Combined oral contraceptive pill (COCP) versus no pretreatment (Rx), outcome: 1.2 Pregnancy loss.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2oAAAMQCAMAAABhTGaeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2017-08-09 08:46:45 +1200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.1 Live birth or ongoing pregnancy.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3YAAAHQCAMAAADaqQhlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2017-08-09 08:46:45 +1200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-003.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Oestrogen versus no pretreatment (Rx), outcome: 3.2 Pregnancy loss.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3YAAAGwCAMAAADSXQc/AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2017-08-09 08:46:04 +1200" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2017-08-09 08:46:04 +1200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-07-14 16:42:12 +1200" MODIFIED_BY="[Empty name]">Feedback from Georg Greisinger July 2017</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2017-08-09 08:43:05 +1200" MODIFIED_BY="[Empty name]">
<P>Main points of feedback were as follows:</P>
<UL>
<LI>For the E2 pre-treatment, you report mean and SDs from the Fanchin study, which <I>obviously</I> are SEMs resulting in a skewed precision estimate, wrong weighting of the study and a potentially wrong interpretation of the clinical utility of E2 pre-treatment to &#8220;synchronize the follicular cohort&#8221;.</LI>
<LI>What made you not even mention the large RCT on E2 pretreatment from France? <A HREF="https://www.ncbi.nlm.nih.gov/pubmed/20022282">https://www.ncbi.nlm.nih.gov/pubmed/20022282</A>
</LI>
</UL>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2017-08-09 08:46:04 +1200" MODIFIED_BY="[Empty name]">
<P>Thank you for raising these points. The review authors agree that the Fanchin data incorrectly reported SEs rather than SDs and have corrected analyses 3.6.1 and 3.8.1 accordingly. This change has not substantially influenced the effect estimates for these analyses.</P>
<P>The review authors also agree that we should have referenced the French study (Guivarc&#8217;h-Levêque 2009). This study was not eligible for inclusion in the review as it is quasi-randomised and we have added it to the list of excluded studies.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2017-07-14 15:31:40 +1200" MODIFIED_BY="[Empty name]">
<P>Georg Griesinger, Professor for Gynecological Endocrinology and Reproductive Medicine<I>, </I>University Hospital of Schleswig-Holstein, Campus Luebeck</P>
<P>Review authors</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2017-05-12 00:59:38 +1200" MODIFIED_BY="Anne Lawson">
<APPENDIX ID="APP-01" MODIFIED="2017-05-11 20:45:18 +1200" MODIFIED_BY="Anne Lawson" NO="1">
<TITLE MODIFIED="2009-01-29 12:40:29 +1300" MODIFIED_BY="[Empty name]">Glossary</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-11 20:45:18 +1200" MODIFIED_BY="Anne Lawson">
<P>
<B>Embryo</B> The product of conception from the time of fertilisation to the end of the embryonic stage eight weeks after fertilisation.</P>
<P>
<B>Embryo transfer (ET)</B> Procedure of which embryos are placed in the uterus or fallopian tube.</P>
<P>
<B>Endogenous</B> Developed or originated inside the organism. For example, hormones produced by the pituitary gland would be an endogenous supply, but hormones produced in the laboratory and then given to the body is called an <B>exogenous</B> supply.</P>
<P>
<B>Fertilisation</B> The penetration of the ovum by the sperm cell and fusion of genetic materials, resulting in the development of an embryo.</P>
<P>
<B>Follicle</B> The sac in which an egg develops in the ovary.</P>
<P>
<B>Follicle cohort synchronisation</B> In the ovaries, a few eggs are maturing at the same time. These eggs are all in a different stage of maturation. If one egg reaches a threshold at the right time in the menstrual cycle, the final maturation process will start and this egg will reach ovulation. For in vitro fertilisation/intra-cytoplasmic sperm injection cycles it is important that more than one egg reaches this threshold at the same time, so they can be retrieved at once before spontaneous ovulation occurs. This is called synchronisation of the follicle cohort.</P>
<P>
<B>Follicle-stimulating hormone (FSH)</B> A hormone produced and released from the pituitary gland. In women it stimulates the production of oestrogen and follicles in the ovary ready for ovulation.</P>
<P>
<B>Gestational sac</B> A fluid-filled structure containing an embryo that develops early in pregnancy, usually within the uterus.</P>
<P>
<B>Gonadotrophin releasing hormone (GnRH)</B> A substance produced by the hypothalamus (part of the brain) to enable the pituitary gland to secrete LH and FSH.</P>
<P>
<B>Gonadotrophins</B> Pituitary hormones FSH and LH which stimulate the ovaries in women.</P>
<P>
<B>Human menopausal gonadotrophin (hMG)</B> An injectable preparation that is obtained from the urine of menopausal women and has biological activity similar to that of FSH.</P>
<P>
<B>Luteal phase</B> The last 14 days of the menstrual cycle.</P>
<P>
<B>Luteinising Hormone (LH)</B> A hormone produced and released by the pituitary gland. In women it is responsible for ovulation and progestogen production.</P>
<P>
<B>Negative feedback</B> A common regulation mechanism to stabilise the body's internal environment. An example is the temperature control of the human body. When body temperature is too high, the body will react in such a way that it cools down, by opening pores and sweating. In this way the body's temperature will not fluctuate too much. The same type of mechanism is used to keep hormone values stable. An increase in gonadotrophin values will (through negative feedback) result in fewer GnRH receptors. The binding of GnRH to a GnRH receptor in the pituitary gland will result in the release of gonadotrophins, but with fewer GnRH receptors, the releasing process will be lowered and the gonadotrophin levels in the body will drop.</P>
<P>
<B>Oocyte</B> The egg from a woman's ovary.</P>
<P>
<B>Ova</B> A woman's reproductive cell, also known as egg or oocyte.</P>
<P>
<B>Ovarian hyperstimulation syndrome (OHSS) </B>A condition that occurs from fertility drugs when a large number of follicles in the ovary are stimulated to develop and ovulate. This stimulation causes an enlargement of the ovaries.</P>
<P>
<B>Ovulation</B> The release of an egg/ova from an ovarian follicle.</P>
<P>
<B>Ovulation induction</B> Medical procedure to produce ovulation.</P>
<P>
<B>Polycystic ovary syndrome (PCOS)</B> When a woman has enlarged ovaries with multiple cysts and the surface of the ovary is thickened. The woman may ovulate infrequently or not at all.</P>
<P>
<B>Premature LH-surge</B> In a normal menstrual cycle an increase in LH levels (LH-surge) is needed to start ovulation. In in vitro fertilisation (IVF)/intra-cytoplasmic sperm injection (ISCI) cycles it is important that the ovulation does not start before the oocytes are mature enough to be retrieved. A LH-surge that occurs too early is called premature and is an unwanted event in IVF/ICSI cycles.</P>
<P>
<B>Recombinant</B> (as in recombinant FSH or rFSH) A naturally occurring hormone which has been made in the laboratory with the use of DNA technology.</P>
<P>
<B>Subfertility</B> Failure to achieve pregnancy after at least one year of unprotected coitus.</P>
<P>
<B>Ultrasound</B> Radiology sounds waves of a high frequency used to visualise the developing foetus in the uterus to check size, growth and the presence of abnormalities.</P>
<P>All these definitions (except for follicle cohort synchronisation, negative feedback and premature LH-surge) were obtained from the glossary of the <LINK REF="REF-MDSG-Module-2008" TYPE="REFERENCE">MDSG Module 2008</LINK>.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-05-10 19:28:22 +1200" MODIFIED_BY="Anne Lawson" NO="2">
<TITLE MODIFIED="2017-04-10 13:25:56 +1200" MODIFIED_BY="[Empty name]">Cochrane Gynaecology and Fertility (CGFG) specialised register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-04-10 13:27:13 +1200" MODIFIED_BY="[Empty name]">
<P>Searched 17 January 2017</P>
<P>Procite platform</P>
<P>Keywords CONTAINS "IVF" or "in vitro fertilization" or "in-vitro fertilisation" or "ICSI" or"intracytoplasmic sperm injection" or "Embryo" or "in-vitro fertilization" or "ART" or "controlled ovarian " or "COH" or Title CONTAINS "IVF" or "in vitro fertilization" or "in-vitro fertilisation" or "ICSI" or"intracytoplasmic sperm injection" or "Embryo" or "in-vitro fertilization" or "ART" or "controlled ovarian " or "COH"</P>
<P>AND</P>
<P>Keywords CONTAINS "oral contraceptive" or "Oral Contraceptive Agent" or "oral contraceptives" or "combined oral contraceptives" or "Pretreatment" or "OCP" or "Oral Contraception" or "oral contraceptive pill" or "oral conjugated estrogen" or "OCP pretreatment" or "progestagen" or progestin"or"progestins"or"progestogen"or"progestogens"or"Progesterone"or"Norgestrel"or"Norethindrone"or "Norethisterone"or"desogestral"or"desogestrel"or"Gestagen"or"Gestodene"or"gestrinone"or"Estradiol"or"estradiol acetate" or "estradiol valerate"or"Estriol"or"oestrodiol"or"oestrogen"or"estrogen"or"Estrogens"or Title CONTAINS "oral contraceptive" or "Oral Contraceptive Agent" or "oral contraceptives" or "combined oral contraceptives" or "Pretreatment" or "OCP" or "Oral Contraception" or "oral contraceptive pill" or "oral congugated estrogen" or "OCP pretreatment" or "progestagen" or "progestin"or"progestins"or"progestogen"or"progestogens"or"Progesterone"or"Norgestrel"or"Norethindrone"or "Norethisterone" or "Estradiol" (888 hits)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-05-11 20:14:31 +1200" MODIFIED_BY="Anne Lawson" NO="3">
<TITLE MODIFIED="2017-04-10 13:28:27 +1200" MODIFIED_BY="[Empty name]">CENTRAL Register of Studies Online (CRSO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-11 20:14:31 +1200" MODIFIED_BY="Anne Lawson">
<P>Searched 17 January 2017</P>
<P>Web platform</P>
<P>
<BR/>
</P>
<P>#1 MESH DESCRIPTOR Reproductive Techniques, Assisted EXPLODE ALL TREES 2792</P>
<P>#2 (IVF or ICSI):TI,AB,KY 3537</P>
<P>#3 (embryo* transfer*):TI,AB,KY 2049</P>
<P>#4 (vitro fertili?ation ):TI,AB,KY 1954</P>
<P>#5 (intracytoplasmic sperm injection*):TI,AB,KY 1076</P>
<P>#6 COH:TI,AB,KY 212</P>
<P>#7 (ovar* adj2 stimulat*):TI,AB,KY 1197</P>
<P>#8 (assisted reproduct*):TI,AB,KY 694</P>
<P>#9 (ovarian hyperstimulation):TI,AB,KY 849</P>
<P>#10 (pituitary desensiti?ation):TI,AB,KY 82</P>
<P>#11 (pituitary adj2 suppression):TI,AB,KY 170</P>
<P>#12 (poor responder*):TI,AB,KY 391</P>
<P>#13 (poor ovar* response):TI,AB,KY 84</P>
<P>#14 (low responder*):TI,AB,KY 137</P>
<P>#15 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 6479</P>
<P>#16 MESH DESCRIPTOR Contraceptives, Oral EXPLODE ALL TREES 3215</P>
<P>#17 (oral contracepti*):TI,AB,KY 2278</P>
<P>#18 (pretreatment* or pre-treatment*):TI,AB,KY 14480</P>
<P>#19 (gestrinone or estradiol):TI,AB,KY 7388</P>
<P>#20 (norgestrel or desogestrel):TI,AB,KY 893</P>
<P>#21 (dimethisterone or levonorgestrel):TI,AB,KY 1169</P>
<P>#22 (norethindrone or gestodene):TI,AB,KY 1021</P>
<P>#23 (norgestimate or dienogest):TI,AB,KY 233</P>
<P>#24 (progestogen* or progestagen*):TI,AB,KY 839</P>
<P>#25 (progestin* or gestagen*):TI,AB,KY 1576</P>
<P>#26 (Medroxyprogesterone or Diane-35):TI,AB,KY 1851</P>
<P>#27 (norethisterone or ?estrogen):TI,AB,KY 9170</P>
<P>#28 E2:TI,AB,KY 3182</P>
<P>#29 #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 32193</P>
<P>#30 #15 AND #29 1355<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2017-05-10 19:28:17 +1200" MODIFIED_BY="Anne Lawson" NO="4">
<TITLE MODIFIED="2008-10-23 15:22:11 +1300" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-04-10 13:39:00 +1200" MODIFIED_BY="[Empty name]">
<P>From 1946 to 17 January 2017</P>
<P>Ovid MEDLINE(R) Epub Ahead of Print, In Process &amp; Other Non-Indexed Citations, Ovid MEDLINE (R) Daily, and Ovid MEDLINE</P>
<P>
<BR/>1 reproductive techniques/ or exp reproductive techniques, assisted/ or exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ or exp gamete intrafallopian transfer/ (65927)<BR/>2 (IVF or ICSI).tw. (24183)<BR/>3 embryo transfer.tw. (9681)<BR/>4 (in vitro fertilisation or in vitro fertilization).tw. (20881)<BR/>5 intracytoplasmic sperm injection$.tw. (6213)<BR/>6 COH.tw. (1533)<BR/>7 ovar$ stimulat$.tw. (5130)<BR/>8 assisted reproduct$.tw. (12517)<BR/>9 ovarian hyperstimulation.tw. (4687)<BR/>10 pituitary desensitisation.tw. (21)<BR/>11 pituitary desensitization.tw. (242)<BR/>12 pituitary suppression.tw. (327)<BR/>13 poor responder$.tw. (2039)<BR/>14 poor ovar$ response.tw. (327)<BR/>15 low responder$.tw. (2153)<BR/>16 or/1-15 (84391)<BR/>17 oral contracepti$.tw. (26678)<BR/>18 (OC or OCP$).tw. (22318)<BR/>19 (pretreatment$ or pre-treatment$).tw. (202425)<BR/>20 gestrinone$.tw. (199)<BR/>21 estradiol.tw. (81366)<BR/>22 desogestrel.tw. (1096)<BR/>23 dimethisterone.tw. (25)<BR/>24 levonorgestrel.tw. (4400)<BR/>25 norethindrone.tw. (1328)<BR/>26 norgestrel.tw. (1071)<BR/>27 norgestrienone.tw. (33)<BR/>28 gestodene.tw. (767)<BR/>29 norgestimate.tw. (363)<BR/>30 dienogest.tw. (376)<BR/>31 progestogen$.tw. (5441)<BR/>32 progestagen$.tw. (2202)<BR/>33 progestin$.tw. (11982)<BR/>34 gestagen$.tw. (1640)<BR/>35 Medroxyprogesterone.tw. (6404)<BR/>36 Diane-35.tw. (87)<BR/>37 norethisterone.tw. (2044)<BR/>38 estrogen.tw. (120036)<BR/>39 E2.tw. (67681)<BR/>40 oestrogen.tw. (17720)<BR/>41 exp Contraceptives, Oral/ (47656)<BR/>42 or/17-41 (500004)<BR/>43 randomized controlled trial.pt. (508490)<BR/>44 controlled clinical trial.pt. (98223)<BR/>45 randomized.ab. (438894)<BR/>46 randomised.ab. (87375)<BR/>47 placebo.tw. (210117)<BR/>48 clinical trials as topic.sh. (197894)<BR/>49 randomly.ab. (299032)<BR/>50 trial.ti. (202001)<BR/>51 (crossover or cross-over or cross over).tw. (79992)<BR/>52 or/43-51 (1282048)<BR/>53 exp animals/ not humans.sh. (4854866)<BR/>54 52 not 53 (1184243)<BR/>55 16 and 42 and 54 (977)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2017-05-10 19:28:16 +1200" MODIFIED_BY="Anne Lawson" NO="5">
<TITLE MODIFIED="2017-04-10 13:39:40 +1200" MODIFIED_BY="[Empty name]">Embase search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-04-10 13:39:28 +1200" MODIFIED_BY="[Empty name]">
<P>From 1980 to 17 January 2017<BR/>Ovid platform</P>
<P>
<BR/>1 (IVF or ICSI).tw. (31186)<BR/>2 embryo transfer.tw. (11462)<BR/>3 (in vitro fertilisation or in vitro fertilization).tw. (21776)<BR/>4 intracytoplasmic sperm injection$.tw. (6743)<BR/>5 COH.tw. (1621)<BR/>6 ovar$ stimulat$.tw. (6451)<BR/>7 assisted reproduct$.tw. (14279)<BR/>8 ovarian hyperstimulation.tw. (5543)<BR/>9 pituitary desensitisation.tw. (21)<BR/>10 pituitary desensitization.tw. (263)<BR/>11 pituitary suppression.tw. (364)<BR/>12 poor responder$.tw. (2466)<BR/>13 poor ovar$ response.tw. (383)<BR/>14 low responder$.tw. (2074)<BR/>15 exp infertility therapy/ (81759)<BR/>16 exp embryo transfer/ or exp fertilization in vitro/ or exp intracytoplasmic sperm injection/ (55779)<BR/>17 or/1-16 (97457)<BR/>18 exp oral contraceptive agent/ (53046)<BR/>19 oral contracepti$.tw. (23779)<BR/>20 (OC or OCP$).tw. (21319)<BR/>21 (pretreatment$ or pre-treatment$).tw. (195469)<BR/>22 gestrinone$.tw. (187)<BR/>23 estradiol.tw. (74210)<BR/>24 norgestrel.tw. (706)<BR/>25 desogestrel.tw. (1122)<BR/>26 dimethisterone.tw. (11)<BR/>27 levonorgestrel.tw. (4344)<BR/>28 norethindrone.tw. (954)<BR/>29 norgestrel.tw. (706)<BR/>30 norgestrienone.tw. (15)<BR/>31 gestodene.tw. (758)<BR/>32 norgestimate.tw. (348)<BR/>33 dienogest.tw. (500)<BR/>34 progestogen$.tw. (5070)<BR/>35 progestagen$.tw. (2022)<BR/>36 progestin$.tw. (10993)<BR/>37 gestagen$.tw. (1564)<BR/>38 Medroxyprogesterone.tw. (5918)<BR/>39 Diane-35.tw. (334)<BR/>40 norethisterone.tw. (1847)<BR/>41 estrogen.tw. (111911)<BR/>42 E2.tw. (68712)<BR/>43 oestrogen.tw. (16612)<BR/>44 or/18-43 (485744)<BR/>45 Clinical Trial/ (845200)<BR/>46 Randomized Controlled Trial/ (372794)<BR/>47 exp randomization/ (66611)<BR/>48 Single Blind Procedure/ (20323)<BR/>49 Double Blind Procedure/ (120763)<BR/>50 Crossover Procedure/ (43072)<BR/>51 Placebo/ (257085)<BR/>52 Randomi?ed controlled trial$.tw. (117242)<BR/>53 Rct.tw. (17142)<BR/>54 random allocation.tw. (1418)<BR/>55 randomly allocated.tw. (22469)<BR/>56 allocated randomly.tw. (2023)<BR/>57 (allocated adj2 random).tw. (728)<BR/>58 Single blind$.tw. (15832)<BR/>59 Double blind$.tw. (150922)<BR/>60 ((treble or triple) adj blind$).tw. (452)<BR/>61 placebo$.tw. (214589)<BR/>62 prospective study/ (292450)<BR/>63 or/45-62 (1465071)<BR/>64 case study/ (31878)<BR/>65 case report.tw. (282490)<BR/>66 abstract report/ or letter/ (925645)<BR/>67 or/64-66 (1233732)<BR/>68 63 not 67 (1425818)<BR/>69 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.) (5289150)<BR/>70 68 not 69 (1369914)<BR/>71 17 and 44 and 70 (1757)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2017-05-10 19:28:14 +1200" MODIFIED_BY="Anne Lawson" NO="6">
<TITLE MODIFIED="2008-11-17 15:28:21 +1300" MODIFIED_BY="[Empty name]">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-04-10 13:43:36 +1200" MODIFIED_BY="[Empty name]">
<P>From 1806 to 17 January 2017<BR/>Ovid platform</P>
<P>
<BR/>1 exp Infertility/ or exp Reproductive Technology/ (3107)<BR/>2 (IVF or ICSI).tw. (512)<BR/>3 (Reproducti$ adj2 Technolog$).tw. (980)<BR/>4 embryo transfer.tw. (104)<BR/>5 (in vitro fertilisation or in vitro fertilization).tw. (648)<BR/>6 intracytoplasmic sperm injection$.tw. (49)<BR/>7 or/1-6 (3603)<BR/>8 exp Oral Contraceptives/ (844)<BR/>9 oral contracepti$.tw. (1413)<BR/>10 (OC or OCP$).tw. (1978)<BR/>11 estradiol.tw. (5475)<BR/>12 (progestogen$ or progestin$).tw. (741)<BR/>13 (progestagen$ or gestagen$).tw. (50)<BR/>14 (norethisterone or norethindrone).tw. (41)<BR/>15 (estrogen or oestrogen).tw. (6861)<BR/>16 (pretreatment$ or pre-treatment$).tw. (16904)<BR/>17 or/8-16 (30114)<BR/>18 7 and 17 (58)<BR/>19 random.tw. (48701)<BR/>20 control.tw. (377497)<BR/>21 double-blind.tw. (20370)<BR/>22 clinical trials/ (10102)<BR/>23 placebo/ (4773)<BR/>24 exp Treatment/ (671953)<BR/>25 or/19-24 (1038320)<BR/>26 18 and 25 (23)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2017-05-10 19:28:12 +1200" MODIFIED_BY="Anne Lawson" NO="7">
<TITLE MODIFIED="2017-04-10 13:39:49 +1200" MODIFIED_BY="[Empty name]">CINAHL Plus search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-04-10 13:44:27 +1200" MODIFIED_BY="[Empty name]">
<P>From 1961 to 17 January 2017<BR/>Ebsco platform</P>
<TABLE COLS="3" ROWS="41">
<TR>
<TD>
<P>#</P>
</TD>
<TD>
<P>Query</P>
</TD>
<TD>
<P>Results</P>
</TD>
</TR>
<TR>
<TD>
<P>S40</P>
</TD>
<TD>
<P>S27 AND S39</P>
</TD>
<TD>
<P>111</P>
</TD>
</TR>
<TR>
<TD>
<P>S39</P>
</TD>
<TD>
<P>S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38</P>
</TD>
<TD>
<P>1,105,194</P>
</TD>
</TR>
<TR>
<TD>
<P>S38</P>
</TD>
<TD>
<P>TX allocat* random*</P>
</TD>
<TD>
<P>5,945</P>
</TD>
</TR>
<TR>
<TD>
<P>S37</P>
</TD>
<TD>
<P>(MH "Quantitative Studies")</P>
</TD>
<TD>
<P>15,237</P>
</TD>
</TR>
<TR>
<TD>
<P>S36</P>
</TD>
<TD>
<P>(MH "Placebos")</P>
</TD>
<TD>
<P>9,967</P>
</TD>
</TR>
<TR>
<TD>
<P>S35</P>
</TD>
<TD>
<P>TX placebo*</P>
</TD>
<TD>
<P>43,010</P>
</TD>
</TR>
<TR>
<TD>
<P>S34</P>
</TD>
<TD>
<P>TX random* allocat*</P>
</TD>
<TD>
<P>5,945</P>
</TD>
</TR>
<TR>
<TD>
<P>S33</P>
</TD>
<TD>
<P>(MH "Random Assignment")</P>
</TD>
<TD>
<P>42,264</P>
</TD>
</TR>
<TR>
<TD>
<P>S32</P>
</TD>
<TD>
<P>TX randomi* control* trial*</P>
</TD>
<TD>
<P>117,316</P>
</TD>
</TR>
<TR>
<TD>
<P>S31</P>
</TD>
<TD>
<P>TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )</P>
</TD>
<TD>
<P>870,796</P>
</TD>
</TR>
<TR>
<TD>
<P>S30</P>
</TD>
<TD>
<P>TX clinic* n1 trial*</P>
</TD>
<TD>
<P>197,987</P>
</TD>
</TR>
<TR>
<TD>
<P>S29</P>
</TD>
<TD>
<P>PT Clinical trial</P>
</TD>
<TD>
<P>79,975</P>
</TD>
</TR>
<TR>
<TD>
<P>S28</P>
</TD>
<TD>
<P>(MH "Clinical Trials+")</P>
</TD>
<TD>
<P>208,852</P>
</TD>
</TR>
<TR>
<TD>
<P>S27</P>
</TD>
<TD>
<P>S18 AND S26</P>
</TD>
<TD>
<P>364</P>
</TD>
</TR>
<TR>
<TD>
<P>S26</P>
</TD>
<TD>
<P>S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25</P>
</TD>
<TD>
<P>30,510</P>
</TD>
</TR>
<TR>
<TD>
<P>S25</P>
</TD>
<TD>
<P>TX Estradiol or TX oestrogen or TX estrogen or TX oestradiol</P>
</TD>
<TD>
<P>17,624</P>
</TD>
</TR>
<TR>
<TD>
<P>S24</P>
</TD>
<TD>
<P>TX desogestral or TX desogestrel or TX Gestagen</P>
</TD>
<TD>
<P>76</P>
</TD>
</TR>
<TR>
<TD>
<P>S23</P>
</TD>
<TD>
<P>TX Norgestrel or TX Norethindrone TX Norethisterone</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
<TR>
<TD>
<P>S22</P>
</TD>
<TD>
<P>TX progestagen* or TX progestin* or TX progestogen*</P>
</TD>
<TD>
<P>1,722</P>
</TD>
</TR>
<TR>
<TD>
<P>S21</P>
</TD>
<TD>
<P>TX Pretreatment</P>
</TD>
<TD>
<P>7,437</P>
</TD>
</TR>
<TR>
<TD>
<P>S20</P>
</TD>
<TD>
<P>TX oral contraceptive*</P>
</TD>
<TD>
<P>6,329</P>
</TD>
</TR>
<TR>
<TD>
<P>S19</P>
</TD>
<TD>
<P>(MH "Contraceptives, Oral Combined") OR (MM "Contraceptives, Oral")</P>
</TD>
<TD>
<P>3,014</P>
</TD>
</TR>
<TR>
<TD>
<P>S18</P>
</TD>
<TD>
<P>S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17</P>
</TD>
<TD>
<P>7,460</P>
</TD>
</TR>
<TR>
<TD>
<P>S17</P>
</TD>
<TD>
<P>TX (ovari* N2 induction)</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>S16</P>
</TD>
<TD>
<P>TX COH</P>
</TD>
<TD>
<P>119</P>
</TD>
</TR>
<TR>
<TD>
<P>S15</P>
</TD>
<TD>
<P>TX ovarian hyperstimulation</P>
</TD>
<TD>
<P>403</P>
</TD>
</TR>
<TR>
<TD>
<P>S14</P>
</TD>
<TD>
<P>TX superovulat*</P>
</TD>
<TD>
<P>24</P>
</TD>
</TR>
<TR>
<TD>
<P>S13</P>
</TD>
<TD>
<P>TX ovulation induc*</P>
</TD>
<TD>
<P>660</P>
</TD>
</TR>
<TR>
<TD>
<P>S12</P>
</TD>
<TD>
<P>TX intrauterine insemination</P>
</TD>
<TD>
<P>185</P>
</TD>
</TR>
<TR>
<TD>
<P>S11</P>
</TD>
<TD>
<P>TX IUI</P>
</TD>
<TD>
<P>117</P>
</TD>
</TR>
<TR>
<TD>
<P>S10</P>
</TD>
<TD>
<P>TX assisted reproduct*</P>
</TD>
<TD>
<P>1,678</P>
</TD>
</TR>
<TR>
<TD>
<P>S9</P>
</TD>
<TD>
<P>(MM "Reproduction Techniques+")</P>
</TD>
<TD>
<P>4,518</P>
</TD>
</TR>
<TR>
<TD>
<P>S8</P>
</TD>
<TD>
<P>TX intracytoplasmic sperm injection*</P>
</TD>
<TD>
<P>308</P>
</TD>
</TR>
<TR>
<TD>
<P>S7</P>
</TD>
<TD>
<P>TX embryo* N3 transfer*</P>
</TD>
<TD>
<P>985</P>
</TD>
</TR>
<TR>
<TD>
<P>S6</P>
</TD>
<TD>
<P>TX ovar* N3 hyperstimulat*</P>
</TD>
<TD>
<P>406</P>
</TD>
</TR>
<TR>
<TD>
<P>S5</P>
</TD>
<TD>
<P>TX ovari* N3 stimulat*</P>
</TD>
<TD>
<P>335</P>
</TD>
</TR>
<TR>
<TD>
<P>S4</P>
</TD>
<TD>
<P>TX IVF or TX ICSI</P>
</TD>
<TD>
<P>1,757</P>
</TD>
</TR>
<TR>
<TD>
<P>S3</P>
</TD>
<TD>
<P>(MM "Fertilization in Vitro")</P>
</TD>
<TD>
<P>1,659</P>
</TD>
</TR>
<TR>
<TD>
<P>S2</P>
</TD>
<TD>
<P>TX vitro fertilization</P>
</TD>
<TD>
<P>3,491</P>
</TD>
</TR>
<TR>
<TD>
<P>S1</P>
</TD>
<TD>
<P>TX vitro fertilisation</P>
</TD>
<TD>
<P>3,491</P>
</TD>
</TR>
</TABLE>
<P>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2017-05-10 19:28:10 +1200" MODIFIED_BY="Anne Lawson" NO="8">
<TITLE MODIFIED="2015-06-22 13:59:17 +1200" MODIFIED_BY="[Empty name]">Virtual health library, clinicaltrials.gov and PubMed search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2017-04-10 13:48:23 +1200" MODIFIED_BY="[Empty name]">
<P>Searched on 13 January 2017</P>
<P>Web platform </P>
<P>
<B>Clinicaltrials.gov</B>
</P>
<P>1. ivf and pretreatment (27 hits)</P>
<P>2. ivf and contraceptive* (53 hits)</P>
<P>3. ivf and estradiol (109 hits)</P>
<P>4. ivf and progestogen* (53 hits)</P>
<P>
<B>Virtual health library (LILACS)</B>
</P>
<P>1. ivf and pretreatment (1hit, limited to LILACS)</P>
<P>2. ivf and contraceptive* (4 hits, limited to LILACS and IBECS)</P>
<P>3. ivf and estradiol (4 hits, limited to LILACS and MEDCARIB)</P>
<P>4. ivf and progestogen* (35 hits no limit)</P>
<P>
<B>Pubmed</B>
</P>
<P>1. ivf and pretreatment (21 hits, limited from 01.01.14 to 11.06.15)</P>
<P>2. ivf and contraceptive* (23 hits, limited from 01.01.14 to 11.06.15)</P>
<P>3. ivf and estradiol (47 hits, limited from 01.12.14 to 11.06.15)</P>
<P>4. ivf and progestogen* (0 hits, limited from 01.01.14 to 11.06.15)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2017-05-12 00:59:30 +1200" MODIFIED_BY="Anne Lawson" NO="9">
<TITLE MODIFIED="2008-12-19 10:44:31 +1300" MODIFIED_BY="[Empty name]">Data extraction form (part 1)</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-12 00:59:30 +1200" MODIFIED_BY="Anne Lawson">
<TABLE COLS="2" ROWS="3">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Assessment</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assessor</P>
</TD>
<TD VALIGN="TOP">
<P>SvO / BS</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Date</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
</TABLE>
<TABLE COLS="1" ROWS="3">
<TR>
<TD VALIGN="TOP">
<P>
<B>Final conclusion</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Inclusion</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Exclusion<BR/>Reason for exclusion:</P>
<P>
<BR/>
</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>A. Study information</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> 1. Title</P>
</TD>
<TD VALIGN="TOP">
<P>  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2. First author</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3. Year</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4. Published</P>
</TD>
<TD VALIGN="TOP">
<P>Yes / No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5. Journal</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
</TABLE>
<TABLE COLS="4" ROWS="4">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>B. Criteria for eligibility</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>YES</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>NO</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Design</P>
</TD>
<TD VALIGN="TOP">
<P>Described as randomised?<BR/>
<I>                                                        If no, then exclude</I>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Patients</P>
</TD>
<TD VALIGN="TOP">
<P>Women with subfertility, regardless of any cause, undergoing ART</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Intervention</P>
</TD>
<TD VALIGN="TOP">
<P>·   OCP prior to gonadotrophins<BR/>·   OCP prior to gonadotrophins + GnRH agonist<BR/>·   OCP prior to gonadotrophins + GnRH antagonist<BR/>·   Oestrogen prior to gonadotrophins<BR/>·   Oestrogen prior to gonadotrophins + GnRH agonist<BR/>·   Oestrogen prior to gonadotrophins + GnRH antagonist<BR/>·   Progestogen prior to gonadotrophins<BR/>·   Progestogen prior to gonadotrophins + GnRH agonist<BR/>·   Progestogen prior to gonadotrophins + GnRH antagonist</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<TABLE COLS="4" ROWS="4">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>B. Criteria for eligibility (continued)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>YES</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>NO</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Comparison</P>
</TD>
<TD VALIGN="TOP">
<P>·   Placebo prior to gonadotrophins<BR/>·   Placebo prior to gonadotrophins + GnRH agonist<BR/>·   Placebo prior to gonadotrophins + GnRH antagonist<BR/>·   No pretreatment prior to gonadotrophins<BR/>·   No pretreatment prior to gonadotrophins + GnRH agonist<BR/>·   No pretreatment prior to gonadotrophins + GnRH antagonist<BR/>·   OCP prior to gonadotrophins<BR/>·   OCP prior to gonadotrophins + GnRH agonist<BR/>·   OCP prior to gonadotrophins + GnRH antagonist<BR/>·   Oestrogen prior to gonadotrophins<BR/>·   Oestrogen prior to gonadotrophins + GnRH agonist<BR/>·   Oestrogen prior to gonadotrophins + GnRH antagonist<BR/>·   Progestogen prior to gonadotrophins<BR/>·   Progestogen prior to gonadotrophins + GnRH agonist<BR/>·   Progestogen prior to gonadotrophins + GnRH antagonist<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Outcome</P>
</TD>
<TD VALIGN="TOP">
<P>Primary:</P>
<P>·   number of live births<BR/>
</P>
<P>Secondary:</P>
<P>·   no. of ongoing pregnancies<BR/>·   no. of clinical pregnancies<BR/>·   no. of oocytes retrieved<BR/>·   total days of gonadotrophin treatment<BR/>·   amount of gonadotrophin administered</P>
<P>Adverse:</P>
<P>·   no. of pregnancy loss<BR/>·   no. of ovarian cyst formation<BR/>·   no. of multiple pregnancies<BR/>·   no. of ovarian hyperstimulation syndrome</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Remarks:</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>  </P>
</TD>
</TR>
</TABLE>
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>C. Characteristics</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<I>
<B>C1. Trial characteristics</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Country of investigation</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Setting</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Single                   Multicentre                 Unclear</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Academic             Non-academic            Unclear</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Duration of trial</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Y =                            M =                                 D =</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Design</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Parallel                 Crossover            </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Number of participants</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Intervention group:<BR/>Comparison group:<BR/>Total:</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Remarks:</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>  </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<I>
<B>C2. Participants characteristics</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>Intervention group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Comparison group</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Age</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Mean:<BR/>SD:<BR/>Not reported:</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>Mean:<BR/>SD:<BR/>Not reported:</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>BMI</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Mean:<BR/>SD:<BR/>Not reported:</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Mean:<BR/>SD:<BR/>Not reported:</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of subfertility</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Mean:<BR/>SD:<BR/>Not reported:</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Mean:<BR/>SD:<BR/>Not reported:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>No. of previous IVF trials</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Mean:<BR/>SD:<BR/>Not reported:</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Mean:<BR/>SD:<BR/>Not reported:</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Subfertility</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Primary:<BR/>Secondary:<BR/>Not reported:</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>N =<BR/>N =</P>
</TD>
<TD VALIGN="TOP">
<P>Primary:<BR/>Secondary:<BR/>Not reported:</P>
</TD>
<TD VALIGN="TOP">
<P>N =<BR/>N =</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Causes of subfertility</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Tubal:<BR/>Male:<BR/>Endometriosis:<BR/>Idiopathic:<BR/>Other:<BR/>Not reported:<BR/>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>N =<BR/>N =<BR/>N =<BR/>N =<BR/>N =</P>
</TD>
<TD VALIGN="TOP">
<P>Tubal:<BR/>Male:<BR/>Endometriosis:<BR/>Idiopathic:<BR/>Other:<BR/>Not reported:</P>
</TD>
<TD VALIGN="TOP">
<P>N =<BR/>N =<BR/>N =<BR/>N =<BR/>N =</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Poor response</P>
</TD>
<TD COLSPAN="6" VALIGN="TOP">
<P>YES             NO</P>
<P>Defined as: * Mature ovarian follicles:<BR/>&lt; 3 with a mean diameter &#8805; 17 mm<BR/>                   * Oocytes retrieved:<BR/>&lt; 3                  </P>
<P>                   * Other:</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<I>
<B>C2. Flowchart of participants</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>                                       </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>Remarks:</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<I>
<B>C3. Protocol characteristics</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Pretreatment</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>Combined OCP        Oestrogen           Progestogen</P>
<P>Name of preparation:</P>
<P>Dosage:</P>
<P>Start:                                            Stop: </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Ovarian stimulation</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>hMG                         rFSH</P>
<P>Name of preparation:</P>
<P>Dosage:</P>
<P>Start:                                             Stop:</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Pituitary desensitization</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>GnRH agonist         GnRH antagonist</P>
<P>Name of preparation:</P>
<P>Dosage:</P>
<P>Start:                                             Stop:</P>
<P>Protocol:</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>Treatment schedule </P>
<P/>
</TD>
</TR>
</TABLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<I>
<B>C4. Follow-up</B>
</I>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of follow-up</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Analysis of loss to follow-up</P>
</TD>
<TD VALIGN="TOP">
<P>Per protocol               Intention-to-treat</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Remarks:</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="5" ROWS="14">
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>
<B>D. Risk of bias assessment</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>YES</P>
</TD>
<TD VALIGN="TOP">
<P>NO</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Study size</P>
</TD>
<TD VALIGN="TOP">
<P>Was a power calculation performed and adhered?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Selection bias</P>
</TD>
<TD VALIGN="TOP">
<P>Was the allocation sequence adequately generated?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the patient allocation concealment adequate?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Detection bias</P>
</TD>
<TD VALIGN="TOP">
<P>Was the length of follow-up long enough to detect stated outcomes?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the investigator (performer of hormone administration) blinded?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the outcome assessor blinded?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Were the participants blinded?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Attrition bias</P>
</TD>
<TD VALIGN="TOP">
<P>Was loss to follow-up accounted for?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was an intention-to-treat analysis performed?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Reporting bias</P>
</TD>
<TD VALIGN="TOP">
<P>Where there any suggestions of selective report of outcome?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Source of funding</P>
</TD>
<TD VALIGN="TOP">
<P>Is the source of funding stated?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Remarks:</P>
</TD>
<TD VALIGN="TOP">
<P>  </P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2017-05-12 00:59:38 +1200" MODIFIED_BY="Anne Lawson" NO="10">
<TITLE MODIFIED="2008-12-19 10:44:09 +1300" MODIFIED_BY="[Empty name]">Data extraction form (part 2)</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-12 00:59:38 +1200" MODIFIED_BY="Anne Lawson">
<TABLE COLS="5" ROWS="14">
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>
<B>D. Risk of bias assessment</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>YES</P>
</TD>
<TD VALIGN="TOP">
<P>NO</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Study size</P>
</TD>
<TD VALIGN="TOP">
<P>Was a power calculation performed and adhered?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Selection bias</P>
</TD>
<TD VALIGN="TOP">
<P>Was the allocation sequence adequately generated?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the patient allocation concealment adequate?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Detection bias</P>
</TD>
<TD VALIGN="TOP">
<P>Was the length of follow-up long enough to detect stated outcomes?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the investigator (performer of hormone administration) blinded?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the outcome assessor blinded?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Were the participants blinded?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Attrition bias</P>
</TD>
<TD VALIGN="TOP">
<P>Was loss to follow-up accounted for?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was an intention-to-treat analysis performed?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Reporting bias</P>
</TD>
<TD VALIGN="TOP">
<P>Where there any suggestions of selective report of outcome?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Source of funding</P>
</TD>
<TD VALIGN="TOP">
<P>Is the source of funding stated?</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Remarks:</P>
</TD>
<TD VALIGN="TOP">
<P>  </P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<TABLE COLS="9" ROWS="2">
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<B>E. Outcomes </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Comparison</P>
</TD>
<TD COLSPAN="8" VALIGN="TOP">
<P>a. Define treatment:</P>
<P>b. Define control: </P>
<P> </P>
</TD>
</TR>
</TABLE>
<TABLE COLS="9" ROWS="6">
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>
<B>E1. Primary outcomes </B>
</I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="4" VALIGN="TOP">
<P>
<U>Live births</U> </P>
<P>Defined: YES</P>
<P>              NO</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. of live birth</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. of no live birth</P>
</TD>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Control group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Total</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>Remarks: </P>
</TD>
</TR>
</TABLE>
<TABLE COLS="6" ROWS="1">
<TR>
<TD COLSPAN="6">
<P>
<I>
<B>E2. Secondary outcomes </B>
</I>
</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="9" ROWS="5">
<TR>
<TD COLSPAN="2" ROWSPAN="4" VALIGN="TOP">
<P>
<U>Ongoing pregnancy</U>
</P>
<P>Defined: YES</P>
<P>              NO</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. of ongoing pregnancy</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. of no ongoing pregnancy</P>
</TD>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Control group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Total</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>Remarks:</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="9" ROWS="5">
<TR>
<TD COLSPAN="2" ROWSPAN="4" VALIGN="TOP">
<P>
<U>Clinical pregnancy</U>
</P>
<P>Defined: YES</P>
<P>              NO</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. of clinical pregnancy</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>No. of no clinical pregnancy</P>
</TD>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Control group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Total</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>Remarks:</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="9" ROWS="4">
<TR>
<TD COLSPAN="3" ROWSPAN="3" VALIGN="TOP">
<P>
<U>Oocytes retrieved</U>  </P>
<P>Defined: YES</P>
<P>              NO</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Mean no. of oocytes retrieved</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>SD</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Control group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>Remarks: </P>
</TD>
</TR>
</TABLE>
<TABLE COLS="9" ROWS="4">
<TR>
<TD COLSPAN="3" ROWSPAN="3" VALIGN="TOP">
<P>
<U>Days of gonadotrophins</U> <U>treatment</U>
</P>
<P>Defined: YES</P>
<P>              NO</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Mean no. of days of<BR/>gonadotrophins treatment</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> SD</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Control group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>Remarks:</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="9" ROWS="4">
<TR>
<TD COLSPAN="3" ROWSPAN="3" VALIGN="TOP">
<P>
<U>Total days of treatment</U> </P>
<P>Defined: YES</P>
<P>              NO</P>
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Mean no. of days of pituitary suppression</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>SD</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>Control group</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>Remarks: </P>
</TD>
</TR>
</TABLE>
<TABLE COLS="9" ROWS="1">
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<I>
<B>E3. Adverse outcomes </B>
</I>
</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<U>Pregnancy loss</U>
</P>
<P>Defined: YES</P>
<P>              NO</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No. of pregnancy loss</P>
</TD>
<TD VALIGN="TOP">
<P>No. of no pregnancy loss</P>
</TD>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Control group</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>Remarks: </P>
</TD>
</TR>
</TABLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<U>Ovarian cyst formation</U>
</P>
<P>Defined: YES</P>
<P>              NO</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No. of ovarian<BR/>cyst formation</P>
</TD>
<TD VALIGN="TOP">
<P>No. of no ovarian<BR/>cyst formation</P>
</TD>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Control group</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>Remarks:</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<U>Multiple pregnancy</U>
</P>
<P>Defined: YES</P>
<P>              NO</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No. of multiple<BR/>pregnancies</P>
</TD>
<TD VALIGN="TOP">
<P>No. of no multiple<BR/>pregnancies</P>
</TD>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Control group</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>Remarks:</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<U>Ovarian hyperstimulation</U>
<BR/>
<U>syndrome</U>
</P>
<P>Defined: YES</P>
<P>              NO</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No. of OHS syndrome</P>
</TD>
<TD VALIGN="TOP">
<P>No. of no OHS syndrome</P>
</TD>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Treatment group</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Control group</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Total</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>Remarks:</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_3" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="3">
<FLOWCHARTBOX TEXT="&lt;p&gt;23 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="160">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;29 &lt;/span&gt;studies (&lt;span&gt;42&lt;/span&gt; references) included in qualitative synthesis (see &lt;a link_type=&quot;SECTION&quot; href=&quot;CHARACTERISTICS_OF_INCLUDED_STUDIES&quot; protected=&quot;true&quot;&gt;Characteristics of included studies&lt;/a&gt; table)&lt;/p&gt;" WIDTH="160">
<FLOWCHARTBOX TEXT="&lt;p&gt;137 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;1528 records screened&lt;/p&gt;" WIDTH="160">
<FLOWCHARTBOX TEXT="&lt;p&gt;1528 records after duplicates removed&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;1792 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1392 records excluded&lt;/p&gt;" WIDTH="150"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;span&gt;8&lt;/span&gt;7full-text articles (95 references) excluded, with reasons (see &lt;a link_type=&quot;SECTION&quot; href=&quot;CHARACTERISTICS_OF_EXCLUDED_STUDIES&quot; protected=&quot;true&quot;&gt;Characteristics of excluded studies&lt;/a&gt; table)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;6 studies did not report any of the review's outcomes or reported them in a form such as 'per cycle' that could be included in meta-analysis. These studies were thus not included in quantitative analysis.&lt;/p&gt;" WIDTH="160"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>